

### (19) World Intellectual Property Organization International Bureau



# I DIN TRIBLO TATA NUMBAN I DIN BAN BUT ANI DIN DIN TATA NUMBAN BAN

#### (43) International Publication Date 17 May 2001 (17.05.2001)

#### **PCT**

## (10) International Publication Number WO 01/35317 A1

(51) International Patent Classification7:

G06F 19/00

(21) International Application Number: PCT/US00/31152

(22) International Filing Date:

13 November 2000 (13.11.2000)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

US 12 November 1999 (12.11.1999) 60/165,086 12 November 1999 (12.11.1999) US 60/165,124 US 1 February 2000 (01.02.2000) 60/179,531

(71) Applicant (for all designated States except US): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 12th floor, 1111 Franklin Street, Oakland, CA 94607-5200 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): EISENBERG, David [US/US]; 342 Comstock Avenue, Los Angeles, CA 90024 (US). ROTSTEIN, Sergio, H. [-/US]; - (US). MARCOTTE, Edward, M. [US/US]; 2230 S. Carmelina Avenue, Los Angeles, CA 90064 (US).

- (74) Agent: EINHORN, Gregory, P.; Fish & Richardson P.C., Suite 500, 4350 La Jolla Village Drive, San Diego, CA 92122 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FL, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CL, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

#### Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DETERMINING THE FUNCTIONS AND INTERACTIONS OF PROTEINS BY COMPARATIVE ANALYSIS

(57) Abstract: The invention provides novel methods for characterizing the function of nucleic acids and polypeptides. The invention provides a novel method for identifying a nucleic acid or a polypeptide sequence that may be a target for a drug. The invention provides a novel method for identifying a nucleic acid or a polypeptide sequence that may be essential for the growth or viability of an organism. The characterization is based on use of methods of the invention comprising algorithms that can identify functional relationships between diverse sets of non-homologous nucleic acid and polypeptide sequences. The invention provides a computer program product, stored on a computer-readable medium, for identifying a nucleic acid or a polypeptide sequence that may be essential for the growth or viability of an organism. The invention provides a computer program product, stored on a computer-readable medium, for identifying a nucleic acid or a polypeptide sequence that may be a target for a drug. The invention provides a computer system, comprising a processor and a computer program product of the invention.

# DETERMINING THE FUNCTIONS AND INTERACTIONS OF PROTEINS BY COMPARATIVE ANALYSIS

## Related Applications

The present application is a continuation-in-part application ("CIP") of Patent Convention Treaty (PCT) International Application Serial No: PCT/US00/02246, filed in the U.S. receiving office on January 28, 2000, and this application claims the benefit of priority under 35 U.S.C. § 119(e) of U.S. Provisional Application Nos. 60/165,124, and 60/165,086, both filed November 12, 1999, and U.S. Provisional Application No. 60/179,531, filed February 1, 2000. International Application Serial No: PCT/US00/02246 claims the benefit of priority under 35 U.S.C. § 119(e) of U.S. Provisional Application Serial No. 60/117,844, filed January 29, 1999, U.S. Provisional Application Serial No. 60/118,206, filed February 1, 1999, U.S. Provisional Application Serial No. 60/126,593, filed March 26, 1999, U.S. Provisional Application Serial No. 60/134,093, filed May 14, 1999, and U.S. Provisional Application Serial No. 60/134,092, filed May 14, 1999. Each of the aforementioned applications is explicitly incorporated herein by reference in their entirety and for all purposes.

#### TECHNICAL FIELD

This invention generally relates to genetics and microbiology. The invention provides novel methods to identify the function of and relationships between nucleic acid and protein sequences. The method is particularly useful for finding the identifying genes and polypeptides having potential therapeutic relevance in organisms, e.g., microorganisms, such as *Mycobacterium tuberculosis*. The invention also provides *Mycobacterium tuberculosis* genes and polypeptides found by these methods. These genes and polypeptides are useful as potential drug targets.

#### **BACKGROUND**

25

30

5

10

15

20

The determination of the functions of and relationships between nucleic acid and protein sequences has traditionally relied on either the study of homology and sequence identity with genes and proteins of known function or, in the absence of informative homology, laborious experimental work. The availability of many complete genome sequences has made it possible to develop new strategies for computational determination of protein functions. Several methods have been developed which can predict the general

function of proteins by analyzing their functional relationships rather than sequence similarity. Generally, two proteins can be considered functionally related when they form part of the same biochemical pathway or biological process. For example, although malate dehydrogenase is not homologous to pyruvate carboxylase, and the two enzymes do not catalyze the same reaction, they are functionally related because they both catalyze steps of a common biochemical pathway, namely the tricarboxylic acid cycle.

New methods that can establish such functional relationships could provide valuable information on the functions of uncharacterized nucleic acid and protein sequences.

The disease tuberculosis, caused Mycobacterium tuberculosis (MTB) is one of the world's leading killers. The World Health Organization estimates that 30 million deaths from pulmonary tuberculosis will occur during this decade. Alarming reports on the emergence of drug-resistant strains of this bacterium underscore the importance of the search for new therapeutic agents. Identifying the function of every protein produced by MTB will provide researchers with promising new targets for anti-tuberculosis drug design.

SUMMARY

The invention provides novel methods for characterizing the function of nucleic acids and polypeptides. The invention provides a novel method for identifying a nucleic acid or a polypeptide sequence that may be a target for a drug. The invention provides a novel method for identifying a nucleic acid or a polypeptide sequence that may be essential for the growth or viability of an organism. The characterization is based on use of methods of the invention comprising algorithms that can identify functional relationships between diverse sets of non-homologous nucleic acid and polypeptide sequences. Characterization of nucleic acid and protein sequences can be the basis for the development of compositions that can interact with those nucleic acids and polypeptides. For example, such characterization can provide a basis for screening methods. Such characterization may allow use of these sequences as targets for drug discovery. Discovery of such compositions can provide the basis for the design of novel drugs, particularly if the characterized sequences are derived from a pathogen.

The invention provides a method for identifying a nucleic acid or a polypeptide sequence that may be a target for a drug comprising the following steps: (a)

5

10

15

20

25

providing a first nucleic acid or a polypeptide sequence that is known to be a drug target; (b) providing at least one algorithm selected from the group consisting of a "domain fusion" method, a "phylogenetic profile" method and a "physiologic linkage" method, wherein the algorithm is capable analyzing a functional relationship between nucleic acid or polypeptide sequences; and, (c) comparing the first nucleic acid or the polypeptide drug target sequence to a plurality of sequences using at least one of the algorithms as set forth in step (b) to identify a second sequence that has a functional relationship to the first sequence, thereby identifying a nucleic acid or a polypeptide sequence that may be a target for a drug.

The invention provides a method for identifying a nucleic acid or a polypeptide sequence that may be essential for the growth or viability of an organism comprising the following steps: (a) providing a first nucleic acid or a polypeptide sequence that is known to be essential for the growth or viability of an organism; (b) providing at least one algorithm capable analyzing a functional relationship between nucleic acid or polypeptide sequences selected from the group consisting of a "domain fusion" method, a "phylogenetic profile" method and a "physiologic linkage" method; and, (c) comparing the first nucleic acid or the polypeptide sequence to a plurality of sequences using at least one of the algorithms as set forth in step (b) to identify a second sequence that has a functional relationship to the first sequence, thereby identifying a nucleic acid or a polypeptide sequence that may be essential for the growth or viability of an organism.

....

In one aspect of the methods of the invention, the drug is an anti-microbial drug. In another aspect, the first nucleic acid or a polypeptide sequence is derived from a pathogen. The pathogen can be a microorganism, such as *Mycobacterium tuberculosis* (MTB).

The plurality of sequences used to identify a second sequence can comprise a database of the gene sequences of an entire genome of an organism. The plurality of sequences used to identify a second sequence can comprise a database of the gene sequences derived from a pathogen.

In one aspect of the methods of the invention, the "phylogenetic profile" method algorithm comprises (a) obtaining data, comprising a list of proteins from at least two genomes; (b) comparing the list of proteins to form a protein phylogenetic profile for each protein, wherein the protein phylogenetic profile indicates the presence or absence of a

5

10

15

20

25

protein belonging to a particular protein family in each of the at least two genomes based on homology of the proteins; and (c) grouping the list of proteins based on similar profiles, wherein proteins with similar profiles are indicated to have a functional relationship. The phylogenetic profile can be in the form of a vector, matrix or phylogenetic tree. The "phylogenetic profile" method can further comprise determining the significance of homology between the proteins by computing a probability (p) value threshold. The probability can be set with respect to the value 1/NM, based on the total number of sequence comparisons that are to be performed, wherein N is the number of proteins in the first organism's genome and M in all other genomes. The presence or absence of a protein belonging to a particular protein family in each of the at least two genomes can be determined by calculating an evolutionary distance. The evolutionary distance can be calculated by: (a) aligning two sequences from the list of proteins; (b) determining an evolution probability process by constructing a conditional probability matrix: p(aa -> aa'), where aa and aa' are any amino acids, said conditional probability matrix being constructed by converting an amino acid substitution matrix from a log odds matrix to said conditional probability matrix; (c) accounting for an observed alignment of the constructed conditional probability matrix by taking the product of the conditional probabilities for each aligned pair during the alignment of the two sequences, represented by  $P(p) = \prod_{n} p(aa_n \to aa'_n)$ ; and, (d)

determining an evolutionary distance  $\alpha$  from powers equation  $p'=p^{\alpha}(aa \rightarrow aa')$ , maximizing for P. The conditional probability matrix can be defined by a Markov process with substitution rates, over a fixed time interval. The conversion from an amino acid substitution matrix to a conditional probability matrix can be represented by:

$$P_B(i \to j) = p(j)2^{\wedge} \frac{\text{BLOSUM62}_{ij}}{2},$$

where BLOSUM62 is an amino acid substitution matrix, and  $P(i \rightarrow j)$  is the probability that amino acid i is replaced by amino acid j through point mutations according to BLOSUM62 scores. In one aspect, the Pj's are the abundances of amino acid j and are computed by solving a plurality of linear equations given by the normalization condition that:

$$\sum_{i} P_{B}(i \to j) = 1.$$

5

10

15

20

In alternative aspects of the methods of the invention, the "physiologic linkage" method algorithm identifies proteins and nucleic acids that participate in a common functional pathway; identifies proteins and nucleic acids that participate in the synthesis of a common structural complex; and, identifies proteins and nucleic acids that participate in a common metabolic pathway.

In one aspect of the invention, the "domain fusion" method algorithm comprises (a) aligning a first primary amino acid sequence of multiple distinct nonhomologous polypeptides to second primary amino acid sequence of a plurality of proteins; and, (b) for any alignment found between the first primary amino acid sequences of all of such multiple distinct non-homologous polypeptides and at least one protein of the second primary amino acid sequences, outputting an indication identifying the aligned second primary amino acid sequence as an indication of a functional link between the aligned first and second polypeptide sequences. The aligning can be performed by an algorithm selected from the group consisting of a Smith-Waterman algorithm, Needleman-Wunsch algorithm, a BLAST algorithm, a FASTA algorithm, and a PSI-BLAST algorithm. The multiple distinct non-homologous polypeptides can be obtained by translating a nucleic acid sequence from a genome database. The plurality of proteins can have a known function. At least one of the multiple distinct non-homologous polypeptides can have a known function. At least one of the multiple distinct non-homologous polypeptides can have an unknown function. The alignment can be based on the degree of homology of the multiple distinct non-homologous polypeptides to the plurality of proteins. The "domain fusion" method can comprise determining the significance of the aligned and identified second primary amino acid sequence by computing a probability (p) value threshold. The probability threshold can be set with respect to the value 1/NM, based on the total number of sequence comparisons that are to be performed, wherein N is the number of proteins in a first organism's genome and Min all other genomes. The "domain fusion" method can further comprising filtering excessive functional links between one first primary amino acid sequence of multiple distinct nonhomologous polypeptides and an excessive number of other distinct non-homologous polypeptides for any alignment found between the first primary amino acid sequences of the

: ₹

÷...

5

10

15

20

25

distinct non-homologous polypeptides and at least one of the second primary amino acid sequences of the plurality of proteins.

The invention provides a computer program product, stored on a computer-readable medium, for identifying a nucleic acid or a polypeptide sequence that may be a target for a drug, the computer program product comprising instructions for causing a computer system to be capable of: (a) inputting a first nucleic acid or a polypeptide sequence that is known to be a drug target; (b) accessing at least one algorithm capable analyzing a functional relationship between nucleic acid or polypeptide sequences selected from the group consisting of a "domain fusion" method, a "phylogenetic profile" method and a "physiologic linkage" method; and (c) comparing the first nucleic acid or the polypeptide drug target sequence to a plurality of sequences using at least one of the algorithms set forth in step (b) to identify a second sequence that has a functional relationship to the first sequence and generating an output identifying a nucleic acid or a polypeptide sequence that may be a target for a drug.

The invention provides a computer program product, stored on a computer-readable medium, for identifying a nucleic acid or a polypeptide sequence that may be essential for the growth or viability of an organism, the computer program product comprising instructions for causing a computer system to be capable of: (a) providing a first nucleic acid or a polypeptide sequence that is known to be essential for the growth or viability of an organism; (b) accessing at least one algorithm capable analyzing a functional relationship between nucleic acid or polypeptide sequences selected from the group consisting of a "domain fusion" method, a "phylogenetic profile" method and a "physiologic linkage" method; and, (c) comparing the first nucleic acid or the polypeptide sequence to a plurality of sequences using at least one of the algorithms set forth in step (b) to identify a second sequence that has a functional relationship to the first sequence and generating an output identifying a nucleic acid or a polypeptide sequence that may be essential for the growth or viability of an organism.

The invention provides a computer system, comprising: (a) a processor; and, a computer program product of the invention.

30

5

10

15

20

All publications, patents, patent applications, GenBank sequences and ATCC deposits, cited herein are hereby expressly incorporated by reference for all purposes.

The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.

# DESCRIPTION OF DRAWINGS

Figure 1 is an example of functional linkages predicted between InhA (Rv 1484) and other TB genes.

Figure 2 is an example of predicted functional linkages between embB (Rv 3795), which is a target of the drug ethambutol, and other TB genes using the phylogenetic profile method.

Figure 3 is an example of predicted functional linkages between five TB genes having homology to penicillin binding proteins and other TB genes.

Figure shows that gcpE (Rv 2868C) is predicted to be functional linked to cell wall metabolism.

Figure 5 shows predicted functional linkages of htrA (Rv 1223C) with other TB genes.

Like reference symbols in the various drawings indicate like elements.

# DETAILED DESCRIPTION

The present invention provides novel methods for identifying the relationships between and the function of nucleic acid and polypeptide sequences. The methods of the invention identify novel genes and polypeptides on the basis of their functional linkage to other proteins whose biological function or processes is known or inferred by homology.

. 4 . 5 . 4 . 1 . 1 . 1

The genes and polypeptides identified by the methods of the invention can be used in screening methods for the identification of compositions which, by binding or otherwise interacting with the gene or polypeptide, are capable of modifying the physiology and growth of an organism. The compositions identified by these screening methods are useful as drugs and pharmaceuticals. Thus, genes and polypeptides identified by the methods

5

10

15

20

of the invention, including the genes and polypeptides identified herein, can be used as potential drug targets.

One aspect of the invention provides methods for identifying the function of genes and polypeptides from *Mycobacterium tuberculosis* (MTB or TB). Based on this new functional determination, these genes and polypeptides can be used to screen for compositions capable of modifying the physiology and growth of *Mycobacterium* tuberculosis (TB). Thus, genes and polypeptides identified by the methods of the invention, including the genes and polypeptides identified herein, can be used as targets in screening protocols and can be useful as potential drug targets.

10

15

5

The function of the TB genes and polypeptides of the present invention were identified using the methods of the invention; i.e., they were identified on the basis of their functional linkage to other proteins whose biological function or processes were known by experiment or inferred by homology. TB genes and polypeptides that are functionally linked to genes known to be involved in pathogenesis or organisms survival are potential drug targets. Genes or polypeptides associated with TB pathogenesis, survival or that are important or unique to TB biochemical pathways are potential drug targets. TB genes and polypeptides that have no homologues identified in humans are potential drug targets. The function of many of the TB genes and polypeptides identified is based on the genes or polypeptides with which they are functionally linked.

20

25

TB genes whose function was identified using the methods of the invention are effectively targeted by a drug (i.e., they can act as bona fide drug targets) provides proof of principle that the invention's methods for identifying functionally linked genes can identify TB genes and polypeptides that are drug targets. Further confirmation that the genes identified by the methods of the invention include bona fide drug targets can be supported by the fact that genes already known to be targets for drugs have been independently identified, or "re-discovered," by the invention's methods.

30

The novel TB genes described herein are identified as being functionally related or linked to other genes, including other TB genes, such as a known TB drug target (e.g., InhA polypeptide, which is a target of isoniazid). These functional linkages are established using mathematical algorithms. The assignment or inference of a function to TB genes and polypeptides based on their linkage or relatedness to other genes and polypeptides

is described in U.S. provisional application serial no. 60/165,086. Potential TB drug targets are identified by several methods discussed herein and in further detail in U.S. provisional application serial no. 60/134,092. Through the use of these methods, TB genes and polypeptides have been identified as potential drug targets and are illustrated on Tables 1 and 2, and Figures 1 to 5. The nucleotide and amino acid sequences of these potential drug targets are illustrated on Tables 3 and 4, respectively (see below).

The phrase "functional link," "functionally related" and grammatical variations thereof, when used in reference to genes or polypeptides, means that the genes or polypeptides are predicted to be linked or related. A particular example of functionally related or linked proteins is where two proteins participate in a biochemical or metabolic pathway (e.g., malate dehydrogenase and fumarase, which are both present in the TCA cycle). Thus, although functionally linked or related proteins may not have sequence homology to each other, they are linked by virtue of their participation in the same biochemical pathway. Other examples of linked or related polypeptides are where two polypeptides are part of a protein complex, physically interact, or act upon each another.

The "domain fusion" or "Rosetta Stone" method searches protein sequences across all known genomes and identifies proteins that are separate in one organism but joined as intramolecular domains into one larger protein in another organism. Such proteins that are separate in some organisms but joined in others often carry out related or sequential functions and are therefore functionally linked.

The phylogenetic profile method compares protein sequences across all known genomes and analyzes the pattern of inheritance of each protein across the different organisms. Proteins that have similar patterns of inheritance, either acquired or lost as a part of a group of proteins through evolution, are functionally linked. The gene proximity method identifies genes that remain physically close or "clustered" throughout evolution and are therefore functionally linked.

A particular example of the identification of a potential TB drug target would be to identify a TB gene or polypeptide functionally linked to a known drug target. Anti-TB drugs include isoniazid, rifampicin, ethambutol, streptomycin, pyrazxinamide, and thiacetazone. For isoniazid, this drug is believed to act through enoyl-acyl reductase InhA, resulting in mycolic acid biosynthesis inhibition. Thus, TB genes or polypeptides

5

10

15

20

25

functionally linked to enoyl-acyl reductase InhA are potential drug targets; see Figure 1, which shows an analysis of InhA, the target for isoniazid, the most widely used anti-tuberculosis drug, and functional linkages to a set of genes mostly known or hypothesized to be involved in cell wall-related processes and lipid and polyketide metabolism. Particular examples of the identification of several TB genes and polypeptides that are functionally related to the target of these anti-TB drugs is shown in Figures 1 to 5.

# "Domain Fusion" or "Rosetta Stone" Method

The "domain fusion" or "Rosetta Stone" method compares protein sequences across known nucleic acid databases (e.g., known genomes) to identify genes and proteins that are separate entities in one organism but are joined into one larger multidomain protein in another organism. In such cases, the two separate proteins often carry out related or sequential functions or form part of a larger protein complex. Therefore, the general function of one component (e.g., one or more of the unknown proteins) can be inferred from the known function of the other component. In addition, merely identifying links between proteins using the method described herein provides valuable information (e.g., usefulness as a target for an antibacterial drug), regardless of whether the function of one or more of the proteins used to form the link(s) is known. Because the two components do not have similar amino acid sequence the function of one could not be inferred from the other on the basis of sequence similarity alone.

20

25

30

5

10

15

The methods for identifying drug targets (e.g., TB drug targets) described herein (e.g., the "Rosetta Stone Method") are based on the idea that proteins that participate in a common structural complex, metabolic pathway, biological process or with closely related physiological functions, are functionally linked. In addition, these methods also are capable of identifying proteins that interact physically with one another. Functionally linked proteins in one organism can often be found fused into a single polypeptide chain in a different organism. Similarly, fused proteins in one organism can be found as individual proteins in other organisms. For example, in a first organism one might identify two unlinked proteins "A" and "B" with unknown function. In another organism, one may find a single protein "AB" with a part that resembles "A" and a part that resembles "B". Protein AB allows one to predict that "A" and "B" are functionally related.

The functional activity of each distinct protein in the "Rosetta Stone" method need not be known prior to performing the method (i.e., the function of A, B, or AB need not be known). Using the "Rosetta Stone" method to compare and analyze several unknown protein sequences can provide information regarding relationships of each protein absent knowledge about the functional activity of the initially analyzed proteins themselves. For example, the information (i.e., the links) can provide information that the proteins are part of a common pathway, function in a related process or physically interact. Such information need not be based on the biological function of the individual proteins.

These methods can provide information regarding links between previously un-linked proteins that function, for example, in a concerted process. A marker, for example, for a particular disease state is identified by the presence or absence of a protein (e.g., Her2/neu in breast cancer detection). Links (i.e., information) identified by the method, which link proteins "B" and "C" to such a marker suggest that proteins "B" and "C" are related by function, physical interaction or part of a common biological pathway with the marker. Such information is useful in designing screening methods and identifying drug targets (e.g., TB drug targets), making diagnostics, and designing therapeutics.

In one approach, the "Rosetta Stone" method is performed by sequence comparison that searches for incomplete "triangle relationships" between, for example, three proteins, *i.e.*, for two proteins A' and B' that are different from one another but similar in sequence to another protein AB. Completing the triangle relationship provides useful information regarding the proteins' biological function(s), functional interaction, pathway relationships or physical relationships with other proteins in the "triangle."

Either nucleotide sequences or amino acid sequences can be used in the methods for identifying functionally related or linked genes or polypeptides. Where a nucleic sequence is to be used it can be first translated from a nucleic acid sequence to amino acid sequence. Such translation may be performed in all frames if the coding sequence is not known. Programs that can translate a nucleic acid sequence are known in the art. In addition, for simplicity, the description of this method discusses the use of a "pair" of proteins in the determination of a "Rosetta Stone" protein, more than 2 may be used (e.g., 3, 4, 5, 10, 100 or more proteins). Accordingly, one can analyze chains of linked proteins, such as "A" linked by a Rosetta Stone protein to "B" linked by a Rosetta Stone protein to "C", etc.

5

10

15

20

25

By this method, groups of functionally related proteins can be found and their function

A method can start with identifying the primary amino acid sequence for a identified. plurality of proteins whose functional relationship is to be determined (e.g., protein A' and protein B'). A number of source databases are available, as described above, that contain either a nucleic acid sequence and/or a deduced amino acid sequence for use with the first step. The plurality of sequences (the "probe sequences") are then used to search a sequence database, e.g., GenBank (NCBI, NLM, NIH), PFAM (a large collection of multiple sequence alignments and hidden Markov models covering many common protein domains; Washington University, St. Louis MO) or ProDom (a database based on recursive PSI-BLAST searches and designed as a tool to help analyze domain arrangements of proteins and protein families, see, e.g., Corpet (1999) Nucleic Acids Res. 27:263-267), either simultaneously or individually. Every protein in the sequence database is examined for its ability to act as a "Rosetta Stone" protein (i.e., a single protein containing polypeptide sequences or domains from both protein A' and protein B'). A number of different methods of performing such sequence searches are known in the art. Such sequence alignment methods include, for example, BLAST (see, e.g., Altschul (1990) J. Mol. Biol. 215: 403-410), BLITZ (MPsrch) (see, e.g., Brenner (1995) Trends Genet. 11:330-331; and infra), and FASTA (see, e.g., Pearson (1988) Proc. Natl. Acad. Sci. USA 85(8):2444-2448; and infra). The probe sequence can be any length (e.g., about 50 amino acid residues to about 1000 amino acid residues).

Probe sequences (e.g., polypeptide sequences or domains) found in a single protein (e.g., an "AB" multidomain protein) are defined as being "linked" by that protein. Where the probe sequences are used individually to search the sequence database, one can mask those segments having homology to the first probe sequence found in the proteins of the sequence database prior to searching with the subsequent probe sequence. In this way, one eliminates any potential overlapping sequences between the two or more probe sequences.

The linked proteins can then be further compared for similarity with one another by amino acid sequence comparison. Where the sequences are identical or have high homology, such a finding can be indicative of the formation of homo-dimers, -trimers, etc.

5

10

15

20

25

Typically, "Rosetta Stone"-linked proteins are only kept when the linked proteins show no homology to one another (e.g., hetero-dimers, trimers, etc.).

In another method for identifying functional linkages, a potential fusion protein lacking any functional information that is suspected of having two or more domains (e.g., a potential "Rosetta Stone" protein) may be used to search for related proteins. In this method, the primary amino acid of the fusion protein is determined and used as a probe sequence. This probe sequence is used to search a sequence database (e.g., GenBank, PFAM or ProDom). Every protein in the sequence database is examined for homology to the potential fusion protein (i.e., multiple proteins containing polypeptide sequences or domains from the potential fusion protein). A number of different methods of performing such sequence searches are known in the art, e.g., BLAST, BLITZ (Biocomputing Research Unit, University of Edinburgh, Scotland, the "MPsrch program" performs comparisons of protein sequences against the Swiss-Prot protein sequence database using the Smith and Waterman best local similarity algorithm), and FASTA.

Probe sequences found in more than one protein (e.g., A' and B' proteins) are defined as being "linked" so long as at least one protein per domain containing that domain but not the other is also identified. In other words, at least one protein or domain of the plurality of proteins must also be found alone in the sequence database. This verifies that the protein or domain is not an integral part of a first protein but rather a second independent protein having its own functional characteristics.

Statistical methods can be used to judge the significance of possible matches. The statistical significance of an alignment score is described by the probability, P, of obtaining a higher score when the sequences are shuffled. One way to compute a P value threshold is to first consider the total number of sequence comparisons that are to be performed. For example, if there are N proteins in E, coli and M in all other genomes this number is  $N \times M$ . If a comparison of this number of random sequence would result in one pair to yield a P value of 1/NM by chance this then is set as the threshold.

This method provides information regarding which proteins are functionally related (e.g., related biological functions common structural complexes, metabolic pathways or biological process) a subset of which physically interact in an organism.

5

10

15

20

25

## Alignment Algorithms

To align sequences, a number of different procedures can be used that produce a good match between the corresponding residues in the sequences. Typically, the Smith-Waterman (Smith (1981) Adv. Appl. Math. 2:482) or Needleman-Wunsch algorithm (Needleman (1970) J. Mol. Biol. 48:443) algorithm, are used, however, other, faster procedures such as BLAST, FASTA, PSI-BLAST (a version of Blast for finding protein families), or others known in the art (see infra discussion), can be used.

## Filtering Methods

5

10

15

20

25

30

The Rosetta Stone Method provides at least two pieces of information. First the method provides information regarding which proteins are functionally related. Second the method provides information regarding which proteins are physically related. Each of these two pieces of information has different sources of error and prediction. The first type of error is introduced by protein sequences that occur in many different proteins and paired with many other protein sequences. The second type of error is introduced due to there often being multiple copies of similar proteins, called paralogs, in a single organism. In general, the "Rosetta Stone" method predicts functionally related proteins well, with no filtering of results required. However, it is possible to filter the error associated with either the first or second type of information.

The invention recognizes that a few domains are linked to an excessive number of other domains by a "Rosetta Stone" protein. For example, 95% of the domains are linked to fewer than 25 other domains. However, some domains, e.g., the Src Homology 3 (SH3) domain or ATP-binding cassette (ABC domains), link to more than a hundred other domains. These links were filtered by removing all links generated involving these 5% of domains (i.e., the domains linked to more than 25 other domains). For example, in E. coli, without filtering, 3531 links were identified using the domain-based analysis, but after filtering only 749 links were identified. This method improved prediction of functionally related proteins by 28% and physically related proteins by 47%. Accordingly, there are a number of ways to filter the results to improve the significance of the functional links. As described above, as the number of functional links increases there is an increased higher chance of finding a "Rosetta Stone" protein. By reducing the excessively linked proteins one

. ..

reduces the chance number of "Rosetta Stone" proteins thereby increasing the significance of a functional link.

Error introduced by multiple paralogs of linked proteins should have little effect on functional prediction, as paralogs usually have very similar function, but will affect the reliability of prediction of protein-protein interactions. This estimate is calculated for each linked protein pair, and can be estimated roughly as:

Fractional Error = 
$$1 - \frac{\sqrt{N}}{N}$$
,

where N is the number of paralogous protein pairs, (e.g., A linked to B, A' linked to B', A linked to B', and A' linked to B, in the case that A and A' are paralogs, as are B and B', and the linking proteins is AB as above).

The error can also be estimated as 1-T, where T is the mean percent of potential true positives calculated for all domain pairs in an organism. For each domain pair linked by a Rosetta Stone protein, there are n proteins with the first domain but not the second, and m proteins with the second domain but not the first. The percent of true positives T is therefore estimated as the smaller of n or m divided by n times m. As this error T can be calculated for each set of linked domains, it can describe the confidence in any particular predicted interaction.

In addition, the error in functional links can be caused by small conserved regions or repeated common amino acid sequences being repeatedly identified in a "Rosetta Stone" protein by a plurality of distinct non-homologous polypeptides. To reduce this error the percent of identity between the "Rosetta Stone" and the distinct non-homologous polypeptide can be measured. Alignment percentages of about 50% to about 90%, or, alternatively, about 75%, between the "Rosetta Stone" and the distinct polypeptide are indicative of links that are not subject to the small peptide sequence.

## Phylogenetic Pathway Method

The "phylogenetic profile" method compares protein sequences across all known genomes and analyzes the pattern of inheritance of each protein across the different organisms. In its simplest form, each protein is simply characterized by its presence or absence in each organism. For example, if there are 16 known genomes, then each protein may be assigned a 16-bit code or phylogenetic profile. Since proteins that function together

5

10

15

20

25

(e.g., in the same metabolic pathway or as part of a larger functional or structural complex) evolve in a correlated fashion, they should have the same or similar patterns of inheritance, and therefore similar phylogenetic profiles. Therefore, the function of one protein may be inferred from the function of another protein, which has a similar profile, if its function is inferred from the known. As with the Rosetta Stone method, the function of one protein is inferred from the function of another protein which is dissimilar in sequence. Furthermore, the predicted link function of another proteins has utility in developing, for example, drug targets, diagnostics and therapeutics.

The phylogenetic profile method can be implemented in a binary code (i.e., describing the presence or absence of a given protein in an organism) or a continuous code that describes how similar the related sequences are in the different genomes. In addition, grouping of similar protein profiles may be made wherein similar profiles are indicative of functionally related proteins. Furthermore, the requirements for similarity can be modified depending upon particular criteria by varying the difference in similar bit requirements. For example, criteria requiring that the degree of similarity in the profile include all 16 bits being identical can be set, but may be modified so that similarity in 15 bits of the 16 bits would indicate relatedness of the protein profiles as well. Statistical methods can be used to determine how similar two patterns must be in order to be related.

The phylogenetic profile method is applicable to any genome including, e.g., viral, bacterial, archaeal or eukaryotic. The method of phylogenetic profile grouping provides the prediction of function for a previously uncharacterized protein(s). The method also allows prediction of new functional roles for characterized proteins based upon functional linkages. It also provides potential informative connections (i.e., links) between uncharacterized proteins.

25

30

5

10

15

20

To represent the subset of organisms that contain a homolog a phylogenetic profile is constructed for each protein. The simplest manner to represent a protein's phylogenetic history is via a binary phylogenetic profile for each protein. This profile is a string with N entries, each one bit, where N corresponds to the number of genomes. The number of genomes can be any number of two or more (e.g., 2, 3, 4, 5, 10, 100, to 1000 or more). The presence of a homolog to a given protein in the nth genome is indicated with an entry of unity at the nth position (e.g., in a binary system an entry of 1). If no homolog is

found the entry is zero. Proteins are clustered according to the similarity of their phylogenetic profiles. Similar profiles show a correlated pattern of inheritance, and by implication, functional linkage. The method predicts that the functions of uncharacterized proteins are likely to be similar to characterized proteins within a cluster.

5

10

In order to decide whether a genome contains a protein related to another particular protein, the query amino acid sequence is aligned with each of the proteins from the genome(s) in question using known alignment algorithm (see above). To determine the statistical significance of any alignment score, the probability, p, of obtaining a higher score when the sequences are shuffled is described. One way to compute a p value threshold is to first consider the total number of sequence comparisons that are being aligned. If there are Nproteins in a first organism's genome and M in all other genomes this number is  $N \times M$ . If this number were compared to random sequences it would be expected that one pair would yield a p value of  $\frac{1}{NM}$ . This value can be set as a threshold. Other thresholds may be used and will be recognized by those of skill in the art.

15

A non-binary phylogenetic profile can be used. In this method, the phylogenetic profile is a string of N entries where the  $n^{th}$  entry represents the evolutionary distance of the query protein to the homolog in the  $n^{th}$  genome. To define an evolutionary distance between two sequences an alignment between two sequences is performed. Such alignments can be carried out by any number of algorithms known in the art (for examples, see those described above). The evolution is represented by a Markov process with substitution rates, over a fixed interval of time, given by a conditional probability matrix:

 $p(aa \rightarrow aa')$ 

25

20

where aa and aa' are any amino acids. One way to construct such a matrix is to convert the BLOSUM62 amino acid substitutions matrix (or any other amino acid substitution matrix, e.g., PAM100, PAM250) from a log odds matrix to a conditional probability (or transition) matrix:

$$P_B(i \to j) = p(j)2 \frac{\text{BLOSUM62}_{ij}}{2} \tag{1}$$

30

 $P(i \rightarrow j)$  is the probability that amino acid i will be replaced by amino acid j through point mutations according to the BLOSUM62 scores. The  $p_j$ 's are the abundances of amino

acid j and are computed by solving the 20 linear equations given by the normalization conditions that:

$$\sum_{i} P_{B}(i \to j) = 1 \qquad (2)$$

The probability of this process is computed to account for the observed alignment by taking the product of the conditional probabilities for each aligned pair:

$$P(p) = \prod_{n} p(aa_n \to aa'_n) \qquad (3)$$

A family of evolutionary models is then tested by taking powers of the conditional probability matrix:  $p'=p^{\alpha}(aa\rightarrow aa')$ . The power  $\alpha$  that maximized P is defined to be the evolutionary distance.

Many other schemes may be imagined to deduce the evolutionary distance between two sequences. For example, one might simply count the number of positions in the sequence where the two proteins have adapted different amino acids.

Although the phylogenetic history of an organism can be presented as a vector (as described above), the phylogenetic profiles need not be vectors, but may be represented by matrices. This matrix includes all the pair wise distances between a group of homologous protein, each one from a different organism. Similarly, phylogenetic profiles could be represented as evolutionary trees of homologous proteins. Functional proteins could then be clustered or grouped by matching similar trees, rather than vectors or matrices.

In order to predict function, different proteins are grouped or clustered according to the similarity of their phylogenetic profiles. Similar profiles indicate a correlated pattern of inheritance, and by implication, functional linkage.

Grouping or clustering may be accomplished in many ways. The simplest is to compute the Euclidean distance between two profiles. Another method is to compute a correlation coefficient to quantify the similarity between two profiles. All profiles within a specified distance of the query profile are considered to be a cluster or group.

Typically a genome database will be used as a source of sequence information. Where the genome database contains only the nucleic acid sequence that sequence is translated to an amino acid sequence in frame (if known) or in all frames if unknown. Direct comparison of the nucleic acid sequences of two or more organisms may be feasible but will likely be more difficult due to the degeneracy of the genetic code.

5

10

15

20

25

Programs capable of translating a nucleic acid sequence are known in the art or easily programmed by those of skill in the art to recognize a codon sequence for each amino acid.

The phylogenetic profile provides an indication of those proteins in each of the at least two organisms that share some degree of homology. Such a comparison can be done by any number of alignment algorithms known in the art or easily developed by one skilled in the art (see, for example, those listed above, e.g., BLAST, FASTA etc.) In addition, thresholds can be set regarding a required degree of homology. Each protein is then grouped at 224 with related proteins that share a similar phylogenetic profile using grouping algorithms.

# "Functionally-, Structurally- or Metabolically- Linked" Method

The "physiologic linkage" method is a computational method that detects (i.e., identifies) proteins, and the genes that encode them, that participate in a common functional pathway (e.g., cell motility or cell division), that participate in the synthesis of the same or a similar structural complex (e.g., a cell wall) or participate in the same or similar metabolic pathway (e.g., glycolysis, lipid synthesis, and the like). Proteins within these common functional pathway groups are examples of "functionally linked" proteins. Having a common functional "goal" they evolve in a correlated fashion. Thus, "homologs" in different organisms can be comparatively identified. While these detection methods are very effective in identifying functional homologues in the same subset of organisms, functional linkages can be made between widely genetically disparate organisms.

In one aspect, metabolic pathways are defined as links between proteins that operate in the same metabolic pathway that can be identified by sequence identity searching, e.g., by performing a BLAST search to find top-scoring polypeptides with high similarity (BLAST alignment E-value < 10<sup>-20</sup>) to polypeptides identified in a known pathway. For example, M. tuberculosis proteins were so analyzed against E. coli proteins; MTB proteins whose E. coli homologs (i.e., having high similarity by BLAST alignment) act adjacently in metabolic pathways as defined in the EcoCyc database (see, e.g., Karp (1998) Nucleic Acids Res. 26:50-53) were identified.

4.5

In another example, flagellar proteins are found in bacteria that possess flagella but not in other organisms. Accordingly, if two proteins have homologs in the same subset of fully sequenced organisms, they are likely to be functionally linked. The methods

5

10

15

20

25

of the invention use this concept to systematically map links between all the proteins coded by a genome.

Typically, functionally linked proteins have no amino acid sequence similarity with each other and, therefore, cannot be linked by conventional sequence alignment techniques. Accordingly, the methods of the invention identify drug targets that could not be identified using conventional sequence comparison (i.e., sequence homology or sequence identity) techniques.

Prediction of functionally linked proteins by the "phylogenetic method" can also be used in conjunction with the "domain fusion" or "Rosetta Stone" method and also can be filtered by other methods that predict functionally linked proteins, such as the protein phylogenetic profile method or the analysis of correlated mRNA expression patterns. It was found that filtering by these two methods for the Rosetta Stone prediction for S. cerevisiae, that proteins predicted to be functionally linked by two or more of these three methods were as likely to be functionally related as proteins that were observed to physically interact by experimental techniques like yeast 2-hybrid methods or co-immunoprecipitation methods.

For example, a combination of these methods of prediction can be used to establish links between proteins of closely related function. The methods of the invention (i.e., the "Rosetta Stone" method and the "phylogenetic profile" method) can be combined with one another or with other protein prediction methods known in the art; see, for example, Eisen (1998) "Cluster analysis and display of genome-wide expression partners," Proc. Natl. Acad. Sci. USA, 95:14863-14868.

The various techniques, methods, and variations thereof described can be implemented in part or in whole using computer-based systems and methods. Additionally, computer-based systems and methods can be used to augment or enhance the functionality described above, increase the speed at which the functions can be performed, and provide additional features and aspects as a part of or in addition to those of the invention described elsewhere in this document. Various computer-based systems, methods, and implementations in accordance with this technology are described herein.

# Proteins linked to current drug targets

The invention also provides a novel method for identifying a polypeptide, or the nucleic acid sequence that encodes it, that is a target for a drug. The method analyzes the

5

10

15

20

25

functional relationship between at least two sequences, wherein at least one of the sequences is a known target of a drug or encodes a polypeptide drug target. The method comprises identifying proteins, and the genes that encode them, that are functionally linked to the targets of known drugs. The functional linkage is determined by using the "domain fusion" method, the "phylogenetic profile" method or the "physiologic linkage" method, or a combination thereof, as described herein.

Thus, this aspect of the invention provides methods identifying drug targets from among all or a subset of genes in a genome using computationally-determined functional linkages. In one implementation of the method, functional linkages are calculated using the "domain fusion" method, the "phylogenetic profile" method or the "physiologic linkage" method, or a combination thereof, between all "query genome genes." Next, each set of genes predicted to be functionally linked to either a known drug target or to a sequence homolog or ortholog (defined below) to a known drug target are examined. These proteins (and the nucleic acids that encode them) are functionally linked to known drug targets; thus, they are operating in the same pathways or systems targeted by the known drug. Accordingly, the methods of the invention have identified them as drug targets.

This method is particularly effective for identifying drug targets in pathogens, such as microorganisms, e.g., bacteria, viruses and the like. This method allows for the identification of novel drug targets that cannot be identified by other techniques, such as traditional sequence homology or sequence identity comparison techniques. Several known drug targets in *M. tuberculosis* were used with the methods of the invention to use functional linkages to identify potential new drug targets in the same pathways as the known drug targets.

There are very few drugs that are effective for anti-tuberculosis therapy, since the complex lipid-rich mycobacterial cell wall is impermeable to many antibacterial agents. Additionally, single- and multi-drug resistance is rapidly emerging against these drugs. To address this issue, the methods of the invention were used to identify *Mycobacterium* address (MTB or TB) proteins that are functionally linked to the targets of known drugs. Inhibiting these proteins should have the same effect on the organism as the drug, since the same processes or pathways would be disrupted. Targeting multiple components of a given biochemical pathway would also diminish the opportunity for the development of resistance

5

10

15

20

25

because various related proteins would have to mutate against inhibitors while preserving the overall functionality of the pathway.

A list of targets of essential anti-TB drugs (World Health Organization, Geneva, Switzerland) was compiled. The anti-TB drugs included isoniazid, rifampicin, ethambutol, streptomycin, pyrazinamide and thiacetazone. Although not enough is known about the molecular basis of action of the latter two, the functional linkages of the known drug targets was examined.

Isoniazid. This is one of the most widely used of all anti-tuberculosis drugs. It is believed that the compound is activated by the catalase-peroxidase KatG. Once activated, it then attaches to a nicotinamide adenine dinucleotide bound to the enoyl-acyl carrier protein reductase InhA, resulting in the inhibition of mycolic acid biosynthesis Rozwarski (1998) Science 279:98-102.

Using the "phylogenetic profile, the inhA gene was "linked," or functionally associated with, to two polyketide synthases, pks1 and pks6 (Figure 1), both of which contain acyl carrier protein motifs. The polyketide synthase pks6 is in turn known from established metabolic pathways to be linked to fatty acid biosynthesis gene accD3. Further, pks6 is linked to fadD28 and to the operon containing the genes ppsA-E, all recently reported to be crucial for bacterial replication in host lungs (see, e.g., Cox (1999) Nature 402:79-83).

12.0

The inhA gene was also linked to an operon encoding two putative oxidoreductases and a gene of entirely unknown function. The inhA gene was further linked to a second operon that includes pepR and gpsI. PepR is a protease whose *Bacillus subtilis* homolog is adjacent to the genes coding for enzymes that synthesize diaminopimelate, a component of the cell wall incorporated by the murE gene product and diaminopicolinate (see, e.g., Chen (1993) J. Biol. Chem. 268:9448-9465). PepR is an ortholog of an essential yeast gene and is likely to be essential for MTB (see below). GpsI is a putative multifunctional enzyme involved in guanosine pentaphosphate synthesis and polyribonucleotide nucleotidyltransfer. The high reliability of the predicted functional link between gpsI and pepR and the absence of eukaryotic homologs suggests that gpsI could be a promising target for drug design.

Rifampicin. This compound, along with the related rifabutin and KRM-1648 are believed to act by directly targeting the RNA polymerase  $\beta$ -subunit (rpoB) given that

5

10

15

20

25

96% of resistant isolates were found to have mutations of various types in a limited region of the rpoB gene (see, e.g., Yang (1998) J. Antimicrob. Chemother. 42:621-628).

Using the methods of the invention, as expected, functional linkages were found to another RNA polymerase subunit, rpoC, as well as to various tRNA synthases and ribosomal proteins. However, no functional links to uncharacterized proteins were found.

Ethambutol. This drug is effective against tuberculosis when used in combination with isoniazid. It is believed that the drug interacts with the EmbB protein, a probable arabinosyl-transferase, inhibiting the biosynthesis of arabinan, a component of cell-envelope lipids. As with rifampicin, the evidence for this interaction is indirect, since mutations in the embB gene are responsible for ethambutol resistance (see, e.g., Lety (1997) Antimicrob. Agents Chemother. 41:2629-2633).

The "gene proximity" method correctly clusters embB with embA (Rv3794). This cluster is linked to a set of mostly uncharacterized genes by the "phylogenetic profile" method; see Figure 2, which shows an analysis of EmbB, the target for the anti-tuberculosis drug Ethambutol, and shows functional linkages to genes mostly of unknown function but with some indications of localization at the bacterial membrane.

Two of the uncharacterized genes, Rv1706c and Rv1800, belong to the abundant PE/PPE family of proteins hypothesized to be a source of antigenic variation with the potential ability to interfere with immune responses by inhibiting antigen processing (see, e.g., Cole (1998) Nature 393, 537-544). A third uncharacterized gene, Rv1967 belongs to the one of the four copies of the mce operon. This operon consists of eight genes coding for integral membrane proteins and proteins that have N-terminal signal sequences or hydrophobic segments and are believed to be involved in pathogenicity (see, e.g., Cole (1998) supra). Rv0528 codes for a hypothetical membrane protein and Rv2159c corresponds to the murF gene, which participates in the biosynthesis of peptidoglycan precursors.

.

The majority of the "links," or functionally associated sequences, involved proteins associated with processes related to the bacterial cell wall (with the possible exception of atsA and the putative choline dehydrogenase Rv1279, whose relationship to these processes is not immediately obvious). The proteins of unknown function are therefore also expected to play some role in these processes and are thus of interest as potential drug targets.

5

10

15

20

25

Streptomycin. This drug acts by binding to the 16S rRNA and inhibits protein synthesis. Resistance to this compound emerges from mutations in the corresponding gene (rrs), as well as in the gene encoding for the ribosomal protein S12 (rpsL). Disruptions to RpsL effect streptomycin resistance by altering the higher order structure of 16S rRNA (see, e.g., Sreevatsan (1996) Antimicrob. Agents Chemother. 40:1024-1026).

Although streptomycin doesn't directly target RpsL, the functional links generated for this protein was examined, as any target whose inhibition will ultimately disrupt bacterial protein synthesis is likely to be an effective antigrowth/ anti-microbial target. As with the rifampicin target, the only functional linkages found for this protein were the expected protein synthesis-related proteins, including large ribosomal subunit proteins L2, L5, L11, and L14; small ribosomal subunit proteins S4, S5, S7, S8, and S11; elongation factors fusA and Ef-Tu; the chaperones GroEL, clpB and ftsH; and the Clp protease subunits clpC and clpX.

# Proteins linked to cell-wall related proteins

The invention also provides a novel method for identifying a nucleic acid or a polypeptide sequence in an organism that is linked to a cell-wall related protein. The method analyzes the functional relationship between at least two sequences, wherein at least one of the sequences is a cell-wall related protein, or, the sequence is a nucleic acid sequence that encodes a cell-wall related protein. The method comprises identifying proteins, and the genes that encode them, that are functionally linked to a cell-wall related protein. The functional linkage is determined by using the "domain fusion" method, the "phylogenetic profile" method or the "physiologic linkage" method, or a combination thereof, as described herein.

Approximately eleven M. tuberculosis proteins are indicated by sequence homology to be penicillin-binding proteins, thought to synthesize peptidoglycan in the course of cell elongation and cell wall metabolism (see, e.g., Broome-Smith (1985) Eur. J. Biochem. 147:437-446). Using the methods of the invention, the functional linkages found for these proteins map out many of the known cell wall synthetic enzymes and reveal more than 10 proteins of unknown function that may also participate in cell wall metabolism. Figure 3 shows an analysis of five of the approximately eleven MTB proteins presumed to bind penicillin to reveal functional linkages to various potential operons consisting of genes

۲۰:

5

10

15

20

25

involved in various aspects of cell wall metabolism, including cell shape determination and peptidoglycan biosynthesis, as well more than ten genes of unknown function, which we can now associate with cell wall metabolism.

Three of the proteins (pbpA, pbpB, and ponA1) reside in conserved gene clusters, presumably operons. Other genes in the clusters around pbpA and pbpB are also implicated in cell wall metabolism. For example, pbpA resides next to rodA, a membrane-associated protein whose *E. coli* homolog determines cell shape and is required for enzymatic activity of penicillin binding proteins (see, e.g., Matsuzawa (1989) J. Bacteriol. 171:558-560). Likewise, pbpB resides next to six peptidoglycan biosynthesis genes and the two septum and cell wall formation proteins ftsW and ftsZ.

Two additional gene clusters were linked to these penicillin binding proteins by either the "phylogenetic profile" or "Rosetta Stone" pattern methods of the invention. One cluster is composed of the peptidoglycan synthetic protein murB and a putative membrane protein of unknown function that the functional linkages suggest is involved in cell wall metabolism. The second gene cluster contains four genes, three of which are predicted to reside in the cell membrane or envelope. Therefore, the uncharacterized genes in these clusters are likely to be involved in cell wall metabolism, closely related to the function of the penicillin binding proteins and are therefore promising drug targets.

Another gene linked to cell wall metabolism by the computationally-derived linkage methods of the invention is gcpE, see Figure 4, which shows that the uncharacterized gene gcpE, known to be essential for bacterial survival (see, e.g., Baker (1992) FEMS Microbiol. Lett. 73:175-180), is predicted to be involved in cell wall metabolism through its functional links to a putative membrane protein and two murein hydrolase genes, lytB1 and lytB2, involved in cell separation. The genes forming a putative operon with gcpE are proposed as potential drug targets. The functional linkages place gcpE in a conserved gene cluster with two genes of unknown function, one of which encodes a membrane protein. However, the three genes show correlated inheritance with two homologs of lytB, an *E. coli* gene involved in penicillin tolerance (see, e.g, Gustafson (1993) J. Bacteriol. 175:1203-1205) and recently shown to encode a murein hydrolase essential for cell separation (see, e.g., Garcia (1999) Mol. Microbiol. 31:1275-1277). The uncharacterized proteins from this

5

10

15

20

25

cluster are therefore expected to participate in processes similar to GcpE and might therefore be promising drug targets.

# Proteins linked to potentially novel pathways

The invention also provides a novel method for identifying a polypeptide, or a nucleic acid that encodes it, that is linked to potentially novel biochemical (e.g., biosynthetic, metabolic) pathways. The method analyzes the functional relationship between at least two sequences, wherein at least one of the sequences is associated with a biochemical pathway, such as a pathway in a microorganism that enables the pathogen to evade an immune process. The method comprises identifying proteins, and the genes that encode them, that are functionally linked to the pathway-linked sequences. The functional linkage is determined by using the "domain fusion" method, the "phylogenetic profile" method or the "physiologic linkage" method, or a combination thereof, as described herein.

For example, the htrA gene encodes for a putative heat shock protein homologous to HtrA from Salmonella typhimurium, a serine protease that degrades aberrant periplasmic proteins. Mutations in this protein have been linked with reduced viability in host macrophages (see, e.g., Johnson (1991) Mol. Microbiol. 5:401-407). Thus, it was decided to investigate the function of htrA. Using the methods of the invention, results indicated that the htrA protein is part of a process that has not yet been characterized. The gene is predicted with very high reliability to function with the uncharacterized gene Rv1224c, see Figure 5, which shows the involvement of htrA in a potentially novel pathway and the gene encoding the putative heat shock protein HtrA is functionally linked to a set of genes mostly of unknown function, suggesting the existence of a novel pathway. The partially characterized proteins suggest that the pathway relates to membrane-associated processes such as signaling and/or transport. The lack of eukaryotic homologs for most of the genes linked to htrA, suggests that proteins of this pathway could be promising drug targets.

Through its phylogenetic profile, htrA is linked to a group of uncharacterized proteins, including a putative lipid esterase (Rv1900c), an ABC transporter (Rv3783) and the uncharacterized protein Rv1216c, which has weak homology to the laminin B receptor of Xenopus laevis, suggesting that it might be a membrane protein. From this analysis, it can be concluded that htrA is part of a novel pathway that involves membrane-associated processes,

5

10

15

20

25

such as signaling and/or transport. Because the majority of the proteins linked to htrA have no eukaryotic homologs, and given the importance of htrA in S. typhimurium pathogenesis, this pathway represents another potential source of novel targets for anti-tuberculosis drugs.

# Proteins linked to essential proteins

5

10

15

20

25

30

The invention also provides a novel method for identifying a polypeptide, or the nucleic acid sequence that encodes it, that is linked to an essential protein (e.g., a protein necessary for the growth of an organism, such as a bacterium). The method analyzes the functional relationship between at least two sequences, wherein at least one of the sequences is linked to an essential protein, or, the sequence is a nucleic acid sequence that itself is essential or encodes a polypeptide linked to an essential protein. The functional linkage is determined by using the "domain fusion" method, the "phylogenetic profile" method or the "physiologic linkage" method, or a combination thereof, as described herein.

For example, the MIPS database (Munich Information Center for Protein Sequences; MIPS provides access through its WWW server to a spectrum of generic databases, including PEDANT, MYGD, MATD, MEST, the PIR-International Protein Sequence Database, the protein family database PROTFAM, the MITOP database, and the all-against-all FASTA database; see, e.g., Mewes (1999) Nucleic Acids Res. 27:44-48) contains a list of 734 genes that are essential for Saccharomyces cerevisiae viability (see, e.g., Mewes (1999) supra). A list of Mycobacterium tuberculosis genes orthologous to these essential genes was generated. Using the methods of the invention, 60 such genes were found. The products of these genes have a high likelihood of also being essential to the tuberculosis bacterium and therefore could be promising therapeutic targets. Furthermore, since the list of essential genes came from a eukaryote, there is a significant chance that these genes would also be found in the human genome.

Automatic Method to Identify Drug Targets from Functional Linkages

One aspect of the invention provides a computational method to identify potential drug targets among the proteins expressed by a genome. This aspect takes advantage of the functional linkages calculated between genes in a genome using the methods described herein, as well as the detection of sequence homology and the knowledge of a set of lethal or "essential" genes in one or more organisms.

To identify drug targets in a query genome, the sequence homology between all of the genes in that genome and all of the genes in the genome of an organism for which essential genes are known is calculated. For example, as discussed herein, the query genome is Mycobacterium tuberculosis (TB) and the genome with known essentials is the yeast S. cerevisiae. Sequence homology between all TB genes and all yeast genes was calculated using the methods of the invention.

"Equivalent" or "orthologous" genes were also identified by another aspect of the invention that comprises doing a reverse sequence search (e.g., yeast vs. TB) and then choosing pairs of genes that are the symmetric best-scoring sequence search. In one exemplary aspect, MTB orthologs of Saccharomyces cerevisiae genes were generated by finding all pairs of genes (TB<sub>i</sub>,SC<sub>j</sub>) where TB<sub>i</sub> was the top hit from a BLAST search of the yeast gene SC<sub>j</sub> against the MTB genome, SC<sub>j</sub> was the top hit from a BLAST search of the MTB gene TB<sub>i</sub> against the Saccharomyces cerevisiae genome and both top hits had a BLAST E-value  $\leq 1 \times 10^{-5}$ .

For example, a TB gene is an ortholog of a yeast gene if the yeast gene is the best scoring sequence match when yeast is searched with the TB gene, and the TB gene is the best scoring sequence match when TB is searched with the yeast gene. We define these "symmetric" pairs as "orthologs."

After identifying orthologs between the query genome and the genome with known essential genes, a set of query genome genes that are orthologs of known essential genes in the other genome was chosen. These genes were designated the set of "putative essentials". For the purposes of the algorithm of the invention, these query genome genes are assumed to be essential genes, since they are the equivalents of essential genes in another genome. These genes act as "markers" or indicators of essential pathways in the query genome. One could supplement this set with genes already known to be essential in the query organism. Functional linkages (determined by the methods of the invention) between all query genome genes were examined. The query genome genes linked to all of the putative essential genes were examined. This set of genes was designated as the "predicted members of essential pathways." These genes are likely to be involved in important pathways, since the (predicted) pathways have members that are putative essentials. Lastly, the method removes from the set of genes in predicted essential pathways all of those genes

5

10

15

20

25

that have sequence homology to eukaryotic genes or proteins. The genes that remain after this filtering step are the predicted drug targets for the query organism.

As a benchmark, this method was applied to the *M. tuberculosis* genome. Of the over 3900 genes in TB, 11 were identified as potential drug targets. Comparing this list of 11 predicted targets to the less than 10 known drug anti-TB drug targets, one gene was a known drug target and one was linked to a known drug target. Accordingly, the algorithm of the invention performed statistically significantly much better than a random choice of genes. A rough estimate of statistical significance suggests that one would expect to see 2 of 10 known drug targets in a sample of 11 out of 3900 genes only 3.8 times out of 10,000 trials (probability of occurring by random chance of 3.8 x 10<sup>-4</sup>). Therefore, this embodiment of the method is an entirely computational algorithm drawing on the demonstrated ability of the general methods of the invention to predict functional linkages between genes and to effectively identify drug targets in bacteria. The effectiveness of this method to identify novel drug targets was clearly demonstrated when the algorithm was applied to the *M. tuberculosis* genome.

The specific inhibition of the MTB homologs might be difficult. To address this issue, using the methods of the invention, functional links to the essential genes were searched. Functional links were selected which either do not have homologs in yeast, or the enzymatic activity of their products are known to be absent in human cells. Using the highest confidence data, functional links for 23 of the genes (indicated in **bold** in Table 1) were found.

5

10

15

Table 1. MTB orthologs of essential yeast proteins.

penA polynderediae Polynia	Rv3907c po	probable helicase. Ski2 subfamily	one hely	KVIYOT
		ribonucleotide reductase small subunit		Rv1844c
		similar to Q46822 ORF_O182	<u> </u>	Rv1745c
fole GTP cyclohydrolase I	Ry3608c fo	30S ribosomal protein SI	30 rpsA	Rv1630
		ribollavin blos) initoris		Rv1409
	Rv3490 otsA	similar to Fmu protein		Rv1407
		putative guanyliste kinase	99 gmk	Rv1389
	<u> </u>	acetyl-CoA C-acetyltransierase (aka uiic)	3   fadA4	Rv1323
nA mannose-6-phosphate isomerase	<u>c</u> _	homoserine dehydrogenase	4 thrA	Rv1294
_		probable magnesium and cobalt transport protein	<u> </u>	Rv1239c
	Ry3080c pknK	similar to MRP/NBP35 ATP-binding proteins	9c mrp	Rv1229c
			<u>ह</u>	Rv1106c
A DNA ligase	<u> </u>	16S rRNA dimethyllransterase	)   ksgA	Rv1010
	Rv2925c rnc		<u>-</u>	Rv0861c
	<del></del>	possible lanosterol 14-demethylase cytochronic	<u> </u>	Rv0764c
		[[beta] subunit of RNA polymerase	rpoC	Rv0668
	<del></del>	[beta] subunit of RNA polymerase		Rv0667
	<u>:-</u> -	pyrroline-5-carhoxylate reductase	proC	Rv0500
	<u> </u>	sensor histidine kinase	senX3	Rv0490
	<u>:-</u> -	phosphoglycerate mutase t	gpm	Rv0489
alanyl-tRNA synthase	Rv2555c alas	60 kD chaperonin 2	groEL2	Rv0440
	Rv2524c fas	CDP-diacyiglycerol-serine o-phosphanes		Rv0436c
putative oxidoreductase			1	Rv0435c
	_	Colase	fba	Rv0363c
	439c proB		dnaK	Rv0350
similar to YHN4_YEAST P387	138c -	C-terminal similar to b. suctins become replication	biof2	Rv0032
		scrine-threoning protein kinase	pknB	Rv0014c
	<u>.                                    </u>		gyrB	Rv0005
probable helicase, Snf2/Rad54 family			Gene	Name.
	me Gene	Comments		

We follow the Sanger Centre naming convention for MTB genes.

<sup>\*</sup> Genes for which high-confidence functional links were found shown in boldface

Eight of these were linked to 12 unique MTB genes that satisfied the criteria of the invention's methods (Table 1). Exemplary findings include:

- (1) the gene folP, which encodes the enzyme dihydropteroate synthase (DHPS) known to be the target of sulfonamide antibacterial drugs. Although it is found in some eukaryotes, DHPS activity is not found in human cells (see, e.g., Huovinen (1995) Antimicrob. Agents Chemother. 39:279-2890.
- (2) the product of the gene folk, a 7,8-dihydro-6-hydroxymethyl-pterinpyrophosphokinase, has recently been proposed as a target for broad-spectrum antibacterial drugs (see, e.g., Stammers (1999) FEBS Lett. 456:49-53).
- 10 (3) the gene gpsI, is not only strongly linked to the essential yeast gene pepR, but it is also functionally linked to inhA, the target of the drug isoniazid (see above), making it a very compelling candidate for drug design.

Table 2. Subset of genes from Table 1 that are functionally linked to genes without yeast homologs.

C	Link <sup>†</sup>		Comments
Gene		dnaN	DNA polymerase III, β-subunit
Rv0005		recF	DNA replication and SOS induction
	KVUUUU		DNA gyrase subunit A
		grpE	stimulates DnaK ATPase activity
Rv0350	RV0351 RV0352	dnaJ	acts with GrpE to stimulate DnaK ATPase
	RV1008		Ginilare F coli hypothetical protein YCIH
1	RV1008		Possible lipoprotein, similar to various other MID proteins
	Rv1009		Similar to E.coli hypothetical protein YcbH
	RV2427c	proA	γ-glutamyl phosphate reductase
Rv2439c	Rv24276	obg	Obg GTP-binding protein
	RV2440C	rpmA	50S ribosomal protein L27
	Rv2441C	rplU	sos -ibosomal protein L21
- 0200-	RV2442C	gpsI	and polyribonucleotide phosphorylase
RV2/820	RV3600c	Igpu-	rimiler to Racillus subtilis hypothetical protein Yaco
	Rv3606c	folK	7.8-dihydro-6-hydroxymethylpterin pyrophosphokinase
Rv35980	1	folX	may be involved in folate biosynthesis
	Rv3608c	1	m t toursts methase (DHPS)
	Rv3610c		have protein chaperone
	Rv3598c		hand +DMA cynthase
Rv3608	Rv3600c	1 -	similar to Racillus subtilis hypothetical protein Yach
	Rv36060		7.8-dihydro-6-hydroxymethylpterin pyrophosphokmase
	Rv36070	,	folgte higsynthesis
	Rv36090	·  -	GTP cyclohydrolase l
	R√3610¢	, I	the manufacture protein, chaperone
	Rv36066		7.8-dihydro-6-hydroxymethylpterin pyrophosphokmase
B#360	9c Rv3607	_	way be involved in folate biosynthesis
1,000	Rv3608		to anthase (DHPS)

<sup>†</sup> Genes without yeast homologs shown in boldface

In summary, the methods of the invention allowed identification of this combination of functional linkages to essential genes. This information, together with the lack of eukaryotic homologs for these genes, makes this group of proteins promising drug targets, particularly because their inhibition is expected to disrupt vital bacterial processes with a low likelihood of toxicity from the inhibition of a host equivalent.

<sup>&</sup>lt;sup>‡</sup> DHPS activity is found in some eukaryotic cells but not in human cells

# Computer Implementation

The various techniques, methods, and aspects of the invention described herein can be implemented in part or in whole using computer-based systems and methods. Additionally, computer-based systems and methods can be used to augment or enhance the functionalities and algorithms described herein, increase the speed at which the functions can be performed, and provide additional features and aspects as a part of or in addition to those of the invention described elsewhere in this document. Various exemplary computer-based systems, methods and implementations in accordance with the above-described technology are presented herein.

10

15

5

The processor-based system can include a main memory, such as a random access memory (RAM), and can also include a secondary memory. The secondary memory can include, for example, a hard disk drive and/or a removable storage drive, representing a floppy disk drive, a magnetic tape drive, an optical disk drive, etc. The removable storage drive reads from and/or writes to a removable storage medium. Removable storage media can be a floppy disk magnetic tape, an optical disk, and the like, which can be read by and written to by removable storage drive. The removable storage media can includes a computer usable storage medium having stored therein computer software and/or data.

In alternative embodiments, secondary memory may include other similar means for allowing computer programs or other instructions to be loaded into a computer system. Such means can include, for example, a removable storage unit and an interface. Examples of such can include a program cartridge and cartridge interface (such as the found in video game devices), a movable memory chip (such as an EPROM, or PROM) and associated socket, and other removable storage units and interfaces that allow software and data to be transferred from the removable storage unit to the computer system.

25

30

20

The computer system can also include a communications interface. Communications interfaces allow software and data to be transferred between computer system and external devices. Examples of communications interfaces include modems, network interfaces (such as, for example, an Ethernet card), communications ports, PCMCIA slots and cards, and the like. Software and data transferred via a communications interface can be in the form of signals that can be electronic, electromagnetic, optical or other signals capable of being received by a communications interface. These signals can be provided to

communications interface via a channel capable of carrying signals and can be implemented using a wireless medium, wire or cable, fiber optics or other communications medium. Some examples of a channel can include a phone line, a cellular phone link, an RF link, a network interface, and other communications channels.

As used herein, the terms "computer program medium" and "computer usable medium" are used to generally refer to media such as a removable storage device, a disk capable of installation in a disk drive, and signals on a channel, or equivalents thereof. These computer program products are means for providing software or program instructions to computer systems. Computer programs (also called computer control logic) can be stored in main memory and/or secondary memory. Computer programs can also be received via a communications interface. Such computer programs, when executed, enable the computer system to perform the features of the present invention as discussed herein. Computer programs, when executed, enable the processor to perform the features of the present invention. Accordingly, in one aspect of the invention, such computer programs represent controllers of the computer system.

In another aspect of the invention the methods and algorithms are implemented using software, the software may be stored in, or transmitted via, a computer program product and loaded into a computer system using a removable storage drive, hard drive or communications interface. The control logic (software), when executed by the processor, causes the processor to perform the functions of the invention as described herein.

In another aspect, the elements are implemented primarily in hardware using, for example, hardware components such as PALs, application specific integrated circuits (ASICs) or other hardware components. Implementation of a hardware state machine so as to perform the functions described herein will be apparent to person skilled in the relevant art(s). In yet another embodiment, elements are implanted using a combination of both hardware and software.

In another aspect, the computer-based methods can be accessed or implemented over the World Wide Web by providing access via a Web Page to the methods of the present invention. Accordingly, the Web Page is identified by a Universal Resource Locator (URL). The URL denotes both the server machine, and the particular file or page on that machine. In this embodiment, it is envisioned that a consumer or client computer system

5

10

15

20

25

interacts with a browser to select a particular URL, which in turn causes the browser to send a request for that URL or page to the server identified in the URL. Typically the server responds to the request by retrieving the requested page, and transmitting the data for that page back to the requesting client computer system (the client/server interaction is typically performed in accordance with the hypertext transport protocol ("HTTP")). The selected page is then displayed to the user on the client's display screen. The client may then cause the server containing a computer program of the present invention to launch an application comprising a method of the invention, for example, to identify a nucleic acid or a polypeptide sequence that may be a target for a drug comprising the steps of (a) providing a first nucleic acid or a polypeptide sequence that is known to be a drug target; (b) providing an algorithm capable analyzing a functional relationship between nucleic acid or polypeptide sequences selected from the group consisting of a "domain fusion" method, a "phylogenetic profile" method and a "physiologic linkage" method; and, (c) comparing the first nucleic acid or the polypeptide drug target sequence to a plurality of sequences using at least one algorithm to identify a second sequence that has a functional relationship to the first sequence, thereby identifying a nucleic acid or a polypeptide sequence that may be a target for a drug, based on a query sequence provided by the client.

# **Nucleic Acids and Polypeptides**

The invention also provides isolated nucleic acids and polypeptides comprising the sequences as set forth in Table 3 and Table 4 (below). As used herein, "isolated," when referring to a molecule or composition, such as, e.g., an isolated infected cell comprising a nucleic acid sequence derived from a library of the invention, means that the molecule or composition (including, e.g., a cell) is separated from at least one other compound, such as a protein, DNA, RNA, or other contaminants with which it is associated in vivo or in its naturally occurring state. Thus, a nucleic acid or polypeptide or peptide sequence is considered isolated when it has been isolated from any other component with which it is naturally associated. An isolated composition can, however, also be substantially pure. An isolated composition can be in a homogeneous state. It can be in a dry or an aqueous solution. Purity and homogeneity can be determined, e.g., using any analytical chemistry technique, as described herein.

5

10

15

20

25

The term "nucleic acid" or "nucleic acid sequence" refers to a deoxyribonucleotide or ribonucleotide oligonucleotide, including single- or double-stranded, or coding or non-coding (e.g., "antisense") forms. The term encompasses nucleic acids, i.e., oligonucleotides, containing known analogues of natural nucleotides. The term also encompasses nucleic-acid-like structures with synthetic backbones, see e.g., Oligonucleotides and Analogues, a Practical Approach, ed. F. Eckstein, Oxford Univ. Press (1991); Antisense Strategies, Annals of the N.Y. Academy of Sciences, Vol 600, Eds. Baserga et al. (NYAS 1992); Milligan (1993) J. Med. Chem. 36:1923-1937; Antisense Research and Applications (1993, CRC Press), WO 97/03211; WO 96/39154; Mata (1997) Toxicol. Appl. Pharmacol. 144:189-197; Strauss-Soukup (1997) Biochemistry 36:8692-8698; Samstag (1996) Antisense Nucleic Acid Drug Dev 6:153-156. As used herein, the "sequence" of a nucleic acid or gene refers to the order of nucleotides in the polynucleotide, including either or both strands (sense and antisense) of a double-stranded DNA molecule, e.g., the sequence of both the coding strand and its complement, or of a single-stranded nucleic acid molecule (sense or antisense). For example, in alternative embodiments, promoters drive the transcription of sense and/or antisense polynucleotide sequences of the invention, as exemplified by Table 3.

The terms "polypeptide," "protein," and "peptide" include compositions of the invention that also include "analogs," or "conservative variants" and "mimetics" ("peptidomimetics") with structures and activity that substantially correspond to the exemplary sequences, such as the sequences in Table 4. Thus, the terms "conservative variant" or "analog" or "mimetic" also refer to a polypeptide or peptide which has a modified amino acid sequence, such that the change(s) do not substantially alter the polypeptide's (the conservative variant's) structure and/or activity (e.g., immunogenicity, ability to bind to human antibodies, etc.), as defined herein. These include conservatively modified variations of an amino acid sequence, i.e., amino acid substitutions, additions or deletions of those residues that are not critical for protein activity, or substitution of amino acids with residues having similar properties (e.g., acidic, basic, positively or negatively charged, polar or non-polar, etc.) such that the substitutions of even critical amino acids does not substantially alter structure and/or activity. Conservative substitution tables providing functionally similar amino acids are well known in the art. For example, one exemplary guideline to select conservative substitutions includes (original residue followed by exemplary substitution):

5

10

15

20

25

ala/gly or ser; arg/ lys; asn/ gln or his; asp/glu; cys/ser; gln/asn; gly/asp; gly/ala or pro; his/asn or gln; ile/leu or val; leu/ile or val; lys/arg or gln or glu; met/leu or tyr or ile; phe/met or leu or tyr; ser/thr; thr/ser; trp/tyr; tyr/trp or phe; val/ile or leu. An alternative exemplary guideline uses the following six groups, each containing amino acids that are conservative substitutions for one another: 1) Alanine (A), Serine (S), Threonine (T); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5)
Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); (see also, e.g., Creighton (1984) Proteins, W.H. Freeman and Company; Schulz and Schimer (1979) Principles of Protein Structure, Springer-Verlag). One of skill in the art will appreciate that the above-identified substitutions are not the only possible conservative substitutions. For example, for some purposes, one may regard all charged amino acids as conservative substitutions for each other whether they are positive or negative. In addition, individual substitutions, deletions or additions that alter, add or delete a single amino acid or a small percentage of amino acids in an encoded sequence can also be considered "conservatively modified variations."

The terms "mimetic" and "peptidomimetic" refer to a synthetic chemical compound that has substantially the same structural and/or functional characteristics of the polypeptides of the invention (e.g., ability to bind, or "capture," human antibodies in an ELISA). The mimetic can be either entirely composed of synthetic, non-natural analogues of amino acids, or, is a chimeric molecule of partly natural peptide amino acids and partly nonnatural analogs of amino acids. The mimetic can also incorporate any amount of natural amino acid conservative substitutions as long as such substitutions also do not substantially alter the mimetics' structure and/or activity. As with polypeptides of the invention which are conservative variants, routine experimentation will determine whether a mimetic is within the scope of the invention, i.e., that its structure and/or function is not substantially altered. Polypeptide mimetic compositions can contain any combination of non-natural structural components, which are typically from three structural groups: a) residue linkage groups other than the natural amide bond ("peptide bond") linkages; b) non-natural residues in place of naturally occurring amino acid residues; or c) residues which induce secondary structural mimicry, i.e., to induce or stabilize a secondary structure, e.g., a beta turn, gamma turn, beta sheet, alpha helix conformation, and the like. A polypeptide can be characterized as a

5

10

15

20

25

mimetic when all or some of its residues are joined by chemical means other than natural peptide bonds. Individual peptidomimetic residues can be joined by peptide bonds, other chemical bonds or coupling means, such as, e.g., glutaraldehyde, N-hydroxysuccinimide esters, bifunctional maleimides, N,N'-dicyclohexylcarbodiimide (DCC) or N,N'-diisopropylcarbodiimide (DIC). Linking groups that can be an alternative to the traditional amide bond ("peptide bond") linkages include, e.g., ketomethylene (e.g., -C(=O)-CH<sub>2</sub>- for -C(=O)-NH-), aminomethylene (CH<sub>2</sub>-NH), ethylene, olefin (CH=CH), ether (CH<sub>2</sub>-O), thiozole, retroamide, thioamide, or ester (see, e.g.,

Spatola (1983) in Chemistry and Biochemistry of Amino Acids, Peptides and Proteins, Vol. 7, pp 267-357, "Peptide Backbone Modifications," Marcell Dekker, NY). A polypeptide can also be characterized as a mimetic by containing all or some non-natural residues in place of naturally occurring amino acid residues; non-natural residues are well described in the scientific and patent literature.

The invention comprises nucleic acids comprising sequences as set forth in Table 3, or comprising nucleic acids encoding the polypeptides as set forth in Table 4, operably linked to a transcriptional regulatory sequence. As used herein, the term "operably linked," refers to a functional relationship between two or more nucleic acid (e.g., DNA) segments. Typically, it refers to the functional relationship of a transcriptional regulatory sequence to a transcribed sequence. For example, a promoter (defined below) is operably linked to a coding sequence, such as a nucleic acid of the invention, if it stimulates or modulates the transcription of the coding sequence in an appropriate host cell or other expression system. Generally, promoter transcriptional regulatory sequences that are operably linked to a transcribed sequence are physically contiguous to the transcribed sequence, i.e., they are cis-acting. However, some transcriptional regulatory sequences, such as enhancers, need not be physically contiguous or located in close proximity to the coding sequences whose transcription they enhance. For example, in one embodiment, a promoter is operably linked to an ORF-containing nucleic acid sequence of the invention, as exemplified by, e.g., a nucleic acid sequence as set forth in Table 3.

As used herein, the term "promoter" includes all sequences capable of driving transcription of a coding sequence in an expression system. Thus, promoters used in the constructs of the invention include *cis*-acting transcriptional control elements and regulatory

5

10

15

20

25

sequences that are involved in regulating or modulating the timing and/or rate of transcription of a nucleic acid of the invention. For example, a promoter can be a cis-acting transcriptional control element, including an enhancer, a promoter, a transcription terminator, an origin of replication, a chromosomal integration sequence, 5' and 3' untranslated regions, or an intronic sequence, which are involved in transcriptional regulation. These cis-acting sequences typically interact with proteins or other biomolecules to carry out (turn on/off, regulate, modulate, etc.) transcription.

The invention comprises expression cassettes comprising nucleic acids comprising sequences as set forth in Table 3, or comprising nucleic acids encoding the polypeptides as set forth in Table 4. The term "expression vector" refers to any recombinant expression system for the purpose of expressing a nucleic acid sequence of the invention in vitro or in vivo, constitutively or inducibly, in any cell, including prokaryotic, yeast, fungal, plant, insect or mammalian cell. The term includes linear or circular expression systems. The term includes expression systems that remain episomal or integrate into the host cell genome. The expression systems can have the ability to self-replicate or not, i.e., drive only transient expression in a cell. The term includes recombinant "expression cassettes" which contain only the minimum elements needed for transcription of the recombinant nucleic acid.

Alignment Analysis of Sequences

The nucleic acid and polypeptide sequences of the invention include genes and gene products identified and characterized by sequence identify analysis (i.e., by homology) using the exemplary nucleic acid and protein sequences of the invention, including, e.g., those set forth in Tables 3 and 4. In alternative aspects of the invention, nucleic acids and polypeptides within the scope of the invention include those having 98%, 95%, 90%, 85% or 80% sequence identity (homology) to the exemplary sequences as set forth in Tables 3 and 4.

For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters are used unless alternative parameters are designated herein. The sequence comparison algorithm then calculates the percent sequence identity for the test

5

10

15

20

25

sequence(s) relative to the reference sequence, based on the designated or default program parameters. A "comparison window", as used herein, includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of from 25 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Natl. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (CLUSTAL, GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection.

15

20

25

30

5

10

In one aspect of the invention (in the methods of the invention, and, to determine if a sequence is within the scope of the invention), a CLUSTAL algorithm is used, e.g., the CLUSTAL W program, see, e.g., Thompson (1994) Nuc. Acids Res. 22:4673-4680; Higgins (1996) Methods Enzymol 266:383-402. Variations can also be used, such as CLUSTAL X, see Jeanmougin (1998) Trends Biochem Sci 23:403-405; Thompson (1997) Nucleic Acids Res 25:4876-4882. In one aspect, the CLUSTAL W program described by Thompson (1994) supra, is used with the following parameters: K tuple (word) size: 1, window size: 5, scoring method: percentage, number of top diagonals: 5, gap penalty: 3, to determine whether a nucleic acid has sufficient sequence identity to an exemplary sequence to be with the scope of the invention. In another aspect, the algorithm PILEUP is used in the methods and to determine whether a nucleic acid has sufficient sequence identity to be with the scope of the invention. This program creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments to show relationship and percent sequence identity. It also plots a tree or dendogram showing the clustering relationships used to create the alignment. PILEUP uses a simplification of the progressive alignment method of Feng & Doolittle, J. Mol. Evol. 35:351-360 (1987). The method used is similar to the method described by Higgins & Sharp, CABIOS 5:151-153 (1989). Using PILEUP, a

reference sequence (e.g., an exemplary GCA-associated sequence of the invention) is compared to another sequence to determine the percent sequence identity relationship (i.e., that the second sequence is substantially identical and within the scope of the invention) using the following parameters: default gap weight (3.00), default gap length weight (0.10), and weighted end gaps. In one embodiment, PILEUP obtained from the GCG sequence analysis software package, e.g., version 7.0 (Devereaux(1984) Nuc. Acids Res. 12:387-395), using the parameters described therein, is used in the methods and to identify nucleic acids within the scope of the invention. In a another aspect, a BLAST algorithm is used (in the methods, e.g., to determine percent sequence identity (i.e., substantial similarity or identity) and whether a nucleic acid is within the scope of the invention), see, e.g., Altschul (1990) J. Mol. Biol. 215:403-410. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information, NIH. This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul (1990) supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues, always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. In one embodiment, to determine if a nucleic acid sequence is within the scope of the invention, the BLASTN program (for nucleotide sequences) is used incorporating as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=4, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as default parameters a wordlength (W) of 3, an expectation (E) of 10, and the

, - a

5

10

15

20

25

BLOSUM62 scoring matrix (see, e.g., Henikoff (1989) Proc. Natl. Acad. Sci. USA 89:10915).

Hybridization for Identifying Nucleic Acids of the Invention

Nucleic acids within the scope of the invention include isolated or recombinant nucleic acids that specifically hybridize under stringent hybridization conditions to an exemplary nucleic acid of the invention (including a sequence encoding an exemplary polypeptide) as set forth in Tables 3 and 4. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in, e.g., Tijssen (1993) infra. Generally, stringent conditions are selected to be about 5 to 10°C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength, pH, and nucleic acid concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at Tm, 50% of the probes are occupied at equilibrium). Stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., 10 to 50 nucleotides) and at least about 60°C for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide.

For selective or specific hybridization, a positive signal (e.g., identification of a nucleic acid of the invention) is about 10 times background hybridization. "Stringent" hybridization conditions that are used to identify substantially identical nucleic acids within the scope of the invention include hybridization in a buffer comprising 50% formamide, 5x SSC, and 1% SDS at 42°C, or hybridization in a buffer comprising 5x SSC and 1% SDS at 65°C, both with a wash of 0.2x SSC and 0.1% SDS at 65°C. Exemplary "moderately stringent hybridization conditions" include a hybridization in a buffer of 40% formamide, 1 M NaCl, and 1% SDS at 37°C, and a wash in 1X SSC at 45°C. Those of ordinary skill will readily recognize that alternative but comparable hybridization and wash conditions can be utilized to provide conditions of similar stringency. Nucleic acids which do not hybridize to each other under stringent hybridization conditions are still substantially identical if the

5

10

15

20

25

polypeptides which they encode are substantially identical. This may occur, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code, as discussed herein (see discussion on "conservative substitutions"). However, the selection of a hybridization format is not critical - it is the stringency of the wash conditions that set forth the conditions that determine whether a nucleic acid is within the scope of the invention. Wash conditions used to identify nucleic acids within the scope of the invention include, e.g.: a salt concentration of about 0.02 molar at pH 7 and a temperature of at least about 50°C or about 55°C to about 60°C; or, a salt concentration of about 0.15 M NaCl at 72°C for about 15 minutes; or, a salt concentration of about 0.2X SSC at a temperature of at least about 50°C or about 55°C to about 60°C for about 15 to about 20 minutes; or, the hybridization complex is washed twice with a solution with a salt concentration of about 2X SSC containing 0.1% SDS at room temperature for 15 minutes and then washed twice by 0.1X SSC containing 0.1% SDS at 68°C for 15 minutes; or, equivalent conditions. See Sambrook, Tijssen and Ausubel (see below) for a description of SSC buffer and equivalent conditions.

## General Techniques

é

5

10

15

20

25

30

The nucleic acid and polypeptide sequences of the invention and other nucleic acids used to practice this invention, whether RNA, cDNA, genomic DNA, vectors, viruses or hybrids thereof, may be isolated from a variety of sources, genetically engineered, amplified, and/or expressed recombinantly. Any recombinant expression system can be used, including, in addition to bacterial cells, e.g., mammalian, yeast, insect or plant cell expression systems.

Alternatively, these nucleic acids and polypeptides can be synthesized in vitro by well-known chemical synthesis techniques, as described in, e.g., Carruthers (1982) Cold Spring Harbor Symp. Quant. Biol. 47:411-418; Adams (1983) J. Am. Chem. Soc. 105:661; Belousov (1997) Nucleic Acids Res. 25:3440-3444; Frenkel (1995) Free Radic. Biol. Med. 19:373-380; Blommers (1994) Biochemistry 33:7886-7896; Narang (1979) Meth. Enzymol. 68:90; Brown (1979) Meth. Enzymol. 68:109; Beaucage (1981) Tetra. Lett. 22:1859; U.S. Patent No. 4,458,066.

Techniques for the manipulation of nucleic acids, such as, e.g., generating mutations in sequences, subcloning, labeling probes, sequencing, hybridization and the like

are well described in the scientific and patent literature, see, e.g., Sambrook, ed., Molecular Cloning: a Laboratory Manual (2nd ed.), Vols. 1-3, Cold Spring Harbor Laboratory, (1989); Current Protocols in Molecular Biology, Ausubel, ed. John Wiley & Sons, Inc., New York (1997); Laboratory Techniques in Biochemistry and Molecular Biology: Hybridization With Nucleic Acid Probes, Part I. Theory and Nucleic Acid Preparation, Tijssen, ed. Elsevier, N.Y. (1993).

Polypeptides and peptides of the invention can also be synthesized, whole or in part, using chemical methods well known in the art. See e.g., Caruthers (1980) Nucleic Acids Res. Symp. Ser. 215-223; Horn (1980) Nucleic Acids Res. Symp. Ser. 225-232; Banga, A.K., Therapeutic Peptides and Proteins, Formulation, Processing and Delivery Systems (1995) Technomic Publishing Co., Lancaster, PA. For example, peptide synthesis can be performed using various solid-phase techniques (see e.g., Roberge (1995) Science 269:202; Merrifield (1997) Methods Enzymol. 289:3-13) and automated synthesis may be achieved, e.g., using the ABI 431A Peptide Synthesizer (Perkin Elmer) in accordance with the instructions provided by the manufacturer.

The skilled artisan will recognize that individual synthetic residues and polypeptides incorporating mimetics can be synthesized using a variety of procedures and methodologies, which are well described in the scientific and patent literature, e.g., Organic Syntheses Collective Volumes, Gilman, et al. (Eds) John Wiley & Sons, Inc., NY. Polypeptides incorporating mimetics can also be made using solid phase synthetic procedures, as described, e.g., by Di Marchi, et al., U.S. Pat. No. 5,422,426. Peptides and peptide mimetics of the invention can also be synthesized using combinatorial methodologies. Various techniques for generation of peptide and peptidomimetic libraries are well known, and include, e.g., multipin, tea bag, and split-couple-mix techniques; see, e.g., al-Obeidi (1998) Mol. Biotechnol. 9:205-223; Hruby (1997) Curr. Opin. Chem. Biol. 1:114-119; Ostergaard (1997) Mol. Divers. 3:17-27; Ostresh (1996) Methods Enzymol. 267:220-234. Modified peptides of the invention can be further produced by chemical modification methods, see, e.g., Belousov (1997) Nucleic Acids Res. 25:3440-3444; Frenkel (1995) Free Radic. Biol. Med. 19:373-380; Blommers (1994) Biochemistry 33:7886-7896.

Peptides and polypeptides of the invention can also be synthesized and expressed as fusion proteins with one or more additional domains linked thereto for, e.g.,

5

10

15

20

25

producing a more immunogenic peptide, to more readily isolate a recombinantly synthesized peptide, to identify and isolate antibodies and antibody-expressing B cells, and the like. Detection and purification facilitating domains include, e.g., metal chelating peptides such as polyhistidine tracts and histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle WA). The inclusion of a cleavable linker sequences such as Factor Xa or enterokinase (Invitrogen, San Diego CA) between the purification domain and GCA-associated peptide or polypeptide can be useful to facilitate purification. For example, an expression vector can include an epitope-encoding nucleic acid sequence linked to six histidine residues followed by a thioredoxin and an enterokinase cleavage site (see e.g., Williams (1995) Biochemistry 34:1787-1797; Dobeli (1998) Protein Expr. Purif. 12:404-414). The histidine residues facilitate detection and purification while the enterokinase cleavage site provides a means for purifying the epitope from the remainder of the fusion protein. Technology pertaining to vectors encoding fusion proteins and application of fusion proteins are well described in the scientific and patent literature, see e.g., Kroll (1993) DNA Cell. Biol., 12:441-53.

The invention provides antibodies that specifically bind to the polypeptides of the invention, as set forth in Table 4. These antibodies can be useful in the screening methods of the invention. The polypeptides or peptide can be conjugated to another molecule or can be administered with an adjuvant. The coding sequence can be part of an expression cassette or vector capable of expressing the immunogen *in vivo*. (see, *e.g.*, Katsumi (1994) Hum. Gene Ther. 5:1335-9). Methods of producing polyclonal and monoclonal antibodies are known to those of skill in the art and described in the scientific and patent literature, see, *e.g.*, Coligan, Current Protocols in Immunology, Wiley/Greene, NY (1991); Stites (eds.) Basic and Clinical Immunology (7th ed.) Lange Medical Publications, Los Altos, CA; Goding, Monoclonal Antibodies: Principles and Practice (2d ed.) Academic Press, New York, NY (1986); Harlow (1988) Antibodies, a Laboratory Manual, Cold Spring Harbor Publications, New York.

.

Antibodies also can be generated *in vitro*, e.g., using recombinant antibody binding site expressing phage display libraries, in addition to the traditional *in vivo* methods using animals. See, e.g., Huse (1989) Science 246:1275; Ward (1989) Nature 341:544;

5

10

15

20

25

Hoogenboom (1997) Trends Biotechnol. 15:62-70; Katz (1997) Annu. Rev. Biophys. Biomol. Struct. 26:27-45. Human antibodies can be generated in mice engineered to produce only human antibodies, as described by, e.g., U.S. Patent No. 5,877,397; 5,874,299; 5,789,650; and 5,939,598. B-cells from these mice can be immortalized using standard techniques (e.g., by fusing with an immortalizing cell line such as a myeloma or by manipulating such B-cells by other techniques to perpetuate a cell line) to produce a monoclonal human antibody-producing cell. See, e.g., U.S. Patent No. 5,916,771; 5,985,615.

## TABLE 3

>Rv0002 dnaN DNA polymerase III, b-subunit TB.seq 2052:3257 MW:42114 ATGGACGCGGCTACGACAAGAGTTGGCCTCACCGACTTGACGTTTCGTTTGCTACGAGAGTCTT CCGGCGTGTTGTTGACCGGCTCGGACAACGGTCTGACGATTTCCGGATTCGACTACGAGGTTTC CGCCGAGGCCCAGGTTGGCGCTGAAATTGTTTCTCCTGGAAGCGTTTTAGTTTCTGGCCGATTG TTGTCCGATATTACCCGGGCGTTGCCTAACAAGCCCGTAGACGTTCATGTCGAAGGTAACCGGG TCGCATTGACCTGCGGTAACGCCAGGTTTTCGCTACCGACGATGCCAGTCGAGGATTATCCGAC GCTGCCGACGCTGCCGGAAGAGACCGGATTGTTGCCTGCGGAATTATTCGCCGAGGCAATCAG TCAGGTCGCTATCGCCGCCGGCCGGGACGACACGTTGCCTATGTTGACCGGCATCCGGGTCGA AATCCTCGGTGAGACGGTTTTTGGCCGCTACCGACAGGTTTCGCCTGGCTGTTCGAGAACTG AAGTGGTCGGCGTCGCCAGATATCGAAGCGGCTGTGCTGGTCCCGGCCAAGACGCTGGC GGGTGGGCAAGGATGGCCTGCTCGGTATCAGTGGGAACGGCAAGCGCAGCACCACGCGACTT CTTGATGCCGAGTTCCCGAAGTTTCGGCAGTTGCTACCAACCGAACACACCGCGGTGGCCACC ATGGACGTGGCCGAGTTGATCGAAGCGATCAAGCTGGTTGCGTTGGTAGCTGATCGGGGCGCG CAGGTGCGCATGGAGTTCGCTGATGGCAGCGTGCGGCTTTCTGCGGGTGCCGATGATGTTGGA CGAGCCGAGGAAGATCTTGTTGTTGACTATGCCGGTGAACCATTGACGATTGCGTTTAACCCAA CCTATCTAACGGACGGTTTGAGTTCGTTGCGCTCGGAGCGAGTGTCTTTCGGGTTTACGACTGC GGGTAAGCCTGCCTTGCTACGTCCGGTGTCCGGGGACGATCGCCCTGTGGCGGGTCTGAATGG CAACGGTCCGTTCCCGGCGGTGTCGACGGACTATGTCTATCTGTTGATGCCGGTTCGGTTGCCG **GGCTGA** 

>Rv0003 recF DNA replication and SOS induction TB.seq 3280:4434 MW:42181
>emb|AL123456|MTBH37RV:3280-4437, recF SEQ ID NO:2
GTGTACGTCCGTCATTTGGGGCTGCGTGACTTCCGGTCCTGGGCATGTGTAGATCTGGAATTGC
ATCCAGGGCGGACGGTTTTTGTTGGGCCTAACGGTTATGGTAAGACGAATCTTATTGAGGCACT

5

10

15

20

25

30

10

15

20

25

30

35

GTGGTATTCGACGACGTTAGGTTCGCACCGCGTTAGCGCCGATTTGCCGTTGATCCGGGTAGGT ACCGATCGTGCGGTGATCTCCACGATCGTGGTGAACGACGGTAGAGAATGTGCCGTCGACCTC GAGATCGCCACGGGGCGAGTCAACAAAGCGCGATTGAATCGATCATCGGTCCGAAGTACACGT GATCCCGCTGACCGGCGCGCTATCTGGATGATCTGGCGATCGTGCGTAGGCCTGCGATCGCT GCGGTACGAGCCGAATATGAGAGGGTGTTGCGCCAGCGGACGGCGTTATTGAAGTCCGTACCT GGAGCACGGTATCGGGGTGACCGGGGTGTTTTGACACTCTTGAGGTATGGGACAGTCGTTTG GCGGAGCACGGGCTGAACTGGTGGCCGCCCGCATCGATTTGGTCAACCAGTTGGCACCGGA AGTGAAGAAGGCATACCAGCTGTTGGCGCCGGAATCGCGATCGGCGTCTATCGGTTATCGGGC CTGTTGGCGGCGCCGGCCCGTCGGGATGCCGAACTCGAGCGTGGGGTTTGTCTAGTTGGT CCGCACCGTGACGACCTAATACTGCGACTAGGCGATCAACCCGCGAAAGGATTTGCTAGCCATG GGGAGGCGTGGTCGTTGGCGGTGGCACTGCGGTTGGCGGCCTATCAACTGTTACGCGTTGATG GTGGTGAGCCGGTGTTGTTGCTCGACGACGTGTTCGCCGAACTGGATGTCATGCGCCGTCGAG CGTTGGCGACGCCGAGTCCGCCGAACAGGTGTTGGTGACTGCCGCGGTGCTCGAGGAT GATGTCGGTGGTTCTGCCATGA

>Rv0005 gyrB DNA gyrase subunit B TB.seq.5123:7264 MW:78441

>emb|AL123456|MTBH37RV:5123-7267, gyrB SEQ ID NO:3 ATGGGTAAAAACGAGGCCAGAAGATCGGCCCCTGGCGCCCCGATCACGGTACAGTGGTGCGAC CCCCTGCGGCGACTCAACCGCATGCACGCAACCCCTGAGGAGAGTATTCGGATCGTGGCTGCC CAGAAAAAGAAGGCCCAAGACGAATACGGCGCTGCGTCTATCACCATTCTCGAAGGGCTGGAG GCCGTCCGCAAACGTCCCGGCATGTACATTGGCTCGACCGGTGAGCGCGGTTTACACCATCTC ATTTGGGAGGTGGTCGACACGCGGTCGACGAGGCGATGGCCGGTTATGCAACCACAGTGAAC GTAGTGCTGCTTGAGGATGGCGGTGTCGAGGTCGCCGACGACGCCGCGCGCATTCCGGTCGC CACCCACGCCTCCGGCATACCGACCGTCGACGTGGTGATGACACAACTACATGCCGGCGGCAA GTTCGACTCGGACGCGTATGCGATATCTGGTGGTCTGCACGGCGTCGGCGTGTCGGTGGTTAA CGCGCTATCCACCCGGCTCGAAGTCGAGATCAAGCGCGACGGGTACGAGTGGTCTCAGGTTTA TGAGAAGTCGGAACCCCTGGGCCTCAAGCAAGGGGGCGCCGACCAAGAAGACGGGGTCAACGG TGCGGTTCTGGGCCGACCCCGCTGTTTTCGAAACCACGGAATACGACTTCGAAACCGTCGCCC GCCGCTGCAAGAGATGCCTTCCTCAACAAGGGGCTGACCATCAACCTGACCGACGAGAGGG TGACCCAAGACGAGGTCGTCGACGAAGTGGTCAGCGACGTCGCCGAGGCGCCGAAGTCGGCA AGTGAACGCGCAGCCGAATCCACTGCACCGCACAAAGTTAAGAGCCGCACCTTTCACTATCCGG GTGGCCTGGTGGACTTCGTGAAACACATCAACCGCACCAAGAACGCGATTCATAGCAGCATCGT GGACTTTTCCGGCAAGGGCACCGGGCACGAGGTGGAGATCGCGATGCAATGGAACGCCGGGT ATTCGGAGTCGGTGCACACCTTCGCCAACACCCATCAACACCCACGAGGGCGGCACCCACGAAG

AGGGCTTCCGCAGCGCGCTGACGTCGGTGGTGAACAAGTACGCCAAGGACCGCAAGCTACTGA AGGACAAGGACCCCAACCTCACCGGTGACGATATCCGGGAAGGCCTGGCCGCTGTGATCTCGG TGAAGGTCAGCGAACCGCAGTTCGAGGGCCAGACCAAGACCAAGTTGGGCAACACCGAGGTCA AATCGTTTGTGCAGAAGGTCTGTAACGAACAGCTGACCCACTGGTTTGAAGCCAACCCCACCGA CGCGAAAGTCGTTGTGAACAAGGCTGTGTCCTCGGCGCAAGCCCGTATCGCGGCACGTAAGGC ACGAGAGTTGGTGCGGCGTAAGAGCGCCACCGACATCGGTGGATTGCCCGGCAAGCTGGCCG GTTCTGCAAAAAGCGGTCGCGATTCGATGTTCCAGGCGATACTTCCGCTGCGCGGCAAGATCAT CAATGTGGAGAAAGCGCGCATCGACCGGGTGCTAAAGAACACCGAAGTTCAGGCGATCATCAC GGCGCTGGGCACCGGGATCCACGACGAGTTCGATATCGGCAAGCTGCGCTACCACAAGATCGT GCTGATGGCCGACGCCGATGTTGACGGCCAACATATTTCCACGCTGTTGTTGACGTTGTTGTTC CGGTTCATGCGGCCGCTCATCGAGAACGGGCATGTGTTTTTGGCACAACCGCCGCTGTACAAAC TCAAGTGGCAGCGCAGTGACCCGGAATTCGCATACTCCGACCGCGAGCGCGACGGTCTGCTGG AGGCGGGGCTGAAGGCCGGGAAGAAGATCAACAAGGAAGACGGCATTCAGCGGTACAAGGGT CTAGGTGAAATGGACGCTAAGGAGTTGTGGGAGACCACCATGGATCCCTCGGTTCGTGTTGC GTCAAGTGACGCTGGACGACGCCGCCGCCGACGAGTTGTTCTCCATCCTGATGGGCGAGG ACGTCGACGCGCGCGCAGCTTTATCACCCGCAACGCCAAGGATGTTCGGTTCCTGGATGTCTA Α

>Rv0006 gyrA DNA gyrase subunit A TB.seq 7302:9815 MW:92276 20 >emb|AL123456|MTBH37RV:7302-9818, gyrA SEQ ID NO:4 ATGACAGACACGACGTTGCCGCCTGACGACTCGCTCGACCGGATCGAACCGGTTGACATCGAG GAGGTGCGCGACGGCTCAAGCCCGTGCATCGCCGGGTGCTCTATGCAATGTTCGATTCCGGC TTCCGCCCGGACCGCCACGCCAAGTCGGCCCGGTCGGTTGCCGAGACCATGGGCAACTA CCACCGCACGCGACGCGTCGATCTACGACAGCCTGGTGCGCATGGCCCAGCCCTGGTCGC 25 TGCGCTACCCGCTGGTGGACGGCCAGGGCAACTTCGGCTCGCCAGGCAATGACCCACCGGCG GCGATGAGGTACACCGAAGCCCGGCTGACCCCGTTGGCGATGGAGATGCTGAGGGAAATCGAC GAGGAGACAGTCGATTTCATCCCTAACTACGACGGCCGGGTGCAAGAGCCGACGGTGCTACCC AGCCGGTTCCCCAACCTGCCGGCCAACGGGTCAGGCGGCATCGCGGCATGGCAACCAAT ATCCCGCCGCACAACCTGCGTGAGCTGGCCGACGCGGTGTTCTGGGCGCTGGAGAATCACGAC 30 GCCGACGAAGAGGAGACCCTGGCCGCGGTCATGGGGCGGGTTAAAGGCCCGGACTTCCCGAC CGCCGGACTGATCGTCGGATCCCAGGGCACCGCTGATGCCTACAAAACTGGCCGCGGCTCCAT TCGAATGCGCGGAGTTGTTGAGGTAGAAGAGGATTCCCGCGGTCGTACCTCGCTGGTGATCAC CGAGTTGCCGTATCAGGTCAACCACGACAACTTCATCACTTCGATCGCCGAACAGGTCCGAGAC GGCAAGCTGGCCGGCATTTCCAACATTGAGGACCAGTCTAGCGATCGGGTCGGTTTACGCATC 35 GTCATCGAGATCAAGCGCGATGCGGTGGCCAAGGTGGTGATCAATAACCTTTACAAGCACACCC

5

10

AGCTGCAGACCAGCTTTGGCGCCAACATGCTAGCGATCGTCGACGGGGTGCCGCGCACGCTGC GGCTGGACCAGCTGATCCGCTATTACGTTGACCACCAACTCGACGTCATTGTGCGGCGCACCAC CTACCGGCTGCGCAAGGCAAACGAGCGAGCCCACATTCTGCGCGGCCTGGTTAAAGCGCTCGA CGCGCTGGACGAGGTCATTGCACTGATCCGGGCGTCGGAGACCGTCGATATCGCCCGGGCCG GACTGATCGAGCTGCTCGACATCGACGAGATCCAGGCCCAGGCAATCCTGGACATGCAGTTGC GGCGCCTGGCCGCACTGGAACGCCCAGCGCATCATCGACGACCTGGCCAAAATCGAGGCCGAG ATCGCCGATCTGGAAGACATCCTGGCAAAACCCGAGCGCAGCGTGGGATCGTGCGCGACGAA CTCGCCGAAATCGTGGACAGGCACGGCGACGGCGTACCCGGATCATCGCGGCCGACGG AGACGTCAGCGACGAGGATTTGATCGCCCGCGAGGACGTCGTTGTCACTATCACCGAAACGGG ATACGCCAAGCGCACCAAGACCGATCTGTATCGCAGCCAGAAACGCGGCGGCAAGGGCGTGCA GATCCTGTTCTTCACCACCCAGGGACGGGTTTATCGGGCCAAGGCCTACGACTTGCCCGAGGC CTCCCGGACGCGCGCGCGCACCACCTGTTAGCCTTCCAGCCCGAGGAACGCA TCGCCCAGGTCATCCAGATTCGCGGCTACACCGACGCCCCGTACCTGGTGCTGGCCACTCGCA ACGGGCTGGTGAAAAAGTCCAAGCTGACCGACTTCGACTCCAATCGCTCGGGCGGAATCGTGG GCCAATGGGTCGTGCCACCTCGGGTGTGCAGGGCATGCGGTTCAATATCGACGACCGGCTGCT GTCGCTGAACGTCGTGCAGGCACCTATCTGCTGGTGGCGACGTCAGGGGGCTATGCGAA ACGTACCGCGATCGAGGAATACCCGGTACAGGGCCGCGGCGGTAAAGGTGTGCTGACGGTCAT GTACGACCGCCGGCGCAGGTTGGTTGGGGCGTTGATTGTCGACGACGACAGCGAGCTGT 20 ATGCCGTCACTTCCGGCGGTGGCGTGATCCGCACCGCGGCACGCCAGGTTCGCAAGGCGGGA CGGCAGACCAAGGGTGTTCGGTTGATGAATCTGGGCGAGGGCGACACACTGTTGGCCATCGCG CGCAACGCCGAAGAAGTGGCGACGATAATGCCGTGGACGCCAACGGCGCAGACCAGACGGG CAATTAA 25

>Rv0014c pknB serine-threonine protein kinase TB.seq 15593:17470 MW:66511 >emb|AL123456|MTBH37RV:c17470-15590, pknB SEQ ID NO:5 ATGACCACCCTTCCCACCTGTCCGACCGCTACGAACTTGGCGAAATCCTTGGATTTGGGGGCA TGTCCGAGGTCCACCTGGCCCGCGACCTCCGGTTGCACCGCGACGTTGCGGTCAAGGTGCTGC GCGCTGATCTAGCCCGCGATCCCAGTTTTTACCTTCGCTTCCGGCGTGAGGCGCAAAACGCCG GGCCATTGCCCTACATCGTCATGGAATACGTCGACGGCGTTACCCTGCGCGACATTGTCCACAC CGAAGGCCGATGACGCCCAAACGCGCCATCGAGGTCATCGCCGACGCCTGCCAAGCGCTGA ACTTCAGTCATCAGAACGGAATCATCCACCGTGACGTCAAGCCGGCGAACATCATGATCAGCGC GACCAATGCAGTAAAGGTGATGGGATTTCGGCATCGCCCGCGCCATTGCCGACAGCGGCAACAG CGTGACCCAGACCGCAGTGATCGGCACGGCGCAGTACCTGTCACCCGAACAGGCCCGGG

5

10

15

30

₹.

5

10

15

20

25

30

GTGATTCCGTCGACGCCCGATCCGATGTCTATTCCTTGGGCTGTTCTTTATGAAGTCCTCACC GGGGAGCCACCTTTCACCGGCGACTCACCCGTCTCGGTTGCCTACCAACATGTGCGCGAAGAC CCGATCCCACCTTCGGCGCGCACGAAGGCCTCTCCGCCGACCTGGACGCCGTCGTTCTCAAG GCGCTGGCCAAAAATCCGGAAAACCGCTATCAGACAGCGGCGGAGATGCGCGCCGACCTGGTC CGCGTGCACAACGGTGAGCCGCCCGAGGCGCCCAAAGTGCTCACCGATGCCGAGCGGACCTC GCTGCTGTCGCGGCCGGCAACCTTAGCGGTCCGCGCACCGATCCGCTACCACGCCAGGA CGTGCTCGCTGTCGCCGTCGTCGCCATCAACACGTTCGGCGGCATCACCCG CGACGTTCAAGTTCCCGACGTTCGGGGTCAATCCTCCGCCGACGCCATCGCCACACTGCAAAA CCGGGGCTTCAAAATCCGCACCTTGCAGAAGCCGGACTCGACAATCCCACCGGACCACGTTAT CGGCACCGACCCGGCCAACACGTCGGTGAGTGCAGGCGACGAGATCACAGTCAACGTGT CCACCGGACCCGAGCAACGCGAAATACCCGACGTCTCCACGCTGACATACGCCGAAGCGGTCA TGGTGGCAAGGTCATCGGGACCAACCCGCCAGCCAACCAGACGTCGGCCATCACCAATGTGG TCATCATCATCGTTGGCTCTGGTCCGGCGACCAAAGACATTCCCGATGTCGCGGGCCAGACCGT CAGCCCCGTCCCGCCGGCGAGGTGACCGGCACCAATCCACCCGCAGGCACCACAGTTCCGG TCGATTCAGTCATCGAACTACAGGTGTCCAAGGGCAACCAATTCGTCATGCCCGACCTATCCGG CATGTTCTGGGTCGACGCGAACCACGATTGCGCGCGCGCTGGGCTGGACCGGGATGCTCGACAA AGGGCCGACGTCGACGCCGGTGGCTCCCAACACCAGGGTCGTCTATCAAAACCCGCCGG CGGGGACCGCGTCAACCGGGACGCATCATCACGCTGAGGTTCGGCCAGTAG

>Rv0016c pbpA TB.seq 18762:20234 MW:51577 >emb|AL123456|MTBH37RV:c20234-18759, pbpA SEQ ID NO:6

ATGAACGCCTCTCTGCGCCGAATATCGGTGACCGTGATGGCGTTGATCGTGTTGCTACTGCTCA ACGCGACCATGACGCAGGTCTTCACCGCCGACGGGCTGCCGTGCCGATCCCCGCAACCAGCGA GTGTTGCTCGACGAGTATTCACGGCAGCGCGGCCAGATCACCGCTGGTGGCCAACTGCTGGCG TACTCGGTAGCCACCGACGCCGCTTTCGTTTCCTGCGGGTCTATCCCAATCCTGAGGTGTACG CGCCGGTTACCGGCTTCTACTCCCTGCGCTATTCCAGCACCGCCCTAGAACGAGCCGAGGACC GCGACCCACGCGGCGTAATGTCGATACCACGATCAACCCGCGCATTCAGCAAGCCGGCTGGG ACGCGATGCAGCAAGGCTGCTACGGGCCCTGTAAGGGAGCGGTGGTCGCCCTTGAGCCATCAA CCGGCAAGATTTTGGCGTTGGTGTCTTCTCCGTCCTACGACCCCAACCTGCTGGCGTCGCATAA CCCCGAGGTGCAGGCGCAAGCCTGGCAGCGGCTTGGCGACAATCCCGCCTCTCCACTGACCAA CCGTGCCATCTCTGAGACGTATCCACCGGGTTCGACTTTCAAAGTGATCACCACTGCGGCCGCG CTGGCCGCGGGGCCACCGAGACCGAACAGCTGACTGCGGCGCCCACAATTCCGTTGCCAGG 35 CAGCACCGCCAGCTAGAGAACTACGGCGGTGCGCCGTGCGGGGGACGAACCCACCGTGTCGC

>Rv0017c rodA TB.seq 20234:21640 MW:50612 >emb|AL123456|MTBH37RV:c21640-20231, rodA SEQ ID NO:7

ATGACGACACGACTGCAAGCGCCGGTGGCCGTAACGCCCCCGTTGCCGACTCGGCGCAACGC TGAACTGCTGCTGCTGTGCCGCCGTAATCACGTTTGCCGCACTGCTGGTCGTGCAGGCC AATCAAGACCAGGGGTGCCCTGGGACTTGACTAGCTACGGACTGGCCTTCCTGACCCTGTTC GGATCCGCGCATCTGGCCATCCGGCGCTTCGCCCCCTACACTGACCCGCTGTTGCTCCCGGTG GTGGCACTGCTCAACGGACTTGGCCTGGTAATGATCCACCGCCTCGATCTGGTGGACAACGAG ATCGGCGAGCATCGGCACCCCAGCGCAAACCAGCAGATGCTGTGGACGCTGGTGGGCGTAGC TGCCTTCGCGCTCGTGGTGACCTTCCTCAAGGACCACCGACAGCTCGCACGCTACGGCTACATT TGCGGGCTCGCGGTTTTCTTGGCAGTTCCCGCGCTGCTCCCGGCAGCACTGTCCGAA CAGAACGGCGCCAAGATCTGGATCCGGTTGCCCGGCTTCTCGATTCAACCCGCCGAATTTTCAA AGATTCTGCTGCTGATCTTCTTTTCGGCGGTACTGGTGGCCAAACGCGGCCTGTTCACCAGCGC CGGCAAACATTTGCTCGGAATGACCCTGCCGCGCCCCGCGAGACCTCGCGCCACTGTTGGCAGC CTGGGTCATCTCGGTGGGTGTGATGGTCTTCGAGAAAGACCTCGGCGCTTCGCTGCTGCTAC ACATCGTTTCTGGTGGTGTTTACCTCGCCACCCAGCGGTTCAGTTGGGTCGTCATCGGCCTGA CTCTGTTCGCGGCAGGAACCTTGGTGGCGTACTTCATTTTTGAGCACGTCCGGCTCCGCGTACA GACCTGGCTGGATCCGTTCGCAGATCCAGACGGCACCGGATATCAGATCGTGCAGTCGCTTTTC AGCTTCGCTACAGGCGGTATCTTCGGCACCGGGCTCGGTAATGGTCAACCCGACACCGTGCCC GCGGCATCCACCGATTTCATCATCGCCGCGTTCGGCGAAGAGCTTGGGTTGGTGGGCTTGACG GCCATCCTGATGCTCTACACCATCGTGATCATCCGGGGTTTGCGCACGGCCATCGCCACCCGC GATAGCTTCGGCAAGCTGCTGGCCGCCGGCCTCTCATCGACGCTAGCCATTCAGCTGTTCATCG TCGTCGGCGGTGTGACCCGACTCATTCCGCTGACCGGGTTGACCACACCGTGGATGTCCTACG GCGGGTCTTCACTGCCGACCACTACATATTGCTGGCCATCCTGGCACGCATCTCGCACGGAGC 

5

10

15

20

25

30

35

**TCATCGAACGCGTATGA** 

>Rv0018c ppp TB.seq 21640:23181 MW:53781 >emb|AL123456|MTBH37RV:c23181-21637, ppp SEQ ID NO:8

CAACAACGAAGACTCGGTCTACGCTGGGCACGGCTATTGGCCCTGGCCGACGGCATGGGTG GGCATGCGGCCGAGGTGGCGTCCCAGTTGGTGATTGCCGCATTGGCCCATCTCGATGACG 5 ACGAGCCCGGTGGCGATCTGCCGACCCAAGCTGGATGCCGCGGTGCGCCGGCAACTCGGCT ATCGCAGCGCAAGTCGAGATGGAGCCCGATCTCGAAGGCATGGGTACCACGCTCACCGCAATC CTGTTCGCGGCCAACCGGCTCGGCCTGGTGCATATCGGTGACTCGCGCGGTTACCTGCTGCGC GACGGTGAGCTGACGCAGGATCACCAAGGACGACACGTTTGTCCAAACGCTGGTCGACGAAGGC CGGATCACCCGGAGGAGGCGCACAGCCACCCGCAACGCTCGTTGATCATGCGGGCGTTGAC 10 GTGCTCGGACGGGTTGTCCGATCCGGTTAGCGATGAAACTATCCTCGAGGCCCTGCAGATCCC CGAGGTTGCCGAGAGCGCTCACCGCCTCATTGAACTGGCGCTGCGCGGCGGCGCCCCGACA ACGTCACTGTCGTCGCCGACGTCGTCGACTACGACTACGGCCAGACCCAACCGATTCTGG 15 TCTGCCATCAGCCAGCGCAAGGAGATCGTTAAACGCGTTCCGCCACAGGCCGATACATTCAGTC GGCCACGGTGGTCGGCCGACGGCTAGCATTCGTTGTCGCACTGGTGACCGTGCTGATGACTG CGGGCCTGCTCATTGGTCGCGCGATCATCCGCAGCAACTACTACGTAGCGGACTACGCCGGCA GCGTGTCCATCATGCGGGGGATTCAAGGGTCGCTACTGGGCATGTCCCTGCACCAGCCTTACC TGATGGGCTGCCTCAGCCCGCGTAACGAGCTGTCGCAGATCAGCTACGGACAGTCTGGGGGCC 20 CTCTCGACTGCCATCTGATGAAACTGGAGGATCTGCGACCGCCGGAGCGCGCACAGGTTCGGG CCGGTCTCCCGGCCGCACTCTCGATGACGCCATCGGGCAGTTGCGCGAACTGGCGGCCAACT CCCTGCTGCCGCCTTGCCCGGCGCGCGCGCCCACCC CCGCGCCGGCCCCACCGGAACTACTCCTGCCATCCCCACGAGTGCCTCCCCGGCAGCGCCC 25 GCGTCGCCGACGCCTTGGCCCGTCACCAGCTCGCCGACGATGGCCGCACTTCCGCCACC CCCGCCTCAGCCGGGCATCGACTGCCGGGCGGCGCATGA

WO 01/35317

10

15

20

25

30

CCTGGACAGGCGAAGGTGACGACTGCGGTACGAGTTCCGATCGGAACGCCGGTTCGCATCG GCAAAACTGCAATCGAGTTGCGCCCGTGA

>Rv0020c - TB.seq 23864:25444 MW:56881

>emb|AL123456|MTBH37RV:c25444-23861, Rv0020c SEQ ID NO:10 5

ATGGGTAGCCAGAAAAGGCTGGTTCAGCGCGTTGAGCGCAAACTCGAGCAGACGGTTGGCGAT GCGTTTGCCCGCATCTTTGGAGGCTCGATCGTCCCGCAAGAGGTCGAAGCCCTGCTGCGCCGC GAGGCGGCCGACGCATCCAGTCGCTGCAGGGAAATCGCCTTTTGGCGCCCAACGAATACATC ATTACCCTCGGTGTGCACGACTTTGAGAAGTTGGGCGCTGATCCTGAGCTGAAGTCAACCGGTT TTGCTCGGGACTTGGCGGACTATATCCAAGAACAGGGGTGGCAAACGTATGGTGATGTGGTCGT CCGATTCGAGCAGTCGTCGAACCTGCATACCGGCCAGTTCCGCGCCCCGCGCACTGTTAACCC CGACGTTGAGACCCACCCGCCGGTCATCGATTGCGCCCGGCCACAATCAAACCACGCGTTTGG CGCAGAACCAGGAGTAGCACCAATGAGTGACAATTCGAGCTACCGTGGCGGTCAGGGGCAGGG GCGTCCCGACGAGTATTACGACGACCGCTATGCGCGTCCGCAAGAGGATCCGCGTGGTGGCCC GGATCCGCAAGGCGGATCTGACCCCGCGGGGGGTATCCACCCGAGACGGGCGGCTACCCGC CCCAGCCGGGCTACCCACGCCCGCGCCACCCGGACCAGGGCGACTACCCCGAGCAAATCGGG TACCCGACCAGGGGGTTACCCCGAGCAACGCGGTTACCCCGAGCAACGCGGCTACCCCGA CCAGCGCGGGTACCAGGACCAGGGTCGAGGCTACCCCGACCAAGGGCAGGGGGGCTATCCGC ACGACCAGGGCTATCGCCAAAGCGGCGGCTACGGCCCTTCACCCGGTGGCGGCCAGCCCGGC TACGGCGGGTACGGGGGGGGCGGGCGGCCCGGCCACGAGGAGGGCAGCTATGTGCC CTCTGGCCCTCCGGGCCCGAGCAACGACCGGCTTACCCCGACCAAGGCGGTTACGACC AGGGCTACCAGCAAGGCGCCACGACATACGGCCGGCAAGACTATGGCGGCGGCGCTGACTAC ACCCGCTACACCGAATCCCCGCGGGTCCCGGGATACGCTCCTCAGGGTGGCGGGTACGCCGA CCGGTGGCTACAGCGGTTACGGGCAGGGCGGCTATGGGTCCGCCGGAACGTCGGTTACGCTG CAGCTCGACGACGCAGCGGACGCACTTACCAGCTCCGCGAGGGCTCCAACATCATCGGTCGC GGACAGGACGCCAGTTCCGGCTGCCCGACACCGGTGTGTCACGCCGTCACTTGGAGATCCG GTGGGACGGCAGGTCGCATTGCTCGCAGACCTGAACTCCACCAACGGCACCACTGTTAACAA TGCACCGGTACAGGAGTGGCAGTTGGCCGACGGTGATGTGATCCGCTTGGGACACTCCGAGAT CATCGTCCGCATGCACTGA

>Rv0032 bioF2 C-terminal similar to B. subtilis BioF TB.seq 34295:36607 MW:86245 >emb|AL123456|MTBH37RV:34295-36610, bioF2 SEQ ID NO:11

ATGCCCACTGGCTTGGGCTATGACTTTCTGCGCCCTGTCGAGGACTCGGGGGATCAACGACCTGA AGCACTATTACTTCATGGCGGATTTGGCCGATGGGCAACCGCTAGGCCGGGCAAACCTCTATAG 35 CGTCTGTTTCGACCTGGCCACCACCGACCGCCAAGCTCACTCCGGCCTGGCGAACGACCATCAA

10

15

20

25

ACGGTGGTTTCCGGGGTTTATGACCTTCCGTTTCCTCGAGTGCGGGTTGCTCACCATGGTGAGC ATGGACCAGTTGGCGCATGACGACGGGTCGGATTTCTTGATGATCCGGGACGTGGACCCGGAA CACTACCAGCGATACCTTGACATCCTGCGCCCGTTGGGCTTTCGGCCTGCGCTGGGCTTTTCCC GGGTAGACACGACCATCAGCTGGTCGAGCGTGGAAGAGGGCACTGGGCTGCCTGTCTCACAAAA GGCGCCTGCCGTTGAAGACGTCGCTGGAGTTTCGTGAGCGGTTCGGTATCGAGGTCGAGGAAC TCGACGAGTATGCCGAGCATGCGCCGGTATTGGCCCGGCTTTGGCGCAACGTCAAGACGGAGG CAAAGGATTACCAGCGCGAGGACCTGAACCCTGAGTTCTTCGCGGCGTGTTCTCGGCATCTGCA TGGACGTAGCAGACTGTGGTTGTTCCGCTACCAGGGCACGCCAATTGCCTTCTTTTTGAACGTTT GAAGGCGAATCTGTACCGGGCGCGCGCTGATGCTCAGCCTAAAAGATGCGATCAGCCGAGATAA ACGGCGAATGGAAATGGGTATTACGAACTATTTCACAAAACTTCGCATTCCGGGTGCCCGAGTC ATACCGACCATCTATTTCCTGCGTCACAGCACGGATCCGGTGCATACGGCAACGTTAGCGCGAA TGATGATGCACAATATTCAACGGCCAACGCTACCCGACGATATGTCGGAGGAATTCTGTCGCTG GGAAGAGCGAATACGTCTGGACCAGGACGGGCTACCCGAACACGATATCTTTCGCAAGATCGAT CGTCAGCACAAATACACGGGGCTCAAACTCGGCGGAGTCTACGGTTTTTATCCCCGATTCACCG GACCGCAGCGATCCACGGTCAAGGCCGCGGAGCTGGGCGAGATCGTGTTGCTGGGCACGAAC TCGTATCTGGGCCTGGCCACCCATCCAGAGGTGGTGGAGGCCTCGGCGGAGGCCACGCGACG GTACGGCACCGGCTGCTCGGGTTCGCCGTTGCTGAACGGCACGTTGGACTTGCACGTCTCGCT TGAGCAGGAACTAGCCTGTTTTTTGGGCAAACCCGCCGCGTGTTGTGCTCCACCGGATATCAG AGCAACCTGGCGGCGATCAGCGCGCTATGCGAATCCGGGGACATGATCATCCAAGACGCGCTG AACCACCGCAGCCTGTTCGACGCCGCCAGGTTGTCCGGGGCCGACTTCACCTTGTACCGGCAC AACGACATGGACCACCTGGCGCGGGTGCTACGCCGCACCGAGGGGCGCCGCCGGATCATCGT CGTGGACGCGGTGTTCAGCATGGAAGGCACCGTCGCCGACCTGGCCACCATCGCCGAGCTTG CCGACCGGCACGGCTGCCGGGTCTATGTGGACGAGTCCCATGCGCTGGGCGTGCTCGGCCCC GACGGGCGAGGAGCTTCGGCCGCGTTGGGTGTCTTGGCGCGCATGGACGTGGTGATGGGCAC GTTCAGCAAATCCTTTGCCTCCGTCGGCGGGTTCATCGCCGGAGATCGGCCCGTCGTGGACTA CACCCACGCGGCTCTGCGCGTCAGTCGGCGTGAACCCGACCGGCGGGCTCGGGTGCTGGCCG CGGCCGAGTACATGGCCACCGGCCTGGCACGGCAGGGCTATCAGGCCGAGTATCACGGAACC GCGATCGTGCCGGTGATCCTGGGCAACCCGACCGTGGCGCATGCGGGCTATCTGCGGCTGAT 30 GCGCTCCGGGGTGTATGTGAACCCGGTGCCCCCCCCAGCCGTGCCGGAGGAGCGTTCGGGAT TCCGCACCAGCTACCTAGCCGACCACCGACAATCTGACCTCGACCGGGCCTTGCACGTGTTTGC CGGCCTTGCCGAGGACCTGACCCCGCAAGGAGCCGCGCTATGA

<sup>&</sup>gt;Rv0050 ponA1 TB.seq 53661:55694 MW:71119 >emb|AL123456|MTBH37RV:53661-55697, ponA SEQ ID NO:12

GTGGTGATCCTGTTGCCGATGGTCACCTTCACGATGGCCTACCTGATCGTCGACGTTCCCAAGC CAGGTGACATCCGTACCAACCAGGTCTCCACGATCCTTGCCAGCGACGGCTCGGAAATCGCCA AAATTGTTCCGCCCGAAGGTAATCGGGTCGACGTCAACCTCAGCCAGGTGCCGATGCATGTGC GCCAGGCGGTGATTGCGGCCGAAGACCGCAATTTCTATTCGAATCCGGGATTCTCGTTCACCGG CTTCGCGCGGCAGTCAAGAACAACCTGTTCGGCGGCGATCTGCAGGGCGGATCGACGATTAC CCAGCAGTACGTCAAGAACGCGCTGGTCGGTTCCGCACAGCACGGGTGGAGCGGTCTGATGC 5 GCAAGGCGAAAGAATTGGTCATCGCGACGAAGATGTCGGGGGAGTGGTCTAAAGACGATGTGC TGCAGGCGTATCTGAACATCATCTACTTCGGCCGGGGCGCCCTACGGCATTTCGGCGGCGTCCA AGGCTTATTTCGACAAGCCCGTCGAGCAGCTGACCGTTGCCGAAGGGGCGTTGTTGGCAGCGC TGATTCGGCGGCCTTCGACGCTGGACCCGGCGGTCGACCCCGAAGGGGCCCATGCCCGCTGG AATTGGGTACTCGACGGCATGGTGGAAACCAAGGCTCTCTCGCCGAATGACCGTGCGGCGCAG 10 GTGTTTCCCGAGACAGTGCCGCCCGATCTGGCCCGGGCAGAGAATCAGACCAAAGGACCCAAC GGGCTGATCGAGCGGCAGGTGACAAGGGAGTTGCTCGAGCTGTTCAACATCGACGAGCAGACC CTCAACACCCAGGGGCTGGTGGTCACCACCACGATTGATCCGCAGGCCCAACGGGCGGCGGA GAAGGCGGTTGCGAAATACCTGGACGGCAGGACCCCGACATGCGTGCCGCCGTGGTTTCCAT CGACCCGCACAACGGGGCGGTGCGTGCGTACTACGGTGGCGACAATGCCAATGGCTTTGACTT 15 CGCTCAAGCGGGATTGCAGACTGGATCGTCGTTTAAGGTGTTTGCTCTGGTGGCCGCCCTTGAG CAGGGGATCGGCCTGGGCTACCAGGTAGACAGCTCTCCGTTGACGGTCGACGGCATCAAGATC ACCAACGTCGAGGGCGAGGGTTGCGGGACGTGCAACATCGCCGAGGCGCTCAAAATGTCGCT GAACACCTCCTACTACCGGCTGATGCTCAAGCTCAACGGCGGCCCACAGGCTGTGGCCGATGC CGCGCACCAAGCCGGCATTGCCTCCAGCTTCCCGGGCGTTGCGCACACGCTGTCCGAAGATGG 20 CAAGGGTGGACCGCCAACAACGGGATCGTGTTGGGCCAGTACCAAACCCGGGTGATCGACAT GGCATCGGCGTATGCCACGTTGGCCGCGTCCGGTATCTACCACCCGCCGCATTTCGTACAGAA GGTGGTCAGTGCCAACGGCCAGGTCCTCTTCGACGCCAGCACCGCGGACAACACCGGCGATCA GCGCATCCCCAAGGCGGTAGCCGACAACGTGACTGCGGCGATGGAGCCGATCGCAGGTTATTC GCGTGGCCACACCTAGCGGGTGGGCGGGATTCGGCGGCCAAGACCGGCACTACGCAATTTG 25 GTGACACCACCGCGAACAAAGACGCCTGGATGGTCGGGTACACGCCGTCGTTGTCTACGGCTG TGTGGGTGGCACCGTCAAGGGTGACGAGCCACTGGTAACCGCTTCGGGTGCAGCGATTTACG GCTCGGGCCTGCCGTCGGACATCTGGAAGGCAACCATGGACGCCCCTTGAAGGGCACGTCG AACGAGACTTTCCCCAAACCGACCGAGGTCGGTGGTTATGCCGGTGTGCCGCCGCCGCCGCCG CCGCCGGAGGTACCACCTTCGGAGACCGTCATCCAGCCCACGGTCGAAATTGCGCCGGGGATT 30 GCGACTCCCACGCCGCCGCCGTGA

35 >Rv0051 - TB.seq 55694:57373 MW:61210 >emb|AL123456|MTBH37RV:55694-57376, Rv0051 SEQ ID NO:13

GTGACCGGCGCTGTCCCAAAGCAGCAACATCTCGCCACTTCCTTTGGCCGCCGATCTGCGG AGCGCCGATAACCGCGATTGCCCCAGCCGCACCGACGTATTGGGTGCCGCTCTGGCGAATGTC GTCGGTGGCCCGGTAGGCCGGCACCCGCTGATCGGCCGCACCCGGCTGATGACCCCGCTGCG GGTGATGTTTGCAATCGCGTTGGTGTTCCTGGCGCTCGGTTGGTCGACGAAAGCGGCCTGCTT GCAGTCCACCGGAACCGGTCCAGGTGATCAGCGGGTGGCCAACTGGGATAACCAGCGTGCTTA CTACCAGTTGTGCTACTCCGATACGGTGCCGCTCTATGGCGCTGAGTTATTGAGCCAAGGCAAG TTTCCGTACAAATCAAGCTGGATCGAAACCGACAGCAACGGCACACCGCAGCTGCGCTACGAC GGACAGATCGCGGTGCGCTATATGGAGTATCCGGTGCTGACTGGGATCTATCAGTACCTGTCGA TGGCGATAGCCAAGACCTACACCGCGTTAAGCAAGGTGGCTCCCCTCCCGGTGGTTGCCGAAG TGGTGATGTTCTTCAACGTCGCCGCGTTCGGTTTGGCGCTGGCGTGGCTGACAACCGTCTGGG CGACCTCGGGCCGGCCGGCCGGATATGGGATGCGGCGCTGGTGGCCGCCTCACCGCTG GTGATCTTTCAGATATTCACCAATTTCGATGCGCTGGCAACGGGTTTGGCGACGAGTGGGCTGC TGGCCTGGGCGCGCGCGAGACCGGTGCTTGCCGGTGTGCTGATCGGGTTGGGCTCCGCGGCG AAACTGTATCCGCTGTTGTTCTTGTACCCGTTGTTGCTGCTGGGCATCCGGGCCGGTCGCCTGA ATGCTCTGGCCCGCACCATGGCGGCGCCGCGGCGACCTGGTTGTTGGTGAATCTGCCGGTGA TGCTGCTCTTTCCGCGCGGCTGGTCGGAGTTCTTCCGGCTCAACACCCCGGCGCGCGACGACA TGGACTCGTTGTACAACGTCGTCAAGTCGTTCACCGGCTGGCGTGGCTTCGACCCCACCCTGG GCTTCTGGGAGCCGCCGCTGGTGCTGAACACGGTTGTCACGCTCTTGTTCGTGTTATGTTGTGC GACGGTGGCCAGCTTCCTGTTGGTCAACAAGGTGTGGAGTCCCCAGTTCTCGCTTTGGCTGGTG CCGCTGGCCGTGCTGCCTTTGCCGCACCGCCGGATCTTGCTGGCGTGGATGACGATCGACGCG TGGTTCACCACGACGGTGTTGCTGCGTGACATCGCCGTGATGGTGCTGTGCGGACTGGTGGTC TGGCAGATCTACCGCCCCGGGCGCGACCTCGTGCGTACCGGCGGGCCAGGGGCACTGCCGGC TTGTGGGGGGGTCGACGCCGGTGGGAGGGGTCTTTGCCAACGCCGCCGACGCCCAG GTCGGCTACCGTCGTGCGTCCCCGGCTGGGCGACGAGCATGCGCGAGAGAGGACGCCC GATGCAGGTCGCGATCGCACTTTTTCCGGGCAACACCGCGCTTGA

>Rv0106 - TB.seq 124372:125565 MW:43701

>emb|AL123456|MTBH37RV:124372-125568, Rv0106 SEQ ID NO:14 30 ATGCGTACTCCGGTGATATTGGTGGCAGGTCAGGATCACCCGACGAGGTGACGGGCGCCTTG TTGCGCCGGACCGGAACGGTGGTCGTGGAGCACCGGTTTGACGGCCATGTGGTGCGACGGAT GACTGCCACGCTGAGCCGTGGCGAATTGATCACCACGGAGGACGCTTTGGAGTTCGCCCACGG CTGTGTGTGCGCACAATCCGCGACGACCTGCTGGTGCTGTTACGCAGACTGCACCGCCGAGA CAATGTCGGCCGGATCGTCGCACCTGGCGCCGTGGCTGGAGCCCCAGCCCATCTGCTGGG 35 CGATCGACCACGTGCGGGTTTGCGTCGGACACGGATACCCAGACGGACCAGCCGCCCTCGAC GTGCGGGTCGCGGGGTGACCTGTGTGGACTGCGTAAGGTGGCTGCCGCAGTCACTCGG

5

10

15

20

>Rv0125 - TB.seq 151146:152210 MW:34927 15 >emb|AL123456|MTBH37RV:151146-152213, pepA SEQ ID NO:15 GGGCTGGCCTGGCCACGGCCCCAGGCGCCCCGCCGGCCTTGTCGCAGGACCGGT TCGCCGACTTCCCCGCGCTGCCCCTCGACCCGTCCGCGATGGTCGCCCAAGTGGGGCCACAG GTGGTCAACATCAACACCAAACTGGGCTACAACAACGCCGTGGGCGCCCGGGACCGGCATCGTC ATCGATCCCAACGGTGTCGTGCTGACCAACAACCACGTGATCGCGGGCGCCCCCGACATCAAT 20 GCGTTCAGCGTCGGCTCCGGCCAAACCTACGGCGTCGATGTGGTCGGGTATGACCGCACCCAG GATGTCGCGGTGCAGCTGCGCGGTGCCGGTGCCGTCGCCGCGATCGGTGGCG GCGTCGCGGTTGGTGAGCCCGTCGTCGCGATGGGCAACAGCGGTGGGCAGGGCGGAACGCC CCGTGCGGTGCCTGGCAGGGTGGTCGCCCCCCCAAACCGTGCAGGCGTCGGATTCGCTGA CCGGTGCCGAAGAGACATTGAACGGGTTGATCCAGTTCGATGCCGCGATCCAGCCCGGTGATT 25 CGGGCGGCCCGTCGTCAACGGCCTAGGACAGGTGGTCGGTATGAACACGGCCGCGTCCGAT AACTTCCAGCTGTCCCAGGGTGGGCAGGGATTCGCCATTCCGATCGGGCAGGCGATGGCGATC GCGGGCCAGATCCGATCGGGGGGGGGCCCACCGTTCATATCGGGCCTACCGCCTTCCTC GGCTTGGGTGTTGTCGACAACAACGGCAACGGCGCACGAGTCCAACGCGTGGTCGGGAGCGC TCCGGCGCAAGTCTCGGCATCTCCACCGGCGACGTGATCACCGCGGTCGACGGCGCTCCGAT 30 CAACTCGGCCACCGCGATGGCGGACGCGCTTAACGGGCATCATCCCGGTGACGTCATCTCGGT GACCTGGCAAACCAAGTCGGGCGCACGCGTACAGGGAACGTGACATTGGCCGAGGGACCCC CGGCCTGA

>Rv0350 dnaK 70 kD heat shock protein, chromosome replication TB.seq 419833:421707 MW:66832 SEQ ID NO:16

35

5

N

>emb|AL123456|MTBH37RV:419833-421710, dnaK

ATGGCTCGTGCGGTCGGGATCGACCTCGGGACCACCAACTCCGTCGTCTCGGTTCTGGAAGGT GGCGACCCGGTCGTCGCCAACTCCGAGGGCTCCAGGACCACCCCGTCAATTGTCGCGTTC GCCGCAACGGTGAGGTGCTGGTCGGCCAGCCCGCCAAGAACCAGGCAGTGACCAACGTCGA TCGCACCGTGCGCTCGGTCAAGCGACACATGGGCAGCGACTGGTCCATAGAGATTGACGGCAA GAAATACACCGCGCGGAGATCAGCGCCCGCATTCTGATGAAGCTGAAGCGCGACGCCGAGGC 5 CGTCAGGCCACCAAGGACGCCGGCCAGATCGCCGGCCTCAACGTGCTGCGGATCGTCAACGA GCCGACCGCGCCGCCCTGGCCTACGGCCTCGACAAGGGCGAGAAGGAGCAGCGAATCCTGG TCTTCGACTTGGGTGGCACTTTCGACGTTTCCCTGCTGGAGATCGGCGAGGGTGTGGTTGA GGTCCGTGCCACTTCGGGTGACAACCACCTCGGCGGCGACGACTGGGACCAGCGGGTCGTCG 10 ATTGGCTGGTGGACAAGTTCAAGGGCACCAGCGGCATCGATCTGACCAAGGACAAGATGGCGA TGCAGCGGCTGCGGGAAGCCGCCGAGAAGGCAAAGATCGAGCTGAGTTCGAGTCAGCCT CGATCAACCTGCCCTACATCACCGTCGACGCCGACAAGAACCCGTTGTTCTTAGACGAGCAGCT GACCCGCGCGGAGTTCCAACGGATCACTCAGGACCTGCTGGACCGCACTCGCAAGCCGTTCCA 15 TTCGACCCGGATGCCCGCGGTGACCGATCTGGTCAAGGAACTCACCGGCGGCAAGGAACCCAA CAAGGCGTCAACCCCGATGAGGTTGTCGCGGTGGGAGCCGCTCTGCAGGCCGGCGTCCTCA AGGGCGAGGTGAAAGACGTTCTGCTGCTTGATGTTACCCCGCTGAGCCTGGGTATCGAGACCA AGGCGGGGTGATGACCAGGCTCATCGAGCGCAACACCACGATCCCCACCAAGCGGTCGGAG ACTTTCACCACCGCCGACGACAACCAACCGTCGGTGCAGATCCAGGTCTATCAGGGGGAGCGT 20 GAGATCGCCGCGCACAACAAGTTGCTCGGGTCCTTCGAGCTGACCGGCATCCCGCCGGCGCCC GCGGGGGATTCCGCAGATCGAGGTCACTTTCGACATCGACGCCAACGGCATTGTGCACGTCAC CGCCAAGGACAAGGGCACCGGCAAGGAGAACACGATCCGAATCCAGGAAGGCTCGGGCCTGT CCAAGGAAGACATTGACCGCATGATCAAGGACGCCGAAGCGCACGCCGAGGAGGATCGCAAGC GTCGCGAGGGCCGATGTTCGTAATCAAGCCGAGACATTGGTCTACCAGACGGAGAAGTTCG 25 TCAAAGAACAGCGTGAGGCCGAGGGTGGTTCGAAGGTACCTGAAGACACGCTGAACAAGGTTG ATGCCGCGGTGGCGAAGCGAAGGCGGCACTTGGCGGATCGGATATTTCGGCCATCAAGTCG GCGATGGAGAAGCTGGGCCAGGAGTCGCAGGCTCTGGGGCAAGCGATCTACGAAGCAGCTCA GGCTGCGTCACAGGCCACTGGCGCTGCCCACCCCGGCGGCGAGCCGGGCGGTGCCCACCCC GGCTCGGCTGATGACGTTGTGGACGCGGAGGTGGTCGACGACGGCCGGGAGGCCAAGTGA 30

>Rv0351 grpE stimulates DnaK ATPase activity TB.seq 421707:422411 MW:24501 >emb|AL123456|MTBH37RV:421707-422414, grpE SEQ ID NO:17

GTGACGGACGGAAATCAAAAGCCGGATGGCAATTCGGGCGAACAGGTAACCGTCACTGACAAG 35 GACGGCTGCGGCCGATGCGGCGCACACCGAAGACAAGGTCGCCGAGCTGACCGCCGATCTGC

10

15

20

25

30

35

5

>Rv0352 dnaJ acts with GrpE to stimulate DnaK ATPase TB.seq 422450:423634 MW:41346 >emb|AL123456|MTBH37RV:422450-423637, dnaJ SEQ ID NO:18 ATGGCCCAAAGGGAATGGGTCGAAAAAGACTTCTACCAGGAGCTGGGCGTCTCCTCTGATGCC AGTCCTGAAGAGATCAAACGTGCCTATCGGAAGTTGGCGCGCGACCTGCATCCGGACGCGAAC CCGGGCAACCCGGCCGCCGAACGGTTCAAGGCGGTTTCGGAGGCGCATAACGTGCTGTC GGATCCGGCCAAGCGAAGGAGTACGACGAAACCCGCCGCCTGTTCGCCGGCGGCGGGTTCG GCGGCCGTCGGTTCGACAGCGGCTTTGGGGGGCGGGTTCGGCGGTTTCGGGGGTCGGTGGAGAC GGCGCGAGTTCAACCTCAACGACTTGTTCGACGCCGCCAGCCGAACCGGCGGTACCACCATC GGTGACTTGTTCGGTGGCTTGTTCGGACGCGGCGGCGCCCGCGCCGCGACG CGGCAACGACCTGGAGACCGAGACCGAGTTGGATTTCGTGGAGGCCGCCAAGGGCCGTGGCGA TGCCGCTGCGATTAACCAGCCCGGCGCCCGTGCACCAACTGCCATGGCAGCGGGGCCCGGCCA GGCACCAGCCCAAAGGTGTCCCACTTGCAACGGGTCGGGCGTGATCAACCGCAATCAGGGC GCGTTCGGCTTCTCCGAGCCGTGCACCGACTGCCGAGGTAGCGGCTCGATCATCGAGCACCCC TGCGAGGAGTGCAAAGGCACCGGCGTGACCACCCGCACCACCATCAACGTGCGGATCCC GCCCGGTGTCGAGGATGGGCAGCCCATCCGGCTAGCCGGTCAGGGCGAGGCCGGGTTGCGC GGCGCTCCCTCGGGGGATCTCTACGTGACGGTGCATGTGCGGCCCGACAAGATCTTCGGCCGC GACGGCGACGACCTCACCGTCACCGTTCCGGTCAGCTTCACCGAATTGGCTTTGGGCTCGACG CTGTCGGTGCCTACCCTGGACGGCACGGTCGGGGTCCGGGTGCCCAAAGGCACCGCTGACGG CCGCATTCTGCGTGTGCGCGGACGCGGTGTGCCCAAGCGCAGTGGGGGTAGCGGCGACCTAC TTGTCACCGTGAAGGTGCCGCCCCAATTTGGCAGGCGCCGCTCAGGAAGCTCTGGAAG CCTATGCGGCGGGGGGGCCAGTGGTTTCAACCCGCGGGCCGGATGGGCAGGTAATCGC TGA

ACGCCGGCAGTGACGGAATCATCCAGTTCTCGACCGGTGGCGCAGAATTCGGCTCCGGCCTCG
GGGTCAAAGACATGGTGACCGGTGCGCTCGCCTTGGCGGAGTTCACCCACGTTATCGCGGCCA
AGTACCCGGTCAACGTGGCGCTGCACACCGACCACTGCCCCAAGGACAAGTTGGACAGCTATG
TCCGGCCCTTGCTGGCGATCTCGGCGCAACGCGTGAGCAAAGGTGGCAATCCTTTGTTCCAGT
CGCACATGTGGGACGGCTCGGCAGTGCCAATCGATGAGAACCTGGCCATCGCCCAGGAGCTGC
CGCACATGTGGGACGGCCGCAAGATCATTCTGGAGATCGAGAACCTGGCCATCGCCCAGGAGCTGC
TCAAGGCGGCGGCGGCGCCAAGATCATCTGGAGATCGAGAATCGCCGGAGGACTTCGAGAAA
ACCATCGAGGCGCTGGCGACGAGATCAACGAGAAGCTGTACACCAGCCCGGAGGACTTCGGCAA
ACCATCGAGGCGCTGGGCGCCGGTGAGCACGCCAAATACCTGCTGGCCGCAAGGCAA
CGTGCATGGCGTCTACAAGCCCGGCAACGTCAAGCTTCGCCCCGACATCCTTGCGCAAGGCA
ACAGGTGGCGGCGCCAAGCTCGGACTGCCGGCCGACGCCAAGCCGTTCGACTTCCTGTCC
ACGCGGCTCGGGTTCGCTTAAGTCGGAGATCGAGGAGGCGCTGCGCTACGGCGTGAAG
ATGAACGTCGACACCCAGTACGCGTTCACCCGCCCGATCGCCGGTCACATGTTCACC
AACTACGACGGAGTGCTCAAGGTCGATGGCGAGGTGGTTCAAGAAGGTCTACGACCCGCCG
AACTACGACGGAGTGCTCAAGGTCGATGAGCCAGCGGTTCAAGAAGGTCTACGACCCGCCG
AGCTACCTCAAGAAGGCCGAAGCTTCGATGAGCCAGCGGTTCAAGAAGGTCTACGACCTGC
CACTGCGCCGGAAAGTCCCTAACCCACTAA

>Rv0405 pks6 TB.seq 485729:489934 MW:147615 >emb|AL123456|MTBH37RV:485729-489937,
pks6 SEQ ID NO:20

ATGACAGACGGTTCGGTCACTGCGGATAAGCTTCAAAAATGGTTTCGAGAGTACTTGTCCACGC ATATCGAGTGTCATCCAAATGAGGTCAGCCTAGACGTTCCGATTAGAGATTTAGGTTTGAAATCG ATTGATGTCTTAGCGATTCCCGGCGACCTCGGTGACAGATTTGGGTTTTGTATTCCCGATTTGGC CGTTTGGGATAATCCTAGCGCTAATGATTTGATTGATAGTCTGTTGAACCAGCGTAGTGCTGACT CGTTAAGAGAGAGTCATGGACACGCCGACAGGAACACGCAGGGTCGGGGCAGCATAAACGAGC CGGTTGCGGTCATCGGAGTGGGCTGTCGATTTCCGGGAGATATTGACGGCCCGGAACGGCTAT GGGACTTTCTGACCGAGAAGAAGTGTGCGATAACAGCGTATCCAGATCGTGGGTTCACGAATGC TGGAACTTTCGCGGAGTCCGGAGGCTTTTTAAAGGATGTCGCGGGTTTCGATAATAGATTTTTTG ATATCCCGCCGGACGAGGCTCTGCGAATGGATCCGCAACAACGGTTGTTACTGGAGGTCTCTTG GGAAGCGTTAGAGCATGCAGGAATTATTCCTGAGTCATTAAGACTTTCACGTACGGGCGTATTC GTTGGGGTGTCGTCAACTGACTACGTCCGGCTTGTGTCAGCTAGCGCTCAGCAAAAGTCTACTA TTTGGGATAACACCGGCGGTTCTTCGAGTATTATTGCCAATAGAATCTCATACTTTCTCGATATTC AGGGTCCGTCCATTGTCATTGACACGGCATGCTCGTCATCCCTGGTCGCCGTGCATCTAGCCTG TCGAAGTCTCAGTACCTGGGACTGCGATATCGCACTTGTCGGTGGGACGAATGTTCTTATTTCAC CAGAACCATGGGGTGGGTTTAGGGAAGCGGGCATCTTGTCGCAGACAGGCTGCTGTCACGCGT TCGATAAATCCGCCGACGGGATGGTACGCGGTGAGGGATGCGGAGTTATCGTGCTGCAGCGCC TCAGTGATGCACGCCTTGAGGGCCGGCGGATATTAGCGATTCTGACGGGTTCAGCGGTCAATC AGGACGGTAAGTCCAACGGTATTATGGCGCCAAATCCTAGTGCGCAAATTGGTGTTCTTGAAAAT GCATGCAAGAGCGCTCGCGTCGATCCGCTGGAAATCGGCTACGTCGAGGCCCACGGGACCGG

5

10

15

20

25

30

10

15

20

25

30

35

AACGTCGTTAGGGGATAGGATCGAGGCGCACGCCTTAGGCATGGTCTTTGGTCGCAAGAGACC GGGATCTGGGCCCCTGATGATCGGGAGCATCAAGCCGAATATCGGCCATCTGGAAGGTGCGGC TGGCATCGCCGGATTGATCAAGGCGGTGTTGATGGTTGAGCGTGGCTCGCTGCTTCCGAGCGG GGGGTTTACGGAGCCAAATCCAGCTATCCCATTCACGGAATTGGGCCTGAGAGTTGTAGACGAA CTTCAGGAGTGGCCGGTGGCGGGGTCGGCCGGGCCGGGGTGTCATCGTTCGGCTT TGGCGCACCAATGCGCATGTGATTGTCGAGGAAGCTGGTTCGGTTGGGGCGGACACGGTTTC GGGCCGCGCGATGTTGGCGGTTCCGGTGGTGGGGTGGTGGCGTGGTGATTTCGGGGGAAGA TGGTGGTCGGCCAGACTCGCGATGAGTTGCTGGCTGGGTTGGCTGGTCGG CCGGAGGCTGGGGTGTCTGCGGTGTTGGCAAGCCGGCGGGCAAGACGGCTTTTGTGTTTGC CGGTCAGGGCTCGCAGTGGCTATGGGTAGCGAGCTTTATGCTGCCTACCCGGTTTTCGC CGAGGCCCTCGATGCTGTGGACGAGTTGGACCGGCACCTGCGGTATCCGCTGCGCATGT GATCTGGGGGCACGACCAAGATCTGTTGAATACCACCGAATTCGCCCAGCCGGCGCTGTTTGC GGTGGAGGTGGCGCTGTATCGGCTGCTCATGTCGTGGGGGGGTGCGGCCGGGTTTGGTGCTGG GCGATGCTGGTGGCCGCGCGGGGGCGTTGATGCAGGCGTTGCCCGCCGGCGCGCCATGTT TGCGGTGCAGGCCCGTGAAGACGAGGTAGCGCCGATGCTGGGGCACGATGTGAGCATCGCGG CGGTCAATGGTCCGGCTTCGGTGGTGATCTCTGGTGCCCACGATGCGGTGAGCGCGATCGCTG ATCGGCTGCGCCAGGGCCGTCGGGTCCACCGGTTGGCGGTCTCGCATGCCTTTCACTCG CCCACGATCCCGGTCATTTCCAATGTGACCGGGCAGTTGGTGGCCGACGACTTCGCCTCAGCT GATTACTGGGCCCGGCATATCCGGGCGGTGGTGCGGTTTGGCGACAGTGTTCGTAGTGCCCAC TGCGCCGGTGCCAGTCGTTTCATCGAAGTCGGGCCCGGTGGCGGCTTGACGTCGTTGATCGAG GCATCGCTGGCCGACGCGCAGATCGTGTCGGTGCCCACGCTGCGCAAAGATCGGCCCGAACC GGTCAGTGTGATGACGGCGGCGGCCCAGGGCTTCGTCTCGGGGATGGGCCTGGATTGGGCCT CGGTGTTTTCCGGGTACCGGCCCAAGCGGGTGGAGTTGCCGACGTATGCCTTCCAGCATCAAA AGTTCTGGCTCGCACCAGCCCCATCGGTCAGCGACCCCACCGCCGGCCAGATCGGGGCT AGCGATGGTGGTGCTGAACTCTTGGCGTCCTCCGGGTTTGCCGCCCGGCTGGCCGGTCGGTCG GCCGACGAGCAACTCGCCGCAGCGATCGAGGTGGTATGTGAGCATGCCGCAGCGGTGCTGGG GCGCGACGCCCCGGACTCGACGCTGGCCAGGCGTTTGCCGATTCGGGATTTAATTCCTT GAGTGCCGTGGGGCTAACCGCTTAACAGCCGTCACCGCAGTAACGCTGCCGGCCACCGC GATCTTCGATCACCCCACCCGACCGAACTAGCCCAGTATCTGATCACCCAAATAGACGGTCAC GGCAGCTCCGCCGCGCGGCGAAACCCGGCGGAGCGAATCGATGCGCTCACCGATCTTTT CTACAAGCTTGCGATGCGGGTCGGGATGCCGATGGTTGGAAGATGGTCGCCCTGGCGTCGAAT ACGCGCGAGCGCATGAGCTCACCGGTTCGGAACAACGTATCGAAGAACGTCGCACTGCTGGCA GATGGTATCTCCGATGTGGTTGTAATTTGTATCCCAACTCTAACTGTGCTATCGGATCAGCGTGA

PCT/US00/31152

5

10

15

20

25

30

ATATCGAGATATTGCGAATGCGATGACAGGCCGCCATTCGGTTTATTCGCTTACGCTTCCCGGG TTCGATTCGTCTGATGCACTGCCGCAAAACGCGGATATGATTGTTGAAACCGTATCTAACGCAAT TATTGATGTGGTAGGCGGCAGCTGCCGTTTTGTGCTGTCGGGCTATTCATCGGGTGGGGTGTTG GCCTATGCCCTCTGCTCCCATCTGTCGGTCAAGCACCAGCGGAATCCCCTCGGAGTCGCACTCA ACTGGGAAGGCCTTTCCCGTGAAGTAATTCGAGTGGCCAGAATGTTGAATCGGTTAACTGCCA CCCGACTCACCGCGCCACCCTATGCTGCAATCTTTCAGGCCTGGGAACCAGGTAGATCAAT GGCTCCGGTTCTTAACATCGTGGCGAAGGACCGAATAGCTACCGTCGAAAATTTACGCGAAGAA CGAATCAACCGGTGGCGAACTGCTGCTGCAGAGGCGGCCTATTCTGTAGCCGAAGTACCCGGG GATCATTTCGGAATGATGAGCACCTCGAGTGAGGCAATAGCTACCGAAATACATGATTGGATTTC TGGGCTCGTTCGAGGGCCTCATCGGTAG

>Rv0435c - ATPase of AAA-family TB.seq 522348:524531 MW:75315 >emb|AL123456|MTBH37RV:c524531-522345, Rv0435c SEQ ID NO:21

GTGACCCACCCGGACCCGGCCCAACTCACCCTTACCGCCCGGCTGAACACCTCGGCCGTC GACTCACGCCGCGCGTCGTTCGGTTGCACCCCAATGCCATTGCTGCCCTTGGCATCCGCGAG AGACACCGCGGTCGGGACGGTGCTCGATGACGTCACACTGTCCAATGCGGGCCTTCGCGA AGGCACCGAGGTGATCGTCAGCCCGGTCACCGTCTACGGAGCGCGATCGGTGACGCTGAGCG GTTCAACGCTGGCCACCCAGTCGGTGCCGCCGGTCACGCTGCGGCAGGCCCTACTCGGCAAG GTGATGACCGTCGGTGACGCGGTCTCGCTGCCCCGCGATCTAGGCCCCGGCACATCCACG TCGGCTGCCAGCCGCATTGGCAGCTGCGGTCGGGATCAGTTGGACCTCGGAGCTGCTGACC GTTACCGGCGTCGACCCGACGGGCCGGTCAGCGTGCAGCCCAACTCGCTGGTCACCTGGGG CGCTGGGGTCCCGGCCAATGGGTACGTCCACGGCCGGCCAAGTGAGCATCTCGAGTCCGG AGATCCAGATCGAAGAGCTCAAGGGCGCCCAGCCGCAGGCTGCCAAGCTCACCGAATGGCTCA AGCTTGCCCTCGATGAGCCGCACCTACTACAGACCTTGGGCGCCCGGCACCAATTTGGGTGTGC TGGTGTCGGGTCCGGCCGGGTGGGCAAGGCGACGCTGGTGCGCGCGGTGTGCGACGGCCG AAGGTTGGTGACACTGGATGGTCCGGAGATTGGAGCTCTGGCCGCCGGAGACCGGGTCAAAGC CGTGGCCTCGGCAGTGCAGGCGGTTCGCCATGAGGGCGGTGTGTTGCTGATCACCGATGCCGA CGCCTGCTGCCAGCCGCCGAGCCGGTAGCCTCGCTGATCCTGTCCGAGCTGCGTACCG CGGTGGCCACCGCCGGTGTGGTATTGATCGCCACCTCAGCACGGCCCGATCAACTCGATGCCC GGCTGCGTTCCCCCGAGTTGTGCGACCGGGAGCTTGGCCTGCCGCCGACGCGGCCACC CGCAAATCGCTGCTGGAGGCGCTGCTGAATCCGGTTCCTACCGGAGACCTCAACCTCGACGAA ATCGCCTCCCGCACACCGGGTTTCGTCGTGGCCGACCTGGCTGCGCTGGTTCGCGAGGCGGC GCTGCGGGCAGCGTCTCGAGCCAGTGCCGACGGCCGACCACCGATGCTGCACCAAGACGACC TCCTCGGTGCGTTGACCGTCATCCGGCCGCTGTCCCGCTCGGCCAGCGACGAAGTCACCGTGG 35 GTGACGTGACGCTCGACGATGTCGGTGACATGGCCGCGGCCAAACAAGCACTGACCGAGGCG

10

15

20

25

30

35

>Rv0436c pssA CDP-diacylglycerol-serine o-phosphatidyltransferase TB.seq 524531:525388 MW:31219 >emb|AL123456|MTBH37RV:c525388-524528, pssA SEQ ID NO:22 ATGATCGGAAAGCCCCGCGCAGGCGAGGGGTAAACCTGCAGATACTGCCCAGCGCGATGAC GGTGCTGTCCATTTGCGCGGGACTGACCGCAATCAAGTTTGCGCTCGAGCACCAGCCGAAGGC CGCGATGGCACTGATCGCCGCAGCGGCCATCCTCGACGGCCTCGACGGCCGGGTGGCCCGCA TCCTGGATGCCCAGTCGCGGATGGGCGCAGAGATCGACTCACTGGCCGACGCGGTGAACTTCG TCGTGCTGCTCTACGCGTGTGCGTGGTATTACGGCTGGCGCGGTACAACGCACTGCAGGACG GTTTCCATGATCGGCCTGCTAGCCCTCAAAATGCAGTTCGGCGAAGGATGGTGGACCTCGGGCT GGTTCCTCAGCTTTTGGGTGACGGGAACGTCGATACTCTTGGTCAGCGGGATCCCGATGAAAAA GATGCACGCCGTGTCGGTACCACCCAACTACGCGGCCGCCCTGCTGGCGGTGCTGGCTATCTG CGCGGCGCCCCAGTCCTGCCCCCTACTTGTTGATCTGGGTGATCATCATCGCCTACATGTGC CATATTCCTTTCGCGGTGCGCAGCCAGCGCTGGCTTGCCCAACACCCTGAGGTGTGGGACGAC CGATGGCGCGGCTGGGCCTGCGCAAGCCGGGTCGACGGCTGTGA

10

25

30

35

ACGTCGCGGCCGCCCAACCCGCTCGGTCTCAAACGCCGCGCATCGAAAAGGCCGTGGAGAAG GTCACCGAGACCCTGCTCAAGGGCGCCAAGGAGGTCGAGACCAAGGAGCAGATTGCGGCCAC CGCAGCGATTTCGGCGGGTGACCAGTCCATCGGTGACCTGATCGCCGAGGCGATGGACAAGGT GGGCAACGAGGCGTCATCACCGTCGAGGAGTCCAACACCTTTGGGCTGCAGCTCGAGCTCAC GGAGGCGGTCCTGGAGGACCCCTACATCCTGCTGGTCAGCTCCAAGGTGTCCACTGTCAAGGA TCTGCTGCCGCTGCTCGAGAAGGTCATCGGAGCCGGTAAGCCGCTGCTGATCATCGCCGAGGA CGTCGAGGGCGAGGCGCTGTCCACCCTGGTCGTCAACAAGATCCGCGGCACCTTCAAGTCGGT GGCGGTCAAGGCTCCCGGCTTCGGCGACCGCCGCAAGGCGATGCTGCAGGATATGGCCATTCT CACCGGTGGTCAGGTGATCAGCGAAGAGGTCGGCCTGACGCTGGAGAACGCCGACCTGTCGC TGCTAGGCAAGGCCCGCAAGGTCGTGGTCACCAAGGACGAGACCACCATCGTCGAGGGCGCC GGTGACACCGACGCCATCGCCGGACGACGAGTGGCCCAGATCCGCCAGGAGATCGAGAACAGCGA CTCCGACTACGACCGTGAGAAGCTGCAGGAGCGGCCGAGCTGGCCGGTGGTGCCGG TGATCAAGGCCGGTGCCGCCACCGAGGTCGAACTCAAGGAGCGCAAGCACCGCATCGAGGAT GCGGTTCGCAATGCCAAGGCCGCCGTCGAGGAGGGCATCGTCGCCGGTGGGGGTGTGACGCT GTTGCAAGCGGCCCCGACCCTGGACGAGCTGAAGCTCGAAGGCGACGAGGCGACCGGCGCCCA 15 ACATCGTGAAGGTGGCGCTGGAGGCCCCGCTGAAGCAGATCGCCTTCAACTCCGGGCTGGAGC CGGGCGTGGTGGCCGAGAAGGTGCGCAACCTGCCGGCTGGCCACGGACTGAACGCTCAGACC GGTGTCTACGAGGATCTGCTCGCTGCCGGCGTTGCTGACCCGGTCAAGGTGACCCGTTCGGCG CTGCAGAATGCGGCGTCCATCGCGGGGCTGTTCCTGACCACCGAGGCCGTCGTTGCCGACAAG CCGGAAAAGGAGAAGGCTTCCGTTCCCGGTGGCGCGACATGGGTGGCATGGATTTCTGA 20

>Rv0482 murB TB.seq 570537:571643 MW:38522 >emb|AL123456|MTBH37RV:570537-571646, murB SEQ ID NO:24

ATGAAACGGAGCGGTGCGGTTCGCTCTTTGCCGGTGCGCATATTGCCGAGGCGGTCCCGTTG GCGCCGCTGACCACTTTGCGTGTGGGCCCGATCGCCCGACGTGTCATCACTTGCACCAGCGCC GAACAGGTGGTGCGCTGCGCCACCTGGATTCGGCGGCCAAGACCGGAGCTGACCGCCC GCGGTTGGCCAATAGCGGCATCACCATCGACGGTAACTTGGTGCGGGCCGAGGCCGGTGCGG TCTTCGATGACGTGGTTAGGGCCATCGAACAGGGTCTGGGCGGACTGGAATGCCTGTCTG GCATCCCAGGATCGGCCGGGGCGACACCCGTGCAGAACGTGGGGGCGTATGGCGCGGAGGT GTCTGACACCATCACTCGGGTTCGGCTTTTGGATCGGTGCACGGGTGAGGTGCGTTGGGTATC CGCGCGCGACCTGCGCTTCGGCTATCGCACGAGCGTGCTCAAACACGCTGATGGGCTTGCGGT GCCCACCGTGGTCTTGGAGGTGGAGTTTGCGCTGGATCCGTCGGGCCGCAGCGCACCGCTGC GCTACGGCGAGCTGATCGCCGCGCTGAATGCGACCAGCGGCGAGCGCGCCGACCCGCAAGCG TGACACCTGGAGCGTGGGATCGTTCTTCACAAACCCGGTGGTCACCCAGGATGTTTACGAACGG

>Rv0483 - TB.seq 571708:573060 MW:47859 >emb|AL123456|MTBH37RV:571708-573063, Rv0483 SEQ ID NO:25 GTGGTCATTCGTGTGTTTCGCCCGGTATCTTTGATACCCGTGAATAACTCCAGCACCCCCCA GAGTCAGGGGCCGATCAGTCGGCGTCTGGCGTTGACGGCCCTTGGGTTTGGGGTGTTGGCACC GAACGTTCTGGTCGCGTGCGCCGGCAAAGTGACCAAGCTGGCCGAGAAGAGGCCGCCACCGG 10 CGCCTCGTCTGACTTTCCGGCCTGCCGACTCTGCCGCCGACGTGGTGCCGATCGCGCCGATCA GTCGCCGGGCATACAGCCGGGATCGCACCATCTACACGATCACCGAGCCGCTGGGCTACGAC ACGACCTACACCTGGAGCGGTTCGGCCGTCGGCCATGACGGCAAGGCGGTTCCGGTGGCGGG CAAGTTCACCACCGTGGCACCCGTCAAGACGATCAACGCGGGATTCCAGCTCGCCGACGGCCA 15 GACCGTCGGGATCGCGGCGCCGGTGATTATTCAGTTCGATTCACCGATCAGCGACAAGGCCGC CGTCGAGCGGCACTAACCGTGACCACCGACCGCCTGTCGAGGGCGGCTGGGCCTGGCTGC CCGACGAGGCGCAGGGCGCTCGCGTGCACTGGCGTCCTCGGGAGTACTACCCGGCGGGTACC GGATATGTCGTTGCACTTCCAGATCGGTCGTCGTCAGGTGGTCAAGGCCGAAGTCTCGTCGCAC 20 CGCATCCAAGTCGTCACCGATGCCGGCGTCATCATGGACTTCCCGTGCAGCTACGGCGAGGCC GACTTGGCGCGCAACGTCACCGCGAACGGCATCCACGTCGTCACCGAGAAATACTCGGACTTC TACATGTCCAACCCGGCCGCCGGTTACAGCCATATCCACGAACGTTGGGCGGTGCGGATTTCC AACAACGGCGAGTTCATCCATGCCAACCCTATGAGCGCCGGTGCCCAGGGCAACAGCAATGTC ACCAACGGCTGTATCAACCTGTCGACGGAGAACGCCGAACAGTACTACCGCAGCGCGGTCTAC 25 GGTGACCCGGTTGAGGTGACCGGCAGTTCGATCCAGCTGTCCTACGCCGACGGTGACATCTGG GACTGGGCGGTGGACTGGGACACCTGGGTGTCGATGTCGGCGCTACCGCCACCGGCGGCCAA ACCGCCGCCACCCCGCCCCGGTCACGCCGGTCGGATGCCCCCACCCCGT CCGGCACACCCACGACTACTAACGGACCGGGTGGGTAG 30

>Rv0489 gpm phosphoglycerate mutase I TB.seq 578424:579170 MW:27217
>emb|AL123456|MTBH37RV:578424-579173, gpm SEQ ID NO:26
ATGGCAAACACTGGCAGCCTGGTGTTGCTGCGCCACGGCGAGAGCGACTGGAATGCCCTCAAC
CTGTTCACCGGCTGGTCGATGTCGGCCTGACGGACAAGGGCCAGGCAGAGGCGGTTCGAAG
CGGCGAGCTGATCGCGGAACACGACCTATTGCCCGACGTGCTCTACACCTCGTTGCTGCGGCG
CGCGATCACCACCGCGCATCTGGCGTTGGACAGCGCCGATCGGCTCTGGATTCCCGTGCGGCG

TAGCTGGCGGCTCAACGAACGCCACTACGGCGCGCTGCAGGGTTTGGACAAGGCCGAGACCAA
GGCCCGCTATGGCGAAGAGCAGTTCATGGCCTGGCGGCGCGCAGCTATGACACGCCGCCGCCGC
CGATCGAGCGGGGCAGTCAGTTCAGCCAGGACGCCGACCCTCGTTACGCCGACATCGGCGGT
GGCCCGCTCACCGAATGTCTGGCTGACGTGGTCGCCCGGTTTTTGCCATATTTCACCGACGTCA
TCGTTGGCGACTTGCGGGTCGGCAAGACGGTGCTGATCGTTGCCCACGGCAACTCGTTGCGCG
CGCTGGTCAAGCACCTGGACCAGATGTCTGACGACGAAATCGTCGGACTGAACATCCCGACCG
GAATTCCGCTGCGCTACGACCTGGATTCCGCGATGAGGCCGCTGGTGCGCGGTGAACATC
TGGACCCGGAGGCGCGCGCCGCCGCGCGCCGCGGCCAGGCCCGCGGGTAA

>Rv0490 senX 3sensor histidine kinase TB.seq 579347:580576 MW:44794 10 >emb|AL123456|MTBH37RV:579347-580579, senX3 SEQ ID NO:27 GTGACTGTGTTCTCGGCGCTGTTGCTGGCCGGGGTTTTGTCCGCGCTGGCACTGGCCGTCGGT GGTGCTGTTGGAATGCGGCTGACGTCGCGGGTCGTCGAACAGCGCCAACGGGTGGCCACGGA GTGGTCGGGAATCACGGTTTCGCAGATGTTGCAATGCATTGTCACGCTGATGCCGCTGGGCGC GGTGCGCGACCGCCAGCTCGATGATCAGGCCTGGCGGGCCCCCGGCAGGCGCTGGGTGGT 15 GAAGACGTCGAGTTCGACCTGTCGCCGCGCAAGCGGTCGGCCACGGGTCGATCCGGGCTATC AGTGCATGGGCATGCCCGGTTGCTGAGCGAGGAAGACCGCCGGTTCGCCGTGGTGTTCGTGCA CGAGCTCAAGACGCCCGTCGGTGCCATGGCTCTACTCGCCGAGGCGCTGCTGGCGTCGGCCG ACGACTCCGAAACCGTTCGGCGGTTCGCCGAGAAGGTGCTCATTGAGGCCAACCGGCTCGGTG 20 ACATGGTCGCCGAGTTGATCGAGCTATCCCGGCTACAGGGCGCCGAGCGGCTACCCAATATGA CCGACGTCGACGTCGATACGATTGTGTCGGAAGCGATTTCACGCCATAAGGTGGCGGCCGACA ACGCCGACATCGAAGTCCGCACCGACGCCCCAGCAATCTGCGGGTGCTGGGCGACCAAACTC TGCTGGTTACCGCACTGGCAAACCTGGTTTCCAATGCGATTGCCTATTCGCCGCGCGGGTCGCT 25 TCGGCATCGCGCCGGAAGACCAGGAGCGGGTCTTCGAACGGTTCTTCCGGGGGGACAAGGCG CGCTCGCGTGCCACCGGAGGCAGCGGACTCGGGTTGGCCATCGTCAAACACGTCGCGGCTAAT CACGACGGCACCATCCGCGTGTGGAGCAAACCGGGAACCGGGTCAACGTTCACCTTGGCTCTT CCGGCGTTGATCGAGGCCTATCACGACGACGAGCGAGCCGAGCAGCGAGGCCCGAACT 30 GCGGTCAAACAGGTCACAACGAGAGGAAGAGCTGAGCCGATGA

>Rv0500 proC pyrroline-5-carboxylate reductase TB.seq 590081:590965 MW:30172
>emb|AL123456|MTBH37RV:590081-590968, proC SEQ ID NO:28
ATGCTTTTCGGCATGGCAAGGATCGCGATTATCGGCGCGGCGGCAGCATCGGTGAGGCATTGCTG
TCGGGTCTGCTGCGGGCGGCCGGCAGGTCAAAGACCTGGTAGTGGCCGAGCGGATGCCCGA
TCGCGCCAACTACCTGGCGCAGACCTATTCGGTGTTGGTGACGTCGGCGGCCGACGCGGTGGA



. 5

10

15

20

25

30

35

>Rv0528 - TB.seq 618303:619889 MW:57132

>emb|AL123456|MTBH37RV:618303-619892, Rv0528 SEQ ID NO:29

ATGTGGCGGTCGTTGACGTCGATGGGCACCGCGCTGGTGCTGCTGTTTTTGCTCGCGCTGGCT GCCATACCCGGGGCCCTGCCGCAGCGTGGCCTCAACGCCGCCAAGGTGGACGACTACCT GGCCGCGCACCCACTCATCGGTCCGTGGCTGGACGAGCTGCAGGCCTTCGACGTGTTCTCCAG CTTCTGGTTCACCGCCATCTACGTGCTGCTGTTCGTGTCCCTCGTCGGCTGTCTGGCCCCGCGG ACGATCGAGCACGCCGCAGCCTGCGGGCTACACCGGTCGCCCCCGCGCAACCTGGCCCG CGGGCCGGCTGCGCGCAGCATCACCCGGCAACAAGGCGACAGCGTGGAAGTCTCC GCCGAGAAGGGCTACCTGCGCGAGTTCGGCAACCTGGTGTTCCACTTCGCGCTGCTGGGTCTG CTGGTGGCGGTGGCCGCAAGCTGTTCGGCTACGAGGGCAACGTGATCGTGATAGCCGA CGGCGGACCCGGTTTTTGTTCGGCGTCGCCGGCCGCGTTCGACTCGTTTCGCGCCGGCAACAC CGTCGACGCACGTCGTTGCACCCGATCTGTGTGCGGGTCAACAACTTCCAAGCGCACTACCT GCCGTCCGGCCACCTCGTTCGCCGCCGACATCGACTATCAGGCCGACCCGGCCACTG CTGACCTGATCGCCAACAGCTGGCGGCCCTACCGGCTGCAGGTCAATCACCCGCTGCGGGTCG GCGGCGACCGGGTGTACCTGCAGGGCCACGGCTATGCGCCCACCTTCACCGTGACGTTCCCG GACGGCAGACCCGCACGTCGACCGTGCAGTGGCGACCCGGACACCCGCAGACCCTGCTGTC GGCGGCGTCGTGCGCATCGACCCGCCGGCCGGCAGCTACCCCAACCCCGACGAGCGTCGCA AACACCAGATCGCCATCCAGGGCCTGCTGGCTCCCACCGAGCAGCTCGACGGCACCCTGCTGT CGTCGCGTTTCCCCGCGCTCAATGCCCCGGCGGTGGCCATCGACATCTACCGCGGCGACACCG GCCTGGACAGCGGCCGCCCAGTCGTTGTTCACCCTGGACCACCGGCTGATCGAGCAGGGC CGGCTGGTCAAGGAAAAGCGGGTCAACCTGCGCGCCGGTCAGCAAGTCCGCATCGACCAAGG CCCGGCGGCCGCACGGTGCCGGTTCGACGGCGCGCGGTGCCGTTCGTCAACCTGCAGGTCT CCCACGACCCCGGCCAGTCCTGGGTGCTGGTCTTCGCAATCACGATGATGGCGGGACTGCTGG TGTCGCTGCTGGCGCAGGCGCCGGGTGTGGGCGCGGATCACGCCGACGACCGCGGGTACG



GTAAACGTCGAGCTGGGCGGCCTGACGCGCACCGACAACTCCGGGTGGGGCGCCGAGTTCGA GCGGCTGACCGGGCGGTTGCTGGCGGGTTTTGAGGCGCGGGTCCCCGGACATGGCCGAAGCGG CCGCAGGGACCGGAAGGGACGTCGATTGA

>Rv0667 rpoB [beta] subunit of RNA polymerase TB.seq 759805:763320 MW:129220 5 >emb|AL123456|MTBH37RV:759805-763323, rpoB SEQ ID NO:30 TTGGCAGATTCCCGCCAGAGCAAAACAGCCGCTAGTCCTAGTCCGAGTCGCCCGCAAAGTTCCT CGAATAACTCCGTACCCGGAGCGCCAAACCGGGTCTCCTTCGCTAAGCTGCGCGAACCACTTG AGGTTCCGGGACTCCTTGACGTCCAGACCGATTCGTTCGAGTGGCTGATCGGTTCGCCGCGCT TACGAGCTGTCTCCGATCGAGGACTTCTCCGGGTCGATGTCGTTGTCGTTCTCTGACCCTCGTT 10 TCGACGATGTCAAGGCACCCGTCGACGAGTGCAAAGACAAGGACATGACGTACGCGGCTCCAC TGTTCGTCACCGCCGAGTTCATCAACAACAACACCGGTGAGATCAAGAGTCAGACGGTGTTCAT GGGTGACTTCCCGATGATGACCGAGAAGGGCACGTTCATCATCAACGGGACCGAGCGTGTGGT GGTCAGCCAGCTGGTGCGCCCGGGGTGTACTTCGACGAGACCATTGACAAGTCCACCGA 15 CAAGCGCGACACCGTCGGCGTGCGCATCGACCGCAAACGCCGGCAACCGGTCACCGTGCTGC TCAAGGCGCTGGGCTGGACCAGCGAGCAGATTGTCGAGCGGTTCGGGGTTCTCCGAGATCATGC GATCGACGCTGGAGAAGGACAACACCGTCGGCACCGACGAGGCGCTGTTGGACATCTACCGCA AGCTGCGTCCGGGCGAGCCCCGACCAAAGAGTCAGCGCAGACGCTGTTGGAAAACTTGTTCT TCAAGGAGAAGCGCTACGACCTGGCCCGCGTCGGTCGCTATAAGGTCAACAAGAAGCTCGGGC 20 TGCATGTCGGCGAGCCCATCACGTCGTCGACGCTGACCGAAGAAGACGTCGTGGCCACCATCG AATATCTGGTCCGCTTGCACGAGGGTCAGACCACGATGACCGTTCCGGGCGCGCGTCGAGGTGC CGGTGGAAACCGACGACATCGACCACTTCGGCAACCGCCGCCTGCGTACGGTCGGCGAGCTG ATCCAAAACCAGATCCGGGTCGGCATGTCGCGGATGGAGCGGGTGGTCCGGGAGCGGATGAC 25 CGATCAAGGAGTTCTTCGGCACCAGCCAGCTGAGCCAATTCATGGACCAGAACAACCCGCTGTC GGGGTTGACCCACAAGCGCCGACTGTCGGCGCTGGGGCCCGGCGGTCTGTCACGTGAGCGTG CCGGGCTGGAGGTCCGCGCGCGCCCGTCGCACTACGGCCGGATGTGCCCGATCGAAACC CCTGAGGGCCCAACATCGGTCTGATCGGCTCGCTGTCGGTGTACGCGCGGGTCAACCCGTTC GGGTTCATCGAAACGCCGTACCGCAAGGTGGTCGACGGCGTGGTTAGCGACGAGATCGTGTAC 30 CCTCGTCTGAGGTGGACTACATGGACGTCTCGCCCGCCAGATGGTGTCGGTGGCCACCGCGA TGATTCCCTTCCTGGAGCACGACGACGCCAACCGTGCCCTCATGGGGGCAAACATGCAGCGCC AGGCGGTGCCGCTGGTCCGTAGCGAGGCCCCGCTGGTGGGCACCGGGATGGAGCTGCGCGC 35 GGCGATCGACGCCGGCGACGTCGTCGTCGCCGAAGAAAGCGGCGTCATCGAGGAGGTGTCGG

. . .

5

CCCGGTCCAACCACGGCACTTGCGCCAACCAGTGCCCCATCGTGGACGGGGCGACCGAGTC GAGGCCGGTCAGGTGATCGCCGACGGTCCCTGTACTGACGACGGCGAGATGGCGCTGGGCAA GAACCTGCTGGTGGCCATCATGCCGTGGGAGGGCCACAACTACGAGGACGCGATCATCCTGTC CAACCGCCTGGTCGAAGAGGACGTGCTCACCTCGATCCACATCGAGGAGCATGAGATCGATGC TCGCGACACCAAGCTGGGTGCGGAGGAGATCACCCGCGACATCCCGAACATCTCCGACGAGGT GCTCGCCGACCTGGATGAGCGGGGCATCGTGCGCATCGGTGCCGAGGTTCGCGACGGGGACA TCCTGGTCGGCAAGGTCACCCCGAAGGGTGAGACCGAGCTGACGCCGGAGGAGCGGCTGCTG CGTGCCATCTTCGGTGAGAAGGCCCGCGAGGTGCGCGACACTTCGCTGAAGGTGCCGCACGG CGAATCCGGCAAGGTGATCGGCATTCGGGTGTTTTCCCGCGAGGACGAGGACGAGTTGCCGGC CGGTGTCAACGAGCTGGTGCGTGTGTATGTGGCTCAGAAACGCAAGATCTCCGACGGTGACAA 10 GCTGGCCGGCCGGCACCAACAAGGGCGTGATCGGCAAGATCCTGCCGGTTGAGGACATGC CGTTCCTTGCCGACGCACCCCGGTGGACATTATTTTGAACACCCACGGCGTGCCGCGACGGA TGAACATCGGCCAGATTTTGGAGACCCACCTGGGTTGGTGTGCCCACAGCGGCTGGAAGGTCG ACGCCGCCAAGGGGGTTCCGGACTGGGCCGCCAGGCTGCCCGACGAACTGCTCGAGGCGCAG CCGAACGCCATTGTGTCGACGCCGGTGTTCGACGCGCCCCAGGAGGCCGAGCTGCAGGGCCT 15 GTTGTCGTGCACGCTGCCCAACCGCGACGGTGACGTGCTGGTCGACGCCGACGGCAAGGCCA TGCTCTTCGACGGCGCGCGCGGGCGGGCCGTTCCCGTACCCGGTCACGGTTGGCTACATGTACA TCATGAAGCTGCACCACCTGGTGGACGACAAGATCCACGCCCGCTCCACCGGGCCGTACTCGA TGATCACCCAGCAGCCGCTGGGCGGTAAGGCGCAGTTCGGTGGCCAGCGGTTCGGGGAGATG GAGTGCTGGGCCATGCAGGCCTACGGTGCTACACCCTGCAGGAGCTGTTGACCATCAAG 20 TCCGATGACACCGTCGGCCGCGTCAAGGTGTACGAGGCGATCGTCAAGGGTGAGAACATCCCG GAGCCGGGCATCCCCGAGTCGTTCAAGGTGCTCCCAAAGAACTGCAGTCGCTGTGCCTCAAC GTCGAGGTGCTATCGAGTGACGGTGCGGCGATCGAACTGCGCGAAGGTGAGGACGAGGACCT GGAGCGGGCCGCGCCAACCTGGGAATCAATCTGTCCCGCAACGAATCCGCAAGTGTCGAGGA 25 **TCTTGCGTAA** 

>Rv0668 rpoC [beta]' subunit of RNA polymerase TB.seq 763368:767315 MW:146740 >emb|AL123456|MTBH37RV:763368-767318, rpoC SEQ ID NO:31 GTGCTCGACGTCAACTTCTTCGATGAACTCCGCATCGGTCTTGCTACCGCGGAGGACATCAGGC AATGGTCCTATGGCGAGGTCAAAAAGCCGGAGACGATCAACTACCGCACGCTTAAGCCGGAGA AGGACGCCTGTTCTGCGAGAAGATCTTCGGGCCGACTCGCGACTGGGAATGCTACTGCGGCA GCCAAGGTGCGTCGTGAGCGGATGGGCCACATCGAGCTTGCCGCGCCCCGTCACCCACATCTG GTACTTCAAGGGTGTGCCCTCGCGGCTGGGGTATCTGCTGGACCTGGCCCCGAAGGACCTGGA GAAGATCATCTACTTCGCTGCCTACGTGATCACCTCGGTCGACGAGGAGATGCGCCACAATGAG CTCTCCACGCTCGAGGCCGAAATGGCGGTGGAGCGCAAGGCCGTCGAAGACCAGCGCGACGG

30

CGAACTAGAGGCCCGGGCGCAAAAGCTGGAGGCCGACCTGGCCGAGCTGGAGGCCGAGGGC GCCAAGGCCGATGCGCGCGAAGGTTCGCGACGGCGGCGAGCGCGAGATGCGCCAGATCC GTGACCGCGCGCGCGGGGCCGGCGGACCGGTTGGAGGACATCTGGAGCACTTTCACCAAGCTGG CGCCCAAGCAGCTGATCGTCGACGAAAACCTCTACCGCGAACTCGTCGACCGCTACGGCGAGT ACTTCACCGGTGCCATGGGCGCGGAGTCGATCCAGAAGCTGATCGACATCGACA CCGAAGCCGAGTCGCTGCGGGATGTCATCCGAAACGGCAAGGGGGCAGAAGAAGCTTCGCGCC 5 CTCAAGCGGCTGAAGGTGGTTGCGGCGTTCCAACAGTCGGGCAACTCGCCGATGGGCATGGTG CTCGACGCCGTCCCGGTGATCCCGCCGGAGCTGCGCCCGATGGTGCAGCTCGACGGCGGCCG GTTCGCCACGTCCGACTTGAACGACCTGTACCGCAGGGTGATCAACCGCAACAACCGGCTGAA AAGGCTGATCGATCTGGGTGCGCCGGAAATCATCGTCAACAACGAGAAGCGGATGCTGCAGGA 10 GTCCGCTCAAGTCGCTTTCCGATCTGCTCAAGGGCAAGCAGGGCCGGTTCCGGCAGAACCTGC TCGGCAAGCGTGTCGACTACTCGGGCCGGTCGGTCATCGTGGTCGGCCCGCAGCTCAAGCTGC ACCAGTGCGGTCTGCCCAAGCTGATGGCGCTGGAGCTGTTCAAGCCGTTCGTGATGAAGCGGC TGGTGGACCTCAACCATGCGCAGAACATCAAGAGCGCCAAGCGCATGGTGGAGCGCCAGCGCC CCCAAGTGTGGGATGTGCTCGAAGAGGTCATCGCCGAGCACCCGGTGTTGCTGAACCGCGCAC 15 CCACCCTGCACCGGTTGGGTATCCAGGCCTTCGAGCCAATGCTGGTGGAAGGCAAGGCCATTC AGCTGCACCCGTTGGTGTGAGGCGTTCAATGCCGACTTCGACGGTGACCAGATGGCCGTGC ACCTGCCTTTGAGCGCCGAAGCGCCGAGGCCGAGGCTCGCATTTTGATGTTGTCCTCCAACAACAT CCTGTCGCCGGCATCTGGCCGTTCGCCATGCCGCGGCTGGACATGGTGACCGGGCTGT ACTACCTGACCACCGAGGTCCCCGGGGGACACCGGCGAATACCAGCCGGCCAGCGGGGATCAC 20 CCGGAGACTGGTGTCTACTCTTCGCCGGCCGAAGCGATCATGGCGGCCGACCGCGGTGTCTTG CGAGCTATTCGGCCACAGCGGCTGGCAGCCGGGCGATGCGTGGATGGCCGAGACCACGCTGG GCCGGGTGATGTTCAACGAGCTGCTGCCGCTGGGTTATCCGTTCGTCAACAAGCAGATGCACAA GAAGGTGCAGGCCGCCATCATCAACGACCTGGCCGAGCGTTACCCGATGATCGTGGTCGCCCA 25 GACCGTCGACAAGCTCAAGGACGCCGGCTTCTACTGGGCCACCCGCAGCGGCGTGACGGTGT CGATGGCCGACGTGCTGGTGCCGCCGCGCAAGAAGGAGATCCTCGACCACTACGAGGAGCGC GCGGACAAGGTCGAAAAGCAGTTCCAGCGTGGCGCTTTGAACCACGACGAGCGCAACGAGGC CCGACGACAACCCGATCATCACCATCGTCGACTCCGGCCCACCGGCAACTTCACCCAGACTC 30 GAACGCTGGCCGGTATGAAGGGCCTGGTGACCAACCCGAAGGGTGAGTTCATCCCGCGTCCG GTCAAGTCCTCCTTCCGTGAGGGCCTGACCGTGCTGGAGTACTTCATCAACACCCCACGGCGCTC GAAAGGCTTGGCGGACACCGCGTTGCGCACCGCCGACTCCGGCTACCTGACCCGACGTCTG CGTCGAGCTGGCCGAGCGTGCACCCGACGCACGCTGATCCGCGACCCGTACATCGAAACCTC 35 GGCCTACGCGCGGACCCTGGGCACCGACGCGGCGACGGCCAACGTCATCGTCGAGC GTGGTCAAGACCTGGGCGATCCGGAGATTGACGCTCTGTTGGCTGCTGGTATTACCCAGGTCAA GGTGCGTTCGGTGCTGACGTGTGCCACCAGCACCGGCGTGTGCGCGACCTGCTACGGGCGTT CCATGGCCACCGGCAAGCTGGTCGACATCGGTGAAGCCGTCGGCATCGTGGCCGCCCAGTCC ATCGGCGAACCCGGCACCCAGCTGACCATGCGCACCTTCCACCAGGGTGGCGTCGGTGAGGA CATCACCGGTGGTCTGCCCCGGGTGCAGGAGCTGTTCGAGGCCCGGGTACCGCGTGGCAAGG CGCCGATCGCCGACGTCACCGGCCGGGTTCGGCTCGAGGACGGCGAGCGGTTCTACAAGATC ACCATCGTTCCTGACGACGGCGGTGAGGAAGTGGTCTACGACAAGATCTCCAAGCGGCAGCGG CTGCGGGTGTTCAAGCACGAAGACGGTTCCGAACGGGTGCTCTCCGATGGCGACCACGTCGAG GTGGGCCAGCAGCTGATGGAAGGCTCGGCCGACCCGCATGAGGTGCTGCGGGTGCAGGGCCC CCGCGAGGTGCAGATACACCTGGTTCGCGAGGTCCAGGAGGTCTACCGCGCCCAAGGTGTGTC GATCCACGACAAGCACATCGAGGTGATCGTTCGCCAGATGCTGCGCCGGGTGACCATCATCGA CTCGGGCTCGACGGAGTTTTTGCCTGGCTCGCTGATCGACCGCGCGGAGTTCGAGGCAGAGAA CCGCCGAGTGGCCGAGGGCGGTGAGCCCGCGGCCGGCCGTCCGGTGCTGATGGGCATC ACGAAGGCGTCGCTGGCCACCGACTCGTGGCTGTCGGCGCGTCGTTCCAGGAGACCACTCG CGTGCTGACCGATGCGGCGATCAACTGCCGCAGCGATAAGCTCAACGGTCTGAAGGAAAACGT GATCATCGGCAAGCTGATCCCGGCCGGTACCGGTATCAACCGCTACCGCAACATCGCGGTGCA GCCCACCGAGGAGGCCCGCGCTGCGGCGTACACCATCCCGTCGTATGAGGATCAGTACTACAG CCCGGACTTCGGTGCGGCCACCGGTGCTGCCGTCCCGCTGGACGACTACGGCTACAGCGACTA **CCGCTAG** 

20

25

30

35

15

5

10

>Rv0711 atsA TB.seq 806333:808693 MW:86216 >emb|AL123456|MTBH37RV:806333-808696, atsA SEQ ID NO:32 ATGGCACCGAGGCCACCGAGGCGTTCAACGGCACCATCGAGCTGGATATTCGTGATTCGGAG CCGGATTGGGGCCCATACGCAGCGCCGGTGGCACCGGAGCACTCACCAAACATCCTGTATCTG GTCTGGGACGACGTCGCGACCTGGGACTGCTTTGGCGGCCTGGTCGAGATGCCCGC GATGACGCGCGCGCGAGCGTGCGCGCGCACTGTCGCAATTTCACACCACCGCACTGTGCTC GCCGACCCGGCGTCGCTGACCGGTCGCAACGCCACCGTAGGCATGGCTACCATCG AAGAGTTCACCGACGGGTTCCCCAACTGCAACGGGCGGATCCCGGCTGACACCGCGTTGCTCC CAGAGGTGCTGGCCGAACATGGCTACAACACCTACTGTGTGGGCAAGTGGCACCTGACGCCAC TCGAAGAATCCAATATGGCGTCGACGAAGCGGCACTGGCCGACCTCGCGTGGGTTCGAGCGGT TCTACGGATTCCTAGGCGGGGAGACCGACCAGTGGTATCCCGACCTGGTATACGACAACCACC CAGTGAGTCCTCCCGGCACACCCGAGGGTGGCTACCACCTGTCAAAAGACATCGCCGACAAGA CGATCGAGTTCATTCGTGATGCCAAGGTGATCGCGCCCGACAAGCCGTGGTTCAGCTACGTGTG GATTCGACATGGGGTATGAGCGCTATCGCGAGATCGTGCTGGAAAGGCAAAAGGCGCTAGGGA TCGTGCCACCCGACACCGAACTGTCGCCCATAAACCCTTATCTGGATGTGCCGGGGCCAAACG GCGAGACCTGGCCGCTGCAGGACACGGTGCGGCCGTGGGACTCGCTGAGCGATGAAGAAAAG

AAGCTGTTTTGCCGGATGGCCGAGGTGTTCGCCGGCTTTCTGAGCTACACCGACGCCCAGATC GGACGGATCCTGGACTACCTCGAGGAATCCGGCCAGCTGGACAACACCATCATCGTGGTGATC TCCGACAACGCCCCAGCGCCGAGGCCGACCCAACGGATCGGTCAACGAAGGCAAGTTCTT CAACGGCTACATCGACACCGTCGCTGAAAGCATGAAGCTCTTCGACCACCTCGGTGGCCCGCA GACCTACAACCACTACCCCATCGGGTGGCCAATGGCCTTCAACACCCCCTACAAGCTGTTCAAG CGCTACGCCTCGCATGAAGGCGGCATTGCCGACCCGGCAATCATCTCCTGGCCCAACGGCATT GCCGCACACGGTGAAATCCGCGACAACTACGTCAATGTCAGCGACATCACGCCCACCGTCTAC GACCTGTTGGGCATGACACCGCCGGGGACCGTCAAGGGGATTCCGCAGAAACCGATGGACGG CGTGAGCTTCATAGCGGCCCTTGCCGACCCGGCCGCCGACACCGGCAAGACCACCCAGTTCTA CACGCCGCCGGCTGGTCGAATTTCAACGCTGACCGCTGGGAACTGTTCCACATCGCAGCAGA CCGCAGCCAGTGCCACGACCTGGCCGCCGAGCATCCCGACAAACTTGAGGAGCTCAAGGCGCT GTGGTTCTCCGAAGCCGCCAAGTACAACGGGCTGCCGCTGGCCGATCTGAACCTCCTGGAAAC GATGACTCGGTCGCGCCTTACCTGGTCAGCGAACGAGCCAGCTACGTCTACTATCCCGACTG CGCTGACGTCGGCATCGGCGCGCCGTAGAGATTCGCGGGCGCTCGTTCGCCGTGCTGGCCG ATGTGACCATCGATACCACCGGCGCCCGAGGGCGTGCTGTTCAAGCACGGCGCGCCCATGGC 15 GGGCACGTGCTGCCGGGGACGGACGCTTGCACTACGTCTACAACTTCCTCGGTGAGCGC CAGCAGCTGGTCAGCTCGGGGTCCCGTCGGGAAGACATCTACTCGGGGTTCGTTAT TTGCGGACCGGAACCGTGCCCAACAGTCACACGCCGGTGGGCGATCTTGAGCTGTTCTTCGAC GCCGCTATCAGCGTTGGCCGCAACGGCGGTTCGGCTGTGTCCAGCCACTACGAAGCGCCGTTC 20 GCGTTCACCGGCGGTACCATCACCCAGGTCACCGTCGACGTGTCAGGCCGACCGTTCGAAGAT GTGGAATCCGATCTTGCGCTTGCTTTTTCGCGTGACTGA

>Rv0764c - lanosterol 14-demethylase cytochrome P450 TB.seq 856683:858035 MW:50879 >emb|AL123456|MTBH37RV:c858035-856680, Rv0764c SEQ ID NO:33 ATGAGCGCTGTTGCACTACCCCGGGTTTCGGGTGGCCACGACGACACGGCCACCTCGAGGAG TTCCGCACCGATCCGATCGGGCTGATGCAACGGGTCCGCGACGAATGCGGAGACGTCGGTACC TTCCAGCTGGCCGGGAAGCAGGTCGTGCTGCTGCCGGCTCGCACGCCAACGAATTCTTCTTC CGGGCGGCGACGACCTGGACCAGGCCAAGGCATACCCGTTCATGACGCCGATCTTCGG CGAGGGCGTGGTGTTCGACGCCAGCCCGGAACGGCGTAAAGAGATGCTGCACAATGCCGCGC TACGCGGCGAGCAGATGAAGGCCACGCTGCCACCATCGAAGATCAAGTCCGACGGATGATCG CCGACTGGGGTGAGGCCGGCGAGATCGATCTGCTGGACTTCTTCGCCGAGCTGACCATCTACA CCTCCTCGGCCTGATCGGCAAGAAGTTCCGCGACCAGCTCGACGGGCGATTCGCCAAGC TCTATCACGAGTTGGAGCGCGGCACCGACCCACTAGCCTACGTCGACCCGTATCTGCCGATCG AGAGCTTCCGTCGCCGCGACGAAGCCCGCAATGGTCTGGTGGCACTGGTTGCGGACATCATGA 35 ACGGCCGGATCGCCAACCCACCCACCGACAAGAGCGACCGTGACATGCTCGACGTGCTCATCG

5

10

25

10

15

20

25

30

35

>Rv0861c - DNA helicase TB.seq 958524:960149 MW:59773 >emb|AL123456|MTBH37RV:c960149-958521, Rv0861c SEQ ID NO:34

GTGCAGTCCGATAAGACGGTGCTGTTGGAAGTCGACCATGAACTGGCCGGCGCTGCACGCGCC GCCATCGCGCCGTTCGCCGAGCTGGAACGTGCACCCGAACATGTCCACACCTACCGCATCACA CCGCTGGCACTGTGGAATGCTCGCGCCGCCGGCCATGATGCCGAGCAAGTCGTCGACGCGCT GGTCAGTTACTCCCGCTACGCGGTGCCGCAACCCTTGCTCGACATCGTCGACACCATGGC CCGCTACGGACGACTGCAGTTGGTCAAGAACCCGGCCCATGGCCTGACGCTGGTGAGCCTGGA CCGCGCGGTGCTTGAGGAAGTGCTGCGCAACAAGAAGATCGCGCCGATGCTTGGCGCCCGCAT CGATGACGACACCGTCGTCCACCCCAGCGAACGCGGCCGGGTCAAGCAGCTGCTCAA GATCGGTTGGCCCGCAGAGGATCTCGCCGGCTACGTCGATGGTGAAGCGCACCCGATCAGCCT GCACCAGGAGGCTGGCAGCTGCGCGATTACCAGCGGCTGGCCGCGGACTCGTTCTGGGCGG GCGGCTCCGGGGTGGTGCTGCCATGTGGGGCCGGCAAGACGCTGGTCGGTGCGGCCGC AATGGCCAAAGCCGGCGCGACGACGTTGATCCTGGTCACCAATATCGTCGCGGCCCGGCAATG GAAACGAGAGCTGGTCGCGCGCACCTCGCTCACCGAGAATGAGATCGGCGAATTCTCGGGAGA ACGCAAGGAAATCCGACCTGTCACCATCTCGACATACCAGATGATCACCCGCCGCACTAAGGGC GAGTACCGCCATCTGGAACTGTTCGACAGCCGCGACTGGGGGCTCATCATCTATGACGAGGTG CACCTGTTGCCGGCACCGGTCTTCCGGATGACCGCTGACCTGCAGTCCAAACGGCGGCTGGGG CTGACCGCCACGTTGATCCGTGAAGACGGACGCGAGGGCGACGTGTTTTCCCTTATCGGACCA AAGCGCTATGACGCCCGTGGAAGGACATTGAGGCGCAGGGCTGGATCGCCCCAGCTGAGTG CGTGGAAGTCCGGGTCACGATGACCGACAGCGAGCGGATGATGTACGCCACCGCCGAACCCG AAGAACGCTACCGGATCTGCTCGACGGTGCACCCAAAATTGCTGTGGTCAAGTCGATTCTGGC GAAGCACCCGGATGAGCAGACCCTGGTCATCGGAGCGTACTTGGATCAGCTCGACGAGCTGGG CGCCGAGCTCGGCGCTCCGGTGATTCAGGGGTCGACAAGGACCAGCGAACGCGAGGCACTGT TCGACGCCTTCCGCCGCGCGAGGTCGCTACGCTCGTGGTGTCCAAGGTGGCTAACTTCTCCA TCGACTTGCCGGAAGCCGCCGTGGCGGTACAGGTTTCGGGAACATTCGGCTCACGCCAGGAAG

>Rv0904c accD3 TB.seq 1006694:1008178 MW:51741 5 >emb|AL123456|MTBH37RV:c1008178-1006691, accD3 SEQ ID NO:35 GTGAGTCGTATCACGACCGACCAACTGCGGCACGCGGTGCTAGACCGGGGATCTTTCGTCAGC TGGGATAGCGAGCCGCTGGCGGTGCCGGTAGCCGACTCCTATGCGCGGGAGCTGGCCGCCGC TCGGGCGCCACCGGCGCGCGACGAATCGGTGCAGACCGGTGAGGGACGCGTATTCGGGCGG CGGGTGGCCGTGGCCTGTGAGTTCGACTTCCTGGGCGGCTCGATTGGGGTGGCAGCGGC CGAACGGATCACCGCCGCCGTCGAGCGGCGGCGACCGCCGAGCGGCTGCCGCTACTGGCGTCAC 10 CAAGCTCGGGAGGCACCCGCATGCAAGAAGGCACGGTCGCGTTTCTGCAGATGGTGAAGATCG CTGCGGCCATCCAGCTGCACAACCAGGCGCGCCTGCCCTACCTGGTCTATTTGCGCCATCCGA CCACGGGTGGAGTTTTCGCGTCGTGGGGCTCGCTGGGGCATCTCACCGTCGCCGAGCCGGGC GCCCTGATCGGCTTTCTGGGACCACGGGTCTATGAGTTGCTCTATGGCGACCCCTTCCCATCCG GCGTCCAAACCGCCGAGAATCTACGGCGCGCATGGGATCATCGACGGCGTCGTTGCACTGGACC 15 GGCTACGACCGATGCTGGATCGTGCGTTGACGGTGCTCATCGACGCTCCCGAACCGCTTCCGG CACCGCAGACGCCCGCGCCCGTACCCGATGTGCCCACGTGGGACTCGGTGGTGGCATCGCGC GTCAGGAACCGATCAAGGCGAAGCGGCGACCACGCTGCTGGCGCCTGGCCCGCTTTGGCGGCC AACCCACGGTGGTCCTCGGCCAGCAAAGGGCAGTAGGCGGGGGGGAAGCACTGTCGGGCCC 20 GCCAGATCGCGCATTGCCTGGCCGAGCTCGTCACGCTGGATACCCCGACCGTGTCGATCCTGC TGGGCCAGGGCAGCGGCGGCGCGCGCGATGTTGCCCGCCGACCGGGTGCTGGCCGC ACTCCACGGCTGGCTGCCCCTTGCCTCCCGAAGGAGCCAGCGCGATCGTGTTCCGAGACAC 25 TGCTCATGCCGCCGAACTCGCTGCCGCCCAAGGCATCCGGTCGGCCGACCTACTGAAGTCGGG GATTGTCGACACCATCGTGCCGGAGTACCCCGACGCCGCAGACGAGCCGATCGAGTTCGCCCT ACGACTGTCGAACGCCATCGCCGCAAGTGCACGCGTTACGGAAGATACCGGCCCCGGAACG CCTCGCGACTCGGTTGCAACGCTACCGCCGGATCGGGTTGCCCCGCGACTAA 30

GACCATGACGCCCCCCCCCGGGATGGTTCGCCAACGCCCTCGTGCAGGCATGTTGGCCATCGG TCAACCGGGCACCCGCCGGCCCAGCGGCGCCCAGTGGCTGCCAGCGCGCCCAAGCAT CCCGCAGCAAACATGCCGCCGGGGTCGGTCGAACAGGTGGCGGCCAAGGTGGTGCCCAGTG CCGAGGGGCTGATCTTGACCAACAACCACGTGATCGCGGCGGCCGCCAAGCCTCCCCTGGGC AGTCCGCCGCAAAACGACGGTAACCTTCTCTGACGGGCGGACCGCACCCTTCACGGTGGTG GGGGCTGACCCACCAGTGATATCGCCGTCGTCCGTGTTCAGGGCGTCTCCGGGCTCACCCCG ATCTCCCTGGGTTCCTCCTCGGACCTGAGGGTCGGTCAGCCGGTGCTGGCGATCGGGTCGCCG CTCGGTTTGGAGGGCACCGTGACCACGGGGATCGTCAGCGCTCTCAACCGTCCAGTGTCGACG ACCGGCGAGGCCGCCAGCACCAGAACACCGTGCTGGACGCCATTCAGACCGACGCCGCGATCAA CCCCGGTAACTCCGGGGCGCGCTGGTGAACATGAACGCTCAACTCGTCGGAGTCAACTCGGC CATTGCCACGCTGGGCGCGGACTCAGCCGATGCGCAGAGCGGCTCGATCGGTCTCGGTTTTGC GATTCCAGTCGACCAGGCCAAGCGCATCGCCGACGAGTTGATCAGCACCGGCAAGGCGTCACA TGCCTCCCTGGGTGTGCAGGTGACCAATGACAAAGACACCCTGGGCGCCAAGATCGTCGAAGT AGTGGCCGGTGCTGCCGCGAACGCTGGAGTGCCGAAGGCGTCGTTGTCACCAAGGTCG ACGACCGCCCGATCAACAGCGCGGACGCGTTGGTTGCCGCCGTGCGGTCCAAAGCGCCGGGC GCCACGGTGGCGCTAACCTTTCAGGATCCCTCGGGCGGTAGCCGCACAGTGCAAGTCACCCTC GGCAAGGCGGAGCAGTGA

20

25

30

35

5

10

15

lipoprot in, similar to various other MTB proteins TB.seq 1128089:1129174 MW:38079 >emb|AL123456|MTBH37RV:1128089-1129177, Rv1009 SEQ ID NO:38 ATGTTGCGCCTGGTAGTCGGTGCGCTGCTGGTGTTGGCGTTCGCCGGTGGCTATGCGGTC GCCGCATGCAAAACGGTGACGTTGACCGTCGACGGAACCGCGATGCGGGTGACCACGATGAAA TCGCGGGTGATCGACATCGTCGAAGAGAACGGGTTCTCAGTCGACGACCGCGACGACCTGTAT CCCGCGCCGCGTGCAGGTCCATGACGCCGACACCATCGTGCTGCGGCGTAGCCGTCCGCT 5 GCAGATCTCGCTGGATGGTCACGACGCTAAGCAGGTGTGGACGACCGCGTCGACGGTGGACG GTCCCGCTGTCCGGGATGGCGCTACCGGTCGTCAGCGCCCAAGACGGTGCAGCTCAACGACGG CGGGTTGGTGCGCACGGTGCACTTGCCGGCCCCCAATGTCGCGGGGCTGCTGAGTGCGGCCG GCGTGCCGCTGTTGCAAAGCGACCACGTGGTGCCCGCCGCCGACGGCCCCGATCGTCGAAGGC 10 ATGCAGATCCAGGTGACCCGCAATCGGATCAAGAAGGTCACCGAGCGGCTGCCGCCGCCG AACGCGCGTCGTGTCGAGGACCCGGAGATGAACATGAGCCGGGAGGTCGTCGAAGACCCGGG GGTTCCGGGGACCCAGGATGTGACGTTCGCGGTAGCTGAGGTCAACGGCGTCGAGACCGGCC GTTTGCCCGTCGCCAACGTCGTGGTGACCCCGGCCCACGAAGCCGTGGTGCGGGTGGGCACC AAGCCCGGTACCGAGGTGCCCCCGGTGATCGACGGAAGCATCTGGGACGCGATCGCCGGCTG 15 TGAGGCCGGTGGCAACTGGGCGATCAACACCGGCAACGGGTATTACGGTGGTGTGCAGTTTGA CCAGGGCACCTGGGAGGCCAACGGCGGGCTGCGGTATGCACCCCGCGCTGACCTCGCCACCC GCGAAGAGCAGATCGCCGTTGCCGAGGTGACCCGACTGCGTCAAGGTTGGGGCGCCTGGCCG GTATGTGCTGCACGAGCGGGTGCGCGCTGA 20

>Rv1010 ksgA 16S rRNA dimethyltransferase TB.seq 1129150:1130100 MW:34647 >emb|AL123456|MTBH37RV:1129150-1130103, ksgA SEQ ID NO:39 ATGTGCTGCACGAGCGGGTGCGCGCTGACCATCCGGCTGCTCGGGCGCACTGAGATCAGGCG GCTGGCCAAAGAGCTCGACTTTCGGCCGCGCAAATCTCTCGGACAGAACTTCGTGCACGACGC CAACACGGTGCGACGGGTTGCCGCCTCCGGGGTCAGCCGTTCCGACCTGGTTTTGGAGGT CGGGCCGGGCCTGGGATCGCTGACCCTGGCACTGCTCGACCGCGGCGCGACCGTCACCGCGG TCGAGATCGATCCACTACTGGCTTCTCGGCTGCAACAGACCGTGGCGGAGCACTCGCACAGCG AGGTTCACCGACTAACGGTGGTCAATCGCGACGTCCTGGCCCTGCGCCGGGAGGATCTAGCCG CGGCGCCGACCGCGGTGGTTGCCAATCTGCCGTACAACGTAGCGGTACCGGCGTTGTTGCATC TGCTTGTCGAGTTCCCGTCGATCCGTGTCGTGACGGTGATGGTGCAGGCCGAGGTCGCCGAAC GGCTCGCCGGGCGGGCAGCAAAGAGTACGGCGTGCCCAGCGTTAAGCTGCGCTTCTTC GGGCGGTTCGCCGCTGCGCATGTTCCGCCGACCGTTTTCTGGCCCATTCCGCGTGTCTAT TCCGGGCTGGTACGCATCGATCGATATGAGACCTCGCCCTGGCCCACCGACGACGCTTTTCGA CGGCGGGTATTCGAACTCGTGGACATCGCATTCGCGCAGCGCGCGAAGACTTCTCGCAACGCG TTTGTGCAGTGGGCGGGCTCGGGAAGCGAGTCGGCGAATCGATTGTTGGCGGCCAGCATCGAC CCCGCCGTCGCGGTGAGACGCTGTCCATCGACGACTTCGTGCGGCTGCTGCGACGGTCCGG

25

30

CGGCTCCGACGAGGCCACCAGCACCGGCCGGGACGCCAGGGCGCCGGACATTTCGGGGCAC **GCGTCGGCGAGCTGA** 

Homology to E.coli protein YcbH TB.seq 1130189:1131106 MW:31350 >Rv1011->emb|AL123456|MTBH37RV:1130189-1131109, Rv1011 SEQ ID NO:40 GTGCCCACCGGGTCGGTCACCGTTCGGGTGCCCGGAAAGGTCAACCTCTATCTGGCGGTCGGC GATCGCCGCGAGGACGGCTATCACGAGCTGACCACGGTATTTCATGCCGTCTCGCTGGTCGAC GAGGTAACCGTTCGTAACGCTGATGTGCTCTCGCTCGAGTTGGTCGGCGAGGGGGCCGACCAG CTGCCGACCGACGCAATCTCGCCTGGCAGGCGGCCGAGCTGATGGCCGAACACGTGGG CCGGGCGCCGGACGTCTCGATCATGATCGACAAATCCATTCCGGTCGCCGGCGGCATGGCCG GTGGCAGCGCGGACGCTGCGGCGGTCCTGGTTGCGATGAACTCGTTGTGGGAACTCAATGTGC 10 CCCGCCGCGCACCTGCCATGCTCGCCGCGCGCGCTAGGCAGCGATGTGCCGTTTGCCCTGCAT GGTGGTACCGCGCGGGGACGGGTCGCGGCGAGGAGTTGGCCACCGTGTTATCCCGCAACAC CTTCCACTGGGTCCTGGCGTTCGCCGACAGCGGGTTGCTCACCTCCGCGGTGTACAACGAGCT CGACCGGCTCAGGGAGGTGGGGGATCCGCCCCGGCTTGGTGAGCCCGGGCCGGTTCTGGCTG CCTTAGCTGCGGGTGATCCGGATCAGCTGGCGCCGTTGCTGGGTAATGAAATGCAAGCGGCCG CGGTGAGCCTGGACCCGGCGCGCTGGCGCGCGTTACGCGCCGGTGTGGAGGCCGGCGCGCTC GCAGGCATCGTGTCCGGTTCGGGTCCCACGTGTGCCTTCCTGTGCACCTCGGCGAGCTCGGCG GCCGGTACCCGGCGCCCGCGTGGTGTCTGCGCCGACCGAAGTGTGA 20

>Rv1106c - cholesterol dehydrogenase TB.seq 1232845:1233954 MW:40743 >emb|AL123456|MTBH37RV:c1233954-1232842, Rv1106c SEQ ID NO:41 ATGCTTCGCCGCATGGGTGATGCATCGCTGACAACCGAGCTCGGCCGCGTTCTGGTCACCGGC GGCGCGGCTTCGTGGCCCCAACCTGGTGACCACCTTGCTGGACCGCGGGCACTGGGTGCG TTCCTTCGACCGCGCCGCCGCTCGCTGCCCGCGCACCTGGAGGTGCTGCAAGGGGA CATCACCGACGCGGACGTCTGCGCCGCGGCCGTGGACGGCATCGACACGATCTTCCACACCG CGGTCAACGTCGGCGCACCGAGAACCTGCTGCACGCCGGCCAGCGGGCCGGGGTGCAGCG GTTCGTCTACACGTCATCCAACAGTGTGGTGATGGGCGGCCAGAACATCGCCGGCGGTGACGA GACGCTGCCCTATACCGACCGGTTCAACGACCTCTACACCGAGACCAAGGTGGTTGCCGAGCG ATTCGTGTTGGCCCAGAACGGTGTCGACGGCATGCTGACGTGCGCGATCCGGCCCAGCGGCAT CTGGGGAAACGGCGATCAGACGATGTTCCGCAAGCTGTTCGAAAGTGTGCTCAAGGGCCACGT CAAGGTGCTGGTCGGCCCAAGTCGGCCCGGCTGGATAACTCTTACGTGCACAACCTGATTCA CGGTTTCATCTTGGCCGCTGCCCATCTGGTGCCGGACGGCACAGCGCCCCGGGCAGGCTTACTT CATCAACGACGCAGAGCCGATCAATATGTTCGAGTTCGCTCGGCCGGTGCTCGAGGCGTGCGG GCAGCGCTGGCCGAAGATGCGGATTTCCGGCCCCGCGGTCCGCTGGGTAATGACGGGGTGGC

5

15

25

30

AGCGGCTGCACTTCCGGTTCGGATTCCCCGCGCCGCTGCTCGAGCCGCTGGCCGTCGAACGAC
TGTACCTGGACAACTACTTTTCGATCGCTAAGGCACGCCGCGACCTGGGCTATGAGCCGCTGTT
CACCACCCAGCAGGCGCTGACCGAATGCCTGCCGTACTACGTGAGTCTGTTTGAGCAGATGAA
GAACGAGGCCCGGGCGGAAAAAACGGCCGCCACAGTCAAGCCGTAG

5

10

15

20

>Rv1110 lytB2 TB.seq 1236183:1237187 MW:36298 >emb|AL123456|MTBH37RV:1236183-1237190, lytB' SEQ ID NO:42 ATGGTTCCGACGGTCGACATGGGGGATTCCCGGGGGCTTCGGTATCGTCGCGATCGGTGGCCGAC CGTCCCAACCGTAAGCGGGTGCTGCCTGGCCGAGCCGCGTGGCTACTGCGCTGGCGTGGATCG GGCCGTCGAAACGGTCGAACGCGCGCTTCAAAAACACGGCCCGCCTGTCTACGTGCGTCACGA GATCGTGCATAACCGCCACGTGGTTGACACCCTGGCTAAGGCCGGTGCGGTTTTCGTCGAAGA GACCGAGCAGGTTCCCGAGGGAGCGATTGTGGTGTTCTCCGCGCACGGGGTCGCGCCTACGG TGCACGTCAGCGCCAGCGAGCGCAACCTGCAGGTCATTGACGCCACCTGCCCGCTGGTCACCA AGGTGCACAACGAGGCCAGGCGGTTCGCCCGGGACGACTACGACATCTTGCTGATCGGTCATG AGGCCACGAGGAAGTCGTCGGTACTGCTGGGGAAGCTCCCGATCATGTGCAGCTGGTCGACG GGGTGGACGCCGTCGACCAGGTGACCGTCCGTGACGAGGACAAAGTGGTTTGGCTGTCGCAG ACCACCCTGTCCGTCGATGAGACCATGGAGATTGTCGGGCGGTTGCGTCGGCGTTTCCCCAAG CTGCAGGATCCGCCCAGCGACGACATCTGCTATGCGACCCAGAATCGGCAGGTCGCGGTCAAG GCGATGGCGCCCGAGTGCGAGCTGGTCATCGTGGTCGGCTCGCGCAATTCGTCGAATTCGGTT CGGCTGGTCGAGGTGCCGGGTGCCGGGGCGGGCCGCCCACCTGGTGGACTGGGCCG ACGATATCGACTCGGCCTGGCTGGACGGCGTTACCACGGTCGGCGTTACGTCGGGGGCATCGG TCCCCGAGGTGCTGCGCGGTGTGCTGGAGCGGCTGGCCGAATGCGGCTACGACATCGTG CAACCGGTGACAACGGCCAACGAGACGTTGGTGTTCGCATTGCCCCGGGAGCTCCGCTCACCT **CGCTGA** 

25

30

35

GTGTTCCGCATCCTCGACGAGGAAAAACTACTGACGCAAGAACTCAGCGGGTACCGCGAATACC GGCAACTGGTGCGCTACCGGTTGGTGCCCTACGTGTGGTAG

>Rv1223 htrA TB.seq 1365810:1367456 MW:56547 >emb|AL123456|MTBH37RV:1365810-1367459, htrA SEQ ID NO:44 5 GTGAGCCACTTGTCGCAGCGCATGGCGGGGTTGCTGCGAGTTCATGGCGAGTGGTCGCGATCC GTGGATACTAGGGTGGACACGGACACGCGATGCCTGCACGTTTTAGCGCCCAGATTCAGAAT GCCGCCCCGGTTTTTCGGCCACCGGTCGACCCGGCGTCGCGTCAAGCGTTCGGGCGTCCGT CCGGGGTCCAAGGGTCCTTTGTGGCCGAGCGTGTGCGCCCGCAGAAGTACCAGGACCAGTCT 10 GACTTCACACCGAACGATCAGCTTGCTGACCCGGTGCTTCAGGAGGCGTTCGGTCGTCCGTTC GCGGCCCGAATCGCTGCAGCGCCATCCCATCGATGCCGGAGCGCTGGCAGCTGAGAAAGA GGGACGCCAGCGCTAGCCGCCGCGCACCGCACGGTGCGCTGGCCGGCAGCGGCAAGCTGG GTGTGCGCGACGTGCTGTTTGGCGGCAAGGTGTCCTACTTGGCGCTGGGCATCTTGGTCGCTA 15 TCGCACTGGTGATCGGCGGCATCGGCGGTGTCATCGGCCGCAAGACCGCGGAAGTAGTCGAT GTTCACCAAGGTGGCGGCCGCCGTGGCCGATTCGGTGACCATTGAGTCGGTCAGCGACCA GGAGGGCATGCAAGGTTCCGGCGTCATCGTCGATGGCCGCGGCTACATCGTCACCAACAATCA CGTGATCTCTGAGGCGGCCAACAATCCCAGCCAGTTCAAGACGACCGTGGTGTTCAACGACGG CAAGGAGGTGCCCGCCAATCTGGTGGGTCGTGACCCCAAGACCGACTTGGCCGTCCTCAAGGT 20 CGACAACGTCGACAATCTGACCGTGGCCCGGCTCGGTGATTCCAGCAAGGTACGGGTCGGTGA CGAAGTCCTCGCGGTCGCGCGCCCCTGGGGCTGCGCAGTACGGTGACCCAGGGCATTGTCA GCGCGCTACACCGCCCCGTTCCGTTGTCGGGCGAGGGCTCTGACACCGACACCGTCATTGACG CAATTCAGACCGACGCCTCGATCAACCACGGTAACTCCGGCGGTCCGCTAATCGACATGGATGC CCAGGTGATTGGCATCAACACCGCCGGTAAGTCACTGTCGGATAGCGCCAGCGGGCTGGGCTT 25 TGCGATCCCGGTCAACGAGATGAAATTGGTGGCAAATTCTCTGATCAAAGACGGAAAGATCGTG CATCCGACGTTGGGCATCAGCACCCGGTCAGTAAGCAACGCGATCGCGTCGGGCGCGCAGGT GGCCAATGTAAAGGCGGGAAGTCCCGCGCAGAAGGGCGGGATCTTGGAGAACGATGTGATCGT CAAGGTCGGTAACCGCGGGTCGCCGACTCCGACGAGTTCGTCGTCGCCGTGCGCCAGTTGG 30 CTATCGGCCAGGACGCTCCGATAGAGGTGGTCCGCGAGGGTCGGCATGTGACGCTGACGGTG AAACCGGACCCCGATAGCACCTAG

>Rv1224 - TB.seq 1367461:1367853 MW:14083

>emb|AL123456|MTBH37RV:1367461-1367856, Rv1224 SEQ ID NO:45

GTGTTCGCCAACATCGGTTGGTGGGAAATGCTCGTCCTCGTCATGGTCGGGCTGGTGGTGCTT

GGCCCGGAGCGCTCCCGGGTGCCATCCGCTGGCCAAGCGCTCTGCGGCAGGCGCGCG

>Rv1229c mrp similar to MRP/NBP35 ATP-binding proteins TB.seq 1371778:1372947 MW:41064 >emb|AL123456|MTBH37RV:c1372947-1371775, mrp SEQ ID NO:46 ATGCCAAGCCGCCTACACTCGGCGGTGATGTCCGGAACTCGTGATGGCGACCTGAACGCGGCG ATACGCACCGCGCTGGGCAAGGTAATCGACCCCGAATTGCGGCGCCCCATCACCGAACTGGGG ATGGTCAAAAGCATCGACACCGGCCCGGATGGGAGCGTGCACGTCGAGATCTACCTGACCATC 10 GCCGGCTGCCCGAAGAAGTCCGAAATCACCGAGCGTGTCACCCGGGCGGTCGCCGACGTGCC AGGCACTTCGGCGGTGCGGGTCAGCTTGGACGTGATGAGCGACGAGCAGCGCACCGAGCTGC GTAAGCAGTTGCGTGGCGATACCCGCGAACCCGTCATCCCGTTCGCGCAACCCGATTCCTTGAC CCGGGTGTATGCCGTGGCTTCCGGTAAGGGCGGAGTCGGAAAGTCCACCGTCACGGTCAACCT GGCCGCCGCGATGGCCGTCCGCGGCCTGTCGATCGGGGTGCTGGACGCTGATATCCACGGCC 15 ACTCTATCCCCGGATGATGGGCACCACCGACCGGCCTACCCAGGTTGAGTCGATGATCCTGC CGCCGATCGCCCACCAGGTGAAGGTCATCTCGATAGCCCAGTTCACCCAGGGCAACACCCCGG TGGTGTGGCGCGGGCGATGCTGCACCGGGCGTTGCAGCAGTTTCTGGCCGACGTGTACTGG GGGGATCTGGACGTGCTGCTGGACTTGCCGCCCGGAACCGGCGACGTCGCCATCTCGGT GGCTCAACTGATCCCCAACGCCGAACTCCTGGTGGTCACCACCCCGCAGCTGGCCGCGGGA 20 GGTGGCCGAACGGCCGCCAGCATCGCCCCCCCAACGCATCGTCGGCGTCGTGG AGAACATGTCGGGGCTCACGCTGCCGGACGGCACCACGATGCAGGTGTTCGGCGAGGGCGGT GGCCGGCTGGCCGAGCGGTTGTCGCGTGCGGTCGGCGCCGACGTGCCGCTGCTGGGTCA GATCCCGCTGGACCCCGCACTGGTGGCCGCCGGCGATTCGGGCGTACCGCTCGTGTTGAGCT CGCCGGACTCGCCAAGGAACTGCATAGCATCGCCGACGGCTTGTCGACTCGACGAC 25 GCGGATTGGCGGCCATGTCGCTGGGGTTGGACCCGACACGACGCTAG

>Rv1279 - TB.seq 1430060:1431643 MW:57332

>emb|AL123456|MTBH37RV:1430060-1431646, Rv1279 SEQ ID NO:48

ATGGACACTCAGAGCGACTACGTCGTGGTCGGTACCGGCTCAGCCGGGGCGGTTGTGGCCAG CCGGCTTAGCACCGATCCGGCCACGACGGTGGCCCTTGGAGGCGGGGCCGCGTGACAAGA ACAGATTCATCGGCGTCCCAGCGGCGTTTTCCAAGCTGTTCCGCAGCGAGATCGACTGGGATTA CCTAACCGAACCGCAGCCGGAGCTCGACGGCCGCGAAATCTATTGGCCTCGTGGCAAGGTGCT CGGTGGCTCGTCCATGAACGCAATGATGTGGGTGCGTGGATTCGCATCAGACTACGATGA GTGGGCCGCGGGCCGGTCCGCGGTGGTCGTACGCCGACGTGCTCGGCTACTTTCGCCGCA TCGAGAACGTCACCGCTGCCTGGCACTTTGTCAGCGGTGACGACAGCGGAGTAACCGGTCCGT AGTGCGGATTTGCCGCTGCGCGGAATTCCCCTCGACCGGAAGGCTTTTGCGAGACCGTCG TCACCCAGCGCCGCGGTGCTCGATTCAGTACTGCCGACGCCTATCTGAAGCCCGCGATGCGCC GTAAAAACCTCCGTGTGCTTACCGGCGCCACTGCTACCCGGGTGGTCATCGACGGCGACCGGG GTGCTCTGCGCTGGTGCCGTCAACAGCCCTCAGCTGCTGATGCTCTCCGGCATCGGCGACCGC GACCACCTCGCCGAACACGACATCGACACCGTTTACCACGCGCCCGAGGTCGGGTGCAACCTG CTCGATCATCTCGTCACGGTGCTGGGTTTCGACGTCGAAAAGGACAGCTTGTTTGCCGCCGAGA AGCCCGGCCAGTTGATCAGCTACTTACTGCGACGCCGCGGCATGCTCACCTCCAACGTCGGCG AGGCGTACGGATTTGTCCGCAGCCGACCCGAACTGAAGCTGCCCGATTTGGAGTTGATTTTTGC CCCGGCGCCGTTTTACGACGAAGCGCTGGTTCCACCGGCTGGTCACGGTGTGGTATTCGGCCC GATTCTGGTCGCCGCAAAGCCGTGGCCAGATCACGCTGCGGTCCGCCGATCCGCATGCCAA GCCTGTCATCGAACCGCGTTACCTGTCCGATCTCGGTGGCGTAGACCGGGCCGCCATGATGGC TCGCGCGACCGCGAACAGCACCGAGCTGGACGAGGCCACTCTCGAGTTGGCGCTGGCCACT TGTTCGCACACCCTGTACCACCCGATGGGCACCTGCCGCATGGGCAGCGACGAGGCCAGCGT

5

10

15

20

25

30

GGTGGATCCGCAGCTGCGGGTCCGCGGTGTCGACGGACTCCGCGTCGCCGACGCGTCGCTGA TGCCCAGCACGGTTCGTGGGCATACGCATGCGCCGTCGGTGCTGATCGGGGAGAAGGCCGCC GACTTAATCCGCAGCTGA

>Rv1294 thrA homoserine dehydrogenase TB.seq 1449373:1450695 MW:45522 5 >emb|AL123456|MTBH37RV:1449373-1450698, thrA SEQ ID NO:49 GTGCCCGGTGACGAAAAGCCGGTCGGCGTAGCGGTACTCGGTTTGGGCAACGTCGGCAGCGA GGTTGTCCGCATCATCGAGAACAGCGCCGAGGATCTCGCGGCTCGTGTCGGTGCCCCATTGGT CCGACGACATTGAAGAGCTCGTGGCCCGCGAGGATGTCGATATCGTGGTGGAAGTGATGGGGC CGGTGGAACCGTCGCGAAGGCGATCCTGGGCGCCCTTGAGCGCGGCAAGTCCGTCGTTACG 10 GCGAACAAGGCTTTACTCGCCACCTCCACCGGCGAATTGGCACAGGCCGCCGAAAGCGCCCAT TCGCTGGCCGGCGACACGGTGCTGCGAGTGGCCGGGATCGTCAACGGCACCAACTACATC CTCTCGGCGATGGACAGCACCGGCGCTGACTATGCCAGCGCCCTGGCCGACGCAAGTGCGCT GGGCTATGCGGAGGCTGATCCCACCGCAGACGTCGAAGGCTACGACGCCGCGGCCAAGGCAG 15 CGATCCTGGCATCCATTGCCTTCCACACCCGGGTGACCGCAGACGACGTGTATCGCGAAGGCA TCACCAAGGTCACTCCGGCCGACTTCGGATCCGCGCACGCGCTGGGTTGCACCATCAAACTGC TGTCGATCTGTGAGCGCATAACCACCGACGAAGGTTCGCAGCGGGTATCGGCCCGCGTCTATC CGGCCCTGGTACCTCTGTCGCATCCGCTTGCCGCGGTCAACGGCGCGTTCAATGCCGTGGTGG TCGAGGCCGAGGCCGGGCCGGCTGATGTTCTACGGCCAGGGCGCGCGGCGCGCCGAC 20 GCCCCGTGAGTCTAAATACGCTCAACTTCCGGTGGCACCAATGGGTTTCATTGAAACGCGCTA TTACGTCAGCATGAACGTCGCCGACAAGCCGGGCGTCTTGTCCGCGGTGGCGGCGGAATTCGC CAAACGCGAGGTGAGCATCGCCGAGGTGCGCCAGGAGGGCGTTGTGGACGAAGGTGGTCGAC GGGTGGGAGCCCGAATCGTGGTGGTCACGCACCTCGCCACTGACGCCGCACTCTCGGAAACC 25 GTTGATGCACTGGACGACTTGGATGTCGTGCAGGGTGTCCAGCGTGATACGACTGGAAGGA ACCGGCTTATGA

>Rv1323 fadA4 acetyl-CoA C-acetyltransferase (aka thiL) TB.seq 1485860:1487026 MW:40049
 >emb|AL123456|MTBH37RV:1485860-1487029, fadA4 SEQ ID NO:50
 GTGATTGTTGCTGGCGCGCGTACACCCATCGGCAAGTTGATGGGCTCCCTGAAGGATTTCAGCG
 CCAGCGAGCTGGGTGCCATCGCCATTAAGGGCGCCCTGGAGAAGGCCAACGTGCCGGCGTCC
 TTGGTCGAGTACGTGATCATGGGCCAGGTGTTGACCGCGGGTGCCGGGCAAATGCCCGCACG
 GCAGGCGGCAGTGGCGGCCGGCATCGGTTGGGATGTCCCTGCGCTGACGATCAACAAGATGT
 GCCTGTCCGGCATCGACGCAATCGCGCTGGCTGATCAACTCATTCGGGCCAGAGAGTTCGACG
 TGGTGGTGGCCGGCGGTCAGGAGTCGATGACGAAGGCGCCCCACCTGTTGATGAATAGCCGGT

putative guanylate kinase TB.seq 1564399:1565022 MW:22064 >Rv1389 gmk 15 >emb|AL123456|MTBH37RV:1564399-1565025, gmk SEQ ID NO:51 GTGAGCGTCGGCGAGGGACCGGACACCAAGCCCACCGCGCGTGGCCAACCGGCGCAGTGG GACGTGTGGTGGTGCTCCGGGTCCGCGGCAAATCCACGGTGGTTCGGTGTCTGC GCGAGCGGATCCCGAATCTGCATTTCAGTGTCTCGGCCACGACGCGGGCGCCACGCCCGGGC GAGGTCGACGGTGTCGACTACCACTTCATCGACCCCACCCGCTTTCAGCAGCTCATCGACCAG GGTGAGTTGCTGGAATGGGCAGAAATCCACGGCGGCCTGCACCGGTCGGGCACTTTGGCCCA 20 GCCGGTGCGGCGGCGCGCGGCGACTGGTGCCGGGTGCTTATCGAGGTTGACCTGGCCGGGG CCAGGGCGATCAAGAAGACGATGCCCGAGGCTGTCACCGTGTTTCTGGCGCCACCTAGCTGGC AGGATCTTCAGGCCAGACTGATTGGCCGCGCGCACCGAAACAGCTGACGTTATCCAACGCCGCC TGGACACCGCGCGGATCGAATTGGCAGCGCAGGGCGACTTTGACAAGGTCGTGGAACAGGC GATTAGAGTCTGCGTGTGCGGAATTGGTATCCTTGCTGGTGGGAACGGCACCGGGCTCCCCGT 25 GA

5

10

15

20

25

30

35

GCGAACTCGCTCCTGATGCGCAGAACGATCCGATCGGGCATGCCGCGTTCGTGCATGCGCATC CCCGATGGATCGCCCAGGCCTTTGCTGACGCGTTGGGCGCGCGGCGGCGGGGGAGCTCGAGGCA GTTTGGCCAGCGACGACGACGGCCAGCGGTGCACCTGGCGGCACGCCCCGGGGTGCTGAC ATCTGCCGCGCGGTGACCCGGGGCGACTGGCGCCGGTGCGCGACGGCCAAGCGCTGGTCCA GGACGAGGCAGCCAGTTAGTCGCCCGAGCATTGACCCTGGCGCCAGTCGACGGCGATACCG GACGGTGGCTGGACCTGTGTGCCGGACCGGGCGAAGACCGCGCTGTTGGCCGGGCTGGGT TTGCAGTGCGCAGCCCGGGTGACCGCGGGACCTCGCCACACCGCGCGGACCTGGTAGC ACAGAACACCCGCGGGCTGCCGGTTGAGCTCTTGCGTGTCGACGGGCGCACACCGACCTCG ACCCGGGTTTCGACCGGGTGCTGGTGGATGCGCCCTGCACCGGGCTGGGCGCGTTACGCCGT CGGCCGGAGGCCCGTTGGCGTCGTCAGCCGGCGGACGTAGCGGCCAAGCTACAACG CGAGTTGTTGAGCGCCGCCATCGCGCTGACTCGGCCCGGCGGTGTCGTGCTCTATGCCACATG CTCGCCGCACCTGGCCGAGACTGTGGGTGCTGTCGCCGACGCGCTACGCCGACATCCGGTTCA TTCAGCTGTGGCCGCACCGGCACGGTACCGACGCCATGTTCGCCGCGGCGTTGCGCCGCCTG **ACGTGA** 

>Rv1409 ribG riboflavin biosynthesis TB.seq 1585192:1586208 MW:35367 >emb|AL123456|MTBH37RV:1585192-1586211, ribG SEQ ID NO:53

ATGAACGTGGAGCAGGTCAAGAGCATCGACGAGGCTATGGGTCTCGCCATCGAGCACTCCTAC CAGGTCAAAGGCACGACTTATCCAAAACCCCCAGTGGGGGCCGTCATTGTGGATCCCAACGGT CGGATCGTCGGCGCCGGCGCCGAGCCGGCCGGTGGCGATCATGCCGAGGTGGTGGCGC TGCGCCGGGCCGGATTGGCTGCCGGCGCCATCGTGGTGGTCACCATGGAACCCTGTAAC CACTACGGCAAGACTCCGCCATGCGTGAACGCTCTGATCGAAGCCAGGGTGGGGACGGTGGTC TACGCCGTCGCCGACCCGAACGGGATCGCTGGGGGGTGGCGGGCCGGCTGTCAGCAGCGG GCCTACAGGTGCGGTCCGGGGTGTTGGCTGAACAGGTGGCGGCCGGACCGCTGCGGGAGTGG CTCCACAAGCAACGCACCGGTCTGCCGCATGTCACCTGGAAGTACGCCACCAGCATCGACGGC CGCAGCGCCGCCGACGGCTCCAGCCAGTGGATCTCCAGCGAGGCCGCACGCCTGGATCT GCATCGCCGCCGCCCATCGCCGACGCGATCTTGGTCGGCACCGGCACCGTCCTCGCCGACG TGATGATCCGCACCCACGAACCTATGGAGGTGCTCAGGGCGTTGTCGGATCGCACCGACGTGC TGCTGGAAGGAGGTCCCACCCTCGCCGGCGCCTTCCTACGAGCGGGTGCGATCAACCGGATCC TGGCCTACGTCGCACCGATCCTGTTGGGCGGTCCGGTTACCGCGGTCGATGACGTCGGGGTGT CCAACATCACCAACGCGTTGCGTTGGCAGTTCGACAGCGTCGAAAAGGTCGGACCGGATCTGTT GCTGAGCTTGGTGGCTCGTTAG

25

30

35

>Rv1484 inhA TB.seq 1674200:1675006 MW:28529 >emb|AL123456|MTBH37RV:1674200-1675009, inhA SEQ ID NO:55 10 ATGACAGGACTGCTGGACGGCAAACGGATTCTGGTTAGCGGAATCATCACCGACTCGTCGATCG CGTTTCACATCGCACGGGTAGCCCAGGAGCAGGGCGCCCAGCTGGTGCTCACCGGGTTCGAC CGGCTGCGGCTGATTCAGCGCATCACCGACCGGCTGCCGGCAAAGGCCCCGCTGCTCGAACT CGGGCAACAAGCTCGACGGGGTGGTGCATTCGATTGGGTTCATGCCGCAGACCGGGATGGGC 15 ATCAACCCGTTCTTCGACGCGCCCTACGCGGATGTGTCCAAGGGCATCCACATCTCGGCGTATT CGTATGCTTCGATGGCCAAGGCGCTGCTGCCGATCATGAACCCCGGAGGTTCCATCGTCGGCA TGGACTTCGACCCGAGCCGGCCGATGCCGGCCTACAACTGGATGACGGTCGCCAAGAGCGCG TTGGAGTCGGTCAACAGGTTCGTGGCGCGCGAGGCCGGCAAGTACGGTGTGCGTTCGAATCTC GTTGCCGCAGGCCCTATCCGGACGCTGGCGATGAGTGCGATCGTCGGCGGTGCGCTCGGCGA 20 GGAGGCCGGCCCAGATCCAGCTGCTCGAGGAGGGCTGGGATCAGCGCGCTCCGATCGGCT GGAACATGAAGGATGCGACGCCGGTCGCCAAGACGGTGTGCGCGCTGCTGTCTGACTGGCTG 

>Rv1630 rpsA 30S ribosomal protein S1 TB.seq 1833540:1834982 MW:53203 >emb|AL123456|MTBH37RV:1833540-1834985, rpsA SEQ ID NO:57 ATGCCGAGTCCCACCGTCACCTCGCCGCAAGTAGCCGTCAACGACATAGGCTCTAGCGAGGAC TTTCTCGCCGCAATAGACAAAACGATCAAGTACTTCAACGATGGCGACATCGTCGAAGGCACCA TCGTCAAAGTGGACCGGGACGAGGTGCTCCTCGACATCGGCTACAAGACCGAAGGCGTGATCC CCGCCGCGAACTGTCCATCAAGCACGACGTCGACCCCAACGAGGTCGTTTCCGTCGGTGACG AGGTCGAAGCCCTGGTGCTCACCAAGGAGGACAAAGAGGGCCGGCTCATCCTCTCCAAGAAAC GCGCGCAGTACGAGCGTGCCTGGGGCACCATCGAGGCGCTCAAGGAGAAGGACGAGGCCGTC AAGGCACGGTCATCGAGGTCGTCAAGGGTGGCCTGATCCTCGACATCGGGCTGCGCGGTTTC CTGCCCGCCTCGCTGGAGATGCGCCGGGTGCGCGACCTGCAGCCCTACATCGGCAAGGA GATCGAGGCCAAGATCATCGAGCTGGACAAGAACCGCAACAACGTGGTGCTGTCCCGTCGCGC CTGGCTGGAGCAGACCCAGTCCGAGGTGCGCAGCGAGTTCCTGAATAACTTGCAAAAAGGCAC CATCCGAAAGGGTGTCGTCCTCGATCGTCAACTTCGGCGCGTTCGTCGATCTCGGCGGTGT GGACGGTCTGGTGCATGTCTCCGAGCTATCGTGGAAGCACATCGACCACCCGTCCGAGGTGGT CCAGGTTGGTGACGAGGTCACCGTCGAGGTGCTCGACGTCGACATGGACCGTGAGCGGGTTTC GTTGTCACTCAAGGCGACTCAGGAAGACCCGTGGCGGCACTTCGCCCGCACTCACGCGATCGG GCAGATCGTGCCGGGCAAGGTCACCAAGTTGGTTCCGTTCGGTGCATTCGTCCGCGTCGAGGA GGGTATCGAGGCCTGGTGCACATCTCCGAGCTGGCCGAGCGTCACGTCGAGGTGCCCGATC AGGTGGTTGCCGTCGGCGACGACGCGATGGTCAAGGTCATCGACATCGACCTGGAGCGCCGTC GGATCTCGTTGTCGCTCAAGCAAGCCAATGAGGACTACACCGAGGAGTTCGACCCGGCGAAGT ACGGCATGGCCGACAGTTACGACGAGCAGGGCAACTACATCTTCCCCGAGGGCTTCGATGCCG AAACCAACGAATGGCTTGAGGGATTCGAAAAGCAGCGCGCCGAATGGGAAGCTCGGTACGCCG AGGCCGAGCGCCGCACAAGATGCACACCGCGCAGATGGAGAAGTTCGCCGCCGCCGAGGCG

5

10

15

20

25

30

GCTGGACGCGGGCGGACGATCAGTCGTCGGCCAGTAGCGCACCGTCGGAAAAGACCGCGGG TGGATCACTGGCCAGCGACGCCCAGCTGGCGGCCCTGCGGGAAAAACTCGCCGGCAGCGCTT GA

>Rv1631 - TB.seq 1835011:1836231 MW:44669 >emb|AL123456|MTBH37RV:1835011-1836234, Rv1631 SEQ ID NO:58 ATGCTGCGCATCGGGCTGACCGGCGCGCATTGGCGCCGGGAAGTCGTTGCTGTCCACGACGTTC TCGCAATGCGGCGAATCGTTGTCGACGGCGATGTTGTCGCGCGTGAAGTGGTCCAGCCGGGC ACCGAGGGCTGGCCTCGCTGGTCGACGCGTCGCGACATCCTGCTTGCAGACGGAGC GCTGGACCGGCAGGCGTTGGCGGCCAAGGCGTTTCGAGATGACGAGTCGCGCGGTGTGCTCA ACGGAATCGTGCACCCGCTGGTCGCCCGGCGCGATCCGAGATCATCGCGGCGGTTTCGGGG 10 GACGCGGTTGTGGCGAAGATATTCCACTGCTGGTGGAATCCGGGATGGCGCCATTGTTTCCGC TGGTGGTGGTGCACGCCGACGTCGAGCTACGGGTGCGACGGCTGGTCGAGCAACGCGGC ATGGCCGAAGCCGACGCCCGGGCTAGGATCGCTGCGCAGGCCAGCGACCAGCAGCGTCGTGC CGTCGCCGACGTCTGGCTGGACAACTCGGGCAGCCCAGAGGATTTGGTGCGGCGGGCCCGCG ACGTCTGGAACACGCGCGCCAGCCCTTCGCGCACAACCTGGCCCAACGTCAGATTGCGCGCG 15 CGGCTAAAGATCGCGTGCGGGCATAAGGCCTTGCGAGTTGACCACATTGGGTCAACCGCCGTG TCGGGCTTCCCCGATTTTCTAGCCAAGGATGTCATCGACATCCAGGTCACCGTCGAATCACTTG ACCCAGGACACCGAAAAGACCGACGCTCGCAGCACCGTCGGCCGCTACGACCACCCGACAGT 20 GCCGCTCTGTGGCACAAGCGCGTGCACGCCTCGGCGGATCCCGGTCGGCCGACCAACGTGCA CAATCCCGGCGCGAGAGAAGACTATTTGACGGTCAAGTGTGACGCCGACAGGCGCGCCGACG GTGAGCTCGCGCCTACGTCACCGCCAAGGAGCCGTGGTTCCTGGATGCCTACCAGCGGGCAT 25 GGGAGTGGGGGATGCGGTGCACTGGCGTCCCTGA

>Rv1706c - TB.seq 1932695:1933876 MW:39779 >emb|AL123456|MTBH37RV:c1933876-1932692, PPE SEQ ID NO:59

30

10

15

20

25

30

35

GGCTGCGGCACAAACCGTTGGCCTGGTCATGGGAGGCAGCGGCACGCCAATACCGTCGGCCA GATATGTCGAGCTCGCGAACGCGCTGTACATGAGTGGCAGCGTCCCGGGTGTTATCGCGCAGG CGCTCTTCACGCCCCAAGGGCTCTACCCGGTGGTCGTGATCAAGAACCTCACTTTCGATTCCTC GGTGGCGCAGGGTGCCGTCATTCTCGAAAGTGCGATTCGGCAGCAAATTGCCGCCGGCAACAA CGTCACCGTCTTCGGCTACTCGCAGAGCGCCACGATCTCGTCACTAGTGATGGCCAATCTTGCG GCTTCGGCCGACCCGCCGTCTCCAGACGAGCTTTCCTTCACGCTGATCGGCAATCCCAACAACC CCAATGGCGGGGTTGCCACCAGGTTCCCGGGGATCTCCTTTCCAAGCTTGGGCGTGACGGCCA CCGGGGCCACTCCGCACAATCTGTACCCGACCAAGATCTACACCATCGAATACGACGGCGTCG CCGACTTTCCGCGGTACCCGCTCAACTTTGTGTCGACCCTCAACGCCATTGCCGGCACCTACTA CGTGCACTCCAACTACTTCATCCTGACGCCGGAACAAATTGACGCAGCGGTTCCGCTGACCAAT ACGGTCGGTCCCACGATGACCCAGTACTACATCATTCGCACGGAGAACCTGCCGCTGCTAGAG CCACTGCGATCGGTGCCGATCGTGGGGAACCCACTGGCGAACCTGGTTCAACCAAACTTGAAG GTGATTGTTAACCTGGGCTACGGCGACCCGGCCTATGGTTATTCGACCTCGCCGCCCAATGTTG CGACTCCGTTCGGGTTGTTCCCAGAGGTCAGCCCGGTCGTCATCGCCGACGCTCTCGTCGCCG GGACCCAGCAGGGAATCGGCGATTTCGCCTACGACGTCAGCCACCTCGAACTGCCGTTGCCGG CAGACGGGTCGACGATGCCAAGCACCGCACCGGGCTCGGGTACGCCGGTCCCCCGCTCTCG ATCGACAGCCTGATAGACGACCTGCAGGTGGCTAACCGCAACCTCGCCAACACGATTTCGAAG GTGGCCGCGACGACGCGACGCGACGCCGACATCGCCAATGCGCCGTTGAC GATCGTGCCGTCGTACAACATCCACCTTTTTTTGGAGGGCATCCAGCAAGCGCTCAAGGGCGAC CCGATGGGACTCGTCAACGCGGTCGGATACCCACTCGCGGCCGACGTGGCACTGTTCACGGCC GCAGGCGGTCTTCAGCTCTTGATCATCAGCGCGGGGCCGAACGATTGCCAATGACATCTCGG CCATTGTCCCCTGA

5

10

15

20

25

30

35

ATGCCAAGACCGCCAAACCGCTCGTCGACGTCATCGTGGACCGGGCCGAGCAGAAAGGCACC GGCCGTTGGACCGTCAAGTCCGCGCTGGACCTGGGTGTGCCGGTGACCGGCATCGCCGAAGC GGTGTTTGCCCGCGCTCTCTCGGGATCCGTGGGGCAACGCTCGGCCGCCAGCGGTCTGGCTTC GGGCAAGCTCGGCGAGCCCGCCGACCCCGCCACGTTCACCGAAGACGTCCGCCAGGCGT TGTACGCCTCCAAGATCGTGGCCTACGCTCAGGGCTTCAACCAGATCCAGGCCGGCAGCGCCG AATTCGGCTGGGACATCACGCCGGGCGACCTGGCCACCATCTGGCGTGGCGGCTGCATCATCC GGGCGAAGTTCCTCAACCACATCAAGGAAGCCTTTGACGCCAGCCCGAACCTGGCCAGTCTGA TTGTGGCCCGTATTTCCGCGGCGCCGTCGAATCGGCGATCGACAGTTGGCGGCGTGTGGTGT CGACGGCGGCCCAACTGGGTATCCCGACCCCGGGATTCTCGTCGGCCCTGTCGTATTACGACG CGCTGCGCACCGCGGCTGCCCGCTGCACTCACCCAGGCCCAGCGCGACTTCTTCGGCGCA CACACCTACGGCCGGATCGACGAACCAGGCAAGTTCCACACACTATGGAGTTCAGACCGCACC GAAGTACCGGTGTAG

>Rv1900c lipJ TB.seq 2146246:2147631 MW:49685

>emb|AL123456|MTBH37RV:c2147631-2146243, lipJ SEQ ID NO:63 GTGGCGCAGGCTCCCCACATTCACAGGACCCGCTACGCAAAATGCGGCGACATGGATATCGCC TACCAGGTGCTGGGTGACGGTCCGACGGATCTGCTGGTGTTGCCGGGGCCGTTCGTGCCGATC GACTCGATCGACGACGAGCCATCGCTGTACCGTTTCCATCGCCGTCTTGCGTCATTCAGCAGGG TGATCCGCCTCGACCATCGTGGGGTCGGCCTGTCGTCACGGCTCGCCGCGATAACCACGCTGG GGCCGAAGTTCTGGGCCCAGGACGCGATCGCGGTGATGGACGCGGTCGGATGCGAGCAGGCG ACAATTTCGCGCCCAGTTTCCACGCCATGAACGGACTTGTTCTCGCCGCCGACTACCCCGAGC GGGTGCGCAGCCTGATCGTCAACGGCTCGGCGCGCCCACTATGGGCGCCCGACTACCCG GTAGGCGCCCAGGTTCGTCGAGCTGACCCGTTCCTGACGGTGGCGCTGGAACCGGATGCCGTC GAGCGGGGCTTCGACGTGCTGAGCATCGTGGCTCCTACCGTGGCCGGAGATGACGTGTTTCGA GCCTGGTGGGATCTCGCCGGCAACCGTGCCGGACCGCCGAGCATTGCCCGTGCCGTTTCAAAG GTCATAGCCGAGGCCGACGTACGAGATGTCTTGGGACACATCGAGGCTCCAACACTGATCTTGC ACCGTGTCGGATCGACGTACATCCCGGTGGGACATGGTCGCTACCTCGCCGAGCACATCGCTG GATCCCGCTTGGTCGAACTACCCGGCACCGATACCCTGTACTGGGTTGGCGACACCGGGCCGA ACCGATGGCGCGACCTGTTGGACAACCACGACACCATCGTGTGCCACGAAATCCAGCGGTTCG GCGGTCGCGAAGTGAACACGGCCGGTGACGGTTTCGTCGCGACGTTCACCAGTCCGAGTGCC GCGATCGCGTGCGCGACGACATCGTCGACGCGGTCGCCGCGCTGGGTATTGAGGTCCGGAT CGGTATTCATGCGGGCGAGGTCGAGGTGCGCGATGCCTCGCACGGTACCGACGTCGCCGGCG TGGCCGTGCATATCGGTGCGCGCGTCTGCGCGCGGGCCGGACCCAGTGAGGTGCTGGTGTCC TCGACCGTGCGAGACATCGTCGCCGGATCACGGCACCGGTTCGCCGAGCGTGGTGAGCAGGA

ACTCAAGGGCGTACCGGGCAGATGGCGGCTATGCGTGCTCATGCGCGACGACGCCACCCGCACCCGCA

>Rv1967 - TB.seq 2210599:2211624 MW:36516

>embjAL123456|MTBH37RV:2210599-2211627, Rv1967 SEQ ID NO:64 ATGAGGGAGAACCTGGGGGGCGTCGTGGTGCGCCTCGGCGTCTTCCTGGCGGTATGCCTGCT 5 GACGGCGTTCCTGCTGATTGCCGTCTTCGGGGAGGTGCGCTTCGGCGACGGCAAGACCTACTA CGCCGAGTTCGCCAACGTGTCCAATCTGCGAACGGGCAAGCTGGTGCGCATCGCCGGCGTCGA GGTCGGCAAGGTCACCAGGATCTCCATCAACCCCGACGCGACGGTGCGGGTGCAGTTCACCGC CGACAACTCGGTCACCCTCACGCGGGGGCACCCGGGCGGTGATCCGCTACGACAACCTGTTCGG TGACCGCTATTTGGCGCTGGAGGAAGGGGCCGGCGGACTCGCCGTTCTTCGTCCCGGTCACAC 10 GATTCCGTTGGCGCGCCCCAACCGGCGTTGGATCTGGATGCCCTGATCGGTGGATTCAAGCC GCTGTTTCGTGCGCTGAACCCCGAGCAGGTCAACGCGCTGAGCGAACAGTTGCTGCACGCGTT TGCCGGACAGGGCCCACGATCGGGTCATTGCTGGCCCAGTCCGCGGCCGTGACCAACACCC TGGCCGACCGTGATCGGCTGATCGGCAGGTGATCACCAACCTCAACGTGGTGCTGGGCTCGC TGGGCGCTCACACCGATCGGTTGGACCAGGCGGTGACGTCGCTATCAGCGTTGATTCACCGGC 15 TCGCGCAACGCAAGACCGACATCTCCAACGCCGTGGCCTACACCAACGCCGCCGGCCCG GTCGCCGATCTGCCGCGCGCGCCGCTTGGCGAAGGTGGTTCGCGAGACCGATCG GGTGGCCGCCACCGCCGACCACGACTACCTCGACAATCTGCTCAACACGCTGCCGGA CAAATACCAGGCGCTGGTCCGCCAGGGTATGTACGGCGACTTCTTCGCCTTCTACCTGTGCGAC GTCGTGCTCAAGGTCAACGGCAAGGGCGGCCAGCCGGTGTACATCAAGCTGGCCGGTCAGGA 20 CAGCGGCGGTGCGCGCGAAATGA

>Rv1975 - TB.seq 2218050:2218712 MW:23650

>Rv1981c nrdF ribonucleotide reductase small subunit TB.seq 2224221:2225186 MW:36591 ATGACCGGCAAGCTCGTTGAGCGGGTGCACGCAATCAATTGGAACCGGTTGCTCGATGCTAAA GATTTGCAGGTCTGGGAACGTTTGACCGGTAACTTTTGGTTGCCGGAAAAGATTCCGCTCTCCA ACGACCTGGCATCTTGGCAAACGTTGAGTTCCACCGAGCAGCAGCACGACGATCCGGGTGTTCA 5 GCGGTCACCCCCACGAAGAGGCGGTCCTGACCAACATGGCGTTCATGGAGTCAGTGCACGCC AAGAGCTACAGCTCGATCTTCTCGACCCTGTGCTCGACCAAGCAGATCGACGATGCCTTCGACT GGTCGGAACAGAACCCTTACCTGCAGCGAAAAGCGCAGATCATCGTCGACTACTACCGCGGTG CTACCTGCCCATGTACTGGTCGCGGGGGTAAGCTCACCAACACCGCCGATCTGATCCGGCT 10 GATCATCCGAGATGAAGCCGTCCACGGCTACTACATCGGCTACAAATGTCAACGAGGTTTGGCC GACCTGACCGACGCGAGCGGCCGACCACCGCGAATACACCTGCGAGCTGCTGCACACGCT CTACGCGAACGAGATCGACTATGCGCACGACTTGTACGACGAGTTGGGCTGGACCGACGACGT TTTGCCCTACATGCGTTACAACGCCAACAAGGCGCTAGCCAACCTGGGATACCAGCCTGCATTC GATCGTGACACCTGCCAGGTGAACCCGGCCGTGCGCGCAGCTCTCGACCCCGGTGCAGGGGA 15 GACACCGACTGGGACTTCTAA

>Rv2092c helY helicase, Ski2 subfamily TB.seq 2349335:2352052 MW:99576 >emb|AL123456|MTBH37RV:c2352052-2349332, helY SEQ ID NO:67 CAGCAGCGGGCTTGCAGCGCGCTGGAACGCGGCCACGGTGTGCTGCTGCGCCCGACCG GCGCTGGCAAGACGGTGGCGCGAGTTCGCCGTGCACCTGGCGCTGGCGCCGGCAGTAAA TGTTTCTACACCACGCCGCTGAAAGCCCTGAGCAACCAAAAGCACACCGATCTCACAGCACGCT ACGGCCGTGACCAGATCGGGCTGCTGACCGGTGACCTGTCGGTCAACGGCAACGCGCCGGTG GTGGTGATGACCACCGAAGTGCTGCGCAACATGCTCTACGCGGATTCGCCTGCGCTGCAGGGG CTTTCCTATGTGGTGATGAGGTGCATTTCCTCGCCGACCGGATGCGGGGTCCGGTGTGG GAGGAGGTGATCCTGCAACTGCCCGACGACGTGCGGGTGGTCAGCCTGTCGGCGACGGTGAG CAACGCCGAGGAGTTCGGCGGTTGGATCCAGACGGTGCGGGGGGGCGACACCACGGTGGTCG ACGAGCATCGGCCGGTGCCGTTGTGGCAACACGTCTTGGTGGGCAAGCGCATGTTCGACCTGT TCGATTACCGGATCGGCGAAGCCGAAGGCCCCAAGTCAACCGCGAGTTGCTGCGCCACA TCGCGCATCGCCGTGAGGCCGACCGGATGGCCGATTGGCAGCCTCGGCGCCGAGGCTCGGGC CGGCCCGGCTTCTACCGGCCACCCGGCCGACCCGAGGTGATCGCCAAACTCGACGCTGAAGG GCTGTTGCCGGCGATCACCTTCGTGTTCTCCCGGGCCGGTTGTGACGCCGCGGTCACCCAATG 35 ACCACCGCTGCGGTGACCTGGCCGACCTGGCGGTACTCGGCTACTACGAATGGCGG

20

25

GAAGGGTTACTGCGCGGTCTGGCCGCCCACCACGCGGGCATGTTGCCGGCCTTCCGGCACAC GGTGGAGGAGCTGTTCACCGCCGGTTTGGTCAAGGCTGTATTCGCCACCGAGACTCTGGCGCT CGGTATCAACATGCCGGCCCGCACGGTGGTGCTGGAGCGGCTGGTGAAGTTCAACGGTGAGCA TCGACGTCGAGGGTCACGCGGTGGTGATCTGGCACCCGGAAATTGAACCGTCCGAGGTGGCG GGCCTGGCCTCCACCCGCACCTTTCCGCTGCGCAGCTCGTTTGCCCCGTCGTACAACATGACG ATCAACCTGGTGCACCGGATGGGTCCGCAACAGGCGCACCGACTGCTCGAGCAGTCGTTCGCC CAATATCAGGCCGACCGATCCGTGGTCGGACTGGTCCGCGGAATTGAGCGGGGCAACAGGATA CTCGGCGAGATCGCAGCCGAACTGGGCGGATCTGATGCGCCCATCCTCGAATACGCTCGATTG AGGCGCCACCGATGCGCCGCGCGCGCGCGCGGTGACATCACCATCACCCACGGC 10 CGCCGCGTGGTCTGGCCGTCCTGGAATCAGCCCGCGACCGCGACGACCCGCGTCCGCT GGTGCTAACCGAACACCGATGGGCGGGACGGATCTCCTCGGCCGACTACTCGGGCACGACGC CGGTGGGGTCGATGACGCTGCCCAAGCGGGTGGAGCACCGCCAGCCGCGGGTCCGGCGTGA CCTGGCCTCGGCGCTCGGCATCGGCAGCCGCGGGGTCTATTCCAGCCGCCCGGCGCGTCA GCGAGGCCGGCGGTTTCACGATCCGGAGCTGGAGTCGTCGCGCGAACAATTGCGCCGTCAT 15 GAACGCGACAACGCGCAATTAGAGAGGAAGGTCGCCGCCGCCACCAACTCGTTGGCCCGCAC GTTCGACCGATTCGTCGGGCTGCTCACCGAACGGGAGTTCATCGATGGCCCGGCCACTGATCC CGTGGTCACCGACGACGGCCGGCTGCTGGCGCGGATTTACAGCGAGAGCGACCTGTTGGTGG 20 TCGGCGGTGGTCTACGAGACGCGCGGTGGTGACGGCCAGGGCGCCCCGTTCGGAGCCGATGT GCCCACACCGCGGTTACGGCAGGCTCTGACTCAGACATCAAGGCTGTCCACGACATTGCGCGC CGACGAGCAGCACCCCCATCACCCCGAGTCGCGAACCCGACGATGGCTTTGTCAGAGTCAT CTACCGCTGGTCGCGAACCGGTGATCTAGCGGCGCATTGGCCGCTGCCGACGTGAACGGCA GCGGATCACCGTTATTGGCAGGGGATTTCGTGCGTTGGTGCCGTCAGGTGCTCGATCTGCTGG 25 ACCAAGTTCGTAACGCTGCGCCCAACCCCGAACTGCGGGCTACCGCAAAGCGCGCTATCGGTG ACATTCGGCGCGCGCTCGTCGCGGTTGACGCCGGGTAG

>Rv2101 helZ helicase, Snf2/Rad54 family TB.seq 2360238:2363276 MW:111632 30 >emb|AL123456|MTBH37RV:2360238-2363279, helZ SEQ ID NO:68 ATGCTGGTTTTGCACGGCTTCTGGTCCAACTCCGGCGGGATGCGGCTGTGGGCGGAGGACTCC GCCGCTGACCTGATCGCCGGCATACATCCGGGCAAACCCGCAACCGCCGTTTTGCTGTTGCC CGCGAACCGATCCGATGCTGTTGGCGTGGACGGTACCGGTGGTGGACCTGGACCCCACCGCG 35 GCGTTGGCCGCCTTCGACCAGCCCGCCCCGACGTCCGCTACGGCGCGCGTCCGACTACCT

10

15

20

25

30

35

GCCGCGACACCCACGGCGCCGCCCTGCTGGCGTCCGGTGTTGCAGGGACGCGACGTGGTC GCGATGACCTCGCTGGTCTCGGCGATGCCGCCGGTCTGCCGCGCGCAAGTTGGTGGGCACGA TGTCACCGATGGACCTGCCCCCGCGACGGGGTCGCTCCAAACGGCATCGGGCCGTGGAG GCTTGGCTGACCGCGTTGACCTGCCCGGACGGCCGGTTCGACGCGGAGCCCGACGAACTCGA CGCGCTGGCCGAGGCGTTGCGGCCATGGGACGACGTCGGTATCGGCACCGTCGGCCCGGCGC GGGCGACGTTTCGGCTGTCCGAAGTCGAGACCGAAAACGAGGAGACGCCCGCGGGCTCGTTG TGGAGGCTGGAGTTCTTATTGCAGTCGACGCAGGACCCCAGCCTGCTGGTCCCCGCCGAGCAG GCATGGAACGACGACGCCAGCCTGCCCGCTGGCTGGACCGGCCGCAGGAGCTGCTGAC CGTCCGGGCTTGAGCTCGACGCCGACGCGCCTACCGATTCCTGTCGGGTACGGCCGCGGTG CTCGACGAGGCTGGGTTTGGCGTGCTGCTGCCGTCCTGGTGGGACCGCCGCCAAGCTGGG CTTGGTCCTGTCCGCATATACCCCGGTCGACGGCGTGGTGGGCAAGGCCAAGTTCGGCCG CGAGCAGCTCGTCGAGTTCCGCTGGGAGCTGGCCGTGGGCGACGATCCGCTCAGCGAGGAGG AGATCGCGGCGCTGACCGAAACCAAGTCCCCGCTGATCCGGCTGCGTGGCCAGTGGGTCGCG CTCGATACCGAACAGATGCGCCGCGGGCTGGAGTTTTTGGAGCGTAAGCCAACCGGCCGCAAG ACCACCGCGAGATCCTCGCGCTGGCCGCCAGCCACCCCGACGACGTGGACACCCCGCTCGA GGTCACCGCCGTACGCCCGACGGCTGGCTCGGGGACCTGCTCGCCGGGGCCGCCGCGCG TCGCTGCAGCCGTTGGACCCGCCCGACGGATTCACCGCGACGCTGCGTCCCTACCAGCAGCGC GGTCTGGCGTGGCGTTTTTGTCCTCGCTCGGTTTGGGCAGCTGCCTGGCCGACGACATG GGCCTGGGCAAGACGGTGCAGCTATTGGCCCTGGAAACCTTGGAATCCGTTCAGCGCCACCAG GATCGCGGCGTCGGACCCACACTGCTACTGTGCCCGATGTCGTTGGTGGGCAACTGGCCGCAG GAAGCGGCCAGGTTTGCACCCAACCTGCGGGTGTACGCCCACCACGGGGGCGCCCGGCTGCA CGGCGAGGCGTTGCGCGACCACCTCGAGCGCACCGACCTGGTCGTGAGCACCTATACCACCG CCACCGCGACATCGACGAGCTGGCGGAATACGAATGGAACCGGGTGGTGCTGGACGAGGCC CAGGCGGTGAAGAACAGCCTGTCCCGGGCGGCCAAGGCGGTGCGACGGCTACGCGCGGCGC ACCGGGTCGCGCTGACCGGGACACCGATGGAGAACCGGCTCGCCGAGCTGTGGTCGATCATG GACTTCCTCAACCCGGGCCTGCTCGGATCCTCCGAACGCTTCCGCACCCGCTACGCGATCCCG ATCGAGCGGCACGGCCGAACCGGCCGAACGGCTGCGCGCATCGACGCGCCCTACAT CCTGCGCCGGCTCAAGACCGACCCGGCGATCATCGACGATCTGCCGGAGAAGATCGAGATCAA GCAGTACTGCCAACTCACCACCGAGCAGGCGTCGCTGTATCAGGCCGTCGTCGCCGACATGAT GGTCCGGGAAGGTGATCCGGCTCGAGGAGAGATCCTGGAAGAGATCCTGGCCGAGGGCGACCGG GTGCTGTGTTTTACCCAGTTCACCGAGTTCGCCGAGCTGCTGGTGCCGCACCTGGCCGCACGC TTCGGCCGTGCCCCGAGACATTGCCTACCTGCACGGTGGCACCCCGAGGAAGCGGCGTGA

>Rv2110c prcB proteasome [beta]-type subunit 2 TB.seq 2369727:2370599 MW:30274
>emb|AL123456|MTBH37RV:c2370599-2369724, prcB SEQ ID NO:69
GTGACCTGGCCGTTGCCCGATCGCCTGTCCATTAATTCACTCTCGGAACACCATCAGCG

= B2126\_C1\_165 (83.6%) TB.seq 2377471:2378310 MW:30091 >Rv2118c -25 >emb|AL123456|MTBH37RV:c2378310-2377468, Rv2118c SEQ ID NO:70 GTGTCAGCAACCGGCCCATTCAGCATCGGCGAACGTGTTCAGCTCACCGACGCTAAGGGGCGC CGCTACACCATGTCGCTGACTCCCGGTGCCGAATTCCACACTCATCGTGGCTCGATCGCCCACG ACGCGGTGATCGGGTTGGAGCAAGGCAGCGTGGTCAAATCCAGCAACGGCGCCCTGTTCCTGG CCAAAGATGCGGCCCAGATCGTGCATGAGGGCGACATATTTCCCGGCGCGCGGGTGCTGGAG 30 GGTGATCTCCTACGAACAGCGCGCCGATCATGCCGAACACGCCCGGCGCAATGTGAGCGGCTG CTACGGCCAGCCGGACAACTGGCGACTGGTCGTCAGCGACCTCGCCGAACTGC CCGACGGATCCGTTGATCGGGCCGTGCTCGACATGCTGGCGCCGTGGGAGGTGCTCGACGCG GTATCGCGGCTGGTCGCCGGCGGAGTGCTGATGGTCTACGTGGCCACCGTCACTCAGCTG 35 TCGAGGATCGTGGAGGCACTGCGGGCCAAGCAGTGCTGGACCGAACCGAGAGCCTGGGAGAC

5

10

15

GCTGCAGCGGGCTGGAACGTCGTAGGGTTGGCGGTTCGGCCGCAGCATTCGATGCGCGGGC ATACCGCGTTCCTGGTAGCAACGCGCCGGTTGGCGCCGGGGGCTGTGGCTCCGGCGCCGCTA GGTCGTAAGCGCGAGGGACGCGACGGGTAG

>Rv2144c - TB.seq 2404166:2404519 MW:12028
 >emb|AL123456|MTBH37RV:c2404519-2404163, Rv2144c SEQ ID NO:71
 ATGCTGATCATTGCGCTGGTCTTGGCCCTGATTGGGCTCCTGGCCTTGGTGTCCGCGTGGTCA
 CCAGCAACCAGCTAGTGGCCTGGGTATGCATCGGGGCCAGCGTGCTGGGTGTGCTGA
 TCGTCGATGCGTTGCGAGAACGCCAGCAAGGTGGCGCGGACGAAGCTGATGGGGCTGGGGAA
 ACGGGTGTCGCGGAGGAAGCCGACGTCGACTACCCGGAGGAAGCCCCCGAGGAAGCCAAGC
 CGTCGACGCCGGTGTCATCGGCAGTGAGGAGCCATCGGAGGAGGCCAGCGAAGCGACCGAGG
 AGTCGGCGGTATCGGCGGACCGAAGCGACGCCCAAGTAG

>Rv2146c - TB.seq 2405667:2405954 MW:10805

>emb|AL123456|MTBH37RV:c2405954-2405664, Rv2146c SEQ ID NO:72
 TTGGTGGTGTTTTTTCAGATCCTTGGGTTCGCGCTGTTCATCTTCTGGCTGCTGCTGATCGCTGG
 GGTCGTCGTTGAGTTCATCCGCTCGTTCAGCCGTGACTGGCGTCCCACCGGTGTCACCGTGGT
 GATCTTGGAGATCATCATGTCGATCACTGATCCGCCGGTGAAGGTGCTGCGCCGGCTGATCCC
 GCAACTCACGATCGGCGGTCCGGTTCGACCTGTCGATCATGGTGCTGCTGCTGCTT
 CATCGGTATGCAACTGGCGTTTGGTGCTGCGGCCTGA

>Rv2148c - TB.seq 2406841:2407614 MW:27694

25

30

>emb|AL123456|MTBH37RV:c2407614-2406838, Rv2148c SEQ ID NO:74

ATGGCGGCGGATCTTTCGGCGTATCCAGACCGCGAATCGGAATTGACGCATGCGTTGGCGGCA

ATGCGATCGCGACTTGCGGCGCGCGCGGAGGCGGCGGGTCGCAATGTCGGCGAAATTGAACT

TCTACCGATTACCAAATTCTTTCCAGCAACCGATGTTGCGATTTTGTTTCGATTGGGTTGTCGGTC

CGTTGGCGAATCGCGCGAACAGGAAGCTTCAGCCAAGATGGCCGAACTTAATCGGTTGTTGGC

GGCTGCCGAGTTGGGTCACTCGGGGGGTGTGCACTGGCACATGGTGGGCCGGATTCAACGCA

ACAAAGCCGGGTCGCTCGCTGGGCGCACACCGCTCACTCGGTGGACAGCTCGCGGTTG

GTGACCGCGCTGGATCGGGCGGTTGTTGCGGCGCTGGCCGAACACCGTCGTGGCGAGCGGCT

GCGGGTTTACGTCCAGGTCAGCCTCGACGGTGACGGATCCCGGGGCGCTCGAACTGGTC

GGCTCGGCGCCGTAGACCGGATTTGCGCGCAGGTGCAGAGGCCTTTGACCGGCTGCAATCG

GGGTTGATGGGCATTCCGCCGCTGGATTGGGACCCGGACGAGCCTTTTGACCGGCTGCAATCG

GAGCACAACCGGGTGCGTGCGATGTTCCCGCACGCGATCGGTCTGCGCGGCATTTCCAAC

GACCTTGAAGTCGCCGTCAAACATGGTTCGACCTGTGTGCGTTCCGCCGCTTATTGGGTC

CGCGGCGGTTACGGTCACCGTGA

15

20

25

30

35

**TCATGCGCCGCTGA** 

5

10

>Rv2150c ftsZ TB.seq 2408386:2409522 MW:38757 >emb|AL123456|MTBH37RV:c2409522-2408383, ftsZ SEQ ID NO:75 ATGACCCCCCGCACAACTACCTGGCCGTCATCAAGGTCGTGGGTATCGGTGGTGGCGGTGTC AACGCCGTCAACCGAATGATCGAGCAGGGCCTCAAAGGCGTGGAATTCATCGCGATCAACACC GACGCCCAGGCGTTGTTGATGAGCGATGCCGACGTCAAACTCGACGTCGGCCGCGACTCCACC CGCGGGCTGGGCGCCGGCCCGATCCGGAGGTCGGCCGTAAGGCCGCCGAGGACGCCAAGG ACGAGATCGAAGAGCTGCTGCGCGGTGCCGACATGGTGTTTGTCACCGCCGGCGAGGGGGGC GGAACCGGCACCGGGGGGCACCCGTCGTCGCCAGCATCGCCCGCAAGCTGGGCGCGTTGAC CGTCGGTGTGGTCACCCGGCCGTTCTCGTTCGAGGGCAAGCGACGCAGCAATCAGGCCGAAAA TGGCATCGCGGCGCTGCGGGAGAGTTGCGACACCCTCATCGTGATTCCCAACGACCGGTTGCT GCAGATGGGAGATGCCGCGGTATCGCTGATGGATGCTTTCCGTAGCGCCGACGAGGTGCTGCT CAACGGCGTGCAGGGCATCACCGACCTGATTACCACCCCGGGTCTAATCAACGTCGACTTCGC CGACGTCAAGGGCATCATGTCCGGTGCCGGCACCGCACTGATGGGCATCGGCTCGGCCCGGG GCGAAGGCCGGTCGCTCAAAGCGGCCGAGATCGCCATCAACTCGCCGTTGCTGGAAGCCTCGA TGGAGGCGCGCAAGGCGTGCTGATGTCGATCGCCGGCGGCAGCGACTTGGGCTTGTTCGAG ATCAACGAGGCGGCCTCGTTGGTACAAGACGCCGCTCACCCCGATGCCAACATCATCTTCGGC GTCAGCGGTCCCGGCCAAGCCGGTGATGGGCGAGACCGGCGCGCCCCACCGGATCGAGT CAGCCAAGGCAGCCAAGCTCACCTCGACCTTGTTCGAGCCGGTCGACGCCGTCAGCGTGCCGT TGCACACCAACGCCAACCCTGAGCATCGGCGGTGATGACGACGATGTCGACGTGCCCCCT

>Rv2152c murC TB.seq 2410639:2412120 MW:51146

>emb|AL123456|MTBH37RV:c2412120-2410636, murC SEQ ID NO:76

GTGAGCACCGAGCAGTTGCCGCCCGATCTGCGGCGGGTGCACATGGTCGGCATCGGCGGAGC CCAAGGAGTCGCGGGTGTGCATGCGCTGCGGGCGCGGGGGCGCGTTGATCCGGATCGGACAC GACGCGTCGTCGCTGGACCTGTTGCCCGGTGGCGCCACGGCGGTCGTCACTACCCATGCCGC CATCCCCAAAACCAACCCCGAGCTCGTCGAAGCGAGGCGCCGCGGCATTCCCGTGGTGCTGCG GCAAGACAACGACGTCCATGCTGATCGTCGCCCTGCAGCACTGCGGGCTTGACCCGTCCT TTGCGGTCGGCGGTGAGCTGGGGGGGGGCCGGTACCAACGCCCATCACGGCAGTGGCGACTGT TTCGTCGCCGAAGCCGACGAAGCGATGGCTCGCTGTTGCAGTACACCCCCACGTCGCGGTG ATCACCAACATCGAGTCCGATCACCTGGACTTCTACGGCAGCGTCGAGGCGTATGTTGCGGTGT TCGACTCCTTCGTGGAGCGCATTGTCCCCGGGGGTGCGCTGGTGGTGTGCACTGACGACCCCG GAGGGCCGCGCTCAGCGCGCGACTGAGCTGGGAATTCGAGTGCTGCGATACGGGTCG GTGCCGGGTGAGACCATGGCAGCCACGTTGGTCTCGTGGCAGCAACAGGGGGTCGGCGCGGT CGCACATATCCGGTTGGCCTCAGAACTAGCCACAGCACAGGGTCCCCGCGTGATGCGGCTGTC GGTGCCCGGGCGACACATGGCGCTCAACGCGCTGGGAGCGCTGCTGGCCGCGGTGCAGATCG GCGCCCGGCCGACGAGGTGCTCGACGGCTGGCCGGCTTCGAAGGAGTGCGGCGACGATTC GAACTGGTTGGGACCTGCGGCGTCGGAAAGGCGTCGGTGCGCGTGTTCGATGACTACGCCCAC TGGCCGCTGCATGGTTTCAACCCCATTTGTATTCGCGGACAAAGGCATTCGCTGAG TTTGGGCGTGCGCTGACGCGCTGACGACGTCTCGACGTCTACGGAGCTCGTGAA CAACCGCTGGCCGGTGTCAGCGGAGCCAGCGTCGCTGAGCACGTCACTGTGCCGATGCGCTA CGTCCCGGATTTTTCGGCGGTCGCACAGCAAGTGGCCGCCGCCGCTAGTCCGGGCGACGTCAT CGTCACGATGGGTGCCGGAGACGTGACCTTGCTGGGCCCGGAAATCCTGACCGCCCTTCGGGT CCGGGCCAACCGAAGCGCCCCCGGCCGTCCGGGGGTGCTGGGATGA

>Rv2153c murG TB.seq 2412120:2413349 MW:41829

>emb|AL123456|MTBH37RV:c2413349-2412117, murG SEQ ID NO:77

5

10

15

20

>Rv2154c ftsW TB.seq 2413349:2414920 MW:56306

>emb|AL123456|MTBH37RV:c2414920-2413346, ftsW SEQ ID NO:78 GTGCTAACCCGGTTGCTGCGTCGGGGCACCAGCGACACCGACGGCTCCCAGACTCGAGGGGC CGAGCCGGTCGAGGGCCAGCGGACGGGCCCGGAAGAAGCCTCTAACCCGGGTTCGGCGAGG CCCGCACCGTTTCGGTGCCTGGCTGGCCGTCCGATGACCTCGTTTCACCTCATCATCGCC GTTGCCGCATTGCTGACCACCCTTGGACTGATCATGGTGCTGTCGGCATCGGCGGTGCGGTCC TACGACGACGACGGATCGGCTTGGGTGATCTTCGGCAAGCAGGTCTTGTGGACGCTTGTGGGT CTTATCGGCGGCTATGTCTGCGGATGTCGGTGCGGTTCATGCGGCGCATCGCCTTCTCCG GTTTCGCGATCACCATCGTGATGCTGGTGCTGGTGCCGGGGGATCGGCAAGGAGGCCA ACGGCTCGCGCGCTGGTTCGTGGTCGCGGGCTTCTCGATGCAGCCCTCTGAGCTGGCTAAGA TGGCGTTCGCCATCTGGGGAGCGCATCTGCTGGCCGCCCGGCGCATGGAACGGGCTTCACTG CGCGAGATGCTGATTCCACTGGTGCCGGCCGCCGTCGTTGCGCTGGCGCTGATCGTGGCCCAG CCCGACCTCGGACAGACCGTGTCGATGGGCATCATCTTGTTGGGCCTGCTGTGGTATGCGGGG CTGCCGCTGCGCGTCTTCCTCAGCTCACTGGCGGCGGTCGTCGTCTCGGCCGCCATCCTGGCG GTGTCCGCGGGCTACCGATCCGACCGGGTGCGGTCGTGGCTCAACCCCGAAAACGATCCGCAA GACTCCGGCTACCAGGCCCGACAGGCAAAGTTCGCGCTGGCTCAAGGTGGCATTTTCGGCGAC GGTCTGGGCCAAGGCGTGGCCAAGTGGAACTACTTGCCCAACGCCCACAACGACTTCATTTTCG CCATCATCGGCGAAGAGCTGGGTCTCGTCGGCGCGCTCGGACTGCTGGGGCTATTCGGATTGT TCGCCTACACCGGCATGCGCATCGCTAGCCGGTCCGGCCGACCCGTTCCTGCGGCTGCTGACCG CCACCACGACACTGTGGGTGCTGGGACAGGCGTTCATCAACATCGGCTATGTGATCGGGCTGC TGCCGTCACCGGCCTGCAGCTGCCGCTCATCTCCGCCGGTGGAACCTCCACGGCCGCAACAC TTTCGCTGATAGGCATCATCGCCAACGCGGCTCGCCACGAACCGGAGGCGGTGGCCGCGCTG CGGGCTGGCGCGACGACAAGGTGAACCGGTTGCTGCGGGCTGCCCGAGCCGTATCT GCCCCTCGTCTCGAGGCGTTTCGTGACCGCAAGCGCGCCAACCCGCAACCGGCCCAAACGCA

5

10

15

20

25

30

GCCGCGCGGAAGACCCCCCGCACGGCGCCCGGACAGCCTGCCCGGCAGATGGGCCTGCCC CCGCGACCCGGCCCCGCACGGCCGATCCGCCGGTTCGTCGATCAGTGCATCATGGAGCT GGCCAGCGGTACGCGGCGCGCGCGCGCGCGCGCGTTCGGGCATTGGAAGGTCAGCGTTA **CGGGTGA** 

5

>Rv2155c murD TB.seq 2414935:2416392 MW:49314 >emb|AL123456|MTBH37RV:c2416392-2414932, murD SEQ ID NO:79 GTGCTTGACCCTCTGGGGCCGGGTGCCCCGTGTTGGTAGCCGGTGGCCGGGTGACCGGTCA TCATGCTGCGACCGCACGCCGAACGTGGGCTGCCGACCGTTAGTTCCTCGGACGCGGTGCAGC AGATAACCGGGTATGCGCTGGTGGTCGCCAGTCCCGGCTTCTCGCCCGCAACCCCGCTACTGG 10 CCGCGCCGCGCGGGGGGGGCCGATCTGGGGTGACGTGGAGTTAGCCTGGCGGCTAGA CGCAGCGGGCTGCTACGGACCGCCGCGCAGCTGGCTGGTGACCGGCACCAACGGCAAGA 15 ACATTGCCGAAGACCACCTGGACTGGCATGCCACGATGGCCGAATACACCGCGGCCAAGGCCC GGGTGCTGACCGGCGGGGTAGCGGTGGCCGGGCTGGATGACAGCCGAGCGGCCGCACTGCT GGACGGCTCACCGGCGCAGGTGCGGGTCGGCTTCCGGCTCGGCGAGCCGGCGCGCGGGAA CTGGGCGTGCGACGCCCACCTGGTCGATCGCGCCTTCTCCGACGACTTGACGCTGCTGCCG GTCGCGTCGATACCGGTGCCAGGTCCGGTCGGCGTGCTTGACGCCCTGGCCGCGGCGCGC 20 GGCCCGCTCGGTGCGGTGCCGCTGCGATCGCCGACGCGGTCACGTCGTTTCGAGTGG GCCGACACCGCGCGAGGTGGTGGCCGTTGCCGACGGCATCACCTACGTGGACGACTCCAAG GCCACCAACCCGCACGCCGCGCGGGCTTCGGTGCTTGCATACCCGAGGGTGGTATGGATCGC CGGTGGCCTGCTCAAGGGCGCGTCGCTTCACGCCGAGGTTGCGGCGATGGCGTCGCGGCTGG TCGGTGCGGTGCTGATCGGCCGGGATCGCGCAGCGGTTGCCGAGGCGTTATCACGACACGCG 25 CCCGATGTCCCAGTCGTTCAGGTTGTGGCAGGCGAGGATACTGGTATGCCTGCGACTGTTGAG GTTCCTGTTGCTTGTGTTCTAGATGTGGCAAAAGATGACAAAGCCGGTGAGACCGTTGGCGCTG CCGTGATGACCGCTGCGGTGGCCGGCCGGCGGATGGCCCAACCCGGTGACACCGTGCTG CTGGCACCGGCCGCCCCATTCGACCAGTTCACCGGTTATGCCGACCGGGCGAGGCATTC 30 GCGACCGCGGTCCGCGCGGTGATCCGGTAG

>Rv2156c murX TB.seq 2416397:2417473 MW:37714

>emb|AL123456|MTBH37RV:c2417473-2416394, murX SEQ ID NO:80

ATGAGGCAGATCCTTATCGCCGTTGCCGTAGCGGTGACGGTGTCCATCTTGCTGACCCCGGTG 

GGGCTACCTGGGCGCCCACCTAGCGGGCCTGGCGTTTGACGGTGAAGGCATCGGCGCATCGG GTCTGTTGGTGCTGGGCCTAGCCACCGCTTTGGGCGGCGTCGGGTTCATCGACGATCTGATCA AGATCCGCAGGTCGCGCAATCTCGGGTTGAACAAGACGGCCAAGACCGTCGGGCAGATCACCT CCGCCGTGCTGTTTGGCGTGCTGGTGCTGCAGTTCCGGAATGCTGCCGGCCTGACACCGGGCA GCGCGGATCTGTCCTACGTGCGTGAGATCGCCACCGTCACATTGGCGCCGGTGCTGTTCGTGT TGTTCTGCGTGGTCATCGTCAGCGCCTGGTCGAACGCGGTCAACTTCACCGATGGCCTGGACG GGCTGGCCGCCGCCACGTGGCGATGGTCACCGCCGCCTACGTGCTGATCACCTTCTGGCAGT ACCGCAACGCGTGCGTGACGGCCCGGGCCTGGGCTGCTACAACGTGCGCGACCCGCTGGAC CTGGCGCTCATCGCGCCGCAACCGCTGGCGCCTGCATCGGTTTTTTGTGGTGGAACGCCGCG CCCGCCAAGATCTTCATGGGTGACACTGGGTCGCTGGCGTTGGGCGGCGTCATCGCGGGGTTG TCGGTGACCAGCCGCACCGAGATCCTTGCGGTGGTGCTGGGTGCGCTGTTCGTCGCCGAGATC ACCTCGGTGGTGTTGCAAATCCTGACCTTCCGGACCACCGGGCGCCGGATGTTTCGGATGGCG CCCTTCCACCACCATTTCGAGTTGGTCGGTTGGGCTGAAACCACGGTCATCATCCGGTTCTGGC TGCTCACCGCGATCACCTGCGGTCTGGGCGTGGCCTTGTTCTACGGTGAGTGGCTTGCCGCGG **TCGGTGCCTGA** 

>Rv2157c murF TB.seq 2417473:2419002 MW:51634

>emb|AL123456|MTBH37RV:c2419002-2417470, murF SEQ ID NO:81

ATGATCGAGCTGACCGTCGCGCAGATCGCCGAGATCGTCGGGGGGCGCAGTGGCCGATATCTCC TCGGCGGTAGCCGCGGCGCCGCCGTCGTGCTGGCCGCCCGGTGGGGGTGCCGGCCA TCGTGGTTCCGCCAGTGGCCGCCGAACGTATTGGCCGGCGTCCTCGAGCACGACAACGAC TGGTGGCCGGCGGCTCACCATCATCGGGATCACCGGCTCGTCGGGCAAGACGTCGACCAAG GGAGATGGCGCACGCCATCACGGCAACATCGCCGCGCTCGAGATCGCGCCCCCGTCGA TCGGAGTCGTGCTCAACGTCGGCACCGCACATTTGGGTGAGTTCGGCTCCCGCGAGGTCATCG CACAGACCAAAGCCGAACTGCCGCAGGCTGTTCCGCATTCCGGAGCGGTCGTCCTCAACGCTG ATGACCCCGCGGTGGCGGCGATGGCCAAGCTGACCGCGGCCCGGGTGGTGCGGGTCAGCCG GGACAACACCGGTGACGTTTGGGCGGGGCCGGTGTCGCTGGACGAATTGGCCAGGCCGCGCT TTACGCTGCATGCCCACGATGCCCAAGCCGAGGTCCGACTCGGGGGTCTGCGGCGACCACCAG GTCACTAACGCGCTGTGCGCCGCGGCGGCGCTCGCGCTGGAGTGTGGGGCCAGCGTTGAACAGGT CGCGGCCGCCGCGCGCCGCCGGTGTCGCGGCATCGGATGCAGGTGACCACCCGC GGCGACGGGGTGACGACGACGACGCCAACCCCGACTCCATGCGGGCCGG GCTGCAGGCGCTGGCCTGGATCGCGCACCAACCCGAGGCCACCCGCCGCAGCTGGGCGGTGC

5

10

15

20

25

30

10

15

20

25

30

TGGGTGAGATGGCCGAGCTGGGTGAGGACGCGÄTAGCCGAGCACGATCGCATCGGCCGGCTC GCGGTGCGCTTAGATGTCTCGACTCGTTGTCGTGGGAACCGGGAGGTCGATCAGCGCCATG GGATCGCACGCCGTCAATGTGGCCGACGGTGACGCCCCCTGGCACTACTGCGCGCCGAGC TGCGACCCGGGGATGTGGTCTTGGTCAAGGCCTCGAACGCGGCCGGGCTGGGTGCGGTGGCC GATGCATTGGTCGCAGACGACACATGCGGGAGTGTGCGCCCATGA

>Rv2158c murE TB.seq 2419002:2420606 MW:55310

>emb|AL123456|MTBH37RV:c2420606-2418999, murE SEQ ID NO:82

GTGTCATCGCTGGCCCGAGGGATCTCGCGGCGGCGAACGGAGGTGGCGACACAGGTGGAGGC TGCGCCCACTGGCTCGCCCCAACGCCGTCGTGGGCGTTCGGTTGGCCGCACTGGCCGATCA GGTCGGCGCGCCCGAGGGTCCAGCTCAGCGTCACCGAGGACCGGACGGTCA CCGGGGTCACGCTGCGCCCCAGGACGTGTCACCCGGTGACCTGTTCGCCGCCCTGACCGGC CACCGACCCGCGGGGTCGCCGAGATCGCCGGACGAGCGGCCGTGCCCGTGTTGGTGCACC TTGACGGTTATCGGGATCACCGGAACGTCCGGCAAGACCACCACCTATCTGGTCGAGGCC GGGTTACGGGCTGCCGGACGCGTCGCCGGGCTGATCGGCACCATCGGCATCCGCGTCGGCGG CGCCGACCTTCCCAGCGCGCTGACCACCCCGGAGGCCCCCACGCTGCAGGCGATGCTGGCGG CGATGGTCGAACGCGGGGTGGACACCGTGGTCATGGAGGTGTCCAGCCACGCGCTGGCGCTG GGCCGGGTGGACGCCCGGTTCGCCGTCGCCCTTCACCAATCTCTCCCGTGACCACCTG GATTTCCACCCAGCATGGCCGACTACTTCGAGGCCAAGGCGTCATTGTTCGATCCGGACTCGG CACTGCGCGCCCCCCCGCGTGGTGTGCATCGACGACGCCGCGGGCGCGCGATGGCGGC GCGGCCGCCGACGCGACCGCCGCCGCCGCCCGCACACTGGCGCCCACG GATGTGGCGCCCACGGACGCGGGCGGCAACAATTCACCGCCATCGACCCCGCCGGCGTAGG GCATCACATCGGAATCCGGCTACCGGGCCGCTACAACGTCGCCAATTGCCTGGTCGCCCTGGC GATTCTGGACACCGTCGGGGTCTCCCCGGAACAGGCGGTGCCGGGCCTGCGTGAGATCCGGG TCCCGGGCGCTCGAGCAGATCGACCGCGGCCAGGGCTTTCTCGCGCTGGTCGACTACGCG CACAAACCGGAAGCGCTGCGGTCGGTGCTGACCACCTTGGCGCACCCGGACCGCCGGCTGGC GGTGGTGTTCGGCGCCGGCGGCGATCGTGACCCGGGCAAGCGGGCCCCGATGGGCCGGATA GCCGCGCAGCTGGCCGACTTGGTGGTCGTCACCGACGACAACCCGCGTGACGAAGATCCCAC GGCGATCCGCCGCAAATCCTGGCTGGGCGGCCGAAGTCGGCGGTGATGCCCAGGTCGTCG 35 .

>Rv2159c - TB.seq 2420632:2421663 MW:36377

>emb|AL123456|MTBH37RV:c2421663-2420629, Rv2159c SEQ ID NO:83 ATGAAATTTGTCAACCATATTGAGCCCGTCGCGCCCCGCCGAGCCGGCGGCGCGGCCGAG GTCTATGCCGAGGCCCGCCGCGAGTTCGGCCGGCTGCCCGAGCCGCCCATGCTGTCCCC GGACGAGGGACTGCTCACCGCCGGCTGGGCGACGTTGCGCGAGACACTGCTGGTGGGCCAGG TGCCGCGTGGCCGAAGGAAGCCGTCGCCGCCGCCGCCGCCAGCCTGCGCTGCCCCTGG TGCGTCGACGCACACCACCATGCTGTACGCGGCAGGCCAAACCGACACCGCCGCGGCGAT 5 CTTGGCCGGCACAGCACCTGCCGCCGGTGACCCGAACGCGCCGTATGTGGCGTGGGCGGCAG GAACCGGGACACCGCGGGACCGCCGGCACCGTTCGGCCCGGATGTCGCCGCCGAATACCTG GGCACCGCGGTGCAATTCCACTTCATCGCACGCCTGGTCCTGGTGCTGCTGGACGAAACCTTC CAAGGTGCGCGGGGCATCGGCCGGGCCGCCCGCCGGCCGAGCCCGAACGCTG 10 CCCGACGATCTGGCATGGGCAACACCGTCCGAGCCCATAGCAACCGCGTTCGCCGCGCTCAGC CACCACCTGGACACCGCGCCGCCACCGCCACCGACTCGTCAGGTGGTCAGGCGGGTCGT CAGGTGACCGACGACGTCGCCGCGCCCGATCCCTGCTCGACACCGATGCGGCGCTGGT 15 TGGCGCCCTGGCCTGGCCGCCTTCACCGCCGCGCGCGCATCGGCACCTGGATCGGCGCCG CCGCCGAGGGCCAGGTGTCGCGGCAAAACCCGACTGGGTGA

>Rv2163c pbpB TB.seq 2425049:2427085 MW:72506 20 >emb|AL123456|MTBH37RV:c2427085-2425046, pbpB SEQ ID NO:84 GTGAGCCGCCCCCCAGGCGGGCCAGTCAGTCGCAGTCGACGCGACCGGCGCGCGTTT GCGCCGGCCACCGGGAGCCCAGGAGGTTGGGCAACGCAAACGGCCCGGCAAAACGCAGAAAG CCCGCCAGGAAGCCACGAAATCCCGCCCTGCGACACGGTCAGACGTCGCACCCGCG GGTCGCTCGACTCGTGCGAGGCGCACCCGGCAGGTGGTGGACGTCGGGACGCGCGGTGCGTC GTTCGTCTTTCGGCATCGGACCGGAAACGCGGTCATCTTGGTGTTGATGTTGGTCGCGGCAACA 25 AAGGTCACCGACGTCCAGCCAGCGGCTCGCGGCAGCATCGTCGACCGCAACAATGACCGGCTC GCGTTCACCATCGAGGCGCGTGCCCTGACGTTCCAGCCGAAGCGGATTCGGCGGCAATTGGAA GAGGCCAGGAAGAAGACGTCGGCTGCACCCGACCCGCAGCAGCACCCGCAGCACCCCA GGAGGTCGCCGGCAAGCTGAACAACAAGCCAGATGCCGCGGCCGTGCTGAAGAAGCTGCAAA 30 GCGACGAGACCTTCGTCTACTTGGCGCGTGCGGTCGACCCGGCTGTCGCCAGCGCGATCTGCG GCGGCAAACGTCGTCGGTGGCATCGACTGGGATGGTCATGGGCTGCTGGGGTCTGGAGGACTCC CTGGATGCGGTGCTGGCCGGAACCGACGGATCGGTCACCTACGACCGTGGGTCAGACGGCGT CGTCATCCCCGGCAGCTACCGGAATCGGCACAAGGCGGTCCACGGTTCCACCGTCGTGCTCAC 35 CCTCGACAACGACATCCAGTTCTACGTGCAGCAGCAGGTGCAGCAGGCCAAGAACCTATCGGG

GGCTCACAACGTCTCGGCCGTCGTCCTGGACGCCAAGACCGGCGAGGTGCTCGCGATGGCCA ACGACAACACCTTCGACCCGTCGCAAGACATCGGGCGCCAGGGGCGACAAGCAGTTGGGCAACC CGGCGGTGTCGCCCTTCGAGCCGGGCTCGGTGAACAAGATCGTCGCCGCGTCCGCGGTC ATCGAGCACGGGTTGAGCAGCCCCGACGAGGTGCTACAGGTGCCTGGCTCGATCCAGATGGG CGGTGTTACCGTGCATGACGCTTGGGAGCACGGCGTGATGCCCTATACCACCACGGGGGTGTT CGGAAAGTCCTCCAACGTCGGCACGCTGATGCTTTCCCAACGTGTCGGACCGGAACGCTATTAC GATATGCTCCGCAAGTTCGGGTTGGGACAGCGCACCGGCGTGGGCCTGCCCGGTGAGAGCGC CGGACTGGTGCCGCCAATCGACCAGTGGTCGGGCAGTACGTTCGCTAATCTTCCTATTGGCCAA GGTCTTTCGATGACTTTGCTGCAGATGACCGGCATGTACCAGGCCATCGCCAACGATGGAGTGC GGGTACCCCACGCATTATCAAGGCCACCGTCGCACCCGACGGCAGCCGAACCGAAGAACCGC GCCCGACGACATTCGCGTGGTGTCGCGCAGACCGCCCAGACCGTGCGCAGATGCTGCGT 10 GCCGTGGTGCAACGCGATCCGATGGGCTACCAGCAGGGTACCGGGCCGACGGCCGGGGTGCC CGGCTATCAGATGGCCGGCAAGACCGGTACCGCGCAGCAGATCAACCCTGGCTGCGGCTGCTA CTTCGACGACGTGTATTGGATCACCTTCGCCGGAATCGCCACTGCCGACAATCCCCGCTACGTG ATCGGCATCATGTTGGACAACCCGGCGCGCAACTCCGACGGCGCGCCTGGGCACTCGGCCGC CCCGCTGTTCCACAACATCGCGGGCTGGCTGATGCAGCGCGAAAACGTCCCGCTGTCACCCGA 15 TCCCGGGCCTCCTTTGGTCTTGCAGGCCACCTAG

>Rv2165c - TB.seq 2428236:2429423 MW:42498

>emb|AL123456|MTBH37RV:c2429423-2428233, Rv2165c SEQ ID NO:85 GTGCAAACCCGTGCACCGTGGTCTCTGCCCGAAGCGACCCTGGCGTACTTCCCCAACGCCAGG TTCGTGTCTTCGGACAGGGACCTCGGTGCAGGGGGGGGCGCCTGGAATAGCCGCGTCCCGAAGT ACGGCTTGCCAGACCTGGGGAGGTATCACGGTGGCTGATCCAGGTTCGGGGCCAACCGGTTTC GGTCATGTGCCGGTATTGGCGCAACGTTGCTTCGAACTGCTTACCCCCGCACTAACCCGCTACT CGGTTTTTGGAGGGATTGCCGGGTCTGCGCCTGATCGGGCTCGACCGTGACCCAACCGCTCTG GACGTCGCGGGTCTCGGCTGGTGCGATTCGCTGACCGACTTACCCTGGTGCACACCCGCTAT GACTGTCTGGGCGCAGCGCTGGCTGAATCCGGTTATGCCGCAGTGGGATCAGTCGACGGAATC CTGTTCGATCTCGGCGTCTCATCCATGCAGCTCGACCGCGCGAGCGGGGCTTCGCCTACGCC ACGGACGCCCATTGGACATGCGGATGGACCCGACGACGCCGTTGACCGCAGCTGACATTGTC AACACTTACGACGAGGCGCACTAGCCGACATCCTGCGTCGCTACGGAGAGGAGCGGTTTGCT CGGCGCATCGCTGCCGGTATCGTCCGCCGACGCGCAAAAACCCCGTTCACCTCGACCGCCGAA AAGCGAACATTCCAGGCGCTGCGCATCGCGGTCAACGATGAGCTGGAATCGCTGCGCACGGCC GTTCCTGCCGCGCTGGATGCCCTCGCTATCGGTGGCGCATCGCGGTGCTGGCCTACCAGTCG CTAGAGGACAGGATCGTCAAACGGGTGTTCGCCGAGGCAGTCGCGTCGGCCACCCCTGCGGG 

5

20

25

30

WO 01/35317 PCT/US00/31152

AGCGAGTGTGGCTGAGATCGAACGCAATCCCCGCAGTACTCCAGTGCGGTTGCGGGCCCTGCAACGAGTCGAGCACCGAGCAACCGAGAAGGGTGATTCATGA

>Rv2166c - TB.seq 2429428:2429856 MW:15912

>emb|AL123456|MTBH37RV:c2429856-2429425, Rv2166c SEQ ID NO:86
 ATGTTTCTCGGCACCTACACGCCCAAACTCGACGACAAGGGGCGGCTGACGCTGCCGGCCAAG
 TTTCGCGACGCGTTGGCAGGGGGGGTTGATGGTCACCAAGAGCCAAGATCACAGCCTGGCCGTT
 TACCCGCGGGCGGCGTTCGAGCAGCTGGCGCGCGGGCCAGCAAGGCGCCACGAAGCAACC
 CCGAGGCGAGAGCGTTCCTACGTAATCTCGCCGCCGGTACCGACGAACAGCATCCCGACAGTC
 AAGGCCGGATCACCTTGTCGGCCGACCACCGCCGCTACGCAAGCCTTTCCAAGGACTGTGTGG
 TGATCGGCGCGGTCGACTATCTCGAGATCTGGGATGCGCAAGCCTGGCAGAACTACCAACAAAT
 CCATGAAGAGAACTTCTCCGCGGCCAGCGATGAAGCACTCGGTGACATCTTCTGA

>Rv2197c - TB.seq 2461505:2462146 MW:22481

>emb|AL123456|MTBH37RV:c2462146-2461502, Rv2197c SEQ ID NO:87
 ATGGTGAGCAGATATTCCGCATACCGGCGTGGGCCGGATGTAATCTCGCCGGACGTCATCGAT
 CGCATCCTGGTTGGGGCATGTGCCGCGGTGTGGCTGTGTTCACCGGCGTGTCGGTGGCCGC
 CGCTGTCGCCCTGATGGACCTGGGTAGGGGCTTCCACGAGATGGCCGGAAACCCGCACACCAC
 GTGGGTGCTGTACGCCGTAATTGTGGTCTCCGCACTGGTCATCGTGGCCGCATACCGGTGCT
 GTTGCGAGCTCGCCGCATGGCTGAGGCCGAGCCCGCGACGAGGCCGACGGGTGCATCCGTGC
 GGGGCGGGCGATCGATCGGATCCGGCAAACGCGCTGTGGCCGAGTCGGCACCC
 GTACAGCACGCGGATGCATTCGAGGTGGCCGCGAGTGGTCCAGTGAGGCGGTGGACCGGAT
 CTGGTTGCGCGGGACAGTCGTTGACCAGTGCGATTGCGTTGATTGCCGTGGCGGC
 GGCGACCTACCTCATGGCGGTCACGACGGGCCATCTTGGATCAGCTACGGGTTGGCCGG
 GGTGGTCACCGCGGGCATGCCGGTGATCGAGTGGCTATACGCTCGGCAGCTGCGCCGGGTGG
 TGGCGCCCCAGTCCAGTTAG

>Rv2198c - TB.seq 2462149:2463045 MW:30955

ACCGGTCCGCGCAAGTCACCTATTCGGTGACCGGTACCAAGGCGCCGGGTGACATTATCTCG GTGACTTACGTCGATGCCGCCGGGCGCCGACGGACACAGCACAATGTGTACATCCCGTGGTCC ATGACGGTCACCCGATCTCGCAATCCGACGTTGGCTCGGTGGAGGCCTCCAGCCTTTTCCGG GTCAGCAAACTCAACTGCTCGATCACCACGAGCGACGGAACGGTGCTCTCATCGAACTCCAACG ATGGACCGCAAACGAGCTGCTGA

>Rv2199c - TB.seq 2463234:2463650 MW:14866

5

20

25

30

35

>emb|AL123456|MTBH37RV:c2463650-2463231, Rv2199c SEQ ID NO:89

ATGCATATCGAAGCCCGACTGTTTGAGTTTGTCGCCGCGTTCTTCGTGGTGACGGCGGTGCTGT ACGCCTGTTGACCTCGATGTTCGCCACCGGTGGTGTCGAGTGGGCTGGCACCACTGCGCTGG 10 CGCTTACCGGCGCATGGCGTTGATCGTCGCCACCTTCTTCCGGTTTGTGGCCCGCCGGTTAG ATTCCCGGCCCGAGGACTACGAAGGCGCTGAAATCAGCGACGGCGCAGGAGAACTTGGATTCT TCAGTCCGCATAGCTGGCCGATCATGGTCGCGTTGTCCGGCTCGGTGGCAGCGGTCGGCA TCGCGTTGTGGCTCCCGTGGCTGATCGCCGCCGGTGTGGCATTCATCCTCGCCTCGGCGGCCG 15 GATTGGTCTTCGAATATTACGTCGGTCCTGAGAAGCACTGA

>Rv2200c ctaC TB.seq 2463661:2464749 MW:40449

>emb|AL123456|MTBH37RV:c2464749-2463658, ctaC SEQ ID NO:90

GTGACACCTCGCGGGCCAGGTCGTTTGCAACGCTTGTCGCAGTGCAGGCCTCAGCGCGGCTCC GGAGGGCCTGCCCGTGGTCTTCGACAGCTGGCGCTCGCAGCAATGCTGGGGGCATTGGCCGT CACCGTCAGTGGATGCAGCTGGTCGGAAGCCCTGGGCATCGGTTGGCCGGAGGGCATTACCC GTAATCGTGTGGGGTCTCATCTTCTGGTCCGCGGTATTTCACCGGAAGAAGAACACCGACACTG AGTTGCCCGCCAGTTCGGCTACAACATGCCGCTAGAGCTGGTTCTCACCGTCATACCGTTCCT CATCATCTCGGTGCTGTTTTATTTCACCGTCGTGGTGCAGGAGAAGATGCTGCAGATAGCCAAG GATCCCGAGGTCGTGATTGATATCACGTCTTTCCAGTGGAATTGGAAGTTTGGCTATCAAAGGGT GAACTTCAAAGACGGCACACTGACCTATGATGGTGCCGATCCGGAGCGCAAGCGCGCCATGGT TTCCAAGCCAGAGGCAAGGACAAGTACGGCGAAGAGCTGGTCGGGCCGGTGCGCGGGCTCA ACACCGAGGACCGGACCTACCTGAATTTCGACAAGGTCGAGACGTTGGGCACCAGCACCGAAA TTCCGGTGCTGCTGCCGTCCGGCAAGCGTATCGAATTCCAAATGGCCTCAGCCGATGTGAT ACACGCATTCTGGGTGCCGGAGTTCTTGTTCAAGCGTGACGTGATGCCTAACCCGGTGGCAAAC AACTCGGTCAACGTCTTCCAGATCGAAGAAATCACCAAGACCGGAGCATTCGTGGGCCACTGCG CCGAGATGTGTGGCACGTATCACTCGATGATGAACTTCGAGGTCCGCGTCGTGACCCCCAACG ATTTCAAGGCCTACCTGCAGCAACGCATCGACGGGAAGACAAACGCCGAGGCCCTGCGGGCGA TCAACCAGCCGCCCTTGCGGTGACCACCCACCCGTTTGATACTCGCCGCGGTGAATTGGCCC CGCAGCCCGTAGGTTAG

proA g-glutamyl phosphate reductase TB.seq 2724231:2725475 MW:43746 >Rv2427c >emb|AL123456|MTBH37RV:c2725475-2724228, proA SEQ ID NO:91 ATGACCGTGCCAGCACCGCCGCACCTCGACTTGCGTCAAGAGGTGCACGACGCCGCACGCCG CGCCCGGGTGGCCCCCCCCGCCGGCTGCCACGACGACTGTCAAAGACCGCGCGCTGC ACGCGGCTGCCGACGACCTACTGGCTCACCGCGACCAGATCCTGGCGGCCAACGCCGAAGAC 5 CTGAACGCGGCGCGGGGGGGGACACCCCGGCCGCCATGCTGGACCGGTTGTCCTTGAACCC GCAACGAGTCGACGGTATCGCCGCGGGTTGCGGCAAGTCGCGGGACTGCGCGATCCGGTCG GTGAAGTGCTGCGTGGCTATACCCTGCCCAACGGGCTGCAGCTGCGCCAGCAGCGCGCCCCC TGGGCGTGGTCGGCATGATCTACGAGGGCCGCCCCAATGTCACCGTGGATGCCTTCGGGCTGA CACTCAAGTCGGGTAACGCTGCATTGCTGCGCGGCAGCTCGTCGGCCGCAAAGTCCAACGAGG 10 GTGGTGATTCCACGCGGGGGGGGGGCCTGATCGAGGCGGTCGTACGCGATGCCCAGGTGCC CACCATCGAGACCGGCGTCGGGAACTGCCATGTCTACGTGCACCAAGCGGCCGACCTGGACGT GGCCGAGCGTATCTTGCTGAACTCCAAGACGCGGCGGCCCAGCGTCTGCAACGCCGCCGAGA 15 CGCTGCTGGTCGACGCAGCGATCGCCGAAACGGCGTTGCCTCGATTGCTGGCCGCCCTGCAGC ACGCCGGTGTCACCGTACATCTCGACCCGGACGAGGCCGACCTGCGCCGAATACCTGTCGC TGGACATCGCGGTGGCGGTGGCGACGGTGCCATCGCCCATATCAACGAATACG GCACCGGGCACACAGAAGCGATTGTGACCACCAATCTTGATGCGGCCCAACGCTTTACCGAACA GATCGATGCGGCCGCGGTGATGGTGAACGCATCAACGGCGTTCACCGACGGCGAGCAATTCGG 20 CTTCGGCGCCGAGATCGGCATCTCCACCCAGAAACTGCATGCCCGCGGACCGATGGGACTACC GGAATTGACGTCGACCAAGTGGATCGCATGGGGAGCCGGCCACACCCGTCCGGCCTGA

similar to YHN4\_YEAST P38795 TB.seq 2734793:2737006 MW:80492 >Rv2438c -25 >emb|AL123456|MTBH37RV:c2737006-2734790, Rv2438c SEQ ID NO:92 ATGGGACTGCTCGGCGGCCAATCAGGGCCCAGGGTCGGCAGCGGCCCAGTCGGTAGCATCCC CACGCCGGTCAATGCCGCCATCTGCCAGCAGCGCGGGGGATTCCACGGTGTCGAGCGTGGAT ACTCGGCGGGTGATTCGGGCGTTCTGACGTCGCTGGGCGACAATGAAAGGACGATGAACTTTT ACTCCGCCTACCAGCACGGGTTCGTGCGCGTTGCCGCCTGCACTCACCACCACCATCGGTG 30 GCGTTGGCGGTCTTTCCTGAGCTGACGCTGTCGGGCTACTCCATCGAGGACGTACTACTGCAG GACTCTCTGCTCGATGCCGTCGAGGACGCGCTGCTCGACCTGGTGACCGAATCCGCCGACCTG TTACCTGTACTGGTGGTCGGGGCTCCGCTGCGGCATCGACACCGCGCGGTC GTCATTCACCGCGCGCGCGTGCTCGGCGTGCCCAAGTCGTATCTACCCACCTATCGCGAG TTCTACGAGCGCCCAGATGGCGCCCGGAGACGGGGAGCGGGGCACGATCCGCATCGGTGG 35 . . CGCCGACGTGGCCTTCGGCACGGACCTGTTGTTCGCCGCGTCAGATCTACCCGGCTTTGTGTT

GCATGTGGAGATCTGCGAGGACATGTTTGTGCCGATGCCGCCCAGCGCCCGAGGCGCCCTGG CGGGCGCGACGGTGCCGAATCTGTCCGGCAGCCCGATCACCATCGGCCGTGCCGAGGAC CGCCGGCTGCTTGCGCGCTCGGCGCGCGCGCGCTGTCTGGCTGCCTATGTCTATGCCGCCGC GGGGGGGGGGGGTCAACGACGGCCTGGCCTGGGACGGTCAGACGATGATCTGGGAGAATG GCGCACTGCTCGCGGAGTCCGAACGTTTCCCCAAAGGAGTGCGCCGCAGTGTCGCCGACGTTG ACACCGAGTTGCTTCGGTCGGAGCGGCTGCGGATGGGCACGTTCGACGACAACCGGCGTCAC CACCGGGAGTTAACGGAATCGTTCCGGCGCATCGACTTCGCACTCGACCCACCGGCAGGCGAC CAGGATTGCTACGAGGCCTACAACATCCAGGTGTCTGGACTCGAGCAACGGTTGCGGGCGCTG CGGATTCGCCACCGGGGAGCACACTAAGAACAACGCGATCAAGCTGGCACGTGCGCTGGGGG TTACCTTCTCCGAAATCGATATCGGCGACACCGCTCGGTTGATGCTGCACACAATCGGCCATCC GTATTCGGTTGGCGAAAAAGTGTACGACGTCACCTTCGAGAACGTCCAGGCCGGGTTGCGCAC CGACTATCTTTCCGTATCGCCAACCAGCGCGGGGGAATCGTACTGGGCACCGGGGACCTGTC GGAGCTGGCACTGGGTCGACATACGGTGTCGGCGACCAGATGTCGCACTACAACGTCAA 15 CGCCGGTGTGCCCAAGACGCTGATCCAGCACCTGATCCGGTGGGTCATTTCGGCGGGTGAGTT CGGTGAGAAGGTGGGTGAGGTATTGCAGTCGGTGCTCGACACCGAGATCACCCCGAACTCAT TCCGACCGGCGAGGAGCTGCAGAGCAGCGAGGCCAAGGTCGGACCTTTCGCCCTACAGG ACTITICGCTTTTTCAGGTACTGCGCTACGGATTTCGCCCGTCGAAGATTGCGTTTTTGGCCTGG CATGCGTGGAACGATGCGGGGGGGGCAACTGGCCGGCCCGGCTTCCCAAAGAGCGAACGCCC 20 GTCCTATTCATTGGCCGAAATCCGGCATTGGCTGCAGATTTTCGTCCAGCGGTTTTATTCGTTTA GCCAGTTCAAGCGTTCGGCATTGCCCAACGGCCCCAAGGTGTCCCACGGGGGCGCGTTGTCGC CGCGTGGGGATTGGCGGGCCCCGTCGGATATGTCAGCGCGAATCTGGCTCGATCAGATCGACC GTGAGGTGCCCAAGGGCTAG 25

>Rv2439c proB glutamate 5-kinase TB.seq 2737118:2738245 MW:38789 >emb|AL123456|MTBH37RV:c2738245-2737115, proB SEQ ID NO:93 CGGTCGAGCGGCGGATGAAGGCGGGTTCCGACGTCGTCATCGTGTCTTCGGGCGCCCATCGCC GCCGCATCGAGCCGCTCGGGCTGTCCCGAAAGATCTGGCGACCAAGCAGGCGGC GGCCAGCGTCGGCAGGTCGCGCTGGTGAACTCGTGGAGCGCGGCGTTCGCCCGCTACGGCC GCACGGTGGGCCAGGTGCTGACCGCGCACGACATTTCGATGCGGGTGCAGCACCAAC GCCCAACGCACGCTGGATCGGCTGCGCGCGTTGCACGCGGTGGCGATTGTCAACGAGAACGA CACCGTGGCCACCAACGAGATCCGGTTCGGTGACAACGATCGGCTGTCTGCACTGGTGGCGCA CCTGGTCGGCGCCGACGCTTTGGTGCTGCTGTCGGACATCGACGGCCTCTACGACTGCGACCC

30

35

10

15

20

25

30

35

obg Obg GTP-binding protein TB.seq 2738248:2739684 MW:50430 >Rv2440c >emb|AL123456|MTBH37RV:c2739684-2738245, obg SEQ ID NO:94 GTGCCTCGGTTTGTCGATCGGGTCGTCATCCACACCAGAGCGGGTTCGGGCGGTAACGGCTGC GCTTCGGTCCATCGCGAGAAATTCAAGCCGCTGGGCGGCCCCGATGGCGGAAATGGCGGCCG GGGCGCAGCATCGTCTCGTCGTCGATCCGCAAGTGCACCCCTGCTCGACTTCCATTTCCGC CCGCATCTCACCGCGGCTTCGGGCAAGCACGGGATGGGCAATAACCGCGACGGGGCCGCCGG GGCCGACCTGGTCGGCGCGGGCACCCGCTTTGAAGCCGCCGCCGGAGGCCGTGGCGGTTTGG GCAACGCCGCGCTGCCTCCCGCGTAAGGCCCCCGGTTTCGCACTCCTCGGCGAAAAGG GACAGTCCCGAGACCTCACCTTGGAACTCAAGACCGTCGCCGACGTCGGCCTGGTCGGGTTTC CGTCGGCCGGAAAATCCTCGCTGGTGTCGGCGATTTCGGCGGCCAAGCCGAAGATCGCCGACT ACCCGTTCACCACCCTGGTGCCCAACCTCGGTGTGGTCTCGGCTGGCGAGCACGCGTTCACCG TCGCCGACGTGCCGGGGTTGATCCCGGGCGCATCCCGGGGCCGTGGTCTGGGGCTGGACTTT CTGCGGCACATCGAGCGCTGCGCTGTACTGGTGCATGTGGTGGATTGCGCTACCGCCGAGCCG GGCCGCGACCCCATCTCGGACATCGACGCGCTGGAAACGGAACTCGCGTGCTACACGCCCAC GCTGCAAGGGGACGCGCTCTGGGCGATCTCGCCGCACGGCCGCGTGCGGTGGTCCTCAACA AAATCGATGTGCCGGAGCCCGCGAGCTCGCGGAGTTCGTCCGTGACGACATCGCCCAGCGC GGCTGGCCGGTGTTCTGCGTGTCGACCGCAACCCGGGAAAACCTGCAGCCGTTGATCTTTGGG CTGTCGCAGATGATCTCGGACTACAACGCTGCGCGGCCGGTGGCGGTGCCACGGCGGCCGGT GATTCGTCCGATTCCGGTGGACGACGGGCTTTTACCGTCGAACCCGACGGGCATGGTGGCTT TGTCGTCAGCGGTGCCCGGCCCGAGCGTTGGATTGACCAGACCAACTTCGACAACGACGAGGC CGTCGGCTATCTCGCCGACCGGCTGGCGCGCCTGGGTGTCGAGGAGGAATTGCTGAGGCTGG GTGCGCGGTCAGGATGCGCGGTGACCATCGGCGAGATGACGTTCGATTGGGAGCCGCAAACG CCTGCGGGTGAGCCGGTCGCGATGTCCGGCCGGGCACCGATCCGCGGCTGGACAGCAACAA GCGGGTGGCCGGCCGAGCGAAAGGCCGCTCGGAGTCGCGTCGCGAACACGGGGATGGC **TGA** 

20

25

rpmA 50S ribosomal protein L27 TB.seq 2739773:2740030 MW:8969 >Rv2441C > mb|AL123456|MTBH37RV:c2740030-2739770, rpmA SEQ ID NO:95 ATGGCACACAAGAAGGGGGCTTCCAGCTCGCGCAACGGTCGCGATTCCGCCGCCCAGCGGCT GGGGGTTAAGCGGTACGGCGGCCAGGTCGTCAAGGCCGGCGAGATCCTGGTCCGCCAGCGCG GTACCAAATTCCATCCCGGCGTCAACGTCGGGCGTGGCGGCGATGACACCTTGTTCGCCAAGA CGGCCGGGGCGGTCGAGTTCGGCATCAAACGCGGACGTAAGACGGTGAGCATCGTCGGTTCG **ACCACTGCCTGA** 

rpIU 50S ribosomal protein L21 TB.seq 2740048:2740359 MW:11152 >Rv2442c 10 >emb|AL123456|MTBH37RV:c2740359-2740045, rplU SEQ ID NO:96 ATGATGGCGACCTACGCAATCGTCAAGACCGGCGGCAAGCAGTACAAAGTCGCTGTCGGAGAT GTGGTCAAGGTCGAAAAGCTGGAATCCGAGCAGGGGGAGAAGGTGTCCCTGCCGGTGGCTCT GGTTGTCGACGGCGCCACCGTCACCACCGATGCGAAGGCACTGGCCAAGGTCGCGGTGACCG GTGAGGTGCTCGGGCACACCAAGGCCCCAAGATCCGTATCCACAAGTTCAAGAACAAGACTG 15 GCTACCACAAACGGCAGGGACACCGTCAGCAGCTGACGGTCCTGAAGGTCACCGGCATCGCAT AA

>Rv2448c valS valyl-tRNA synthase TB.seq 2747596:2750223 MW:97822 >emb|AL123456|MTBH37RV:c2750223-2747593, valS SEQ ID NO:97 ATGCTGCCCAAGTCGTGGGATCCGGCCGCGATGGAGAGCGCCATCTATCAGAAGTGGCTGGAC GCTGGCTACTTCACCGCGGACCGACCAGCACCAAGCCGGCCTATTCGATCGTGCTGCCGCCG CCGAACGTGACCGCAGCCTGCACATGGGCCACGCGCTGGAACACACCATGATGGACGCCTTG ACGCGGCGCAAGCGGATGCAGGGCTATGAGGTGCTCTGGCAGCCGGGCACCGACCATGCCGG GATCGCCACCCAGAGCGTGGTCGAGCAGCAGCTGGCGGTCGACGGCAAGACTAAAGAAGACCT CGGCCGCGAGCTGTTCGTGGACAAGGTGTGGGATTGGAAGCGAGAGTCTGGCGGTGCCATCG GCGGCCAGATGCGCCGACTCGGTGACGGGGTGGACTGGAGCCGCGACCGGTTCACCATGGAC GAAGGTCTGTCGCGGGCGGTGCGCACGATCTTCAAGCGGCTTTATGACGCCGGGCTGATCTAT CGGGCCGAGCGGCTGACTGGTCGCCGGTGCTGCAGACCGCGATCTCCGACCTCGAGGT CAACTACCGCGACGTCGAAGGCGAGCTGGTGTCGTTTAGGTACGGCTCGCTTGACGACTCGCA 30 ACCCCACATCGTGGTCGCCACCACCCGGGTCGAGACGATGCTGGGCGATACCGCGATCGCCGT CCATCCCGATGACGAGCGCTACCGTCACCTGGTCGGCACCAGCCTGGCGCACCCATTCGTCGA CCGGGAGCTGGCCATTGTCGCCGACGAGCACGTGGACCCTGAATTCGGCACCGGCGCGGTCA AAGTCACACCGCCCACGACCCCAACGACTTCGAAATCGGGGTGCGCCACCAGCTGCCGATGC CCTCGATCCTGGACACCAAGGGCCGGATCGTCGACACCGGAACGCGATTCGACGGCATGGACC 35 GCTTCGAGGCACGGGTCGCGGTGCGCCAAGCGCTCGCGGCCCAGGGCCGCGTGGTCGAAGAA AAGCGACCCTACCTGCACAGCGTCGGACACTCCGAACGCAGCGGGGGGGCGATCGAGCCGCG

GCTATCCCTGCAGTGGTGGGTCCGGGTGGAATCGCTGGCCAAAGCGGCCGGGGATGCGGTGC GCAACGGGACACCGTGATTCACCCGGCCAGCATGGAACCCCGCTGGTTCTCCTGGGTCGACG ACATGCACGACTGGTGCATCTCGCGACAGCTCTGGTGGGGGGCATCGGATCCCGATCTGGTACG GACCCGACGGCGAACAGGTGTGCGTCGGCCCGGACGAAACACCCCCGCAGGGCTGGGAACAG GATCCTGACGTGCTGGATACCTGGTTTTCGTCGGCGCTGTGGCCGTTTTCCACGCTGGGTTGGC CGGACAAGACGGCGGAGCTGGAAAAGTTCTATCCGACAAGCGTTCTGGTTACCGGCTATGACAT CTTGTTCTTTTGGGTGGCCAGAATGATGATGTTCGGCACCTTCGTCGGCGACGACGCCCCATC ACCCTCGACGCCCCCGGGGCCCCGCAGGTGCCGTTCACCGACGTGTTTCTGCATGGGCTGATC CGCGACGAGTCTGGCCGCAAGATGAGCAAGTCCAAGGGCAACGTCATCGACCCGCTGGATTGG GTGGAAATGTTCGGGGCCGATGCGCTGCGGTTCACGCTGGCCCGCGGGGCCAGTCCCGGTGG TGACTTGGCGGTGAGCGAGGATGCCGTGCGGGCGTCGCGCAATTTCGGGACCAAGCTGTTCAA CGCCACTCGGTACGCACTGCTCAATGGCGCCGCGCCCAGCACCCCTGCCATCGCCGAACGAGCT GACCGACGCCGACCGCTGGATTCTCGGAAGGTTGGAAGAGGTTCGGGCCGAAGTTGATTCGGC CTTCGACGGATACGAGTTCAGCCGCGCTTGTGAGTCCCTGTATCACTTCGCCTGGGACGAATTC TGCGACTGGTACCTCGAACTGGCCAAAACGCAGCTTGCCCAGGGACTCACACACCACCGCC GTGCTGGCCGCCGGGCTGGACACGCTGCTGCGCCTGCACCCGGTGATTCCCTTCACC GAGGCGCTATGGCTGGCGCTGACCGGCAGGGGAATCGCTGGTCAGCGCCGACTGGCCGGAGCC TTCCGGGATTAGCGTGGACCTTGTTGCCGCGCAACGGATTAACGATATGCAGAAGTTGGTGACC GAAGTGCGGCGGTTCCGCAGCGATCAAGGTCTGGCCGACCGGCAGAAGGTTCCGGCCCGAAT GCACGGTGTGCGGACTCGGATCTGAGCAACCAGGTGGCCGCGCGTGACCTCGCTGGCGTGGC TCACCGAGCCGGGCCCGGATTTTGAGCCGTCGGTCTCGTTGGAGGTTCGGCTCGGCCCCGAGA TGAACCGCACCGTCGTCGAGCTCGACACCTCGGGCACCATCGACGTGGCCGCCGAGCGT CGCCGCCTGGAAAAGGAGTTGGCCGGCGCCCAAAAGGAGCTGGCGTCGACCGCCGCCAAGTT GGCCAACGCGGACTTTCTGGCCAAAGCGCCCGACGCCGTCATTGCCAAGATCCGGGACCGCCA GCGCGTGGCGCAGCAGGAAACCGAGCGCATCACCACCCGGTTGGCTGCGCTGCAATGA 25

>Rv2482c plsB2 TB.seq 2786915:2789281 MW:88284 >emb|AL123456|MTBH37RV:c2789281-2786912, plsB2 SEQ ID NO:98

GTGACCAAACCGGCGGCCGATGCCAGCGCGGTGCTTACTGCCGAGGACACACTGGTGCTGGC TGACGGCACTGGTCGAGCAGCTCGAGCCCGGCTTCGCATCCAGCCCGCAATCTGGCGAGGAC CGTTCTATCGTGCCGGTTCGGGTGATCTGGCTGCCTCCCGCCGATCGCAGCCGGGCGGCAAG GCGCCAGCAGTGGCGCGATACCACGGTGGCAGAGCACAAGCGCGATTTCGCCCAGTTCGTCAG CCGCCGAGCGCTGTTGGCGCTGGCGCGCGCGAATATCGGATCCTTGGACCGCAATACAAATC

5

10

15

20

30

10

15

20

25

TCCCCGCTGGTGAAGCCGGAGATGTTGGCGTCCGCACGATTTCGTGCCGGCCTGGACCGGAT TCCGGCCCCCCGCAAGATGCCGGGAAGATGCTCGACGAACTCTCCACCGGATGGAGCC TCGACTACGACGAGTATCAGGTCGCGGCGATGCGCGCGCACTGGAGGCTCATCCGGCGGTC CTGCTGTTCTCGCACCGGTCCTACATCGACGGCGTGGTGGTACCGGTGGCCATGCAGGACAAC CGGTTACCGCCGGTGCACATGTTCGGCGGCATCAACCTGTCGTTCGGTCTCATGGGACCCCTC ATGCGGCGCTCGGGGATGATCTTCATCCGGCGCAATATCGGCAACGACCCACTGTATAAGTACG TGCTCAAGGAGTACGTGGCTACGTGGTCGAGAAGCGGTTCAACCTGAGCTGGTCCATCGAAG GCACCCGGTCGCGCACCGGAAAGATGTTGCCGCCCAAGCTCGGTTTGATGAGCTACGTGGCCG ATGCTTACCTGGACGCCGCAGTGACGACATCCTGCTGCAGGGGGGTTTCGATTTGCTTCGATCA GCTGCACGAGATCACCGAATACGCCGCCTACGCGCGTGGCGCGGAGAAGACGCCCGAAGGTT TGCGCTGGCTCTACAACTTCATCAAGGCGCAGGGGGAACGCAACTTCGGCAAGATCTACGTTCG CTTCCCGAAGCGGTCTCGATGCGCCAGTACCTCGGCGCACCGCACGGCGAGCTGACCCAGG ATCCGGCCGCGAAACGGCTTGCGTTGCAGAAGATGTCGTTCGAGGTGGCCTGGAGGATTTTGC AGGCGACGCCGGTGACCGCGACGGGTTTGGTGTCCGCACTGCTGCTCACCACCCGCGGCACC GCGTTGACGCTCGACCAGCTGCACCACGTTGCAGGACTCACTGGACTATCTGGAACGCAAA CAATCGCCGGTTTCGACAAGCGCATTGCGACTGCGCTCGCGCGAAGGCGTCCGTGCGGCGC GGACGCGTTGTCCAACGGCCACCCGGTCACTCGGGTCGACAGTGGCCGGGAGCCGGTATGGT ACATAGCGCCTGACGACGACGCCGCGCGCGTTCTACCGGAACTCGGTGATCCATGCGTTTTT GGAGACCTCGATCGTCGAGCTCGCGCTGGCCCATGCCAAGCACGCCGAAGGTGACCGCGTCG CCGCGTTCTGGGCCCAGGCGATGCGGTTGCGGGATCTGCTGAAGTTCGACTTCTATTTCGCGG ATTCCACGGCGTTTCGGGCCAACATCGCCCAAGAGATGGCCTGGCACCAAGACTGGGAGGATC ATCTTGGCGTCGGGGCAATGAGATCGACGCGATGCTGTATGCCAAACGGCCGCTGATGTCGG ACGCGATGTTGCGGGTCTTCTTCGAAGCCTATGAGATCGTTGCCGACGTGTTGCGCGATGCTCC GCCTGACATCGGTCCTGAGGAGTTGACGGAGCTGGCGCTCGGCCTCGGCCGTCAGTTTGTGGC ACAGGGCCGGGTCCGCAGCAGCGAACCGGTATCGACGCTGCTGTTCGCCACTGCACGCCAGG TCGCCGTCGATCAGGAGCTGATAGCGCCGGCCGGCCGACCTCGCCGAACGTAGGGTCGCCTTC CGGCGGGAGTTACGAAACATTCTGCGGGATTTCGACTATGTCGAGCAGATCGCGCGCAACCAG TTCGTCGCCTGCGAGTTCAAAGCGCGTCAAGGACGCGACCGAATCTAA

30

35

>Rv2509 - putative oxidoreductase TB.seq 2824676:2825479 MW:28014
>emb|AL123456|MTBH37RV:2824676-2825482, Rv2509 SEQ ID NO:99
ATGCCGATACCCGCGCCCAGCCCCGACGCACGTGCCGTTGTCACCGGGGCTTCGCAGAACATC
GGCGCGCGCTGGCCACCGAACTGGCCGCACGCGGGCACCACCTGATCGTCACCGCACGACG
CGAGGACGTGTTGACCGAGTTGGCTGCCCGGCTGGCCGACAAGTACCGCGTCACGGTCGACG
TGCGACCGGCCGATCTGGCCGAACAGAACGATCGAAACTGGCCGACGAGCTGGCC
CGGCCCATCTCGATCCTGTGCGCCAACGCGGGTACCGCGACATTCGGCCCGATCGCATCGCTC

fatty acid synthase TB.seq 2840124:2849330 MW:326226 >Rv2524c fas 10 >emb|AL123456|MTBH37RV:c2849330-2840121, fas SEQ ID NO:100 GTGACGATCCACGAGCACGACCGGGTGTCCGCTGATCGCGGGGGGGACAGCCCGCATACCAC CCACGCTCTGGTCGATCGCCTCATGGCTGGTGAGCCCTACGCTGTCGCATTCGGTGGCCAGGG CAGCGCCTGGCAAACCCTCGAAGAGCTGGTGTCGGCCACCGGGATAGAAACCGAGTTGGC GACGTTGGTCGGTGAGGCAGAGCTGTTGCTCGATCCGGTCACCGACGAGCTGATTGTGGTGCG CCCGATCGGTTTCGAGCCGCTGCAATGGGTACGCGCACTGGCGGCCGAGGACCCGGTTCCGT 15 CCGACAAGCACCTGACGTCGGCCGCCGTGTCGGTGCCCGGCGTGTTGCTTACCCAGATCGCGG CGACCCGGGCGCTGGCCGTCAAGGCATGGACCTCGTGGCCACCCCGCCGGTCGCCATGGCG GGGCATTCGCAAGGTGTGCTGGCGGTGGAAGCCCTCAAGGCTGGTGGGGCACGCGACGTCGA GCTGTTTGCCTTGGCCCAGTTGATCGGTGCCGCCGGAACGCTGGTGGCCCGCCGGCGCAA TTTCCGTCCTGGGCGATCGCCCGCCGATGGTATCGGTCACCAACGCCGACCCCGAGCGCATCG 20 GCCGGTTGCTCGACGAGTTCGCCCAGGACGTGCGCACGGTGCTGCCACCGGTGTTGTCCATCC GCAACGGCCGGCGTCGTCATCACCGGCACCCCGAGCAGCTGTCGCGTTTCGAGCTTT ATTGCCGCCAGATCTCCGAGAAGGAAGAAGCCGACCGCAAGAACAAGGTCCGCGGCGGCGAC GTCTTCTCGCCGGTCTTCGAGCCGGTGCAGGTGGAGGTGGGCTTTCACACCCCGCGGCTATCC GACGGGATCGACATCGTCGCGGGCTGGGCCGAGAAGGCGGGCCTCGATGTCGCCTTGGCTCG 25 GGAGCTGGCCGATGCCATCTTGATCAGAAAGGTCGACTGGGTCGACGAGATCACCCGTGTCCA CGCGGCCGCCCGCTGGATCCTCGACCTGGGCCGGGCGACATCCTGACCCGACTGACCG CACCGGTGATCCGCGGCCTGGGCATCGGCATCGTGCCGGGCGGCTACCCGCGGTGGCCAGCGC AACCTGTTCACCGTCGGCGCCACCCCGAGGTTGCCCGGGCCTGGTCGAGCTACGCACCGACC GTGGTTCGCCTCCCGACGGCAGGGTCAAGCTCTCGACGAAGTTCACCCGGCTGACCGGCCGC 30 TCGCCGATCCTGCTCGCGGGCATGACCCCGACCACCGTGGACGCCAAGATCGTCGCCGCGGC GGCCAACGCCGGCACTGGGCCGAGCTGGCCGGCGGCGGCAGGTCACCGAAGAGATCTTC GGTAACCGCATCGAACAAATGGCCGGCCTGCTCGAGCCGGGCCGCACCTATCAGTTCAACGCG CTGTTCCTCGATCCCTACCTGTGGAAGCTTCAGGTGGGCGGCAAGCGGTTGGTGCAGAAGGCC CGCCAGTCCGCCGCGATCGACGCGTGGTGATCAGCGCCGGCATCCCAGACCTCGACGA 35 GGCCGTCGAGCTGATCGACGAACTGGGCGACATCGGCATCAGCCACGTCGTGTTCAAACCCGG

GACCATCGAGCAGATCCGCTCGGTGATTCGCATCGCCACCGAGGTGCCCACCAAGCCGGTGAT CATGCACGTCGAGGGCGGGCGCGCGGGGCACCATTCCTGGGAGGATCTCGACGACCTGC TGCTGGCTACCTACTCGGAGTTGCGCTCACGCGCCAACATCACGGTGTGCGTCGGCGGCGCA TTGGCACCCGAGAAGGGCTGCGGAATATTTGTCCGGGCGCTGGGCGCAGGCCTACGGCTTCC CATTGATGCCGATCGACGGCATCCTGGTCGGCACCGCGGCGATGGCCACCAAGGAATCCACCA CGTCGCCATCGGTCAAGCGGATGCTCGTCGACACTCAGGGCACCGACCAATGGATCAGCGCCG GAAAAGCGCAGGGCGCATGGCCTCCAGCCGCAGTCAGCTCGGTGCCGATATCCACGAGATC GACAACAGCGCATCCCGGTGCGGGCGGCTGCTCGACGAGGTGGCCGGTGACGCGGAGGCGG TCGCGGAGCGTCGCGAGGATCATCGCGGCGATGGCCAAGACCGCCAAGCCCTACTTCGGC GACGTCGCCGACATGACCTACCTGCAGTGGCTGCGGCGCTACGTCGAACTGGCCATCGGGGAA GGCAACTCGACCGCCGACACCGCCTCGGTGGCCAGCCCGTGGCCGACACCTGGCGGGA CCGCTTCGAGCAGATGCTGCAGCGTGCCGAAGCCCGGTTGCACCCACAGGATTTCGGCCCGAT CCAGACGCTATTCACCGATGCTGGCCTGCTGGACAATCCGCAGCAGCGGCGATCGCCCCCTGCT GGCGCGCTACCCCGACGCCGAGACCGTGCAGTTGCATCCCGCGGATGTGCCCTTTTTCGTGAC GTTGTGCAAGACGCTGGGCAAGCCGGTCAACTTCGTGCCGGTGATCGACCAGGACGTGCGGC GCTGGTGGCGCAGCGACTCGCTGTGGCAGGCCCACGACGCCCGCTACGACGCCGATGCGGTG 15 TTGCTGGACCGTTTCGAGCAAGCCGCAATCGATGAAGTGCTCGGCGCCGGTGTCGAGCCGAAG GATGTCGCGTCGCCCGGCTGGCCCGCCCGACGTGGCCGGACCGTTGGCTGTCCTCGA CGCACCGATGTGCGCTGGGCCGGTCGCACCGTGACCAACCCGGTGCATCGGATCGCCGACC 20 GCCCGGCTGCAGACGCACGCGACGACGTCGCCTTGAGCGTGCCCGTCTCGGGCACCTGGGT CGACATCCGATTCACGTTGCCGGCCAACACCGTCGATGGCGGCACCCGGTGATCGCCACCGA GGACGCCACCAGCGCCATGCGCACGGTGCTGGCGATCGCCGGCGGTGTCGACAGCCCGGAGT TCTTGCCTGCGGTGGCCAACGGGACGGCCACTTTGACGGTGGACTGGCACCCCGAGCGTGTTG CCGACCACACCGCCACCCCACGTTCGGTGAGCCGCTGGCACCCAGCCTCACCAACGTG 25 CCCGACGCCTCGTCGGCCCTTGTTGGCCAGCGGTTTTCGCGGCCATCGGATCGGCGGTCACC GACACCGGTGAGCCGGTGGTAGGCCTGCTGAGCCTGGTGCATCTGGACCACGCCGCCCG CGTGGTCGGTCAGCTGCCCACGGTCCCGGCCCAATTGACCGTCACCGCAACGGCTGCCAACGC AACCGATACGGACATGGGCCGCGTCGTGCCGGTCGTCGTCGTTACCGGCGCCGATGGCG CCGTGATCGCCACTCTCGAGGAGCGATTCGCGATCCTGGGTCGCACCGGTTCCGCCGAGCTCG 30 CCGACCCGCCGAGCCGGTGGCGCGGTGTCGGCGAACGCCACCGACACCCCGCGCCGTCG CCGCCGCGACGTCACGATCACCGCGCCGGTCGACATGCGCCCGTTCGCGGTGGTGTCCGGCG ACCACAACCCCATTCACACCGACCGGGCCGCCGCGCTGCTTGCCGGCCTGGAGTCGCCGATC GTGCACGGCATGTGGCTGTCGGCCGCGCGCGACACACGCGGTGACCGCCACCGACGGGCAGG CCCGCCACCGCCCGGCTGGTCGGCTGGACCGCGCGTTTTTGGGCATGGTGCGCCCCGGC 35 GACGAGGTGGACTTCCGCGTCGAGCGCGTCGGAATCGACCAGGGCGCAGAGATTGTGGACGT

5

GGCCGCGCGCGCGCGCGCGCCCCCAAGA CGGTCTACGCATTCCCCGGCCAGGGCATCCAACACAAGGGCATGGGCATGGAGGTGCGCGCC CGCTCCAAGGCGCCCGCAAGGTGTGGGACACCGCGGACAAGTTCACCCGCGACACCCTGGG CTTCTCGGTACTGCACGTGGTCCGCGACAACCCGACCAGCATCATCGCCAGCGGTGTGCACTA CCACCACCCGACGGGGTGCTCTACCTGACGCAGTTCACCCAGGTCGCGATGGCGACGGTGG CGGCCGCGCAGGTCGCCGAGATGCGTGAACAGGGAGCCTTCGTCGAAGGCGCCATCGCGTGC GGCCACTCGGTCGGCGAGTACACCGCGCTGGCCTGCGTGACCGGCATCTACCAACTGGAAGC CTTGCTGGAGATGGTGTTTCACCGCGGGTCGAAGATGCACGACATCGTTCCGCGCGACGAGCT CGGCCGCTCCAACTATCGGCTGGCGGCCATCCGGCCGTCCCAGATCGACCTCGACGACGCCG ACGTGCCCGCGTTCGTCGCCGGGATCGCGGAGAGCACCGGTGAATTCCTGGAGATCGTGAATT TCAACCTGCGTGGCTCGCAATACGCGATCGCGGGCACGGTACGCGGCCTCGAGGCGCTCGAG GCCGAGGTGGAGCGCCGCGAGCTCACCGGCGGCCGACGGTCGTTCATTTTGGTGCCCGG GGACCGGGTCATGCCGCGCGGCCGGGCCCCGACCTGATCATCGGGCGCTACATTCCCAACCT GGTGCCGCGGTTGTTCACCCTGGACCGCGACTTCATCCAGGAAATCCGGGATTTGGTGCCCGC CGAGCCGCTCGACGAGATCCTCGCCGACTACGACACCTGGCTTCGCGAGCGTCCGCGAGAT GGCGCGCACGGTGTTCATCGAGCTGCTGGCATGGCAATTCGCCAGCCCGGTGCGCTGGATCGA GACGCAGGATCTGCTGTTCATCGAGGAGGCCGCCGGCGGGCTGGGTGTGGAGCGATTCGTCG AGATCGGTGTGAAGAGCTCACCGACGGTGGCGGGTCTTGCCACCAACACCCTCAAACTGCCCG AATACGCCCACAGCACAGTGGAAGTGCTCAACGCCGAGCGTGATGCCGCGGTGCTGTTCGCCA GGACGTCGTCTCGGAAGCCGCCCCCGTCGCGCCGGCCGCCTTCGTCGGCGGCCCGCGTCCCG ACGATCTGGTTTTCGACGCCGCCGATGCCACGCTGGCGCTGATCGCGCCTCTCGGCCAAGATGC GCATCGACCAGATCGAAGAACTCGACTCCATCGAGTCCATCACCGACGGTGCGTCGCGGC GCAACCAGCTGCTGGGCCTGGGCTCCGAGCTGAACCTCGGTGCCATTGACGGCGCCGCC GAATCGGACCTGGCCGGTCTGCGCTCACAGGTGACCAAACTGGCGCGCACCTACAAGCCTTAC GGCCCAGTGCTTTCCGACGCCATCAACGACCAGCTTCGCACCGTCCTCGGACCGTCGGGCAAG CGGCCCGGCGCCATCGCCGAGCGGGTGAAGAAGACCTGGGAGCTCGGTGAGGGCTGGGCCA AGCATGTCACCGTCGAGGTCGCGCTGGGCACCCGCGAGGGCAGCAGCGTTCGCGGCGCGCCC ATGGGCCACCTGCACGAGGGCGCGCTGGCCGATGCCGCCTCCGTCGACAAGGTCATCGACGC GGCGGTCGCATCGGTGGCCGCCCCAGGGCGTTTCGGTAGCGCTGCCGTCGGCCGGTAGTG GAGGGCGTGCTGGCCCCGCCCGCCTGGTGCTGGGGCAGCTGGACGACCCCGT CAACGCCTTGCCGGCCCCCCGATTCCGAGCTGATCGACTTGGTCACCGCCGAACTGGGAGC GGACTGGCCGCGGTTGGTGGCACCGGTGTTCGACCCCAAGAAGGCCGTCGTATTCGACGACC GCTGGGCCAGCGCCGCGAGGACCTGGTGAAGCTGTGGCTGACCGACGAGGGCGACATCGAC GCCGACTGGCCGCCCTGGCGGAGCGCTTCGAGGGTGCCGGCCACGTCGTGGCGACCCAGG

10

15

20

25

30

10

15

20

25

CTACCTGGTGGCAAGGTAAGTCGCTGGCCGGGGCCGGCAGATCCATGCATCGCTGTACGGCC GCATCGCCGCCGGCCGAGAACCCCGAACCCGGCCGCTACGGCGGCGAAGTTGCCGTGGTG ACCGCCCTTCGAAGGGTTCGATCGCCGCGTCGGTGGTGGCTCGGCTGCTCGACGGCGGAGC CACCGTCATCGCGACCACCTCCAAGCTCGACGAGGAGCGGCTGGCGTTCTACCGCACGCTGTA CCGACGTCGACGCCCTGGTCGAATGGATCGGCACCGAACAGACCGAAAGCCTTGGGCCGCAGT CGATTCACATCAAAGACGCGCAGACCCCGACGCTGCTGTTCCCGTTCGCGGCGCCACGCGTGG TCGGGGACCTGTCGGAGGCCGGTTCGCGCCCGAGATGGAGATGAAAGTGCTGCTGTGGGCC GTGCAACGGCTGATCGGCGCCTGTCGACGATCGCGCCGAACGCGACATCGCGTCGCGGCT GCACGTGGTGCTGCCCGGCTCGCCCAACCGTGGCATGTTCGGCGGCGACGGCGCCTACGGCG AAGCCAAGTCCGCGCTGGATGCCGTGGTGAGCCGCTGGCACGCCGAGTCGTCCTGGGCGCCA CGGGTCAGCCTGGCGCACGCGCTCATCGGCTGGACCCGCGCACCGGGCTGATGGGCCACAA CGGCGCTGCTGCTCGACCTGTGTGATGCGGAATCCAAGGTGGCTGCGGCGCGTTCGCCGATCA AGGCCGACCTGACCGGGGGCCTGGCCGAGGCCAACCTCGACATGGCCGAGCTGGCGGCCAAG GCGCGCGAGCAGATGTCGGCAGCGGCGGCCGTCGACGAGGACGCCGAGGCCCCTGGCGCCA TCGCCGCGCTGCCGCCCCCGGGGTTTCACCCCCGCACCGCCGCAATGGGACGAC CTCGATGTCGACCCGGCCGACCTGGTGGTGATCGTCGGCGGCGCGCAAATCGGCCCGTACGG AGCTGGCCTGGACCACTGGGTTGATCCGCTGGGAGGACGACCCGCAACCCGGTTGGTACGACA CCGAATCCGGCGAAATGGTCGACGAATCCGAGTTGGTGCAGCGCTACCACGACGCCGTGGTGC AGCGCGTCGGCATTCGCGAATTCGTTGATGACGGCGCGATCGACCCCGACCACGCCTCGCCGC TGCTGGTGTCCGGGGGCCGAGGGCCGATGCGCGTTCGTGGTGTCCTCGGAGGCCGATGCGC GGCAGGTCATCCGCAAGGCCGGCACCGAGATCCGGGTGCCGCGAAAGACCAAGCTGTCCCGC GTCGTCGGCGGCCAGATCCCGACCGGGTTCGACCCGACGGTGTGGGGCATCAGCGCAGACAT GGCCGGTTCCATCGACCGGTTGGCGGTATGGAACATGGTGGCGACCGTCGACGCGTTCCTGTC GTCCGGTTTCAGCCCGGCCGAGGTGATGCGTTACGTGCACCCGAGTTTGGTGGCCAACACCCA GGGCACCGGCATGGGCGCGCACGTCGATGCAGACGATGTACCACGGCAATCTGTTGGGCC GCAACAAGCCGAACGACATCTTCCAGGAAGTCTTGCCGAATATCATTGCCGCGCACGTGGTTCA GTCCTACGTCGGTAGCTACGGTGCGATGATCCACCCGGTAGCCGCGTGCGCCACCGCCGCG 30 GTCGGTCGAGGAAGGTGTCGACAAGATCCGGTTGGGCAAGGCTCAACTGGTGGTGGCCGGCG GCCTGGATGACCTGACGCTGGAGGCATCATCGGATTCGGTGACATGGCCGCCACCGCCGACA CGTCCATGATGTGCGGCCGCGCGCATCCACGACTCGAAGTTTTCCCGGCCCAACGACCGCCGCC GTCTGGGCTTCGTCGAAGCCCAAGGCGGCGGGACGATCCTGTTGGCCCGCGGGGACCTGGCG CTGCGGATGGGCTGCCGGTGCTGGCGTGGCGTTCGCGCAGTCGTTCGGCGACGGCGT 35 GCACACCTCGATCCCGGCCCCGGGCCTGGGCGCGCGGGGCGGCGAAGGAT

WO 01/35317

TCACCGCTGGCGCGGCGCTGGCCAAGCTGGCCGCCGACGACGACGTGGCGGTCATCTC
CAAGCACGACACCTCGACGCTGGCCAACGATCCCAACGAGACCGAGTTGCATGAACGGCTCGC
CGACGCCCTGGGCCGTTCCGAGGGCGCCCCGCTGTTCGTGGTGTCGCAGAAGAGCCTGACCG
GCCACGCCAAGGGCGGCGGCGGCGTCTTCCAGATGATGGGGCTCTGCCAGATATTGCGGGAT
GGGGTGATCCCACCCAACCGCAGCCTCGACTGCGTCGACGACGAGCTGGCCGGCTCCGCGA
TTTCGTGTGGGTGCGTGACACGTTGCGGCTCGGCGGCAAGTTCCCACTCAAGGCCGGCATGCT
GACCAGCCTCGGGTTCGGCCATGTGTCGGGCTGGTCGCGTTGGTGCATCCGCAGGCGTTCAT
CGCCTCGCTGGATCCCGCACAGCGCGCGGACTACCAGCGGCGTGCCGACGCCCGCTGCTGG
CCGGTCAGCGCCGGCTGGCCTCGGCGATTGCCGGTGGTGCCGATGTACCAGCGGCCCGGT
GACCGTCGCTTCGACCACCACGCGCCCGAGCGCCCGCAGGAGGCGTCGATGCTGCAATCC
GGCGGCCCGGCTGGTGACGCGCGCGAGGCGCTGATGCTGCTGAATCC
GGCGGCCCGGCTGGTGACGGCGAGGCGTATATCGGCTGA

>Rv2555c alaS alanyl-tRNA synthase TB.seq 2873772:2876483 MW:97326 >emb|AL123456|MTBH37RV:c2876483-2873769, alaS SEQ ID NO:101

GTGCAGACACGAGATCAGGAAGCGGTTCCTCGATCATTTCGTGAAGGCGGGCCACACCGAG GTGCCCAGCGCCTCGGTGATCCTCGACGACCCCAACCTGTTGTTCGTCAACGCCGGGATGGTC CAGTTCGTGCCTTTCTTCTTGGGACAGCGCCCCCCCCCGCCGCCGCCGCCCACCAGCATCCAG AAGTGCATCCGTACCCCGATATCGACGAGGTGGGCATAACCACCCGGCACAACACGTTTTTTC AGATGGCCGGCAATTTCAGCTTCGGCGACTATTTCAAACGCGGGGCCATTGAACTGGCCTGGG CACTGCTGACCAACAGCCTCGCCGCCGGCGGCTACGGCCTGGACCCGGAAAGAATCTGGACG ACAGTCTATTTCGACGACGACGAGGCTGTCCGGCTATGGCAGGAGGTTGCCGGGCTGCCGGCG GAGCGAATCCAGCGCCGCGCATGGCCGACAACTACTGGTCGATGGGCATTCCCGGACCGTG CGGGCCGTCATCGGAGATCTATTACGACCGCGGACCCGAATTCGGTCCCGCAGGCGGTCCCAT CGTCAGCGAAGACCGCTACCTCGAGGTCTGGAACCTGGTGTTCATGCAGAACGAGCGCGGAGA GGGAACCACCAAGGAGGACTACCAGATCCTCGGGCCGCTGCCCCGCAAGAACATCGACACCG GCATGGGCGTCGAGCGGATCGCGCTGGTGCTGCAAGACGTGCACAACGTCTACGAGACCGAC CTGCTCAGGCCGGTCATCGATACCGTGGCCAGGGTCGCCGCGCGTGCCTACGACGTCGGCAA CCACGAAGACGACGTGCGGTACCGCATCATCGCAGACCACAGCCGCACCGCCGCGATCCTGAT CGGTGACGGCGTCAGCCCCGGCAACGACGGTCGCGGTTATGTGCTGCGCCGGCTGCTGCGTC GGGTGATCCGCTCGCCAAGCTGCTGGGCATCGACGCTGCGATCGTTGGCGACCTGATGGCCA CGGTGCGCAACGCGATGGGCCCGTCATATCCCGAACTCGTCGCCGACTTCGAGCGGATCAGCC GGATCGCGGTCGCCGAGGAGACGCGTTCAACCGCACGCTGGCGTCGGGTTCCAGGCTGTTC GAGGAGGTGGCTAGCTCCACCAAGAAATCCGGAGCCACCGTGCTGTCCGGATCGGACGCTTTC ACGTTGCATGACACCTACGGGTTCCCGATCGAGCTCACGCTGGAGATGGCGGCCGAAACCGGT CTGCAGGTAGACGAAATCGGGTTCCGTGAGCTGATGGCCGAGCAGCGCCGCCGTGCCAAGGC CGACGCCGCGCGCAAACACGCGCATGCTGACCTGAGCGCCTACCGCGAGCTGGTTGACG CCGGCGCCACCGAGTTCACCGGATTCGACGAGTTGCGTTCCCAGGCGCGGATTCTGGGCATCT

5

10

15

20

25

30

TCGTCGACGGTAAGCGGGTTCCGGTGGTGGCGCACGGTGTAGCCGGCGGAGCCGGGGAAGG GCAGCGTGTCGAACTTGTCTTAGATCGCACCCCGCTCTACGCCGAATCGGGTGGGCAGATCGC CGATGAGGGCACCATCAGCGGAACCGGTTCCAGCGAAGCTGCCCGGGCCGCGGTTACCGACG TGCAGAAGATCGCCAAAACGCTTTGGGTGCACCGAGTCAACGTGGAATCCGGGGAATTCGTCG AGGGTGACACCGTAATCGCGGCGGTGGATCCCGGGTGGCGCCGGGGTGCCACGCAGGGCCA CTCGGGCACCCACATGGTGCATGCCGCGCTGCGACAAGTGCTGGGGCCCAACGCGGTTCAGG 5 CGGGATCGCTGAACCGGCCGGGATATTTGCGCTTCGACTTTAACTGGCAGGGTCCGTTGACCG ACGACCAGCGCACCCAGGTCGAAGAGGTCACCAACGAGGCCGTGCAAGCGGACTTCGAGGTG CGCACGTTCACCGAACAGCTCGACAAGGCCAAGGCGATGGGTGCCATCGCGCTGTTCGGCGAG AGCTACCCGACGAAGTGCGGGTGGTGGAGATGGGTGGACCGTTCTCGCTGGAGCTATGTGGC GGCACCCATGTGAGCAACACGGCGCAGATCGGTCCCGTGACGATCCTGGGCGAGTCGTCGATC 10 GGCTCCGGGGTGCCCGGGTGGAGGCCTACGTGGGGTTGGATTCGTTTCGTCACCTGGCCAA GGAGCGTGCGTTGATGGCCGGGTTGGCCTCGTCACTGAAGGTGCCGTCCGAAGAGGTACCGG CCCGGGTGGCCAATCTAGTGGAGCGCCTGCGGGCCGCCGAGAAGGAACTCGAACGTGTCCGG ATGGCCAGCGCCGGGCAGCCGCCACCAATGCCGCCGGGGGCTCAGCGGATCGGTAACGT CCGTTTGGTGGCGCAGCGAATGTCCGGCGGGATGACCGCGGCAGACCTGCGGTCGTTGATCG 15 GCGACATCCGCGGCAAGCTGGGTAGCGAGCCGGCGGTGGTGGCGCTGATTGCCGAGGGCGAA AGCCAAACTGTGCCGTATGCGGTCGCGGCCAATCCCGCTGCCCAGGACCTCGGAATCCGTGCC AACGACCTGGTCAAACAACTTGCGGTGGCGGTCGAAGGCCGCGGTGGCGGTAAGGCGGACCT 20 AGATCGCCGTGATAGCGCGGGTCGGTTGA

>Rv2580c hisS histidyl-tRNA synthase TB.seq 2904822:2906090 MW:45118 >emb|AL123456|MTBH37RV:c2906090-2904819, hisS SEQ ID NO:102

25

30

10

15

CCAGCTTGGCGGCAGGACTTGTCGGGCATCGGGTTCGGGCTGGGCGTGGACCGGACCGTGC TGGCGCTGCGGGCCAGGGCAAGACGGCGGGGGACAGCGCCCGGTGCGACGTGTTCGGCGT GGGGTGCGGGTTGACCTTGCCTATGGTGATCGCGGGCTCAAAGGCGCGATGCGCGCCGCCGC TCGTTCCGGCGCCCGTGTTGCGTTGGTAGCGGGCGACCGCGACATCGAGGCCGGGACGGTCG CAGTGAAGGACTTGACGACGGGTGAGCAAGTTTCGGTCTCGATGGATTCGGTTGTGGCCGAAG TAATTTCGCGGCTGGCTGGGTAG

>Rv2614c thrS threonyl-tRNA synthase TB.seq 2941190:2943265 MW:77123 >emb|AL123456|MTBH37RV:c2943265-2941187, thrS SEQ ID NO:103 ATGAGCGCCCCGCACAACCCGCCCCGGGAGTCGATGGCGGCGACCCGTCGCAAGCCCGAAT TCGGGTTCCTGCCGGGACCACCGCGGCCACCGCCGTCGGCGAAGCGGGTTTACCGCGGCGCG GTACGCCCGATGCGATCGTCGTCGTGCGCGACGCCGACGGCAACCTGCGCGACCTGAGCTGG GTGCCCGACGTCGACACCGATATCACGCCGGTGGCCGCCAACACCGACGACGGTCGCAGCGT GATCCGCCATTCGACCGCGCACGTGTTGGCCCAAGCCGTCCAAGAGCTGTTTCCGCAGGCCAA GCTCGGCATCGGCCCCATCACCGACGCTTCTACTACGACTTCGACGTGCCCGAGCCGTT TACAAGCTGGAACTCGTCGACGACAAATCGGGTGACGCCGAGATCATGGAGGTCGGCGGTGAC GAGCTCACCGCCTACGACAACCTCAACCCCGCACCCGCGAGCGCGTCTGGGGCGACCTGTG 20 CCGCGGACCGCACCACCAAACACATCCCGGCGTTCAAGCTCACCCGCAGCTCGGC CGCCTACTGGCGGGGGGGATCAGAAAAACGCCAGCCTGCAACGGATCTACGGCACCGCGTGGG AATCCCAGGAGGCGCTCGACAGGCACCTGGAGTTCATCGAAGAGGCGCAGCGCCGCGACCAC CGCAAGCTGGGTGTCGAGCTGGACCTGTTCAGCTTCCCCGACGAAATCGGTTCCGGCCTAGCG GTTTCCACCCAAGGGCGCATCGTGCGTCGCGAACTGGAGGACTACTCGCGGCGCAAGCAC 25 ACCGAGGCGGCTACCAGTTCGTCAACAGCCCGCACATCACCAAGGCCCAGTTGTTCCACACC TCGGGACATCTGGACTGGTACGCCGACGCATGTTCCCCCCGATGCACATCGACGCGGAGTAC AACGCCGACGGCTCGCTGCGCAAACCCGGCCAGGACTACTACCTCAAGCCGATGAACTGCCCG ATGCACTGCCTGATCTTCCGCGCGCGCGCGCGCGCTCTTC GAGTTCGGCACGGTGTATCGCTACGAGAAGTCCGGTGTGGTGCACGGGTTGACCCGGGTGCGT 30 GGGCTGACCATGGACGACGCGCACATCTTCTGCACCCGCGACCAGATGCGCGACGAGCTGCG GTCGCTGCTGCGGTTTGTGCTCGACCTGCTCGCCGACTACGGCCTCACCGACTTCTACCTCGAA CTGTCCACCAAGGACCCGGAGAAGTTCGTCGGCGCCGAGGAGGTCTGGGAGGAAGCCACCAC CGTGCTGGCCGAGGTGGCCCGAATCCGGGCTGGAGCTGGTGCCCGATCCAGGCGGCGCG GCGTTCTACGGGCCCAAGATTTCAGTGCAGGTCAAAGACGCGCTGGGCCGCACCTGGCAGATG 35 TCGACCATCCAGCTGGACTTCAACTTTCCGGAACGTTTCGGCCTGGAGTACACCGCCGCCGACG

>Rv2697c dut deoxyuridine triphosphatase TB.seq 3013683:3014144 MW:15772
 >emb|AL123456|MTBH37RV:c3014144-3013680, dut SEQ ID NO:104
 GTGTCGACCACTCTGGCGATCGTCCGCCTCGACCCCGGGCTCCCGCTGCCCAGCCGCGCTCAC
 GACGGCGACGCCGGCGTTGATCTCTACAGCGCCGAAGACGTCGAGCTGGCACCTGGGCGCG
 CGCCCTGGTACGGACGGGTGTTGCGGTCGCCGTCCCGTTCGGCATGGTCGGGCTGGTCCATC
 CGCGCTCCGGGTTGGCCACGCGGGTGGGGCTTTCGATCGTCAACAGTCCGGGCACCATCGAC
 GCGGTTATCGTGGGGAGATCAAGGTGGCCCTGATCAACTTGGACCCAGCCGCCCCATCGTG
 GTACATCGCGGTGACCGAATCGCCCAGTTGCTAGTGCAACGGGTTGAGTTGGTCGAGCTGGTC
 GAGGTCTCGTCGACGAGGCCGGGCTGGCCTCGACATCCCGCGGCGACGGTGGCCACGG
 TTCCTCCGGCGGACATGCGAGTTTGTGA

20

25

30

35

5

>Rv2782c pepR protease/peptidase, M16 family (insulinase) TB.seq 3089045:3090358 MW:47074 >emb|AL123456|MTBH37RV:c3090358-3089042, pepR SEQ ID NO:105 TGGGTCGGCGTCGGACGACGACGACGCCACGGTGGCCGGGGCGCGCACTTCCTTGA GCATTTGCTGTTCAAGTCGACGCCCACCCGCTCTGCCGTGGACATTGCGCAGGCGATGGACGC GGTGGGGGGGAACTGAACGCATTCACCGCCAAGGAGCACACCTGCTACTACGCCCACGTGCT CGGCAGCGACTTGCCGTTGGCCGTCGACCTGGTCGCCGATGTGGTGCTCAACGGCCGCTGTGC CGCCGACGATGTCGAGGTGGAACGTGACGTCGTCCTCGAGGAGATCGCGATGCGCGACGACG GCCCGGTGATCGGCAGCGCGCAATCCGTGTCGGTGATGACGCGGGCTCAACTGCAATCGTTTC ACCTGCGGCGCTATACCCCGGAGCGGATGGTCGTCGCGGCCGCCGGCAATGTGGATCACGAC GGGCTGGTTGGTCCGCGAGCACTTCGGGTCCCGGTTGGTCCGGGGGAGACGGCCAGT TGCGCCGCGAAGGGTACCGGCCGGGTCAACGGCAGCCCCCGGTTGACACTGGTTAGCCGCG ACGCCGAACAGACGCATGTGTCGCTGGGCATCCGCACACCCGGGCGCGCGGCTGGGAGCATCGT TGGGCACTGTCGGTGCTGCACACCGCGCTGGGCGGTGGCTTGAGTTCCCGGCTGTTCCAGGAG GTCCGCGAGACCCGCGGGCTGGCCTACTCGGTCTACTCCGCGCTGGATCTCTTCGCCGACAGC

GGCGCGCTTTCGGTGTACGCGGCCTGCCCGAACGCTTCGCCGACGTGATGCGGGTGAC
CGCCGATGTGCTGGAAAGCGTGGCACGCGACGCATCACCGAGGCGGAATGCGGCATCGCCA
AGGGATCGCTGCGGGGTGGGCTGGTGCTAGGGCTGGAGGATTCCAGCTCCCGGATGAGCCGG
CTCGGCCGCAGCGAGTTGAACTACGGCAAGCACCGCAGCATCGAACACACCTTGCGGCAAATC
GAGCAGGTCACCGTGGAGGAGGTCAACGCGGTGGCCCGCCACCTGCTGAGCAGCGCTACGG
TGCTGCCGTTCTTGGCCCACACGGATCGAAACGATCACTGCCGCAACAACTTCGAGCGATGGTA
GGGTAG

>Rv2783c gpsl pppGpp synthase and polyribonucleotide phosphorylase TB.seq 3090339:3092594 MW:79736 >emb|AL123456|MTBH37RV:c3092594-3090336, gpsl SEQ ID NO:106

ATGTCTGCCGCTGAAATTGACGAAGGCGTGTTCGAGACGACCGCCACCATCGACAACGGGAGC GGTCGCCTACCTCGACGACGACAACATGCTGCTGTCGGCGACCACCGCCAGCAAGAACCCCAA CATCCCGGTTCGTTCCGTCGCGAGGGCCGACCCTCCACCGACGCGATCCTGACCTGCCG GCTCATCGACCGCCGCCGCCGCCGTCGTTTGTCGACGGGCTGCGCAACGAGATCCAAATCGT GGTGACGATTCTCAGCCTGGATCCGGGCGATCTCTACGACGTATTGGCGATCAACGCGGCGTC GGCGTCCACCCAGCTGGGCGGTCTGCCGTTCTCCGGGCCCATCGGCGGTGTGCGGGTGGCGC TCATCGACGGCACCTGGGTCGGCTTCCCCACCGTCGACCAGATCGAGCGCGCCGTGTTCGACA TGGTCGTGGCCGGCCGGATCGTCGAGGGTGATGTTGCCATCATGATGGTCGAAGCCGAGGCCA CCGAAAACGTCGTCGAGCTCGAAGGTGGTGCCCAAGCGCGACGGAAAGCGTGGTGGCC GCGGGCCTGGAGGCGGCCAAGCCGTTTATCGCCGCGCTGTGCACCGCGCAGCAGGAGCTTGC CGATGCCGCTGGAAAGTCGGGCAAACCGACCGTCGACTTCCCGGTGTTCCCTGACTACGGCGA AGACGTGTACTACTCGGTGTCCTCGGTGGCCACCGACGAGTTGGCCGCCGCGTTGACCATCGG CGGTAAAGCCGAGCGCGCCACCGACCGACGAAATCAAGACCCAGGTTGTGCAGCGGCTCGC GGTTCGGCAGCGCATCCTCACCGACCATTTCCGTATCGACGGCCGCGCGCATCACCGACATTCG GCGAAACCCAGATCCTGGGTGTGACCACACTCGACATGATCAAGATGGCCCAGCAGATCGACT CGTTGGGGCCGGAGACATCGAAGCGGTACATGCACCACTACAACTTCCCGCCGTTCTCCACCG GCGAGACCGGTCGGTCGCTCGCCCAAGCGGCGTGAGATCGGGCACGGCGCACTGGCCGA GCGGCCCTGGTGCCGGTGTTGCCGAGCGTCGAGGAATTCCCGTATGCCATTCGCCAGGTGTC GGAGGCTCTGGGCTCCAACGGGTCGACCTCGATGGGGTCGGTGTGCGCGTCGACGCTGGCGC TGCTCAACGCCGGGGTGCCGCTCAAGGCGCCGGTGGCCGGCATCGCGATGGGCCTGGTCTCC GACGACATTCAAGTAGAAGGGGCGGTCGACGGCGTTGTGGAGCGTCGCTTCGTCACCCTCACC GACATCCTCGGCGCCGAAGACGCGTTCGGTGACATGGACTTCAAGGTCGCCGGGACCAAGGAC

5

10

15

20

25

30

PCT/US00/31152

WO 01/35317

5

10

15

20

25

TTCGTCACCGCGCTGCAGCTGGACACCAAGCTCGACGGGATCCCTTCGCAGGTGCTTGCCGGA
GCACTCGAGCAGGCCAAGGACGCCCGCCTCACGATCTTGGAGGTGATGGCTGAGGCCATCGAT
AGACCCGACGAAATGAGTCCCTACGCCCCGCGGGTGACCACCATCAAGGTTCCGGTGGACAAG
ATCGGGGAGGTCATCGGACCCAAGGGCAAGGTCATCAACGCCATCACCGAGGAGACCGGCGC
GCAGATCTCCATCGAAGACGACGCCACCGTGTTCGTCGGCGCCACCGACGGGCCATCGGCACA
GGCCGCGATCGACAAGATCAACGCCATCGCCAACCCGCAGCTGCCGACGGTGGCCGAACGGT
TCCTCGGAACCGTGGTCAAGACCACCGATTTCGGTGCCTTTGTATCGTTGCTGCCTGGCCGCGA
CGGTCTGGTGCACATTTCCAAACTCGGCAAGGGCAAGCGCATCGCGAAGGTCGAGGACGTTGT
CAATGTCGGTGACAAGCTGCGGGTGGAGATCGCCGACATCGCCAAACGGGGCAAGATCTCCCT
GATCCTGGTCGCCGACGAGGACAGCACCGCCGCCGCCGCTACCGATGCCGCGACGGTCACCAGCT
GA

>Rv2793c truB tRNA pseudouridine 55 synthase TB.seq 3102364:3103257 MW:31821 >emb|AL123456|MTBH37RV:c3103257-3102361, truB SEQ ID NO:107

30

35

>Rv2797c - TB.seq 3105619:3107304 MW:58761 >emb|AL123456|MTBH37RV:c3107304-3105616, Rv2797c SEQ ID NO:108 GTGCCACTGACCGTGGCCGATATCGATCGGTGGAACGCGCAAGCGGTCCGGGAGGTGTTTCAC

GCGGCCAGTGCCGAGCGGAGGTGACGTTCGAGGCGTCGCGTCAGTTGGCCGCGCTGTCGAT
TTTTGCGAACTCGGGTGGCAAGACCGCTGAGGCGGCGCACACCACAACGCGGGCATTCGCC
GAGACCTCGACGCCCACGGCAACGAGGCGTTGGCGGTTGCCCGGGCGGCCGACAGGGCCGC
CGACGGGATTGTGAAGGTTCAGTCCGAGCTGGCCGCACTACGCCATGCCGCCGCGCCGCC

AGCTGACGATCGATGCGCTGATCAACCGGGTGGTGCCGATCCCCGGGCTGCGATCCACCGAG GCGCAGTGGGCGGACGCTGGCCAAGCAAACGGAGCTGCAGGCGGAGCTGGATGCGATTAT GGCCGAGGCCAATGCCGTCGACGAGGAGCTGGCCTCAGCGGTCAATATGGCCGACGGTGACG CGCCCATCCCGGCCGATTCCGGCCCGCCGGTCGGTCCCGAGGGGGCTGACCCCGACCCAGCTC AGCGGTTACAGGCGGAGTATGACCAACTGAGTGTGCGGGCCGCCCGTGACTACCACAACGGCA 5 TCCTCGACGGTGACGCGGTGGGCCGACTGGCAGCGTTACCGACGAGCTGAGCGCCCAGG GACCCAGCTGCAGATTCCCGAGGACCCAAATCAGCAGGTGCTGGCGGCCGTGGCCGTCGGTAA TCCCGACACCGCCGATGTGTCGGTGACGGTTCCCGGCGTCGGGTCCACCACCCGGGGCG CCCTGCCCGGCATGGTGACCGAAGCCCGCGACCTGCGGTCGGAGGTAATCCGGCAACTCAATG 10 CTGCCGGCAAGCCCGCATCGGTTGCCACCATCGCCTGGATGGGCTACCACCCGCCCCGAACC GGCGCGGCCGATCTGTCGCGGTATTTGCAGCAGGTGCGCGCCAATAACCCCAGTGGCCACCTG ACCGTGTTGGGGCACTCGTATGGGTCGCTGACGGCGTCGCTGGCGTTGCAGGACCTCGATGCC CAGAGCGCCCATCCGGTCAACGACGTCGTGTTTTACGGCTCACCCGGCTTGGAGCTGTACAGC 15 CCGGCGCAGCTCGGCTCGATCACGGGCACGCTTATGTCATGCAGGCCCCCCACGACCTCATC ACCAATCTGGTGGCGCCGTTGGCGCCGCTGCACGGATGGGGCCCTGGACCCCTATCTGACCCCC GTATGCCCACGGGGACTACCCGCGGTCCTTCCTCGATGCCGCCGGCCAGCCGCAGCTGCGGA TGTCCGGCTATAACCTGGCGGCGATCGCCGCCGGGCTGCCCGACACACGGTGGGCCCGCCG 20 CTGCTTCCGCCAATTCTGGGTGGCGGCATGCCGGCAGCGCCCGGCCCAGCACTGAGAGGGGG **ACGTTGA** 

>Rv2864c ponA2 TB.seq 3175454:3177262 MW:63015 >emb|AL123456|MTBH37RV:c3177262-25 3175451, Rv2864c SEQ ID NO:109 ATGGTAACTAAAACAACATTAGCCTCAGCCACCTCAGGTTTGCTGCTGCTGCGGTCGTCGCCAT GTCGGGCTGCACCCCGCGTCCCCAAGGGCCCGGTCCGGCGCCGCAAAAGTTCTTCGCCGCGC TGGCCATCGGTGACACCGCCTCCGCCGCCCAGCTCAGCGACAACCCCAACGAGGCGCGCGAA GCGCTGAACGCGGCCTGGGCGGGCTGCAGGCCGCCCACCTGGATGCGCAGGTTCTCAGCGC CAAGTACGCCGAGGACACCGGTACGGTCGCTTATCGCTTCAGCTGGCATCTGCCCAAGGACCG 30 AATCTGGACCTATGACGGCCAGCTGAAGATGGCCCGCGACGAAGGGCGTTGGCACGTTCGCTG GACCACCAGCGGGTTGCATCCCAAGCTAGGCGAACATCAAACGTTCGCGCTACGAGCCGACCC GCCGCGCGCCCCCGGTGAACGAAGTCGGCGCACCGATGTGCTGGTGCCGGGCTATCTGT GTGGGCGCGCTGCACCCCTTCGACGACACGCTCAATGATCCGCAGCTGCTGGCCGAACAGGCC 35 AGCTCGTCGACCCAGCCGTTGGACCTGGTCACGTTGCACGCCGACGACAGCAACCGGGTGGC

CGCGGCGATCGGGCAGCTGCCTGGCGTGATCACACCGCAGGCCGAGCTGCTCCCGACCG ACAAGCACTTCGCGCCGGCGGTCCTCAACGATGTCAAGAAGGCCGTCGTCGATGAACTCGACG GCAAGGCGGGTTGGCGGTGGTGAGCGTCAACCAAAATGGCGTCGACGTCTCGGTGCTGCAC GAGGTCGCCCCATCACCTGCGTCGGTTTCGATCACGTTGGATCGGGTCGTGCAAAACGCC GCGCAACACGCGGTGAACACCCGGGGCGGCAAGGCGATGATCGTCGTGATCAAGCCGTCGAC CGGCGAGATCCTGGCGATCGCGCAGAACGCCGGGGCCGATGCGGACGGTCCGGTCGCGACCA 5 CCGGTCTATATCCACCCGGGTCGACATTCAAGATGATCACCGCCGGTGCGGCCGTCGAGCGTG ACCTGGCTACCCCTGAGACGCTGCTGGGTTGCCCCGGGGAGATCGACATCGGGCATCGCACCA TTCCCAACTACGGTGGCTTTGATCTGGGCGTGGTGCCGATGTCACGCGCGTTTGCCAGTTCCTG CAACACCACCTTCGCCGAGCTGAGCAGCAGCTGCCTCCCCGCGGTCTGACTCAGGCGGCCC GGCGGTACGGGATCGGGCTTGACTACCAGGTGGACGGCATCACCACGGTGACCGGTTCGGTG 10 CCGCCGACGGTGGACCTGGCCGAACGCACCGAGGACGGTTTCGGCCAGGGCAAGGTGCTGGC CAGCCCGTTCGGCATGGCCTTGGTGGCGGCGACGGTAGCCGCGGGAAGACCCCGGTTCCAC AGCTGATCGCCGGCCGGCCGACGGCCGTCGAAGGCGATGCCACACCGATCAGCCAGAAGATG ATCGACGCGCTGCGGCCCATGATGCGGTTGGTGGTGACCAATGGCACCGCCAAGGAGATCGCT GGCTGTGGCGAGGTGTTCGGTAAGACCGGCGAAGCCGAATTCCCGGGCGGATCGCATTCCTG 15 ATACGCGGTGCGGATGACCAAGGTGATGTTCGAATCGCTGCCGCGGGGTACCTGGCGTAG

>Rv2868c gcpE TB.seq 3179368:3180528 MW:40451 >emb|AL123456|MTBH37RV:c3180528-20 3179365, gcpE SEQ ID NO:110 CCGTCAGCTGATGGCCAACGTCGGCGTGGGCAGTGACCATCCGGTCTCGGTGCAATCGAT GTGCACCACAAACCCACGACGTCAACTCGACATTGCAACAAATCGCCGAGCTGACCGCGGC CGGATGCGACATCGTGCGGGTGGCCTGCCCGCGCCAGGAGGACGCCGACGCGCCGAG 25 CCGCCATCGACGCTGGATGTGCCGCGGTGCGGGTCAACCCGGGCAACATCAAGGAGTTTGACG GCCGGGTGGGTGAGGTCGCCAAGGCGGCGGGTGCGGCCGGGATCCCGATCCGAATCGGTGT CAACGCCGGTTCGCTGGACAAACGGTTCATGGAGAAGTATGGCAAAGCCACGCCCGAGGCGCT GGTTGAGTCGGCGCTGTGGGAGGCTTCGCTTTTCGAGGAGCATGGCTTCGGTGACATCAAGAT 30 CGACTACCCACTGCACCTCGGTGTCACCGAGGCCGGCCCTGCTTTCCAGGGCACCATCAAGTC CGCGGTTGCCTTCGGCGCGTTGCTGTCGCGGGGCATAGGCGACACCATCCGGGTGTCGTTGTC GGCCCGCCGGTCGAGGAAGTCAAGGTGGGCAATCAGGTTCTCGAGTCGTTGAACCTGCGGCC GCGTTCGCTCGAGATCGTGTCTTGCCCGTCGTGCGGTCGCGCGCAAGTCGACGTCTACACCCT GGCCAACGAGGTAACCGCCGGCCTGGATGGTCTCGATGTGCCGTTGCGGGTGGCCGTGATGG 35 GGTGTGTCGTCAATGGTCCGGGTGAAGCACGTGAGGCCGACCTGGGCGTGGCGTCCGGCAAC

GGCAAAGGTCAGATCTTTGTACGGGGCGAAGTGATCAAGACCGTGCCCGAAGCACAGATCGTC
GAGACGCTGATCGAGGAGGCGATGCGGCTGGCCGCCGAAATGGGCGAGCAAGATCCGGGCGC
GACACCGAGCGGTTCGCCTATTGTGACCGTAAGCTGA

>Rv2869c - TB.seq 3180548:3181759 MW:42835 >emb|AL123456|MTBH37RV:c3181759-3180545, 5 Rv2869c SEQ ID NO:111 ATGATGTTTGTTACCGGCATTGTGCTGTTCGCGCTCGCGATCCTGATTTCGGTGGCCCTGCACG AATGTGGTCACATGTGGGTCGCGCGCGCACCGGGATGAAGGTACGTCGCTATTTCGTCGGCT TTGGCCCCACGTTGTGGTCGACCCGGCGCGCGAGACCGAATACGGTGTCAAAGCCGTTCCGC TGGGCGGCTTCTGTGACATCGCCGGCATGACCCCGGTCGAGGAACTCGACCCCGACGAACGTG ACCGTGCGATGTACAAGCAGGCCACCTGGAAGCGGGTCGCAGTGTTATTCGCCGGGCCCGGAA 10 TGAACCTCGCTATCTGCCTGGTGCTGATCTATGCCATCGCGCTGGTCTGGGGGCTGCCTAACCT GCATCCGCCAACCAGGGCCGTAATCGGCGAAACTGGCTGCGTTGCACAGGAAGTGAGCCAGG GCAAGCTCGAGCAGTGCACCGGGCCCGGTCCGGCGGCGCGCGGAATTCGCTCCGGTGAC GTCGTGGTCAAGGTCGGTGACACCCCGGTGTCCAGTTTCGACGAGATGGCCGCCGCGGTGCG CAAGTCACACGGCAGCGTCCCGATCGTTGTCGAGCGTGACGGCACCGCGATTGTTACCTACGT 15 GGACATCGAATCCACCCAACGCTGGATCCCTAACGGGCAGGGCGGTGAGCTCCAGCCGGCAAC GGTCGGTGCGATTGGGGTGGGCCCCCGGGTCGGGCCTGTGCGCTACGGCGTGTTCTCCG CCATGCCGGCCACATTCGCGGTCACCGGCGACCTGACCGTGGAGGTGGGCAAGGCGCTGGCC AGACGCCGATAAGTGTGGGCGCCCAGCATCATCGGCGGCGACACCGTCGACCATGGGCTG 20 TGGGTGGCGTTCTGGTTCTTGGCCCAGCTGAACCTCATCCTGGCTGCGATCAACCTGCTGC CGTTGCTGCCGTTCGATGGCGGCCATATTGCCGTCGCGGTGTTCGAGAGGATCCGCAACATGG TCCGGTCGGCTCGTGGCAAGGTGGCGGCCGCACCGGTGAATTACCTCAAACTCTTGCCGGCGA CCTATGTGGTCTTGTCGTCGGGTACATGCTCTTGACCGTCACCGCCGACCTGGTCAA 25 CCCGATTAGGCTTTTCCAGTAG

>Rv2870c - TB.seq 3181770:3183077 MW:45324 >emb|AL123456|MTBH37RV:c3183077-3181767,
Rv2870c SEQ ID NO:112

GCCCGGTCAGATCGTGCCGGTCGACTCCGAACACTCCGCGCTGGCCCAGTGCCTGCGCGCG GCACTCCCGACGAGGTCGCCAAGCTGGTGCTGACGGCCTCGGGAGGGCCGTTTCGGGGCTGG GGCCCGATGAACACGCTGAATTCGGCGTCGCTGGTCAACAAGGGACTTGAGGTCATCGAAACC CACCTGCTGTTCGGCATCCCCTACGACCGCATCGATGTCGTGGTGCACCCCCAGTCGATCATCC ATTCGATGGTCACCTTCATCGACGGTTCGACGATCGCCCAGGCCAGTCCCCCGGACATGAAGCT ACCGATTTCGTTAGCGCTGGGCTGGCCGCGCTCGGGTCAGCGGCGCCGCTGCTGATTT CCATACCGCGTCGAGCTGGGAGTTCGAGCCGTTGGACACCGACGTCTTCCCCGCGGTCGAGTT AAGCAGCAGCGCGTTCCTTGCTGGCCGGATCGGCTTCCCGGCCATCGTCGCCCG ACGTGTTGCACGCTGCCGACCAATGGGCCGTCGAACCCGCTACCGTGGATGACGTACTCGACG CGCAGCGCTGGGCCCGCGAGCGAGCGCAGCGCGCGGTATCTGGTATGGCTTCGGTGGCGATC GCAAGCACGGCGAAGCCGGGCGCAGCGGGTCGACACGCATCGACGTTAGAAAGGTCCTGA

member of Smc1/Cut3/Cut14 family TB.seq 3234189:3238055 MW:139610 >Rv2922c smc >emb|AL123456|MTBH37RV:c3238055-3234186, smc SEQ ID NO:113 GTGGGTGCAGGGAGTCGGTTTCCGCTGGTGGACCCGCTGCCGAGCGTTGGAGCTCGGCCTGA CCGGTTACGCGGCCAACCACGCCGACGGACGCGTGCTGGTGGTCGCCCAGGGTCCGCGCGCT CCTCGTGTACCTCAAGAGTCTGACGTTGAAGGGCTTCAAGTCCTTCGCCGCCGACGACTTTA CGCTTCGAGCCGGCCATTACGGCCGTCGTTGGGCCCAACGGCTCCGGCAAATCCAATGTGGTC GATGCCCTGGCGTGGTGATGGGGGGAGCAGGGGGCAAAGACGCTGCGCGGCGGCAAGATGG AAGACGTCATCTTCGCCGGCACCTCGTCGCGTGCGCCGCTGGGCCGCGCGCAAGTCACCGTTA GCATCGACAACTCCGACAACGCACTGCCTATCGAATACACCGAGGTGTCGATCACCCGAAGAAT GGAGTTGCTGAGCGACTCCGGCATCGGCCGTGAGATGCATGTGATTGTTGGGCAAGGGAAGCT CGAGGAGATCTTGCAGTCGCGGCCTGAGGATCGGCGGGGGGTTCATCGAGGAAGCCGCCGGTG TGCTCAAGCATCGCAAGCGCAAGGAAAAAGCTCTGCGCAAACTCGACACGATGGCGGCGAACC TGGCCGGCTCACCGATCTGACCACCGAGCTCCGGCGTCAACTCAAACCGCTGGGCCGGCAG GCCGAGGCGCCCAGCGTGCCGCCCATCCAAGCCGATCTGCGCGACGCCCGGCTGCGCCT GGCGGCCGACGTTGGTAAGCCGCAGAGCCGAACGGGAAGCGGTCTTTCAGGCCGAGGCTG CGATGCGCCGCGGAGCATGACGAGGCCGCCCGCCCGGCTGGCGTGGCATCCGAGGAGCTGGC CGCGCATGAGTCCGCGGAACTCTCGACGCGGGCCGAGTCGATCCAGCACACTTGGTT CGGGCTGTCTGCGCTGGCCGAACGGGTGGACGCTACGGTGCGCATCGCCAGCGAACGCGCCC ATCATCTCGATATCGAGCCGGTAGCGGTCAGCGACCCCAGAAAGCCCGAGGAGCTAG 35 AAGCCGAGGCCCAGCAGGTGGCCGTCGCCGAGCAACAACTGTTAGCGGAGCTGGACGCGGCG

5

10

15

20

25

10

15

20

25

CGTGCCCGACTCGATGCCCGTGCAGAGCTGGCCGACCGGGAGCGCCGCCGCGAGG CCGACCGGGCACACCTGGCGGCGGTCCGGGAGGAGGGGACCGCCGTGAGGGACTGGCGCG GGTTGTCCGAGCGGATCGAGGATGCCGCAATGCGCGCCCAGCAGACCCGAGCCGAGTTCGAA ACCGTGCAGGGCCGCATCGGTGAACTGGATCAAGGCGAGGTCGGCCTGGATGAGCACCACGA GCGTACTGTGGCCGCGTTGCGGTTGGCCGACGAACGCGTCGCCGAGCTGCAATCCGCCGAAC GCGCCGCCGAACGCCAGGTGGCATCGCTACGGGCTCGCATCGATGCGCTCGCAGTGGGGCTA CAGCGCAAGGACGCGCGCGCGCGCGCGCACAATCGCAGTGGCGCAGGGCTTTTCGGTTC CGGCGGCCGACGCACTTGCGGTGGACGGCCTGACTGCCGCGGGTAGTGCCGTCAGCGCACTC CCAATCCGCCTCGGGGGAGATGCTGCCTAGCGGCGCCCAGTGGGCCCTAGACCTGGTCGAGT CTCCACCGCAGTTGGTTGGCGCGATGATCGCCATGCTTTCGGGTGTCGCGGTGGTCAACGACC TGACTGAGGCAATGGGCCTGGTCGAGATTCGTCCGGAGCTACGCGGGGTCACCGTTGACGGTG ATCTGGTGGGCGCCGGCTGGGTCAGCGGCGGATCGGACCGCAAGCTGTCCACCTTGGAGGTC ACCTCCGAGATCGACAAGGCCAGGAGTGAGCTGGCCGCTGCCGAGGCGCTGGCGCGCAATT GCCTTGGCCGCGCTTAACGAATCCGACACGGCCATCTCGGCGATGTACGAGCAGCTGGGCCGC CTCGGGCAGGAGCCCGCGCGCGGAAGAAGAGTGGAACCGGTTGCTGCAGCAGCGTACGGA ACAGGAAGCCGTGCGCACACAGACTCTCGACGACGTCATACAACTTGAGACCCAGCTGCGTAA GGCCCAGGAGACCCAACGGGTGCAGGTGGCCCAACCGATCGACCGCCAGGCGATCAGTGCCG CTGCCGATCGCCCCGCGGTGTCGAAGTGGAAGCCCGGCTGGCGGTGCGCACCGCCGAGGAA CGCGCCAACGCGGTTCGCGGCGGGCCGATTCGCTGCGCCGTGCGGCGGCGGAACGTG AGGCGCGGGTGCGGCCAAGCACGCGCCGCAAGACTGCATGCGGCCGCGGTGGCCGC AGCGGTCGCCGACTGCGGCCGGCTGCCGGGCGGTTGCACCGGGCGGCGGCG TCGCAACTGCGCGACGCGTCGGCCGCGCAACGTCAGCAGCGGTTAGCGGCGATGGCCGCGGT GCGCGACGAGGTGAACACGCTGAGCGCCCGAGTGGGGGAACTCACCGATTCGCTGCACCGCG ACGAGCTGGCTAACGCGCAGGCGCGCGCTGCGTATCGAGCAGCTTGAGCAGATGGTGCTAGAG CAGTTCGGAATGGCGCCGGCCGACTTGATCACCGAATACGGTCCACATGTGGCGCTACCACCG ACCGAGCTCGAGATGGCTGAGTTCGAGCAAGCCCGCGAACGCGGCGAGCAGGTGATTGCGCC CGCCCCATGCCGTTCGACCGGGTTACCCAGGAGCGCCGGGCCAAACGCGCCGAGCGTGCGC 30 TTGCCGAGTTGGGCAGGGTCAACCCGCTGGCGCTCGAAGAGTTTGCTGCCTTGGAGGAGCGCT ACAATTTCCTGTCCACCCAACTCGAGGATGTCAAGGCTGCCCGCAAGGATCTGCTGGGCGTCGT CGCCGATGTTGACGCCCGCATCCTGCAGGTGTTCAATGACGCGTTCGTAGACGTGGAACGCGA ATTTCGCGGCGTGTTCACCGCATTGTTCCCCGGTGGTGAAGGACGGCTGCGGCTGACCGAGCC 35 GACTGTCTTTGCTCTCCGGTGGCGAGAAGGCGCTGACCGCGGTGGCGATGCTGGTCGCGATCT WO 01/35317

TTCGTGCCCGTCCATCGCCGTTCTACATCATGGACGAGGTGGAGGCCGCCCTCGACGACGTGA
ACCTGCGCCGACTGCTCAGCCTGTTCGAACAGCTGCGAGAGCAGTCGCAGATCATCATCAC
CCACCAGAAGCCGACGATGGAGGTCGCGGACGCACTGTACGGCGTAACCATGCAGAACGACG
GCATCACCGCGGTCATCTCGCAGCGCATGCGCGGTCAGCAGGTGGATCAGCTGGTTACCAATT
CCTCGTAG

RNAse III TB.seq 3239829:3240548 MW:25400 >Rv2925c mc >emb|AL123456|MTBH37RV:c3240548-3239826, mc SEQ ID NO:114 ATGATCCGGTCACGACACCCCTGCTCGACGCACTCGGTGTGGACCTCCCGGACGAGCTGCTC TCACTGGCGTTGACCCACCGCAGCTACGCCTACGAGAACGGCGGGCTGCCGACCAACGAGCGT 10 TTGGAGTTTCTCGGCGATGCCGTGCTAGGGCTGACCATCACCGACGCGCTGTTCCATCGTCATC CTGATCGGTCGGAGGGGATCTGGCCAAACTGCGGGCCAGCGTAGTCAACACCCAGGCCCTG GCCGACGTCGCACGCCCCCTCTGTGCGGAAGGCCTCGGTGTTCACGTGCTATTGGGTCGCGGC GAGGCGAACACCGGCGGGGCCGACAAGTCCAGCATTCTGGCCGACGGTATGGAATCGCTGCT GGGCGCGATCTACCTGCAACACGGTATGGAGAAGGCCCGTGAGGTGATCCTGCGGCTGTTTGG 15 CCCGTTGCTGGACGCCGCCCCGACCCTGGGTGCGGGATTGGATTGGAAGACCAGCTTGCAGG AGCTGACTGCAGCGCGAGGGCTGGGTGCGCCGTCATACCTGGTCACCTCCACCGGCCCGGAC CACGATAAGGAATTCACCGCGGTGGTTGTCGTGATGGACAGCGAATACGGTTCAGGAGTGGGC CGGTCCAAAAAGAGCCGAGCAAAAAGCCGCGGCGGCCGCTTGGAAAGCCCTGGAAGTGCTC GACAACGCCATGCCGGGCAAAACCTCCGCCTAA 20

>Rv2934 ppsD TB.seq 3262245:3267725 MW:193317 >emb|AL123456|MTBH37RV:3262245-3267728, ppsD SEQ ID NO:115 ATGACAAGTCTGGCGGAGCGCGCGCGCGCAACTGTCGCCGAACGCGCGAGCGGCCCTGGCGCG CGAGCTCGTCCGGGGTACGACCTTCCCGACCGACATCTGCGAGCCGGTGGCGGTGGTGG GCATCGGCTGTCGCTTTCCGGGGAATGTGACTGGCCAGAGAGCTTTTGGCAGCTACTGGCCG ACGGTGTGGACACAATCGAGCAGGTGCCGCCTGATCGGTGGGATGCGGACGCGTTCTACGATC CCGATCCTTCGGCGTCGGGTCGGATGACGACGAAATGGGGTGGTTTCGTTTCCGATGTCGACG CGTTCGACGCCGACTTTTCGGAATCACTCCTCGGGAAGCCGTGGCGATGGACCCGCAGCATC GGATGCTGCTCGAGGTTGCCTGGGAAGCGTTGGAGCACGCGGGTATTCCGCCGGATTCCTTGA GCGGCACTCGAACCGGCGTGATGATGGGTCTGTCGTCGTGGGACTACACGATCGTCAATATCG AGCGCAGAGCCGACATCGACGCGTACCTGAGCACCGGGAACCCCGCACTGTGCCGCGGTGGGG CGGATCGCGTATCTGTTGGGATTGCGTGGTCCGGCCGTCGCCGTAGATACCGCTTGTTCGTCGT CGCTGGTGGCAATTCACTTGGCGTGTCAGAGCCTTCGCCTGCGTGAAACCGACGTGGCATTGG CGGGCGGGGTGCAGCTCACCTTGTCACCGTTCACCGCCATCGCGCTGTCCAAGTGGTCGGCGC GGCTGCGGCGTGGTGCTCAAGCGGTTGGCCGACGGGTGCGCGACCAGGACCGGGTGCT

5

25

30

CGCGCTGGCGCAGCGTGACGTGATCACATCCGCCCTCAAGCTTGCGGATGTTACCCCTGACAG CGTGAACTATGTCGAAACACACGGCACCGGAACGGTGTTGGGGGGACCCCATCGAGTTCGAGTC GCTGGCGCCACTTATGGCCTGGGTAAAGGCCAGGGCGAGAGCCCGTGCGCATTGGGGTCGG TCAAGACCAACATCGGCCACCTGGAGGCGGCCGCCGGTGTGGCTGGATTCATCAAGGCGGTGC TGGCGGTGCAACGTGGGCACATTCCCCGCAACTTGCACTTCACCCGGTGGAACCCGGCCATCG ACGCGTCGGCGACGCGGCTGTTCGTGCCGACCGAAAGCGCCCCGTGGCCGGCGGCTGCCGGT CCACGCAGGGCTGCGGTGTCATCGTTCGGCCTCAGCGGGACCAACGCGCACGTGGTGGTCGA GCAGGCACCCGACACCGCAGTAGCCGCAGCCGGCGCATGCCGTATGTTTCGGCGCTGAACG GGGGCCGGCGCGCGCACCACTGGCCGACGTGGCACACGCTTGAACCGGCACCGGGCC CGGCACGCCAAGTTCGCCACCGTCATCGCGCGTGACCGCGCGAGGCGATCGCGGGGTTGCG AGCGCTGGCGGCCGGACAACCACGCGTTGGGGTGGTGGATTGCGACCAGCATGCCGGTGGGC CTGGCCGGGTTTTTGTGTATTCGGGTCAGGGCTCGCAGTGGGCCGTCGATGGGCCAGCAGTTGC TGGCCAACGAACCGGCGTTCGCCAAGGCGGTAGCCGAGCTGGATCCGATATTCGTTGACCAGG TTGGCTTTTCGCTGCAGCAAACGCTTATCGACGGCGACGAGGTGGTGGGCATCGACCGCATCC AGCCGGTGCTGGCGGATGCAGTTGGCGCTGACCGAGTTATGGCGGTCCTATGGGGTGATTC CAGATGCCGTGATCGGCACTCGATGGGTGAGGTGTCGGCGGCAGTGGTGGCCGCGCGTTG ACGCCCGAGCAGGGCTTGCGGGTCATCACCACCCGGTCGCGGTTGATGGCGCGGCTGTCGGG GCAGGGAGCGATGCCGAGCTGGATGCCGACGCCGAGGCGCTGATTGCCGGCT ATCCGCAGGTGACGCTGGCGGTGCATGCGTCACCGCGCCAGACGGTGATCGCCGGGCCGCCC AGTCGACGTGGCCTCCCATCACCGATCATCGATCCCATACTGCCCGAGTTGCGAAGCGCGTTA CCGGTGGCGATGCCGACTATTGGTCGGCCAACCTGCGCAACCCGGTGCGATTCCACCAGGCC GTCACCGCCGCCGGTGTCGACCACACACCTTCATCGAAATCAGCCCTCACCCCGTGCTCACG CACGCACTCACCGACACCCTGGATCCGGACGGCAGCCATACAGTCATGTCGACGATGAACCGC CACACCACCGGTCGCCTTGTCGACCTGCCCCCCACACCGTGGCACCATCAGCGATTCTGGGTC GATGCCGCGCAACGGAGACCATGTCTGGCAGACCGATGTCGGCACCGAGGTCTGTCCCTGGTT GGCGGCGGCGAGCCCTCGGCACAGCCGCCGACGCCGTCGCACCCAACATCGTGATCA ACCAGTTCGAGGTGGAGCAGATGCTGCCCCTCGACGGCCACACGCCGCTAACGACGCAGTTAA TTCGCGGCGGGACAGCCAGATTCGGGTCGAGATCTATTCCCGCACGCGTGGCGGAGAGTTCT GCCGACACGCCACGGCCAAGGTTGAACAATCGCCGCGCGAATGTGCGCACGCGCACCCGGAA 

5

10

15

20

25

30

ACCGCCAACACCATGGTCCGGCGTTCGCGGCCTTAAGCCGGATCGTGCGCCTGGCCGATGGT TCCGCGGAAACCGAGATCAGCATTCCCGACGAGGCGCCGCGCCCATCCCGGGTATCGGCTGCA CCCCGTGGTATTGGATGCGGCATTGCAAAGCGTGGGTGCCGCGATACCCGACGGCGAGATCGC . GGGGTCGGCGAAGCCAGCTATCTGCCAGTGTCGTTCGAGACCATCCGGGTGTACCGCGACAT CGGTCGGCACGTCAGGTGTCGTGCCCACCTGACAAACCTCGACGGCGCACCGGAAAGATGG GTCGTGTCGAACGCCGTGCGGTACCCCTGCCACTAGAGCAGAAGATCTTCGATGCCGAATGGA CCGAAAGCCCGATCGCAGCCGTGCCGGCTCCGGAGCCAGCTGCCGAGACGACGCGGGGAAGT TGGCTGGTACTCGCCGATGCAACGGTGGATGCGCCAGGCCAAGGCCCAGGCCAAGTCGATGGC CGACGACTTCGTGCAGCAGTGGCGCTCACCGATGCGGCGGGTGCACACCGCCGATATCCACGA CGAATCGGCGGTGCTGGCCGCATTTGCAGAAACGGCAGGCGATCCCGAGCACCCGCCGGTTG GACACGGTGTGGTCGATCACCACGGTGGTTCGTGCGGTCGTCGGCACGTGGCACGGCCGATCA CCGCGGCTATGGCTGGTCACCGGGGGCGGACTTTCCGTTGCCGACGACGACGCCGGGAACACC CGCGGCGGCTTCCTTGAAAGGGCTGGTGCGGGTGCTCGCCTTCGAGCACCCGGACATGCGCA CCACCCTGGTCGATCTGGACATCACACAAGACCCGCTGACCGCGCTGAGCGCGGAACTGCGGA ATGCCGGGAGTGGCGCCATGATGACGTGATCGCGTGGCGCGGCGAGCGCAGGTTCGTC GAACGGCTGTCGCGCCCACGATCGATGTATCCAAAGGGCATCCGGTGGTGCGCCAGGGAGC ACCGCGCCCCGCCGGGTGGTGCTGGGTGCCGCAGCGATCCCACTGACGAGCAGTGCAAC GTCCTGGCCGAACTGCAGACCCGCGCCGAGATCGTGGTTGTCCGTGGCGACGTGGCATCGCC GGGGGTGGCAGAAAAGCTGATTGAGACGGCCCGACAGTCTGGGGGCCAATTGCGCGGCGTCG TGCACGCCGCCGCGGTCATCGAAGACAGCCTGGTGTTCTCTATGAGCAGGGACAACCTAGAAC GGGTGTGGGCACCCAAGGCCACCGGTGCGCTGCGCATGCACGAAGCCACCGCTGACTGCGAG CTCGACTGGTGGCTCGGATTCTCTTCCGCCGCTTCGCTATTGGGTTCTCCCGGGCAAGCGGCCT ACGCGTGCCCAGCGCGTGGCTGGACGCGCTGGTCGGATGGCGCAGGGCATCCGGCCTGCC GGCCGCGGTGATCAACTGGGGTCCGTGGTCGGAGGTAGGCGTCGCCCAGGCCTTGGTGGGCA CCGGATCCGCACTGGAGTGGCTCGGCTGCCGATCGGGCCCTGGTCGCATTCCCGGAGA TCCGCAGCATCAGCTACTTCACCCAGGTGGTCGAGGAGCTGGACTCGGCGGGTGACCTCGGCG CGAGCGGATGTGCGCGCATCGCTGCGGTGATGGGCTACACTGACCAGTCGACTGTCGAACC CGCCGTGCCCTTGGACAAGCCCCTGACCGAGCTGGGGCTGGATTCTCTGATGGCGGTACGAAT ACGCAACGCCGCGGGCGGATTTCGGCGTGGAACCGCCGGTAGCGCTGATACTGCAAGGCG CGTCCTTGCATGACCTGACGGCGACTTAATGCGCCAACTCGGGCTCAATGATCCCGATCCGG GCCGCGATGCGGCGCCGACCTAAACCTGAAGTACAGGGAGGATAA

5

10

15

20

25

30

10

15

20

25

30

35

>Rv2946c pks1 TB.seq 3291503:3296350 MW:166642

>emb|AL123456|MTBH37RV:c3296350-3291500, pks1 SEQ ID NO:116

GTGATTTCGGCGAGATCGGCTGAGGCGTTGACGGCGCAGGCGGGTCGACTTATGGCCCACGTG CAGGCCAACCCAGGGCTGGATCCGATCGATGTGGGGTGCTCGTTGGCCAGTCGCTCGGTGTTT GTTGCCCGTGTTTGCGCAGGCATTCGATGCGGTGGCCGACGAGTTGGACCGGCATCTGCGGTT GCCGCTGCGCGACGTTATTTGGGGTGCCGATGCGGATTTGCTTGACAGCACCGAATTTGCTCAG GTTGGCGGACGCGGTGCTGGTGGTGGCGCGGGGCCGGTTGATGCAGGCGCTGCCGGCA GGCGGTGCGATGGTGGCGGTGCCAGTGAGGACGAGGTGGAGCCGCTGCTGGGTGAGG GTGTGGGGATCGCTGCGATCAACGCGCCCGAATCGGTGGTGATCTCCGGTGCGCAGGCCGCG GCAAATGCGATTGCGGATCGGTTCGCCGCGCAGGGTCGGCGGGTGCACCAGTTGGCGGTCTC GCATGCGTTTCATTCGCCGTTGATGGAGCCGATGCTCGAGGAGTTCGCGCGTGTCGCGGCCCG CTGATTTCGGGTCGCCCAGTACTGGGTGGACCACGTTCGTCGGCCGGTGCGCTTCGCGGACA TGACTGGCTCGATCGAGCAGTCCTTGGCCCCGGCTGAGGCGATGGTGGTGTCGATGCTGGGCA AAGACCGGCCCGAGCTGGCCTCGGCGCTCGGTGCCGGTCAGGTGTTCACCACCGGTGTG CCGGTGCAGTGGCGGGTGTTCGCCGGCTCGGGTGGACGGCGGGTGCAGCTGCCCACGTA TGCGTTTCAGCGACGCGGTTTTGGGAGACGCCGGGCGCGGATGGGCCCGATGCGGCCG GGTTGGGTCTGGGCGCGACCGAGCATGCCTTGTTGGGTGCGGTGGTCGAGCGGCCCGATTCT GGTGAACGGGGTGCTGTTCCCCGGGGCGGGTTTTGTGGAGTTGGTGATCCGCGCCGGTG ATGAGGTCGGGTGCGCGCTCATCGAAGAGTTGGTGCTGGCCGCACCGTTGGTGATGCACCCGG GTGTCGGGGTTCAGGTGCAGGTGGTCGTCGGGGCTGCCGATGAATCCGGGCACCGTGCGGTG TCGGTGTATTCCCGCGGTGATCAATCCCAGGGTTGGTTGCTGAACGCCGAAGGCATGCTGGGG GTGGCTGCCGCTGAGACGCCGATGGATTTGTCCGTGTGGCCGCCCGAGGGCCGCGGAGAGTGT GGATATCTCGGACGCTATGCGCAGTTGGCCGAGCGCGGTTATGCCTACGGCCCCGCGTTTCA GGGTCTGGTGGCGATCTGGCGGCGGGGGGTCGGAGCTGTTCGCCGAAGTTGTAGCCCCCGGCG AGGCCGGCGTGGCCGACCGAATGGGGATGCATCCGGCGGTGTTGGACGCGGTGCTGCAT GCCCTCGGGCTGGCCGAGAAGACCCAGGCGAGCACCGAGACGAGACTGCCGTTTTGCTG GCGTGGGGTGTCGCTGCATGCCGGCGCGCGCTGGACGGGTGCGGGCCCGCTTCGCGTCCGCG GGCGCGGATGCGATTTCCGTGGACGTCTGCGACGCCACTGGGCTGCCGGTGTTGACGGTGCG

10

CTCGCTGGTTACTCGCCCGATAACCGCAGAACAGCTGCGCGCCGCCGTGACCGCGGCCGCCG GTGCGTCCGATCAGGGGCCGCTGGAAGTGGTGGTCGCCGATCTCGGTGGTCAGCGGCGGC GCTAACGGGTCCGCCCCACCTGCCCCGGTGTCTTGGGCGGACTTTTGCGCCGGCAGTGATGGT GACGCCAGTGTCGTGGTGTGGGAACTCGAGTCTGCCGGTGGCCAAGCATCCTCGGTGGTGGG CTCGGTGTATGCGGCCACCCCACACCGCCCTGGAGGTGTTGCAGTCCTGGCTCGGCGCGGATCG GGCGGCCACGTTGGTGGTGTTGACCCATGGTGGCGTGGGGGCTGGCCGAGGACATCAGCG ACCTGGCCGCCGCGGTGTGGGGCATGGCGCGTTCCGCGCAGGCCGAAAATCCCGGCCG GATCGTGTTGATCGACACCGATGCGGCGTGGTGCTCGGTGCTAGCCGGCGTCGGGGAAC CCCAGCTGCTGCGCGCGCGCACTGTGCACGCCCCCGGCTGTCCCCGGCCCCGGCGTTG CTAGCGTTACCGGCGGCAGAGTCGGCGTGGCGATTGGCCGCCGGTGGTGGCGGGACCCTGGA GGATTTGGTGATCCAGCCCTGCCCGGAGGTACAGGCACCGCTACAGGCGGGGCAGGTGCGCG TGGCGGTGGCGGCCGTCGGGGTCAACTTCCGCGATGTGGTGGCCGCCCTAGGGATGTATCCC GGCCAGGCCCACCGCTGGGTGCCGAAGGCGCCGGGGTGGTGCTTGAGACCGGTCCCGAAGT TGGTGGATCAGCAACTGGTTACCCGGGTGCCGCAAGGCTGGTCGTTTGCTCAGGCAGCCGCTG 15 AATCGGTGCTGATCCATGCCGGTACCGGCGGTGTGGGCATGGCGGCTGTGCAGCTGGCTCGC CAGTGGGGCGTGGAGGTTTTCGTCACCGCCAGCCGTGGCAAGTGGGACACGCTGCGCCCAT GGGGTTTGACGACGACCATATCGGCGATTCCCGCACATGCGAGTTCGAGGAGAAGTTCCTGGC GGTCACCGAGGCCGCGGGGTTGATGTGGTGCTCGACTCGCTGGCCGGTGAGTTCGTGGATG CGTCGCTGCGCTTACTGGTCCGCGGTGGGCGTTTCCTCGAGATGGGCAAGACGGATATCCGCG 20 ATGCGCAGGAGATCGCCGCTAATTATCCCGGCGTGCAGTATCGGGCGTTCGACCTGTCGGAGG CCGGCCCGGCACGCATGCAGGAGATGTTGGCCGAGGTGCGGGAGCTGTTCGACACCCGGGAG CTGCACCGGCTACCGGTCACCACGTGGGATGTGCGCTGCGCCCCGGCGGCCTTCCGGTTCATG AGCCAGGCCCGCCATATCGGCAAGGTTGTCTTAACCATGCCCTCGGCGTTGGCCGACCGGCTT GCCGACGCACGGTGGTGATCACCGGTGCCACCGGGGCGGTTGGTGGGGTGTTGGCCCGCCA 25 AGGGAGCGGCCGAATTGGCCGCCGACTTGACGGAGGCCGGCGCCCAAGGTGCAGGTGGTGGC CTGTGACGTGGCCGATCGCGCTGCGGTAGCGGGGTTGTTTGCCCAGCTGTCGCGGGAGTACCC GCCGGTGCGCGGGGTGATTCATGCCGCCGGCGTGCTCGATGACGCAGTGATCACCTCGTTGAC ACCGGACCGCATCGATACGGTGTTGCGGGCCAAGGTGGACGCGGCGTGGAACCTGCACCAGG 30 GCCGGGCAGGCAACTACTCGGCGGCAAACGCGTTTCTGGACGGGTTGGCCGCTCACCGGC AGGCCGCAGGGTTGGCCGGGATATCACTGGCGTGGGGGTTTGTGGGAACAGCCTGGCGGCATG CCCTGCCGAAGCGGTGGAATTGTTTGACGCTGCGCTGGCCATCGATCACCCTCTGGCGGTGGC 35 CACGCTCTTGGACCGGGCTGCACTAGACGCCCGGGCCCAGGCCGGTGCGTTGCCGGCGCTGT

10

15

20

25

30

TCAGCGGGCTCGCGCCGCCCACGCCGACGCCAAATCGACGACACCGGTGACGCCACCTCG TCGAAGTCGGCGCTGGCTCAACGCCTACACGGGCTGGCCGCGGACGAACAACTCGAGCTGCTA GTGGGGCTGGTGTCTGCAGGCAGCGCAGTGCTGGGTAGGCCCTCCGCCGAGGACGTCGA CCCCGACACCGAATTCGGCGACCTCGGTTTCGACTCATTAACGGCTGTGGAGTTACGCAACCGC CTCAAAACCGCCACCGGACTGACGCTGCCACCTACCGTGATTTTCGATCATCCCACTCCCACTG CGGTCGCCGAGTATGTCGCCCAGCAAATGTCTGGCAGCCGCCCAACGGAATCCGGTGATCCGA CGTCGCAGGTTGTCGAACCCGCCGCCGCGGAAGTATCGGTCCATGCCTAG

>Rv3014c ligA DNA ligase TB.seq 3372545:3374617 MW:75258 >emb|AL123456|MTBH37RV:c3374617-3372542, ligA SEQ ID NO:117 GTGAGCTCCCAGACGCCGATCAGACCGCTCCCGAGGTGTTGCGGCAGTGGCAGCACTGGC CGAGGAGGTGCGTGAGCACCAGTTCCGTTATTACGTGCGGGACGCGCCGATCATCAGCGACGC GGAATTCGACGAGCTGCTGCGCCGTCTGGAAGCCCTCGAGGAGCAGCATCCCGAGCTGCGCA CGCCCGATTCGCCGACCCAGCTGGTCGGCGGTGCCGGCTTCGCCACGGATTTCGAGCCCGTC GACCATCTCGAACGAATGCTCAGCCTCGACAACGCGTTCACCGCCGACGAACTCGCCGCCTGG GCCGCCGCATCCATGCCGAGGTCGGAGACGCCGCACATTACCTGTGTGAGCTCAAGATCGAC GGCGTCGCGCTGTCTTTGGTCTACCGCGAGGGACGGCTGACCCGGGGCCTCCACCCGCGGCGA CGGGCGCACCGGACGTCACCCTGAACGCCCGGACCATCGCCGACGTTCCCGAACGGC TCACCCCGGCGACGACTACCCGGTGCCCGAGGTCCTCGAGGTCCGCGGCGAGGTCTTCTTCC GGCTGGACGACTTCCAGGCGCTCAACGCCAGCCTCGTCGAGGAGGGCAAGGCGCCGTTCGCC CCGGCTGCGGATGATCTGCCACGGGCTGGGCCACGTGGAGGGCTTTCGCCCGGCCACCCTGC ATCAGGCATACCTGGCGTTGCGGGCATGGGGGACTGCCGGTTTCCGAACACACCACCCTGGCAA CCGACCTGGCCGGTGTGCGCGAGCGCATCGACTACTGGGGCGAGCACCGCCACGAGGTGGAC CACGAAATCGACGCGTGGTGGTCAAAGTCGACGAGGTGGCGTTGCAGCGCAGGCTGGGTTC AGCTGCTCGACATCCGGGTGAACGTCGGCCGCACCGGGCGGATCACGCCGTTTGCGTTCATGA CGCCGGTGAAGGTGGCCGGGTCGACGGTGGGACAGGCCACCCTGCACAACGCCTCGGAGATC AAGCGCAAGGCGTGCTGATCGGCGACACCGTGGTGATCCGCAAGGCCGGCGACGTGATCCC CGAGGTGCTGGGACCCGTCGTCGAACTGCGCGATGGCTCCGAACGCGAATTCATCATGCCCAC GCCCAACGCCGGGGCTGCCCGGGGCAACTGCGGGAGCGGGTTTTCCACGTCGCCAGCCGC AACGGCCTAGACATCGAGGTGCTCGGTTACGAGGCGGGTGTGGCGCTCTTGCAGGCGAAGGT GATCGCCGACGAGGCGAGCTGTTCGCGCTGACCGAGCGGGACTTGCTGCGCACCGACCTGT TCCGAACCAAGGCAGCGAACTGTCGGCCAACGGCAAACGGCTGCTGGTCAACCTCGACAAGG 35 CCAAGGCGCACCGCTGTGGCGGGTGCTGGTGGCGCTGTCCATCCGCCATGTCGGGCCGACG 

CCAGCTGGCCGCCGTCGAGGGGGTGGGGCCGACCATTGCCGCCGCGGTCACCGAGTGGTTCG CCGTCGACTGGCACCGCGAGATCGTCGACAAGTGGCGGGCCGCCGGGGTGCGAATGGTCGAC GAGCGTGACGAGAGTGTGCCACGCACGCTGGCCGGGCTGACCATCGTGGTCACCGGCTCGCT GACCGGTTTCTCCCGCGACGACGCCAAGGAGGCGATCGTGGCCCGCGGGGAAGGCCGCCG GCTCGGTGTCGAAGAAGACCAACTATGTCGTCGCCGGAGACTCGCCGGGATCCAAATACGACA AGGCGGTGGAGTTGGGGGTGCCGATTCTGGACGAGGATGGTTCCGGAGACTGCTGGCCGAC

NifS-like protein TB.seq 3383885:3385063 MW:40948 >Rv3025c ->emb|AL123456|MTBH37RV:c3385063-3383882, Rv3025c SEQ ID NO:118 ATGGCCTACCTGGATCACGCTGCCACCACCCCGATGCACCCCGCCGCCATCGAGGCGATGGCG 10 GCCGTGCAGCGCACCATCGGCAATGCGTCGTCGCTGCACACCAGCGGGCGCTCGGCGCGCCCG GCGGATCGAGGAGCCCGTGAGCTGATCGCGGACAAGCTAGGCGCTCGTCCGAGGTGA TCTTCACCGCGGGCGCACCGAAAGCGACAACCTGGCTGTCAAAGGTATCTATTGGGCACGCC GCGATGCGGAGCCGCCGCCGTCGCATCGTCACCACCGAGGTGGAACACCACGCCGTACTG GACTCGGTGAACTGGCTCGTGGAACACGAAGGCGCCCATGTGACCTGGCTGCCGACCGCCGC 15 CGACGGCTCGGTGTCGCCAACTGCGCTGCGCGAGGCACTGCAGAGCCACGACGACGTCGCGC TGGTATCGGTGATGTGGGCCAACAACGAGGTCGGAACTATTCTACCGATCGCCGAAATGTCAGT TGTCGCCATGGAATTCGGCGTGCCGATGCACAGTGATGCCATTCAGGCGGTGGGACAGCTCCC GCTTGACTTCGGGGCCAGCGGGCTGTCGGCGATGAGCGTGGCCGGGCACAAATTCGGTGGCC CGCCAGGAGTGGGTGCGTTGCTGCGCGCGCGACGTCACCTGCGTGCCCCTTATGCACGGC 20 GGTGGGCAGGAGCGCGATATTCGTTCCGGCACACCCGATGTCGCCAGTGCAGTTGGAATGGCG ACGGCCGCGCAGATCGCGGTGGACGGACTCGAGGAAAACAGCGCGCGGTTACGGCTGCTGCG GGATCGTCTGGTCGAGGGTGTGCTGGCTGAGATTGACGATGTTTGCCTTAACGGCGCCGATGA CCCGATGCGGCTAGCGGGTAACGCGCACTTCACTTTCCGTGGCTGCGAAGGCGATGCGCTGTT GATGTTGTTGGACGCTAACGGAATCGAGTGCTCAACCGGATCGGCCTGCACGGCAGGTGTAGC 25 GCAGCCCTCGCATGTTGATTGCAATGGGCGTCGACGCGGCCAGCGCCCGCGGATCATTGCG TCTCTCGCTGGGGCACACCAGTGTTGAGGCTGATGTCGATGCCGCGTTGGAGGTGCTTCCCGG GGCGGTGCACGTGCACGGCGGGCCCCCTAGCCGCCGCGGGAGCATCCCGATGA

>Rv3080c pknk serine-threonine protein kinase TB.seq 3442656:3445985 MW:119420
>emb|AL123456|MTBH37RV:c3445985-3442653, pknk SEQ ID NO:119
ATGACCGACGTTGATCCGCACGCGACGCGGCGGGGACCTGGTCCCGAATATTCCCGCGGAACTG
CTTGAGGCTGGATTCGACAATGTCGAGGAGATCGGGCGCGGGGGATTCGGCGTCGTCTACCGC
TGCGTCCAGCCCTCGCTGGACCGCCGTCGCCGTCAAGGTATTGAGCACCGACCTGGATCGG
GACAATCTCGAGCGCTTCCTGCGCGAGCAGCGGCCCATGGGCCGCCTTTCCGGGCACCCGCA
CATCGTGACCGTCTTGCAGGTGGGCGTGTTGGCGGGTGGGCGCCCTTCATCGTGATGCCCTA

30

35

CCACGCCAAGAATTCGTTGGAGACGCTGATTCGCCGGCACGGGCCGCTGGACTGGCGCGAGA CGCTGTCGATCGGCGTCAAGCTCGCGGGAGCGCTGGAAGCCGCGCATCGCGTCGGCACCCTG CACCGTGACGTGAAGCCGGGGAATATCCTGCTGACCGACTACGGGGAACCGCAGCTGACCGAT TTCGGAATCGCCAGAATCGCCGGGGGTTTCGAGACGGCGACCGGGGTGATTGCCGGTTCCCCG CTGGGCGCGACGTTGTTCTGTGCGCTGACCGGCCATGCCGCCTACGAGCGCCGCAGCGGTGA GCGGGTGATCGCCCAGTTCCTGCGGATCACCTCGCAGCCGATCCCCGACCTGCGGAAGCAGG GACTGCCGCGGACGTGGCCGCCGCCATCGAACGGGCGATGGCCCGCCATCCGGCGGATCGT CCCGCGACCGCGCAGACGTTGGCGAGGAGCTTCGCGACGTTCAGCGCCGCAACGGCGTCAG CGTCGACGAGATGCCCCTCCCCGTCGAGCTGGGCGTGGAACGCCGACGCTCGCCCGAGGCGC ACGCGGCGCATCGGCATACCGGCGGCGCGCCCCGACGGTCCCGACGCCTCCGACACCCGCG ACCAAGTACCGGCCGTCGGTGCCCACCGGCTCGCTGGTCACCGCAGCCGGCTCACCGACAT CCTGCGCGCGGCGGCGCCGGCTGATCCTCATCCACGCGCCCTCGGGATTCGGCAAAA GCACCCTGGCGCGCAATGGCGGGAAGAGCTCTCGCGCGACGGCGCCGCGGTCGCCTGGCT GACAATCGACAACGACGACAACGAGGTGTGGTTCTTGTCGCACCTGCTCGAGTCGATCCG GCGGGTCCGGCCCACGCTGGCCGAGTCGTTGGGGCACGTGCTCGAAGAGCATGGGGATGACG CCGGCCGCTACGTGTTGACTTCGCTGATCGACGAAATCCACGAAAACGACGACCGGATCGCGG TGGTGATCGACGACTGGCATCGGGTGTCCGACAGCCGCACCCAAGCTGCCCTGGGTTTCCTGC TGGACAACGGATGTCACCACCTGCAGCTCATCGTGACCAGCTGGTCTCGCGCCGGTTTGCCGG TGGGCAGGTTGCGGATCGACGAACTAGCCGAGATCGATTCGGCTGCTTTGCGCTTCGATA CCGACGAGGCCGCCGCGCTGCTGAACGATGCTGGTGGTCTGCGATTGCCGCGCGCAGACGTG CAGGCGCTGACTACCGACGGGTGGGCCGCGCGCGCTGCGCCGCGCTGTCGCT GCGCGGCGGGGCGACCCAACTCCTGCGCGGACTTTCCGGCGCCAGTGACGTGATCC ACGAATTCCTGAGCGAAAACGTGCTGGACACCCTGGAACCCGAACTGCGCGAATTCCTACTGGT GGCATCGGTCACCGAACGCACGTGCGGCGGGGCTGGCCTCGGCGCGGGGATCACCAATG GGCGGGCGATGCTGGAAGAGGCCGAGCACCGCGGCTTGTTCCTGCAACGGACCGAAGACGAC CCGAATTGGTTTCGCTTCCACCAAATGTTCGCCGACTTTCTCCACCGTCGCCTCGAACGTGGCG GGTCGCACCGGGGAACTGCACCGCAGGGCATCGGCCTGGTTCGCCGAGAACGGCTAC CGAGCAGGATGAAACGAACCTGCCGGAGCAGTCAAAGATGACCACACTTCTGGCAATCGTGCA GAAACTGCCGACGTCGATGGTGGTTTCACGGGCCCGGCTCCAACTCGCCATCGCGTGGGCGAA CATTCTGCTGCAACGGCCGGCCCGGCCACCGGTGCCCTGAATCGTTTCGAAACGGCCCTTGG CCGGGCCGAGCTTCCCGAGGCGACGCAGGCGGATCTGCGGGCCGAGGCAGACGTGTTGCGG GCGGTCGCCGAGGTGTCGCAGACCGGGTCGAGCGCGTGGATGACCTTCTCGCCGAGGCAAT GTCGAGACCGGGACACCCTGCCCCGCGAGTCCCCGGGACCGCCGGCAACACCGCGGCGTTGG 35 CCGCGATCTGCCGCTTCGAGTTCGCCGAGGTATATCCACTGCTGGACTGGGCCGCGCCCTACC AGGAAATGATGGGACCGTTCGGCACCGTTTATGCGCAGTGCTTGCGCGGCATGGCGGCCAGGA

5

10

15

20

25

10

15

20

25

30

35

>Rv3106 fprA adrenodoxin and NADPH ferredoxin reductase TB.seq 3474004:3475371 MW:49342 >emb|AL123456|MTBH37RV:3474004-3475374, fprA SEQ ID NO:120 ATGCGTCCCTATTACATCGCCATCGTGGGCTCCGGGCCGTCGGCGTTCTTCGCCGCGCATCC TTGCTGAAGGCCGCCGACACGACCGAGGACCTCGACATGCCGACATGCTGGAGATGTTG CCGACTCCCTGGGGGCTGGCGCCCGGGTCGCCCGGATCACCCCAAGATCAAGTCGAT CAGCAAGCAATTCGAAAAGACGGCCGAGGACCCCCGCTTCCGCTTCTTCGGCAATGTGGTCGT CGGCGAACACGTCCAGCCCGGCGAGCTCTCCGAGCGCTACGACGCCGTGATCTACGCCGTCG GCGCGCAGTCCGATCGCATGTTGAACATCCCCGGTGAGGACCTGCCGGGCAGTATCGCCGCC GTCGATTTCGTCGGCTGGTACAACGCACATCCACACTTCGAGCAGGTATCACCCGATCTGTCGG GCGCCCGGGCCGTAGTTATCGGCAATGGAAACGTCGCGCTAGACGTGGCACGGATTCTGCTCA CCGATCCCGACGTGTTGGCACGCACCGATATCGCCGATCACGCTTTGGAATCGCTACGCCCAC GCGGTATCCAGGAGGTGGTGATCGTCGGGCGCGAGGTCCGCTGCAGGCCGCGTTCACCACG GGACGGCATTACCGACGAGGACGCGGCCGCGGTGGGCAAGGTCTGCAAGCAGAACATCAAGG TGCTGCGTGGCTATGCGGACCGCGAACCCCGCCGGGACACCGCCGCATGGTGTTCCGGTTCT TGACCTCTCCGATCGAGATCAAGGGCAAGCGCAAAGTGGAGCGGATCGTGCTGGGCCGCAACG AGCTGGTCTCCGACGGCAGCGGGCGAGTGGCGGCCAAGGACACCGGCGAGCGCGAGGAGCT GCCAGCTCAGCTGGTCGGTCGGTCGGCTACCGCGGGGTGCCCACGCCCGGGCTGCCGT TCGACGACCAGGGGGCCCAACGTCGGCGGCCGAATCAACGGCAGCCCCAACGAAT ACGTCGTCGGGTGGATCAAGCGCGGGCCGACCGGGGTGATCGGGACCAACAAGAAGGACGCC CAAGACACCGTCGACACCTTGATCAAGAATCTTGGCAACGCCAAGGAGGGCGCCGAGTGCAAG GTCACGTCGGCCCACTGGCAGGTGATCGACGCTTTCGAGCGGGCCGCCGGCGAGCCGCACGG GCGTCCCGGGTCAAGTTGGCCAGCCTGGCCGAGCTGTTGCGGATTGGGCTCGGCTGA

>Rv3235 - TB.seq 3611296:3611934 MW:22659 >emb|AL123456|MTBH37RV:3611296-3611937,

15

20

25

30

35

5

10

>Rv3255c manA mannose-6-phosphate isomerase TB.seq 3635040:3636263 MW:43340 >emb|AL123456|MTBH37RV:c3636263-3635037, manA SEQ ID NO:122 GTGGAACTGCTACGTGGCGCGTTACGCACCTACGCTTGGGGGATCGCGCACCGCTATCGCCGAA TTCACCGGGCGTCCGGCCGCCCCCGAGGCCGAACTATGGTTCGGTGCACACCC GGGTGATCCGGCTTGGCTGCAGACGCCGCATGGCCAAACCTCGTTGCTCGAAGCGTTGGTCGC GGATCCGGAGGGGCAGCTCGGCTCCGCGCGCGCGATTCGGCGATGTGTTGCCGTTCT TGGTCAAGGTGTTGGCGGCCGACGAGCCACTATCGTTGCAGGCCCATCCGAGCGCCGAGCAG GCGGTTGAGGGCTACCTGCGGGAAGAGCGAATGGGCATTCCGGTGTCCTCACCCGTCCGCAAC TACCGCGACACCAGTCACAAGCCAGAGTTATTGGTGGCGCTGCAGCCGTTCGAGGCGCTGGCC GGATTCCGGGAGGCGGCTCGCACCACCGAGCTGCTGCGGGCGCTGGCCGTATCCGACCTCGA CCAGTACGTCAGCTCCGGCGCAACGGAATTTGGCGCCGAAGCCAAGACAGTGCTGGAACTCGG CGAACGTTATCCCGGCGACGCCGGTGTGCTGGCGGCGTTGTTGCTCAACCGCATCAGCTTGGC TCCTGGGGAGGCGATCTTCCTGCCGGCCGGCAACCTGCACGCCTATGTGCGTGGTTTCGGTGT GGAAGTGATGGCCAACTCCGACAACGTGTTACGCGGTGGACTTACCCCTAAGCACGTCGATGT GCCCGAGTTGTTGCGGGTGCTGGACTTCGCCCCCACGCCGAAGGCTCGGCTGCGGCCCCCGA TCCGGCGCGAGGGGCTGGGCCTTTGAGACGCCCACCGATGAGTTCGCGGCCACGCTA CTGGTGCTCGACGGCGATCACCTCGGCCACGAGGTCGACGCGTCGTCCGGCCATGACGGTCC ACAGATCTTGTTATGCACCGAGGGTTCGGCGACGGTGCACGGGAAGTGCGGGTCGCTCACGCT ACAGCGCGCCCGCCTGGGTGGCGGCCGACGACGCCCGATCCGGCTGACCGCCGGC CAACCGCCAAGCTGTTCAGGGCGACCGTCGGGTTGTGA

GTCCGACGTTTGA

>Rv3264c rmlA2 glucose-1-phosphate thymidyltransferase TB:seq 3644897:3645973 MW:37840 > mb|AL123456|MTBH37RV:c3645973-3644894, mlA2 SEQ ID NO:123 TTGGCAACTCACCAAGTCGATGCGGTGGTCCTGGTCGGTGGCAAGGGTACCCGACTGCGGCCG TTGACGCTGTCGGCGCCCAAGCCAATGCTGCCTACCGCGGACTGCCGTTCCTCACCCATCTG 5 CTGTCGCGGATCGCCGCAGCGGGCATCGAGCACGTGATCCTGGGTACGTCCTACAAACCCGCA GTCTTCGAAGCGGAGTTCGGCGACGGGTCCGCACTGGGCCTACAGATCGAATACGTGACCGAG GAGCATCCCTTGGGGACTGGCGGCGCATCGCCAACGTTGCCGGCAAGCTGCGCAACGACAC CGCGATGGTGTTTAACGGCGATGTGCTCTCGGGCGCGGATCTGGCCCAACTGCTGGACTTCCA CCGAAGCAATCGAGCCGATGTCACGCTGCAACTGGTGCGGGTGGGCGACCCGCGGGCATTCG GCTGCGTACCCACCGACGAGGAGGACCGCGTAGTCGCCTTTCTGGAGAAGACGGAGGATCCG 10 CCGACCGACCAGATCAATGCCGGCTGCTATGTCTTCGAACGCAACGTCATCGACCGGATTCCGC AGGCCGGGAGGTTTCGGTGGAACGCGAGGTGTTCCCGGCCTTGCTCGCCGACGGCGACTGC AAGATCTACGGCTATGTCGATGCCAGCTATTGGCGGGACATGGGCACACCGGAAGACTTCGTTC GCGGATCGGCGGATCTGGCGCGGCATCGCCCGGTCTCCGGCCTTGCGTGGTCACCGCGGT 15 GAGCAGTTGGTGCACGACGGTGCGGCGGTATCTCCCGGTGCGTTGCTGATTGGCGGCACCGTC GTGGGGCGTGGTGCCGAAATCGGCCCCGGCACCAGATTGGACGGCGCGGTCATCTTCGATGG TGTCCGGGTGGGGCCGGGTGCGTGATCGAGCGTTCGATCATCGGCTTCGGTGCTCGCATCGG 20

>Rv3368c - TB.seq 3780334:3780975 MW:23734 >emb|AL123456|MTBH37RV:c3780975-3780331, Rv3368c SEQ ID NO:124

>Rv3382c lytB1 TB.seq 3796447:3797433 MW:34667 > mb|AL123456|MTBH37RV:c3797433-3796444, lytB SEQ ID NO:125

ATGGCTGAGGTGTTCGTGGGACCGGTCGCACAGGGATACGCTTCGGGTGAAGTCACGGTGCTG TTGGCGTCGCCGGTCGTTTTGCGCCGGTGTAGAGCGTGCTATCGAGACGGTCAAGCGAGTG CTTGACGTGGCCGAAGGCCCGGTGTATGTGCGCAAGCAAATCGTGCACAACACTGTTGTGGTT 5 GCCGAGTTGCGGGGACCGGGGAGCAGTGTTCGTCGAGGATCTCGACGAGATTCCCGATCCGCC GCCGCCGGGGCGTCGTGTTTCTCCGCGCATGGGGTTTCCCCGGCGGTGCGCGCGGGC GCTGATGAGCGGGGACTGCAGGTCGTCGACGCGACCTGCCCACTGGTGGCGAAAGTCCACGC TGAAGCCGCACGGTTTGCCGCGCGCGGTGACACGGTGGTCTTCATCGGGCACGCCGGACATG AGGAGACCGAAGGCACGCTTGGCGTCGCTCCGCGGTCAACATTATTGGTGCAGACACCCGCTG 10 ATGTGGCAGCGTTGAACCTGCCCGAGGGTACCCAGCTATCGTATCTGACCCAGACAACCCTGG CACTTGATGAAACTGCCGATGTCATTGATGCGCTGCGCGCGAGGTTTCCGACGTTGGGCCAACC GAATGTGACGTTGTTGGTGATTGGCTCGTGCAATTCGTCGAATTCGCGGCGTCTGGTCGAGT TGGCGCAGCGAAGTGGGACGCCGGCCTACTTGATTGACGGGCCTGATGACATTGAGCCCGAAT 15 GGCTGTCGTCGGCGACGATCGGTGTCACCGCGGGAGCCTCCGCGCCGCCACGACTGGTG GGGCAGGTGATTGATGCACTTCGCGGATACGCCTCGATCACCGTGGTGGAACGCTCGATAGCG ACCGAGACGGTGCGATTCGGCCTTCCCAAACAGGTTCGCGCGCAATGA

>Rv3423c air TB.seq 3840193:3841416 MW:43357 >emb|AL123456|MTBH37RV:c3841416-3840190, air SEQ ID NO:127

WO 01/35317 PCT/US00/31152

TGGGACCGGCACAATTCCCGGCCATGCTGACCGCGTTACGCCAAGCCATGGCCGAGGACGCC
GTCCGGCTGCGGGGGCTGATGTCGCATATGGTTTACGCCGACAAGCCTGACGATTCCATCAAC
GATGTTCAGGCCCAACGGTTTACCGCCTTTCTGGCGCAGGCCCGCGAACAAGGGGTGCGGTTC
GAGGTGGCGCATCTATCGAACTCATCAGCAACTATGGCGCCCCGGACCTGACGTTCGACCTG
GTGCGGCCGGGCATCGCGGTGTATGGGCTAAGCCCGGTACCCGCCCTCGGTGACATGGGGCT
GGTGCCGGCGATGACCGTGAAATGTGCTGTTGCGCTGGTGAAATCGATTCGTGCGGGGGAGGG
CGTGTCGTATGGGCACACATGGATCGCGCCACGCGACACCAATCTGGCGCTGCTGCCGATCGG
TTACGCAGACGGCGTGTTCCGGTCGCTGGGCGGGCGGCTGGAGGTGCTGATCAACGGCAGAC
GATGCCCCGGTGTGGGGCGGATCTGCATGGACCAGTTCATGGTCGACCTGGGCCCCGGCCG
CTTGATGTGGCCGAAGGCGACCAAGGCGATTTTGTTCGGGCCGGGCATCCGGGGTGAGCCCAC
GGCTCAGGACTGGGCCGATCTTGTCGGCACCATCCACTACGAAGTGGTCACCAGCCCGCGAGG
ACGTATCACCAGGACCTATCGCGAGGCTGAAAACCGTTGA

>Rv3490 otsA [alpha],-trehalose-phosphate synthase TB.seq 3908232:3909731 MW:55864 >emb|AL123456|MTBH37RV:3908232-3909734, otsA SEQ ID NO:128 ATGGCTCCCTCGGGAGGCCAGGAGGCGCAGATTTGCGATTCGGAGACCTTCGGGGACTCTGAC TTCGTGGTGGTAGCCAATCGACTGCCCGTCGATCTGGAGCGTCTTCCCGACGGCAGCACCACC TGGAAACGCAGCCCGGAGGCTTGGTCACCGCCTTGGAGCCGGTGCTGCGGCGCGCGG GGCCTGGGTCGGCCCGGCGTTAACGACGACGGGGCCGAACCCGACCTCCACGTGCTGG ACGGCCCCATCATCCAAGACGAGCTGGAACTTCATCCGGTACGGCTGAGCACCACGGACATAG CTCAGTACTACGAGGGATTCTCCAACGCCACACTGTGGCCGCTGTACCACGACGTCATCGTCAA GCCGCTCTACCACCGCGAATGGTGGGATCGCTACGTCGACGTCAACCAGCGCTTTGCCGAGGC CGCGTCGCGCCGCCCCCCCCGCGCGCAACCGTGTGGGTACAGGACTACCAGCTGCAGCTGG TACCGAAGATGCTGCGCATGCTGCGGCCCGATCTGACCATCGGTTTCTTTTTGCACATCCCGTT CCCGCCGGTAGAGCTGTTTATGCAGATGCCGTGGCGCACCGAGATCATCCAGGGCCTACTGGG CGCCGACCTGGTGGGCTTCCATCTTCCGGGCGGTGCCCAGAATTTCCTGATCCTGTCCCGGCG TCTGGTCGGCACCGACACTTCCCGCGGAACCGTCGGTGTGCGGTCGCGGTTCGGTGCGGCGG TGCTCGGGTCCCGCACCATACGAGTTGGCGCCTTTCCTATCTCGGTTGACTCCGGCGCGCTCG ACCACGCTGCCCGCGACCGCAACATCAGGCGCCGGGGCCCGCGAGATTCGCACCGAACTGGGA AATCCGCGCAAGATCCTGCTCGGTGTTGACCGGCTCGACTACACCAAGGGCATCGACGTACGG CTGAAGGCCTTTTCCGAGCTGCCGAGGGCCGCGTCAAACGCGACGACACCGTCGTGGTC CAGCTGGCTACCCGAGCCGCGAGCGGGTGGAGAGCTACCAGACGCTGCGCAACGACATCGA ACGCCAGGTCGGCCACATTAACGGCGAGTACGGTGAGGTTGGCCATCCGGTAGTGCATTACCT GCATCGACCGGCTCCGCGCGACGACCTTATCGCTTTCTTCGTGGCCAGCGACGTCATGCTGGT CACCCCACTACGCGACGGGATGAACCTGGTGGCCAAGGAGTACGTCGCTTGCCGCAGCGATCT TGGCGGTGCCCTGGTGCTCAGCGAATTCACCGGGGCCGCAGCCGAACTCCGGCACGCATACCT GGTCAACCGCACGACCTGGAAGGCGTCAAGGACGGATAGAGGAAGCGCTCAACCAGACGG

5

10

15

20

25

30

AGGAGGCGGCCGGCGAATGCGGTCGCTGCGACGCCAAGTGCTCGCCCACGACGTGGACCCCGGGGCACACCCGAGGGCCAAGGCTAA

>emb|AL123456|MTBH37RV:c4042937-4041420, lysS SEQ ID NO:129 GTGAGTGCCGCTGACACAGCAGAAGACCTTCCTGAGCAGTTCCGGGATTCGCCGGGACAAGCGC 5 GCTCGCTTGCTGGCCCAGGGGCGCGATCCCTATCCCGTCGCGGTGCCGCGCACTCACACGTTG GCCGAGGTTCGCGCCCCCCCCCCGACTTGCCGATCGATACCGCGACCGAAGACATCGTCGGC GTCGCGGCCGAGTGATCTTTGCGCGCAACTCGGGAAAGCTATGCTTTGCGACACTTCAGGAC GGCGATGGTACCCAGCTGCAAGTGATCAGCCTCGACAAGGTCGGCCAGGCTGCTCTCGAC GCATGGAAAGCCGATGTCGACCTGGGCGACATCGTCTACGTGCATGGCGCGGTGATCAGTTCG 10 CGCCGCGGGGGCTGTCCGTCCTGGCGGATTGCTGGCGGATCGCCGCCAAGTCGCTGCGGCC GCTTCCCGTCGCGCACAAAGAGATGAGTGAAGAGTCGCGGGTTCGTCAGCGCTATGTTGACCT CATAGTTCGACCGGAAGCGCGCGCGGGGGCGCGCCGCGACTACGGATCGCCGCCGCCGATCC GGACGCCCTTCAACGTCGTGGGTTCCTGGAAGTCGAGACGCCCGTCTTGCAGACGTTAGCCG GTGGTGCGGCCCGTCCGTTCGCCACTCATTCCAATGCCCTAGACATCGATCTGTACCTGCG 15 AATCGAGTGTTCCGAAACGAAGGAGCCGATTCCACGCATTCTCCGGAATTCTCCATGCTGGAGA CCTACCAGACCTACGGAACCTATGACGATTCGGCAGTCGTCACCCGGGAGCTTATTCAAGAGGT GGCCGATGAGGCGATCGGAACCAGACAACTGCCGTTGCCCGACGGCAGTGTCTATGACATCGA 20 ACCGCAGACGACGGTCGATCGCTTACGTGGGATCGCCGATAGCCTTGGCCTGGAGAAAGACCC AGCGATTCATGACAACCGTGGCTTCGGCCACGGCAAACTCATCGAGGAACTCTGGGAGCGCAC AGTGGGCAAGAGCTTGAGCGCACCCACATTTGTCAAGGATTTTCCGGTTCAGACAACGCCTTTG ACCCGTCAGCACCGCAGTATCCCCGGCGTAACCGAGAAGTGGGACCTCTATCTGCGCGGAATC GAACTTGCCACCGGCTACTCGGAATTAAGCGACCCGGTAGTCCAGCGGGAGAGATTCGCCGAC 25 CAGGCCCGTGCCGCCGCCGCCGATGACGAAGCGATGGTGCTTGACGAGGATTTTCTGGCC TCTTTGACTGGGTTGTCAATTAGGGAGACAGTTTTGTTCCCGATTGTTCGACCACACTCCAACTG Α 30

>Rv3600c - similar to Bacillus subtilis protein YacB TB.seq 4043041:4043856 MW:29274
>emb|AL123456|MTBH37RV:c4043856-4043038, Rv3600c SEQ ID NO:130
GTGCTGCTGGCGATTGACGTCCGCAACACCCACACCGTTGTGGGCCTGCTGTCCGGAATGAAA
GAGCACGCAAAGGTCGTGCAGCAGTGGCGGATACGCACCGAATCCGAAGTCACCGCCGACGAA
CTGGCACTGACGATCGACGGGCTGATCGGCGAGGATTCCGAGCGGCTCACCGGTACCGCCGC
CTTGTCCACGGTCCCGTCCGTGCTGCACGAGGTGCGGATAATGCTCGACCAGTACTGGCCGTC

>Rv3606c folK 7,8-dihydro-6-hydroxymethylpterin pyrophosphokinase TB.seq 4048181:4048744 MW:20732 >emb|AL123456|MTBH37RV:c4048744-4048178, folK SEQ ID NO:131

25

5

10

35

30

>Rv3608c folP dihydropteroate synthase TB.seq 4049138:4049977 MW:28812 >emb|AL123456|MTBH37RV:c4049977-4049135, folP SEQ ID NO:133

15

20

25

5

10

>Rv3609c fole GTP cyclohydrolase I TB.seq 4049977:4050582 MW:22395
>emb|AL123456|MTBH37RV:c4050582-4049974, fole SEQ ID NO:134
ATGTCGCAGCTGGATTCGCGCAGCGCATCTGCTCGTATCCGTGTTTCGACCAGCAACGTGCC
GAGGCCGCGGTGCGCGAATTGCTGTACGCGATCGGCGAGGATCCGGATAGGGACGGCTTGGT
AGCCACCCCGTCCCGGGTTGCCCGGTCATACCGCGAAATGTTCGCCGGGCTCTACACCGACCC
CGACTCGGTGTTGAACACCATGTTCGACGAAGACCACGACGACGTGGTGTTGGTCAAGGAAATC
CCTATGTACTCCACCTGCGAACACCACCTGGTGGCGTTCCACGGTGTGGCCCACGTCGGCTAC
ATCCCGGGCGACGACGGCAGGGTGACCGGCTTGTCAAAGATCGCGCGATCGTCGATCTGTAC
GCCAAGCGACCTCAGGTCCAGGAGCGGCTCACCAGTCAGATCGCCGATGCCTGATGAAAAAA
CTCGATCCACGCGGGGTAATCGTGGTGATCGAGGCTGAGCATCTGTGCATGCCGGG
GTTCGCAAGCCCGGCTCGGTCACCACTACGTCGCGGTGCCCGGACTGTTCAAAACCAATGCC
GCTTCTCGAGCCGAAGCGCTCGACCTCATTTTGCGGAAGTGA

>Rv3610c ftsH inner membrane protein, chaperone TB.seq 4050601:4052880 MW:81987

>emb|AL123456|MTBH37RV:c4052880-4050598, ftsH SEQ ID NO:135

ATGAACCGGAAAAACGTGACTCGCACCATAACAGCGATCGCCGTCGTGGTGCTCGGCTGG

TCGTTCTTTTACTTCAGCGACGACACCCGCGGCTACAAGCCCGTTGATACCTCGGTGGCGATAA

CACAGATCAACGGCGACAACGTCAAGAGCGCACAGATCGACGATCGCGAGCAACAGCTGCGGC

TGATCCTGAAGAAGGGTAACAACGAGACCGACGGTCCGAGAAGGTCATCACCAAGTACCCCA

TCACCTGAAGAAGGGTAACAACGAGACCGCCCCAAAAAACGCGAAGGTCAGCACGGTCG

TCAACCAGGGCAGCATCCTGGGCGAGCTGCTGGTCTACGTGCTGCTGCTGTTGCTGGTGG

GGCTGTTCGTGATGTTCTCCCGCATGCAAGGCGGCCCCGGATGGGCTTCGGGTTCGGCAAGT

CACGCGCCAAGCAACTGAGCAAGGACATGCCCAAGACCACCTTCGCCGACGTCGCAGGTGTCG ACGAGGCGGTCGAGGAGCTCTACGAGATCAAGGACTTCCTGCAGAACCCCAGCAGGTACCAAG CGCTGGGCGCCAAGATCCCCAAAGGCGTGCTGCTCTACGGGCCGCCGGGAACCGGTAAGACG TTGCTGGCTCGTGCGGCGGCGAAGCCGGAGTGCCGTTCTTCACCATCTCCGGCTCCGAC TTCGTCGAAATGTTCGTCGGCGTCGGCGCATCCCGTGTCAGAGACCTGTTCGAGCAGGCCAAG 5 CAGAACAGCCCGTGCATCATCTTCGTCGACGAGATCGACGCCGTCGGCCGACAAAGAGGCGCC GGGCTGGGCGGCGGCGACGACGTGAGCAGCCCTCAACCAGTTGCTAGTCGAAATGGA CGGTTTTGGCGATCGCGCCGGCGTCATCCTGATCGCGGCCACCAACCGGCCCGACATCCTGGA CCCGCCCTTTGCGCCCGGCCCCCCCCCCCCCGGTATCCCAACCCCGATCTGG CGGGTCGGCGGGCGGTGCCGCGCGCGCGACGCCGA 10 CCTCGACGGACTGGCCAAGCGGACCGTCGGCATGACCGGAGCCGACCTGGCCAACGTCATCA ACGAGGCGCCCCGCCCCGGGAGAACGGCACCGTCATCACCGGTCCCGCCCTCGAG GAAGCGGTGGACCGGGTGATCGGCGGCCGCGCCGCAAAGGCCGGATCATCAGCGAGCAGGA GAAGAAGATCACCGCCTATCACGAGGGCGGCACACCCTGGCCGCTTGGGCGATGCCCGATAT CGAGCCGATTTATAAGGTGACGATCCTGGCGCGCGGGCGTACCGGCGGGCACGCGGTGGCGG TGCCGGAAGAAGACAAGGGCCTGCGGACCCGCTCGGAAATGATCGCGCAACTGGTGTTCGCGA 15 TGGGTGGCGCGCCGAAGAACTGGTGTTTCGTGAGCCGACCACCGGCGCGGTGTCCGAC ATCGAGCAGCCACCAAGATAGCGCGCTCAATGGTCACCGAATTTGGAATGAGCTCCAAGCTG GGCGCGGTCAAATACGGCTCCGAACACGGCGACCCGTTCCTCGGACGTACCATGGGCACCCAG CCGGACTACTCCCACGAGGTCGCCCGCGAGATCGACGAAGAGGTCCGCAAGCTTATCGAGGCG 20 GCGCATACCGAAGCGTGGGAAATCCTGACCGAATACCGCGACGTGCTGGACACTTTGGCCGGC GAGCTGCTGGAAAAGGAGCCCTGCACCGACCCGAGCTGGAAAGCATCTTCGCTGACGTCGAA AAGCGGCCGCGCTCACCATGTTCGACGACTTCGGTGGCCGGATCCCGTCGGACAAACCGCCC ATCAAGACACCCGGCGAGCTCGCGATCGAACGCGGCGAACCTTGGCCCCAGCCGGTCCCCGA GCCGCCTTCAAGCCGCCGATTGCGCAGGCTACCCAAGCCGCTGAGGCCGCCCGGTCCGACG CCGGCCAAACCGGGCACGGCCAACGGTTCGCCCGGCCGCCACCGGTCCGGTGACCGC 25 CAGTACGGCTCCACCCAGCCTGACTACGGTGCCCCGGCGGGCTGGCATGCGCCGGGATGGCC CCCAAGGTCATCTCATCGGCCCAGCTATAGCGGTGAACCGGCACCGACGTATCCGGGTCAGCC CTACCGACCGGTCAAGCCGATCCGGGTTCCGATGAGTCCTCGGCGGAGCAGGATGACGAGGT CAGTCGGACCAAGCCGGCCCACGGCTGA 30

>Rv3671c - TB.seq 4112322:4113512 MW:40722 >emb|AL123456|MTBH37RV:c4113512-4112319, Rv3671c SEQ ID NO:136

ATGACCCCGTCGCAGTGGCTGGATATCGCCGTCTTGGCGGTCGCATTTATTGCAGCCATCTCCG GCTGGCGTGCCGGTGCGCTCAATGCTGTCGTTTGGCGGGGTGCTGCTGGGCGCGACA GCCGCGTGCTGCTGGCGCCGCATATCGTCAGTCAAATCAGCGCTCCGCGGGCCAAACTGTTT GCCGCGCTGTTCCTGATCCTGGCACTGGTCGTAGTCGGCGAGGTCGCTGGTGTGGTGCTGGGC

CGCGCCGTCCGCGGGCGATCCGTAACCGGCCGATCCGGTTGATCGACTCGGTCATTGGGGTA GGGGTGCAGCTGGTGGTGCTCACCGCGGCGTGGTTGTTGGCGATGCCGCTGACACAGTC GAAAGAGCAGCCGAGCTGGCCGCGGTGAAGGGTTCGCGGGTGCTCGCCCGGGTCAACG AGGCGGCACCCACCTGGCTGAAGACGGTGCCCAAGCGGCTGTCGGCCCTGCTGAACACCTCC GGCCTGCCGGGTTTTGGAGCCGTTCAGCCGCACGCCGGTCATTCCAGTGGCCTCACCCGAC CCAGCGCTGGTCAACAATCCGGTGGTGGCGGCCACCGAGCCAAGTGTCGTCAAAATCCGCAGC CTGGCACCCAGATGCCAGAAAGTGTTGGAGGGCACCGGCTTCGTGATCTCACCCGATCGGGTG ATGACCAACGCGCACGTGGTGGCCGGATCCAACAACGTCACGGTGTATGCCGGCGACAAGCCC TTCGAGGCCACGTGGTGTCCTACGACCCGTCGGTCGACGTAGCGATCCTGGCCGTTCCGCAC TTGCCGCCGCCGCCGCTGTCTTCGCTGCGGAGCCGGCGAAAACCGGTGCCGACGTTGTGGT GCTGGGTTATCCCGGCGGCGCAATTTCACTGCCACACCCGCCAGGATTCGCGAGGCCATCAG ACTCAGTGGCCCGATATTTACGGGGACCCGGAGCCGGTTACCCGCGACGTGTACACCATCAG AGCCGATGTGGAGCAAGGTGATTCGGGTGGGCCCCTGATCGACCTCAACGGTCAGGTGCTCGG GGCGGGCAGCTTGCCAAAATCGGTGCTACCCAACCGGTCGGCACCGGGGCCTGCGTCAGCT GA

>Rv3682 ponA2 TB.seq 4121913:4124342 MW:84637 >emb|AL123456|MTBH37RV:4121913-4124345, ponA' SEQ ID NO:137

AGTGTCGTCGCCACTGCGCTGACGTTCCCGTTCGCAGGCGGGCTAGGGCTGATGTCCAATCGT GCCTCTGAGGTCGTTGCCAACGGCTCGGCCCAGCTGCTCGAGGGGCAAGTGCCTGCGGTATCG ACGATGGTCGACGCGAAGGGCAACACGATCGCGTGGCTGTACTCGCAGCGCCGGTTCGAGGT GCCCTCGGACAAGATCGCCAACACGATGAAGCTGGCGATCGTCTCGATTGAAGATAAGCGGTTC GCCGACCACAGCGGCGTGGACTGGAAGGGCACCCTGACCGGCCTGGCGGGCTACGCGTCCG GCGACCTCGACACGCGCGCGCGCTCGACGCTCGAACAACAGTACGTGAAGAACTACCAACTGC TGGTGACAGCCCAAACCGATGCCGAGAAGCGAGCGGCCGTCGAAACCACTCCGGCCCGCAAG CTTCGCGAGATCCGGATGGCACTCACGCTGGACAAGACCTTCACAAAATCTGAAATCCTGACCC GATACTTGAACCTGGTCTCGTTCGGCAATAACTCGTTCGGCGTGCAGGACGCGGCGCAAACGTA CTTCGGCATCAACGCGTCCGACCTGAATTGGCAGCAAGCGGCGCTGCTGGCCGGCATGGTGCA ATCGACCAGCACGCTCAACCCGTACACCCAACCCCGACGGCGCGCTGGCCCGGCGGAACGTGG TCCTCGACACCATGATCGAGAACCTTCCCGGGGAGGCGGAGGCGTTGCGTGCCGCCAAGGCC CCGCGCATTCTTCTGCGACTACGTCCAGGAGTACCTGTCTCGGGCCGGGATCAGCAAGGAGCA GGTCGCCACGGGCGGGTACCTGATCCGCACCACCCTGGACCCAGAGGTGCAGGCACCGGTCA AGGCCGCCATCGACAAGTACGCCAGCCCGAACCTGGCCGGTATTTCCAGCGTGATGAGCGTGA TCAAACCGGGTAAGGATGCGCACAAGGTGTTGGCCATGGCCAGTAACCGCAAATACGGGCTGG

5

10

15

20

25

30

ATCTAGAAGCCGGCGAAACCATGCGGCCGCAGCCATTCTCCCTGGTTGGCGACGGCGCCGGGT CTATCTTCAAGATCTTCACCACGGCCGCTGCTCTGGACATGGGCATGGGTATTAACGCCCAACT CGACGTGCCGCCCGATTCCAGGCCAAAGGTCTGGGAAGTGGCGGGGCAAAGGGGTGCCCCA AAGAGACCTGGTGTGTGAACGCCGGCAACTACCGCGGCTCGATGAATGTCACCGACGCGC 5 GTCGATATGGCCATCAAACTCGGGCTGAGGTCTTATGCGAATCCCGGCACCGCACGCGACTAC TCGGCCCCATCGAGTTAAACGCGCTGGAGCTGTCCAACGTGGCGGCCACGTTGGCATCCGGCG GCGTGTGGTGCCCCCCAACCCAATCGACCAGCTCATCGACCGCAACGGCAACGAAGTCGCGG TCACCACCGAGACGTGCGACCAGGTGGTGCCCGCAGGGCTGGCGAACACCCTCGCCAACGCG 10 TTCACCAACCGCTACGCGGCGAACTACATCTACGACGACTCCAGCTCGCCGACAGATCTGT GTTCCGGCCGCTGCGCCATTGCGGCAGCGGCGACTTGTACGGCGGCAACGAGCCATCCCGC ACCTGGTTCGCCGCGATGAAGCCGATCGCCAACAACTTCGGCGAAGTGCAGCTACCACCGACC 15 GATCCACGCTATGTCGACGGCGCACCAGGCTCACGGGTACCAAGCGTGGCCGGTCTGGATGTC GACGCCGCACGCCCCCAAGGACGCGGGCTTCCAGGTCGCCGACCAAACCAACTCGGT CAACAGCTCCGCCAAGTATGGTGAGGTGGTCGGAACGTCGCCCAGCGGTCAAACAATTCCGGG TTCGATCGTCACGATCCAGATCAGCAACGGCATCCCGCCGGCTCCGCCTCCGCCACCGCTGCC TGAGGATGGTGGGCCGCCACCGCCGGTCGGATCGCAGGTGGTGGAGATTCCGGGGCTGCCGC 20 CGATCACCATTCCGCTGCTGGCGCCCCCCCCCCCGCGCCCCCCCGTAG

>Rv3721c dnaZX DNA polymerase III,[gamma] (dnaZ) and t (dnaX) TB.seq 4164995:4166728

MW:61892 >emb|AL123456|MTBH37RV:c4166728-4164992, dnaZX SEQ ID NO:138

GTGGCTCTCTACCGCAAGTACCGACCGGCAAGCTTCGCGGAGGTGGTGGGGCAGGAGCACGT
CACCGCGCCGCTGTCGGTGGCGCTGGATGCCGGCCGGATCAACCACGCGTACCTGTTCTCTGG
GCCGCGTGGCTGCGGAAAGACGTCGTCAGCGCGTATCCTGGCGCGGTACCTGTTCTCTGG
GCCGCGTGGCTGCGGAAAGACGTCGTCAGCGCGTATCCTGGCGCGGTCGTTGAACTGTGCGCA
GGGCCCTACCGCCAACCCGTGCGGGGTCTGCGAATCCTGCGTTTCGTTGGCGCCCAACGCCC
CGGCAGCATCGACGTGGTAGAGCTGGATGCCGCCAGCCACGGCGGCGTGGACGACACCCGCG
AGCTGCGGGACCGCGCGTTCTATGCGCCGGTCCAGTCACGGTACCGGGTATTTATCGTCGACG
AGGCGCACATGGTGACCACCGCGGGATTCAACGCGCTGCTCAAGATCGTGGAGGAACCGCCC
GAACACCTGATCTTCATATTCGCCACCACCGAACCGGAGAAGGTACTGCCGACGATTCGGTCGC
GCACTCATCACTACCCGTTCCGGCTGCTGCCGCCGCACTATGCGGGCGTTGCTCGCGCGGA
TCTGCGAGCAGGAGGGCGTCGTCGTCGACGATGCGGTTACCCGTTGGTGATCCGGGCCGGC
GGAGGTTCCCCACGGGATACGCTCTCGGTGCTGGACCAATTGCTGGCGCCGCGGACAC
CCACGTGACCTACACCCGGGCGCTTGCGGGCTGCTGGACCAATTGCTGGCCCCTGGACCAC
CCACGTGACCTACACCCGGGCGCTTGCGGGCTGCTGGGGCCCCTGATCGACG
ACGCGGTCGACGACTGGCCGCTTGCGACCAATTGCTGGGGCCGCTGATCGACG
ACGCGGTCGACCACTGGCCGCTTGCGATCGGCCCCTGATCGACG
ACGCGGTCGACCACTGGCCGCTTGCGATCGCGCCCTTGATCGACG
ACGCGGTCGACCACTGGCCGCTTGCGATCGCCCCTGATCGACC

25

30

5

10

15

>Rv3783 - TB.seq 4229255:4230094 MW:32337 >emb|AL123456|MTBH37RV:4229255-4230097, Rv3783 SEQ ID NO:139 ATGACATTCATGGATGCTCAAGCTAGCTTCCAGACACAGTCGCGGACACTGGCCCGCGTCCGA GGCGATCTGGTCGACGGGTTCCGCCGCCACGAGCTGTGGCTGCACCTGGGCTGGCAGGACAT 20 CAAGCAGCGGTACCGCCGCTCGGTGCTGGGGCCGTTCTGGATCACCATCGCCACCGGAACGA CCGCCGTCGCGATGGGCGGCCTGTATTCCAAGCTGTTTCGGCTCGAGCTGTCTGAGCACCTGC CCTACGTCACGCTCGGGCTGATCGTCTGGAACCTGATCAACGCCGCCATCCTGGACGCCGCAG AGGTTTTCGTCGCCAACGAAGGTCTGATCAAACAGCTGCCGGCACCGTTGAGCGTGCACGTCTA TCGGTTGGTGTGGCGCAGATGATCTTCTTCGCCCACAACATCGTCATCTACTTCGTCATCGCG 25 ATCATCTTTCCTAAGCCGTGGTCGTGGGCGGATCTGTCGTTTCTTCCGGCGCTGGCGCTCATTT TCCTCAATTGCGTTTGGGTGTCACTGTGTTTCGGCATCCTGGCGACCCGCTACCGCGACATCGG CCCGCTGCTGTTTCCGTTGTGCAGTTGTTCTTCATGACGCCGATCATCTGGAACGACGAGA CCCTGCGTCGGCAGGGCGCGGGCCGCTGGTCGAGCATCGTCGAGCTCAACCCGCTGCTGCAC 30 GTGCTGGTGTTGACCGTCGTCGGCTGGATGCTGGCGGCGTTCGCGATGCGGCAGTATCGCGC **GCGGGTGCCCTACTGGGTGTAG** 

>Rv3789 - TB.seq 4235371:4235733 MW:13378

>emb|AL123456|MTBH37RV:4235371-4235736, Rv3789 SEQ ID NO:140

ATGCGGTTCGTTGTCACCGGCGCCTCGCTGGGATAGTTGACTTTGGCCTCTACGTCGTGCTGT

ACAAGGTGGCGGCCTACAGGTCGACCTGTCCAAGGCCATCAGCTTCATCGTCGGCACCATCA

CCGCGTACCTGATCAACCGCCGGTGGACATTCCAGGCCGAGCCCAGCACGGCCCGATTCGTCG CGGTCATGCTCCTCTACGGAATCACCTTCGCCGTGCAGGTCGGACTCAACCACCTCTGCCTCGC ACTCTTGCACTACCGGGCGTGGGCCATCCCCGTCGCGTTTGTGATCGCGCAGGGCACCGCCAC GGTAATCAACTTCATCGTGCAGCGAGCCGTGATCTTCCGGATCCGCTGA

5

10

15

20

>Rv3790 - TB.seq 4235776:4237158 MW:50164 >emb|AL123456|MTBH37RV:4235776-4237161, Rv3790 SEQ ID NO:141 ATGTTGAGCGTGGGAGCTACCACTACCGCCACCCGGCTGACCGGGTGGGGCCGCACAGCGCC GTCGGTGGCGAATGTCGCACCCCAGATGCCGAGATGATCGTCAAGGCGGTGGCTCGGGT CGCCGAGTCGGGGGGCGGCGGGGTGCTATCGCGCGCGGGCTGGGCCGCTCCTATGGGGAC AACGCCCAAAACGGCGGTGGGTTGGTGATCGACATGACGCCGCTGAACACTATCCACTCCATTG ACGCCGACACCAAGCTGGTCGACATCGACGCCGGGGTCAACCTCGACCAACTGATGAAAGCCG CCCTGCCGTTCGGGCTGTGGGTCCCGGTGCTGCCGGGAACCCGGCAGGTCACCGTCGGCGGG GCGATCGCCTGCGATATCCACGGCAAGAACCATCACAGCGCTGGCAGCTTCGGTAACCACGTG CGCAGCATGGACCTGCCGACCGCCGACGGCGAGATCCGTCATCTCACTCCGACCGGCGAGGA CGCCGAACTGTTCTGGGCCACCGTCGGGGCCAACGGTCTCACCGGCATCATCATGCGGGCCAC CATCGAGATGACGCCCACTTCGACGGCGTACTTCATCGCCGACGGCGACGTCACCGCCAGCCT CGACGAGACCATCGCCCTGCACAGCGACGGCGCGAAGCGCGCTACACCTATTCCAGTGCCTG CCACCGTCGAGCAATTGCCTGCGAAACTGCGGAGCGAACCTTTGAAATTCGATGCGCCACAGCT ACTTACGTTGCCCGACGTGTTTCCCAACGGGCTGGCCAACAAATATACCTTCGGCCCGATCGGC GAACTGTGGTACCGCAAATCCGGCACCTATCGCGGCAAGGTCCAGAACCTCACGCAGTTCTACC ATCCGCTGGACATGTTCGGCGAATGGAACCGCGCCTACGGCCCAGCGGGCTTCCTGCAATATC AGTTCGTGATCCCCACAGAGGCGGTTGATGAGTTCAAGAAGATCATCGGCGTTATTCAAGCCTC GGGTCACTACTCGTTTCTCAACGTGTTCAAGCTGTTCGGCCCCCGCAACCAGGCGCCCCCCAGC TTCCCCATCCGGGCTGGAACATCTGCGTCGACTTCCCCATCAAGGACGGGCTGGGGAAGTTC 25 CGTACCACCGCGAAACCTTTCATGCCATGTATCCGCGCGTCGACGAATGGATCTCCGTGCGCC GCAAGGTCGATCCGCTGCGCGTATTCGCCTCCGACATGGCCCGACGCTTGGAGCTGCTGTAG

30

35

>Rv3791 - TB.seq 4237162:4237923 MW:27470 >emb|AL123456|MTBH37RV:4237162-4237926, Rv3791 SEQ ID NO:142 ATGGTTCTTGATGCCGTAGGAAACCCCCAGACGGTGCTGCTGCTCGGTGGCACCTCCGAGATC TGGAGCTGATCGACTTTGACGCCCTGGATACCGACAGCCACCCGAAGATGATCGAGGCGGCCT TCTCCGGCGTGATGTGGACGTGGCTATCGTCGCGTTCGGCTTGCTCGGCGACGCCGAAGAGC 5

10

15

20

25

TGTGGCAGAACCAGCGCAAGGCGGTGCAGATCGCCGAAATCAACTACACCGCAGCGGTTTCGG TGGGCGTGCTGGCTGAGAAGATGCGCGCTCAGGGCTTCGGTCAGATCATCGCGATGAGCT CGGCCGCCGGTGAGCGGGTGCGACGGCCGAACTTCGTCTACGGCTCCACCAAGGCCGGTCTG GACGGGTTTTACCTGGGGTTGTCAGAAGCGCTGCGCGAGTACGGTGTTCGTGTGCTGGTGATC CGGCCGGCCAGGTGCGTACCCGGATGAGCGCGCACCTCAAGGAAGCTCCATTGACCGTCGA CAAGGAGTACGTCGCCAACCTCGCGGTGACCGCGTCCGCAAAAGGTAAGGAATTGGTTTGGGC GCCAGCAGCGTTCCGCTACGTCATGATGGTGTTGCGTCACATCCCGCGGAGCATCTTCCGCAA **GCTGCCCATCTGA** 

>Rv3794 embA TB.seq 4243230:4246511 MW:115694 >emb|AL123456|MTBH37RV:4243230-4246514, embA SEQ ID NO:143 GTGCCCACGACGGTAATGAGCGATCTCACCGGATCGCACGCCTAGCAGCCGTCGTCTCGGGA ATCGCGGGTCTGCTGCTGCGGCATCGTTCCGCTGCTTCCGGTGAACCAAACCACCGCGACC ATCTTCTGGCCGCAGGCACCCCCGCCGCCGCCCCCTCTGGTA TCCGGGGCCCACGCGCTGGACATCTCGATCCCCTGCTCGGCCATCGCCACGCTGCCCGC CAACGGCGGCCTGGTGCCACACTGCCGGCCGGTGGCGTGGATACCGGTAAGGCCGGGC TGTTCGTCCGCGCCAACCAGGACACGGTCGTCGTGGCGTTCCGCGACTCGGTGGCCGCGGTG GCGGCCCGCTCCACGATCGCAGCGGGAGGCTGTAGCGCGCTGCATATCTGGGCCGATACCGG AGCCACAGGTTGGCGGCATCTTCACCGACCTGAAGGTCGGAGCGCAGCCCGGGCTGTCGGCC CGCGTCGACATCGACACTCGGTTTATCACGACGCCCGGCGCGCTCAAGAAGGCCGTGATGCTC CTCGGCGTGCTGGCGGTCCTGGTAGCCATGGTGGGGCTGGCCGCGCTGGACCGGCTCAGCAG GGGCCGCACCCTGCGCGACTGGCTGACCCGATATCGCCCGCGGGTGCGGGTCGGATTCGCCA GCCGGCTCGCTGACGCAGCGTGATCGCGACCTTGTTGCTCTGGCATGTCATCGGCGCCACCT CGTCCGATGACGCTACCTTCTGACCGTCGCCCGGGTCGCCCCGAAGGCCGGCTATGTAGCCA ACTACTACCGGTATTTCGGCACGACGGAGGCGCCGTTCGACTGGTATACATCGGTGCTTGCCCA GCTGGCGGCGTGAGCACCGCCGGCGTCTGGATGCGCCTGCCCGCCACCCTGGCCGGAATCG GCGTCCAACCGGGTCGCTGTTCACCGCTGGTGCGGTGTTCCTGTCCGCCTGGCTGCCGTTC AACAACGGCCTGCGTCCCGAGCCGCTGATCGCGCTGGGTGTGCTGGTCACGTGGGTGTTGGTG 30 GAACGGTCGATCGCGCCGGACGGCTGGCCCCGGCCGGTAGCCATCATCGTGGCGACGCT TACCGCGACGCTGGCACCGCAGGGGTTGATCGCGCTGGCCCGCTGCTGACTGGTGCGCGCG CCATCGCCCAGAGGATCCGGCGCCGCCGGGCGACCGATGGACTGCTGGCGCCGCTGGCGGT GCTGGCCGCGCGTTGTCGCTGATCACCGTGGTGTTTTCGGGACCAGACGCTGGCCACGGT GGCCGAATCGGCACGATCAAGTACAAGGTCGGCCCGACCATCGCCTGGTACCAGGACTTCCT 35 GCGCTACTACTTCCTTACCGTGGAGAGCAACGTTGAGGGGTCGATGTCCCGCCGGTTCGCGGT 

GGGGCTGGCCAGCCGGCCTGGCGACTGATCGGCACTACGGCGGTCGGCCTGCTGCTGC TCACGTTCACGCCAACCAAGTGGGCCGTGCAGTTCGGCGGCATTCGCCGGGGCTGGCCGGGGTGT TGGGTGCGGTCACCGCGTTCACCTTTGCCCGCATCGGTCTACATAGTCGACGCAACCTCACGCT GTACGTGACCGCGTTGCTGTTCGTGCTGGCGTGGCCAACCTCGGGCATCAACGGGTGGTTCTA 5 GTCGATGTTTCTGACGCTGTCGATCCTCACCGGATTGCTGGCAGCCTGGTATCACTTCCGGATG GACTACGCCGGGCACACCGAAGTCAAAGACAACCGGCGCAACCGCATCTTGGCCTCTACGCCA CTGCTGGTGGTCGCGGTGATCATGGTCGCAGGCGAAGTCGGCTCGATGGCCAAGGCCGCGGT GTTCCGTTACCCGCTTTACACCACCGCCAAGGCCAACCTGACCGCGCTCAGCACCGGGCTGTC CAGCTGTGCGATGCCGACGCGACGCCGACCCCAATGCCGGCATGCTGCAAC 10 CGGTTCCGGGCCAGGCGTTCGGACCGGACCGCTGGGCGGTATCAGTCCCGTCGGCTTC AAACCCGAGGGCGTGGGCGAGGACCTCAAGTCCGACCCGGTGGTCTCCAAACCCGGGCTGGT CAACTCCGATGCGTCGCCCAACAACCCAACGCCGCCATCACCGACTCCGCGGGCACCGCCGG CACGTACCCGGTGATGGGCAGCTACGGGGAGAACAACCTGGCCGCCACGGCCACCTCGGCC 15 TGGTACCAGTTACCGCCCCGCAGCCCGGACCGGCCGCTGGTGGTGGTTTCCGCGGCCGCCC CATCTGGTCCTACAAGGAGGACGGCGATTTCATCTACGGCCAGTCCCTGAAACTGCAGTGGGG CGTCACCGGCCCGGACGCCGCATCCAGCCACTGGGGCAGGTATTTCCGATCGACATCGGACC GCAACCGCGTGGCGCAATCTGCGGTTTCCGCTGGCCTGGGCGCCGCCGGAGGCCGACGTGG CGCGCATTGTCGCCTATGACCCGAACCTGAGCCCTGAGCAATGGTTCGCCTTCACCCCGCCCC 20 GGGTTCCGGTGCTGGAATCTCTGCAGCGGTTGATCGGGTCAGCGACACCGGTGTTGATGGACA TCGCGACCGCAGCCAACTTCCCCTGCCAGCGACCGTTTTCCGAGCATCTCGGCATTGCCGAGC TTCCGCAGTACCGGATCCTGCCGGACCACAAGCAGACGGCGGCGTCGTCGAACCTATGGCAGT CCAGCTCGACCGGCGTCCGTTCCTGTTCACCCAGGCGCTGCTGCGCACCTCGACGATCGCCA CGTACCTGCGTGGGACTGGTATCGCGACTGGGGATCGGTGGAGCAGTACCACCGGCTGGTG 25 CCGGCCGATCAGGCTCCAGACGCCGTTGTCGAGGAGGGCGTGATCACTGTGCCCGGCTGGGG TCGGCCAGGACCGATCAGGGCGCTGCCATGA

PCT/US00/31152

5

10

15

20

25

30

35

CGCATCGAGGTCACCTCTACCCACGCCGGCACCTTCGCCAACTTCGTCGGGCTCAAGGACCCG TCGGGCGCGCCGCAGCGCGCCCCGACCCCAACCTGCGCCCGCAGATTGTCGGGGT GTTCACCGACCTGACCGGGCCGCCCCGGGCTGGCGGTCTCGGCGACCATCGACACCC GGTTCTCCACCGGCCGACCACGCTGAAACTGCTGGCGATCATCGGGGCGATCGTGGCCACCG TCCTCCTCAGGCCGTTCCGGCCTGCATCGTCGCCGGGCGGCATGCGCCGGCTGATTCCGGCAA GCTGGCGCACCTTCACCCTGACCGACGCCGTGGTGATATTCGGCTTCCTGCTCTGGCATGTCAT CGGCGCGAATTCGTCGGACGACGGCTACATCCTGGGCATGGCCCGAGTCGCCGACCACGCCG GCTACATGTCCAACTATTTCCGCTGGTTCGGCAGCCCGGAGGATCCCTTCGGCTGGTATTACAA CCTGCTGGCGCTGATGACCCATGTCAGCGACGCCAGTCTGTGGATGCGCCTGCCAGACCTGGC CGCCGGGCTAGTGTGCTGCTGCTGTCGCGTGAGGTGCTGCCCCGCCTCGGGCCGGCGG TGGAGGCCAGCAAACCCGCCTACTGGGCGGCGGCCATGGTCTTGCTGACCGCGTGGATGCCG TTCAACAACGGCCTGCGGCCGGAGGGCATCATCGCGCTCGGCTCGCTGGTCACCTATGTGCTG GCCCGATGCTGCGGATCTTGGTGCGCCGTCATCGCCTGGTCGGCACGTTGCCGTTGGTGTCGC CGATGCTGGCCGCCGGCACCGTCATCCTGACCGTGGTGTTCGCCGACCAGACCCTGTCAACGG TGTTGGAAGCCACCAGGGTTCGCGCCAAAATCGGGCCGAGCCAGGCGTGGTATACCGAGAACC TGCGTTACTACCTCATCCTGCCCACCGTCGACGGTTCGCTGTCGCGGCGCTTCGGCTTTTT GATCACCGCGCTATGCCTGTTCACCGCGGTGTTCATCATGTTGCGGCGCAAGCGAATTCCCAGC GTGGCCGCGGACCGGCGTGGCGCTGATGGGCGTCATCTTCGGCACCATGTTCTTCCTGATG TTCACGCCCACCAAGTGGGTGCACCACTTCGGGCTGTTCGCCGCCGTAGGGGCGGCGATGGC CGCGCTGACGACGGTGTTGGTATCCCCATCGGTGCTGCGCTGGTCGCGCAACCGGATGGCGTT CCTGGCGGCGTTATTCTTCCTGCTGGCGTTGTGTGGGCCACCACCAACGGCTGGTGGTATGTC TCCAGCTACGGTGTGCCGTTCAACAGCGCGATGCCGAAGATCGACGGGATCACAGTCAGCACA ATCTTTTCGCCCTGTTTGCGATCGCCGCCGGCTATGCGGCCTGGCTGCACTTCGCGCCCCGC GGCGCCGGCGAAGGGCGGCTGATCCGCGCGCTGACGACAGCCCCGGTACCGATCGTGGCCG GTTTCATGGCGGCGGTGTTCGTCGCGTCCATGGTGGCCGGGATCGTGCGACAGTACCCGACCT ACTCCAACGCTGGTCCAACGTGCGGGCGTTTGTCGGCGGCTGCGGACTGGCCGACGACGTA CTCGTCGAGCCTGATACCAATGCGGGTTTCATGAAGCCGCTGGACGGCGATTCGGGTTCTTGG GGCCCCTTGGGCCCGCTGGGTGGAGTCAACCCGGTCGGCTTCACGCCCAACGGCGTACCGGA ACACACGGTGGCCGAGGCGATCGTGATGAAACCCAACCAGCCCGGCACCGACTACGACTGGGA TGCGCCGACCAAGCTGACGAGTCCTGGCATCAATGGTTCTACGGTGCCGCTGCCCTATGGGCT CGATCCCGCCCGGGTACCGTTGGCAGGCACCTACACCACCGGCGCACAGCAACAGAGCACACT CGTCTCGGCGTGGTATCTCCTGCCTAAGCCGGACGACGGCCATCCGCTGGTCGTGGTGACCGC CGCGGGCAAGATCGCCGGCAACAGCGTGCTGCACGGGTACACCCCCGGGCAGACTGTGGTGC TCGAATACGCCATGCCGGGACCCGGAGCGCTGGTACCCGCCGGGCGGATGGTGCCCGACGAC

CTATACGAGAGCCCAAGGCGTGGCGCAACCTGCGCTTCGCCCGAGCAAAGATGCCCGC
CGATGCCGTCGCGGTCGGGTGGCCGAGGATCTGTCGCTGACACCGGAGGACTGGATCG
CGGTGACCCCGCCGCGGGTACCGGACCTGCGCTCACTGCAGGAATATGTGGGCTCGACGCAG
CCGGTGCTGCTGGACTGGGCGGTCGGTTTGGCCTTCCCGTGCCAGCAGCCGATGCTGCACGC
CAATGGCATCGCCGAAATCCCGAAGTTCCGCATCACACCGGACTACTCGGCTAAGAAGCTGGAC
ACCGACACGTGGGAAGACGGCACTAACGGCGGCCTGCTCGGGATCACCGACCTGTTGCTGCG
GGCCCACGTCATGGCCACCTACCTGTCCCGCGACTGGGCCCGCGATTGGGGTTCCCTGCGCAA
GTTCGACACCCTGGTCGATGCCCCTCCCGCCCAGCTCGAGTTGGGCACCCGCAGCCG
GCCTGTGGTCACCGGGCAAGATCCGAATTGGTCCATAG

10

15

20

25

30

5

>Rv3834c serS seryl-tRNA synthase TB.seq 4307655:4308911 MW:45293 >emb|AL123456|MTBH37RV:c4308911-4307652, serS SEQ ID NO:145 GTGATCGACCTGAAGCTGCTTCGTGAAAACCCCGACGCGGTACGCCGCTCACAACTCAGCCGC TCTCCGAAGAGCGCCGCGCTGCTGCGGCGCGCGAAGGAACTCGCCGAGCAGGTCAAAGC CGCTGAGGCCGACGAGGCGAAGCGGAGGCGCGCTTCACCGCGGCGCACCTGGCGATCTCGA ATGTCATCGTGGACGGGTACCCGCCGGCGGGGGACGACGACTACGCGGTGCTCGACGTCGTC GGCGAGCCCAGCTACCTCGAGAACCCCAAGGACCACCTGGAGCTCGGCGAGTCGCTGGGCCT GATCGACATGCAGCGCGCCCAAGGTGTCGGGTTCACGGTTCTACTTCCTGACCGGTCGGGG TGCCCTACTGCAGCTTGGATTGCTGCAGCTGGCGCTGAAGCTAGCCGTCGACAACGGCTTTGTC CCTACGATCCCGCCGGTGCTGGTGCGCCCGGAAGTGATGGTAGGCACGGGATTTCTAGGCGCC CACGCCGAGGAGGTGTACCGGGTAGAGGGCGACGGCCTCTACCTTGTGGGCACCTCCGAGGT ACCGCTGGCGGGTATCACTCCGGCGAGATTCTGGACCTTTCCCGCGGGCCGCTGCGGTATGC GGGCTGGTCGTCGTCTTCCGACGTGAGGCCGGCAGCCATGGCAAGGACACGCGCGCATCA TCCGGGTGCACCAGTTCGACAAAGTCGAGGGCTTCGTCTACTGCACACCGGCCGACGCGGAGC ACGAACATGAGCGCTGCTGGCAGCGCCAGATGCTGGCACGCATCGAGGTGCCGTAT CGGGTCATCGACGTGGCCGCGGGTGATCTCGGCTCGTCGGCCCGCCAAGTTCGACTGCGA GGCGTGGATTCCGACGCAGGGGGCCTATCGCGAGCTGACGTCGACGTCGAACTGCACCATT TCAGGCGCCGGTTGGCGACCCGCTACCGGGATGCCAGCGGCAAGCCGCAGATCGCGGCCA CCCTCAACGGAACGCTGGCCACCACCGGTGGCTGGTTGCGATCCTGGAGAACCACCAGCGG CCCGACGCAGCGTTAGAGTCCCGGACGCACTGGTTCCGTTCGTGGGTGTCGAAGTGCTGGAG **CCGGTCGCTTAG** 

35 >Rv3907c pcnA polynucleotide polymerase TB.seq 4391631:4393070 MW:53057 >emb|AL123456|MTBH37RV:c4393070-4391628, pcnA SEQ ID NO:146

GTGCCGGAAGCCGTCCAGGAAGCCGATCTGCTAACCGCCGCTGCGGTTGCCTTGAACAGGCAT GCTGCCTTATTGCGGGAACTCGGGTCGGTGTTCGCCGCGGGGACACGAGTTGTATCTGGTC GGCGGTTCGGTGCGAGATGCACTGTTGGGCCGGTTGAGCCCCGACCTGGACTTCACCACCGAC GCCCGTCCCGAGCGGGTGCAGGAGATCGTGCGGCCGTGGGCCGATGCGGTGTGGGATACCG GAATCGAATTCGGCACCGTCGGCGTGGGTAAGAGCGACCACCGCATGGAGATCACCACATTCC GTGCCGACAGCTACGACCGGGTTTCGCGTCATCCAGAGGTACGTTTCGGCGATTGCCTCGAGG GCGATCTGGTCCGCCGCGACTTCACCACGAACGCAATGGCTGTGCGCGTCACCGCCACTGGGC CGGGCGAATTCCTGGATCCGCTTGGTGGCTTGGCGGCGCTGCGGGCCAAGGTGTTAGACACCC GTCTCGCAACTTGGATTCGCGGTGGCGCCGCGGGGGGGCGATCGAAGAGATGGCGCC GCAGTTGGCCCGAATCAGCGCCGAACGGGTGGCCGCCGAGCTGGACAAGCTGCTGGTCGGTG AGGATCCGGCCGCGGGTATCGACCTGATGGTGCAGAGCGGTATGGGTGCTGTGGTCTTGCCTG AAATCGGTGGGATGCGATGGCGATCGACGAACATCACCAGCACAAGGACGTCTATCAGCATTC CTTGACCGTGCTGCGGCAGGCGATCGCGCTGGAGGACGACGGCCCGGATCTGGTGTTGCGCT GGGCGCGCTGCTGCACGACATCGGCAAGCCCGCCACCCGCCGTCACGAACCCGACGGTGGG GTGAGCTTCCATCACCACGAAGTGGTCGGCGCCAAGATGGTGCGCAAGCGGATGCGGGCGCT GAAGTATTCCAAGCAGATGATCGACGACATCTCGCAGCTGGTCTACCTGCATCTGCGGTTTCAC GGCTACGGCGATGGGAAATGGACCGACTCTGCGGTGCGCCGCTATGTCACCGACGCCGGGGC CCTACTGCCACGGCTGCACAAGCTGGTGCGCGCCGACTGCACGACCCGCAACAAGCGCCGGG CCGCGCGGTTGCAGGCCAGTTACGACCGGCTGGAAGAGCGGATCGCGGAGCTGGCCCCAG GAGGATCTGGATCGGGTGCCCCCGACCTGGACGGCAACCAGATCATGGCGGTGCTCGACATT CCGGCGGGCCCGCAAGTCGGCGAGGCGTGGCGCTACTTGAAGGAGCTGCGGCTAGAGCGCG GCCCGTTGTCCACCGAGGAGGCGACAACCGAGCTGCTGTCCTGGTGGAAATCACGGGGGAAC **CGCTAG** 

25

30

35

20

5

10

15

## TABLE 4

>Rv0002 dnaN DNA polymerase III, b-subunit TB.seq 2052:3257 MW:42114 SEQ ID NO:147 MDAATTRVGLTDLTFRLLRESFADAVSWVAKNLPARPAVPVLSGVLLTGSDNGLTISGFDYEVSAEA QVGAEIVSPGSVLVSGRLLSDITRALPNKPVDVHVEGNRVALTCGNARFSLPTMPVEDYPTLPTLPEE TGLLPAELFAEAISQVAIAAGRDDTLPMLTGIRVEILGETVVLAATDRFRLAVRELKWSASSPDIEAAVL VPAKTLAEAAKAGIGGSDVRLSLGTGPGVGKDGLLGISGNGKRSTTRLLDAEFPKFRQLLPTEHTAVA TMDVAELIEAIKLVALVADRGAQVRMEFADGSVRLSAGADDVGRAEEDLVVDYAGEPLTIAFNPTYLT DGLSSLRSERVSFGFTTAGKPALLRPVSGDDRPVAGLNGNGPFPAVSTDYVYLLMPVRLPG

>Rv0003 recF DNA replication and SOS induction TB.seq 3280:4434 MW:42181 SEQ ID NO:148 VYVRHLGLRDFRSWACVDLELHPGRTVFVGPNGYGKTNLIEALWYSTTLGSHRVSADLPLIRVGTDR AVISTIVVNDGRECAVDLEIATGRVNKARLNRSSVRSTRDVVGVLRAVLFAPEDLGLVRGDPADRRR

YLDDLAIVRRPAIAAVRAEYERVLRQRTALLKSVPGARYRGDRGVFDTLEVWDSRLAEHGAELVAARI DLVNQLAPEVKKAYQLLAPESRSASIGYRASMDVTGPSEQSDIDRQLLAARLLAALAARRDAELERG VCLVGPHRDDLILRLGDQPAKGFASHGEAWSLAVALRLAAYQLLRVDGGEPVLLLDDVFAELDVMRR RALATAAESAEQVLVTAAVLEDIPAGWDARRVHIDVRADDTGSMSVVLP

5

10

15

>Rv0005 gyrB DNA gyrase subunit B TB.seq 5123:7264 MW:78441 SEQ ID NO:149
MGKNEARRSALAPDHGTVVCDPLRRLNRMHATPEESIRIVAAQKKKAQDEYGAASITILEGLEAVRKR
PGMYIGSTGERGLHHLIWEVVDNAVDEAMAGYATTVNVVLLEDGGVEVADDGRGIPVATHASGIPTV
DVVMTQLHAGGKFDSDAYAISGGLHGVGVSVVNALSTRLEVEIKRDGYEWSQVYEKSEPLGLKQGA
PTKKTGSTVRFWADPAVFETTEYDFETVARRLQEMAFLNKGLTINLTDERVTQDEVVDEVVSDVAEA
PKSASERAAESTAPHKVKSRTFHYPGGLVDFVKHINRTKNAIHSSIVDFSGKGTGHEVEIAMQWNAG
YSESVHTFANTINTHEGGTHEEGFRSALTSVVNKYAKDRKLLKDKDPNLTGDDIREGLAAVISVKVSE
PQFEGQTKTKLGNTEVKSFVQKVCNEQLTHWFEANPTDAKVVVNKAVSSAQARIAARKARELVRRK
SATDIGGLPGKLADCRSTDPRKSELYVVEGDSAGGSAKSGRDSMFQAILPLRGKIINVEKARIDRVLK
NTEVQAIITALGTGIHDEFDIGKLRYHKIVLMADADVDGQHISTLLLTLLFRFMRPLIENGHVFLAQPPLY
KLKWQRSDPEFAYSDRERDGLLEAGLKAGKKINKEDGIQRYKGLGEMDAKELWETTMDPSVRVLRQ
VTLDDAAAADELFSILMGEDVDARRSFITRNAKDVRFLDV

20

>RV0006 gyra DNA gyrase subunit A TB.seq 7302:9815 MW:92276 SEQ ID NO:150
MTDTTLPPDDSLDRIEPVDIEQEMQRSYIDYAMSVIVGRALPEVRDGLKPVHRRVLYAMFDSGFRPD
RSHAKSARSVAETMGNYHPHGDASIYDSLVRMAQPWSLRYPLVDGQGNFGSPGNDPPAAMRYTEA
RLTPLAMEMLREIDEETVDFIPNYDGRVQEPTVLPSRFPNLLANGSGGIAVGMATNIPPHNLRELADA
VFWALENHDADEEETLAAVMGRVKGPDFPTAGLIVGSQGTADAYKTGRGSIRMRGVVEVEEDSRG
RTSLVITELPYQVNHDNFITSIAEQVRDGKLAGISNIEDQSSDRVGLRIVIEIKRDAVAKVVINNLYKHTQ
LQTSFGANMLAIVDGVPRTLRLDQLIRYYVDHQLDVIVRRTTYRLRKANERAHILRGLVKALDALDEVI
ALIRASETVDIARAGLIELLDIDEIQAQAILDMQLRRLAALERQRIIDDLAKIEAEIADLEDILAKPERQRGI
VRDELAEIVDRHGDDRRTRIIAADGDVSDEDLIAREDVVVTITETGYAKRTKTDLYRSQKRGGKGVQG
AGLKQDDIVAHFFVCSTHDLILFFTTQGRVYRAKAYDLPEASRTARGQHVANLLAFQPEERIAQVIQIR
GYTDAPYLVLATRNGLVKKSKLTDFDSNRSGGIVAVNLRDNDELVGAVLCSAGDDLLLVSANGQSIR
FSATDEALRPMGRATSGVQGMRFNIDDRLLSLNVVREGTYLLVATSGGYAKRTAIEEYPVQGRGGK
GVLTVMYDRRRGRLVGALIVDDDSELYAVTSGGGVIRTAARQVRKAGRQTKGVRLMNLGEGDTLLAI
ARNAEESGDDNAVDANGADQTGN

30

35

25

>Rv0014c pknB serine-threonine protein kinase TB.seq 15593:17470 MW:66511 SEQ ID NO:151 MTTPSHLSDRYELGEILGFGGMSEVHLARDLRLHRDVAVKVLRADLARDPSFYLRFRREAQNAAALN HPAIVAVYDTGEAETPAGPLPYIVMEYVDGVTLRDIVHTEGPMTPKRAIEVIADACQALNFSHQNGIIH RDVKPANIMISATNAVKVMDFGIARAIADSGNSVTQTAAVIGTAQYLSPEQARGDSVDARSDVYSLGC

VLYEVLTGEPPFTGDSPVSVAYQHVREDPIPPSARHEGLSADLDAVVLKALAKNPENRYQTAAEMRA DLVRVHNGEPPEAPKVLTDAERTSLLSSAAGNLSGPRTDPLPRQDLDDTDRDRSIGSVGRWVAVVA VLAVLTVVVTIAINTFGGITRDVQVPDVRGQSSADAIATLQNRGFKIRTLQKPDSTIPPDHVIGTDPAAN TSVSAGDEITVNVSTGPEQREIPDVSTLTYAEAVKKLTAAGFGRFKQANSPSTPELVGKVIGTNPPAN QTSAITNVVIIIVGSGPATKDIPDVAGQTVDVAQKNLNVYGFTKFSQASVDSPRPAGEVTGTNPPAGT TVPVDSVIELQVSKGNQFVMPDLSGMFWVDAEPRLRALGWTGMLDKGADVDAGGSQHNRVVYQN PPAGTGVNRDGIITLRFGQ

>Rv0016c pbpA TB.seq 18762:20234 MW:51577 SEQ ID NO:152

10 MNASLRRISVTVMALIVLLLLNATMTQVFTADGLRADPRNQRVLLDEYSRQRGQITAGGQLLAYS,VAT DGRFRFLRVYPNPEVYAPVTGFYSLRYSSTALERAEDPILNGSDRRLFGRRLADFFTGRDPRGGNV DTTINPRIQQAGWDAMQQGCYGPCKGAVVALEPSTGKILALVSSPSYDPNLLASHNPEVQAQAWQR LGDNPASPLTNRAISETYPPGSTFKVITTAAALAAGATETEQLTAAPTIPLPGSTAQLENYGGAPCGDE PTVSLREAFVKSCNTAFVQLGIRTGADALRSMARAFGLDSPPRPTPLQVAESTVGPIPDSAALGMTSI GQKDVALTPLANAEIAATIANGGITMRPYLVGSLKGPDLANISTTVGYQQRRAVSPQVAAKLTELMVG AEKVAQQKGAIPGVQIASKTGTAEHGTDPRHTPPHAWYIAFAPAQAPKVAVAVLVENGADRLSATGG ALAAPIGRAVIEAALQGEP

>Rv0017c rodA TB.seq 20234:21640 MW:50612 SEQ ID NO:153

20 MTTRLQAPVAVTPPLPTRRNAELLLLCFAAVITFAALLVVQANQDQGVPWDLTSYGLAFLTLFGSAHL AIRRFAPYTDPLLLPVVALLNGLGLVMIHRLDLVDNEIGEHRHPSANQQMLWTLVGVAAFALVVTFLK DHRQLARYGYICGLAGLVFLAVPALLPAALSEQNGAKIWIRLPGFSIQPAEFSKILLLIFFSAVLVAKRG LFTSAGKHLLGMTLPRPRDLAPLLAAWVISVGVMVFEKDLGASLLLYTSFLVVVYLATQRFSWVVIGL TLFAAGTLVAYFIFEHVRLRVQTWLDPFADPDGTGYQIVQSLFSFATGGIFGTGLGNGQPDTVPAAST DFIIAAFGEELGLVGLTAILMLYTIVIIRGLRTAIATRDSFGKLLAAGLSSTLAIQLFIVVGGVTRLIPLTGLT TPWMSYGGSSLLANYILLAILARISHGARRPLRTRPRNKSPITAAGTEVIERV

>RV0018c ppp TB.seq 21640:23181 MW:53781 SEQ ID NO:154

VARVTLVLRYAARSDRGLVRANNEDSVYAGARLLALADGMGGHAAGEVASQLVIAALAHLDDDEPG
GDLLAKLDAAVRAGNSAIAAQVEMEPDLEGMGTTLTAILFAGNRLGLVHIGDSRGYLLRDGELTQITK
DDTFVQTLVDEGRITPEEAHSHPQRSLIMRALTGHEVEPTLTMREARAGDRYLLCSDGLSDPVSDETI
LEALQIPEVAESAHRLIELALRGGGPDNVTVVVADVVDYDYGQTQPILAGAVSGDDDQLTLPNTAAG
RASAISQRKEIVKRVPPQADTFSRPRWSGRRLAFVVALVTVLMTAGLLIGRAIIRSNYYVADYAGSVSI
MRGIQGSLLGMSLHQPYLMGCLSPRNELSQISYGQSGGPLDCHLMKLEDLRPPERAQVRAGLPAGT
LDDAIGQLRELAANSLLPPCPAPRATSPPGRPAPPTTSETTEPNVTSSPASPSPTTSAPAPTGTTPAIP
TSASPAAPASPPTPWPVTSSPTMAALPPPPPQPGIDCRAAA

30

35

>Rv0019c - TB.s q 23273:23737 MW:17153 SEQ ID NO:155 MQGLVLQLTRAGFLMLLWVFIWSVLRILKTDIYAPTGAVMMRRGLALRGTLLGARQRRHAARYLVVT EGALTGARITLSEQPVLIGRADDSTLVLTDDYASTRHARLSMRGSEWYVEDLGSTNGTYLDRAKVTT AVRVPIGTPVRIGKTAIELRP

5

10

15

>Rv0020c - TB.seq 23864:25444 MW:56881 SEQ ID NO:156 MGSQKRLVQRVERKLEQTVGDAFARIFGGSIVPQEVEALLRREAADGIQSLQGNRLLAPNEYIITLGV HDFEKLGADPELKSTGFARDLADYIQEQGWQTYGDVVVRFEQSSNLHTGQFRARGTVNPDVETHP PVIDCARPQSNHAFGAEPGVAPMSDNSSYRGGQGQGRPDEYYDDRYARPQEDPRGGPDPQGGS DPRGGYPPETGGYPPQPGYPRPRHPDQGDYPEQIGYPDQGGYPEQRGYPEQRGYPDQRGYQDQ GRGYPDQGQGGYPPPYEQRPPVSPGPAAGYGAPGYDQGYRQSGGYGPSPGGGQPGYGGYGEY GRGPARHEEGSYVPSGPPGPPEQRPAYPDQGGYDQGYQQGATTYGRQDYGGGADYTRYTESPR VPGYAPQGGGYAEPAGRDYDYGQSGAPDYGQPAPGGYSGYGQGGYGSAGTSVTLQLDDGSGRT YQLREGSNIIGRGQDAQFRLPDTGVSRRHLEIRWDGQVALLADLNSTNGTTVNNAPVQEWQLADGD VIRLGHSEIIVRMH

>Rv0032 bioF2 C-terminal similar to B. subtilis BioF TB.seq 34295:36607 MW:86245 **SEQ ID NO:157** 

MPTGLGYDFLRPVEDSGINDLKHYYFMADLADGQPLGRANLYSVCFDLATTDRKLTPAWRTTIKRWF PGFMTFRFLECGLLTMVSNPLALRSDTDLERVLPVLAGQMDQLAHDDGSDFLMIRDVDPEHYQRYL 20 DILRPLGFRPALGFSRVDTTISWSSVEEALGCLSHKRRLPLKTSLEFRERFGIEVEELDEYAEHAPVLA RLWRNVKTEAKDYQREDLNPEFFAACSRHLHGRSRLWLFRYQGTPIAFFLNVWGADENYILLEWGI DRDFEHYRKANLYRAALMLSLKDAISRDKRRMEMGITNYFTKLRIPGARVIPTIYFLRHSTDPVHTATL ARMMMHNIQRPTLPDDMSEEFCRWEERIRLDQDGLPEHDIFRKIDRQHKYTGLKLGGVYGFYPRFT GPQRSTVKAAELGEIVLLGTNSYLGLATHPEVVEASAEATRRYGTGCSGSPLLNGTLDLHVSLEQEL 25 ACFLGKPAAVLCSTGYQSNLAAISALCESGDMIIQDALNHRSLFDAARLSGADFTLYRHNDMDHLARV LRRTEGRRRIIVVDAVFSMEGTVADLATIAELADRHGCRVYVDESHALGVLGPDGRGASAALGVLAR MDVVMGTFSKSFASVGGFIAGDRPVVDYIRHNGSGHVFSASLPPAAAAATHAALRVSRREPDRRAR VLAAAEYMATGLARQGYQAEYHGTAIVPVILGNPTVAHAGYLRLMRSGVYVNPVAPPAVPEERSGFR TSYLADHRQSDLDRALHVFAGLAEDLTPQGAAL

30

>Rv0050 ponA1 TB.seq 53661:55694 MW:71119 SEQ ID NO:158 VVILLPMVTFTMAYLIVDVPKPGDIRTNQVSTILASDGSEIAKIVPPEGNRVDVNLSQVPMHVRQAVIAA EDRNFYSNPGFSFTGFARAVKNNLFGGDLQGGSTITQQYVKNALVGSAQHGWSGLMRKAKELVIAT KMSGEWSKDDVLQAYLNIIYFGRGAYGISAASKAYFDKPVEQLTVAEGALLAALIRRPSTLDPAVDPE GAHARWNWVLDGMVETKALSPNDRAAQVFPETVPPDLARAENQTKGPNGLIERQVTRELLELFNID EQTLNTQGLVVTTTIDPQAQRAAEKAVAKYLDGQDPDMRAAVVSIDPHNGAVRAYYGGDNANGFDF

5

AQAGLQTGSSFKVFALVAALEQGIGLGYQVDSSPLTVDGIKITNVEGEGCGTCNIAEALKMSLNTSYY RLMLKLNGGPQAVADAAHQAGIASSFPGVAHTLSEDGKGGPPNNGIVLGQYQTRVIDMASAYATLAA SGIYHPPHFVQKVVSANGQVLFDASTADNTGDQRIPKAVADNVTAAMEPIAGYSRGHNLAGGRDSA AKTGTTQFGDTTANKDAWMVGYTPSLSTAVWVGTVKGDEPLVTASGAAIYGSGLPSDIWKATMDGA LKGTSNETFPKPTEVGGYAGVPPPPPPEVPPSETVIQPTVEIAPGITIPIGPPTTITLAPPPPAPPAAT PTPPP

>Rv0051 - TB.seq 55694:57373 MW:61210 SEQ ID NO:159

VTGALSQSSNISPLPLAADLRSADNRDCPSRTDVLGAALANVVGGPVGRHALIGRTRLMTPLRVMFAI

ALVFLALGWSTKAACLQSTGTGPGDQRVANWDNQRAYYQLCYSDTVPLYGAELLSQGKFPYKSSWI

ETDSNGTPQLRYDGQIAVRYMEYPVLTGIYQYLSMAIAKTYTALSKVAPLPVVAEVVMFFNVAAFGLA

LAWLTTVWATSGLAGRRIWDAALVAASPLVIFQIFTNFDALATGLATSGLLAWARRRPVLAGVLIGLG

SAAKLYPLLFLYPLLLLGIRAGRLNALARTMAAAAATWLLVNLPVMLLFPRGWSEFFRLNTRRGDDM

DSLYNVVKSFTGWRGFDPTLGFWEPPLVLNTVVTLLFVLCCAAIAYIALTAPHRPRVAQLTFLTVASFL

LVNKVWSPQFSLWLVPLAVLALPHRRILLAWMTIDALVWVPRMYYLYGNPSRSLPEQWFTTTVLLRD

IAVMVLCGLVVWQIYRPGRDLVRTGGPGALPACGGVDDPVGGVFANAADAPPGRLPSWLRPRLGD

EHARERTPDAGRDRTFSGQHRA

>Rv0106 - TB.seq 124372:125565 MW:43701 SEQ ID NO:160

MRTPVILVAGQDHTDEVTGALLRRTGTVVVEHRFDGHVVRRMTATLSRGELITTEDALEFAHGCVSC
TIRDDLLVLLRRLHRRDNVGRIVVHLAPWLEPQPICWAIDHVRVCVGHGYPDGPAALDVRVAAVVTC
VDCVRWLPQSLGEDELPDGRTVAQVTVGQAEFADLLVLTHPEPVAVAVLRRLAPRARITGGVDRVEL
ALAHLDDNSRRGRTDTPHTPLLAGLPPLAADGEVAIVEFSARRPFHPQRLHAAVDLLLDGVVRTRGR
LWLANRPDQVMWLESAGGGLRVASAGKWLAAMAASEVAYVDLERRLFADLMWVYPFGDRHTAMT
VLVCGADPTDIVNALNAALLSDDEMASPQRWQSYVDPFGDWHDDPCHEMPDAAGEFSAHRNSGES
R

>Rv0125 - TB.seq 151146:152210 MW:34927 SEQ ID NO:161

MSNSRRRSLRWSWLLSVLAAVGLGLATAPAQAAPPALSQDRFADFPALPLDPSAMVAQVGPQVVNI
NTKLGYNNAVGAGTGIVIDPNGVVLTNNHVIAGATDINAFSVGSGQTYGVDVVGYDRTQDVAVLQLR
GAGGLPSAAIGGGVAVGEPVVAMGNSGGQGGTPRAVPGRVVALGQTVQASDSLTGAEETLNGLIQ
FDAAIQPGDSGGPVVNGLGQVVGMNTAASDNFQLSQGGQGFAIPIGQAMAIAGQIRSGGGSPTVHI
GPTAFLGLGVVDNNGNGARVQRVVGSAPAASLGISTGDVITAVDGAPINSATAMADALNGHHPGDVI
SVTWQTKSGGTRTGNVTLAEGPPA

>Rv0350 dnaK 70 kD heat shock protein, chromosome replication TB.seq 419833:421707 MW:66832 SEQ ID NO:162

30

MARAVGIDLGTTNSVVSVLEGGDPVVVANSEGSRTTPSIVAFARNGEVLVGQPAKNQAVTNVDRTV
RSVKRHMGSDWSIEIDGKKYTAPEISARILMKLKRDAEAYLGEDITDAVITTPAYFNDAQRQATKDAG
QIAGLNVLRIVNEPTAAALAYGLDKGEKEQRILVFDLGGGTFDVSLLEIGEGVVEVRATSGDNHLGGD
DWDQRVVDWLVDKFKGTSGIDLTKDKMAMQRLREAAEKAKIELSSSQSTSINLPYITVDADKNPLFLD
EQLTRAEFQRITQDLLDRTRKPFQSVIADTGISVSEIDHVVLVGGSTRMPAVTDLVKELTGGKEPNKG
VNPDEVVAVGAALQAGVLKGEVKDVLLLDVTPLSLGIETKGGVMTRLIERNTTIPTKRSETFTTADDN
QPSVQIQVYQGEREIAAHNKLLGSFELTGIPPAPRGIPQIEVTFDIDANGIVHVTAKDKGTGKENTIRIQ
EGSGLSKEDIDRMIKDAEAHAEEDRKRREEADVRNQAETLVYQTEKFVKEQREAEGGSKVPEDTLN
KVDAAVAEAKAALGGSDISAIKSAMEKLGQESQALGQAIYEAAQAASQATGAAHPGGEPGGAHPGS
ADDVVDAEVVDDGREAK

>Rv0351 grpE stimulates DnaK ATPase activity TB.seq 421707:422411 MW:24501 SEQ ID NO:163

VTDGNQKPDGNSGEQVTVTDKRRIDPETGEVRHVPPGDMPGGTAAADAAHTEDKVAELTADLQRV

15 QADFANYRKRALRDQQAAADRAKASVVSQLLGVLDDLERARKHGDLESGPLKSVADKLDSALTGLG
LVAFGAEGEDFDPVLHEAVQHEGDGGQGSKPVIGTVMRQGYQLGEQVLRHALVGVVDTVVVDAAE
LESVDDGTAVADTAENDQADQGNSADTSGEQAESEPSGS

>Rv0352 dnaJ acts with GrpE to stimulate DnaK ATPase TB.seq 422450:423634 MW:41346 SEQ ID NO:164

MAQREWVEKDFYQELGVSSDASPEEIKRAYRKLARDLHPDANPGNPAAGERFKAVSEAHNVLSDPA
KRKEYDETRRLFAGGGFGGRRFDSGFGGGFGVGGDGAEFNLNDLFDAASRTGGTTIGDLFGG
LFGRGGSARPSRPRRGNDLETETELDFVEAAKGVAMPLRLTSPAPCTNCHGSGARPGTSPKVCPTC
NGSGVINRNQGAFGFSEPCTDCRGSGSIIEHPCEECKGTGVTTRTRTINVRIPPGVEDGQRIRLAGQ
GEAGLRGAPSGDLYVTVHVRPDKIFGRDGDDLTVTVPVSFTELALGSTLSVPTLDGTVGVRVPKGTA
DGRILRVRGRGVPKRSGGSGDLLVTVKVAVPPNLAGAAQEALEAYAAAERSSGFNPRAGWAGNR
>Rv0363c fba fructose bisphosphate aldolase TB.seq 441266:442297 MW:36545

SEQ ID NO:165

MPIATPEVYAEMLGQAKQNSYAFPAINCTSSETVNAAIKGFADAGSDGIIQFSTGGAEFGSGLGVKDM

VTGAVALAEFTHVIAAKYPVNVALHTDHCPKDKLDSYVRPLLAISAQRVSKGGNPLFQSHMWDGSAV

PIDENLAIAQELLKAAAAAKIILEIEIGVVGGEEDGVANEINEKLYTSPEDFEKTIEALGAGEHGKYLLAA

TFGNVHGVYKPGNVKLRPDILAQGQQVAAAKLGLPADAKPFDFVFHGGSGSLKSEIEEALRYGVVKM

NVDTDTQYAFTRPIAGHMFTNYDGVLKVDGEVGVKKVYDPRSYLKKAEASMSQRVVQACNDLHCA

GKSLTH

35 >Rv0405 pks6 TB.seq 485729:489934 MW:147615 SEQ ID NO:166 MTDGSVTADKLQKWFREYLSTHIECHPNEVSLDVPIRDLGLKSIDVLAIPGDLGDRFGFCIPDLAVWD NPSANDLIDSLLNQRSADSLRESHGHADRNTQGRGSINEPVAVIGVGCRFPGDIDGPERLWDFLTEK

20

KCAITAYPDRGFTNAGTFAESGGFLKDVAGFDNRFFDIPPDEALRMDPQQRLLLEVSWEALEHAGIIP ESLRLSRTGVFVGVSSTDYVRLVSASAQQKSTIWDNTGGSSSIIANRISYFLDIQGPSIVIDTACSSSLV AVHLACRSLSTWDCDIALVGGTNVLISPEPWGGFREAGILSQTGCCHAFDKSADGMVRGEGCGVIVL QRLSDARLEGRRILAILTGSAVNQDGKSNGIMAPNPSAQIGVLENACKSARVDPLEIGYVEAHGTGTS LGDRIEAHALGMVFGRKRPGSGPLMIGSIKPNIGHLEGAAGIAGLIKAVLMVERGSLLPSGGFTEPNP 5 AIPFTELGLRVVDELQEWPVVAGRPRRAGVSSFGFGGTNAHVIVEEAGSVGADTVSGRADVGGSGG GVVAWVISGKTASALAAQAGRLGRYVRARPALDVVDVGYSLVSTRSVFDHRAVVVGQTRDELLAGL AGVVAGRPEAGVVCGVGKPAGKTAFVFAGQGSQWLGMGSELYAAYPVFAEALDAVVDELDRHLRY PLRDVIWGHDQDLLNTTEFAQPALFAVEVALYRLLMSWGVRPGLVLGHSVGELAAAHVAGALCLPD AAMLVAARGRLMQALPAGGAMFAVQAREDEVAPMLGHDVSIAAVNGPASVVISGAHDAVSAIADRL 10 RGQGRRVHRLAVSHAFHSALMEPMIAEFTAVAAELSVGLPTIPVISNVTGQLVADDFASADYWARHIR AVVRFGDSVRSAHCAGASRFIEVGPGGGLTSLIEASLADAQIVSVPTLRKDRPEPVSVMTAAAQGFV SGMGLDWASVFSGYRPKRVELPTYAFQHQKFWLAPAPSVSDPTAAGQIGASDGGAELLASSGFAA RLAGRSADEQLAAAIEVVCEHAAAVLGRDGAAGLDAGQAFADSGFNSLSAVELRNRLTAVTAVTLPA TAIFDHPTPTELAQYLITQIDGHGSSAAAAANPAERIDALTDLFLQACDAGRDADGWKMVALASNTRE 15 RMSSPVRNNVSKNVALLADGISDVVVICIPTLTVLSDQREYRDIANAMTGRHSVYSLTLPGFDSSDAL PQNADMIVETVSNAIIDVVGGSCRFVLSGYSSGGVLAYALCSHLSVKHQRNPLGVALIDTYLPSQIAN PSMNEGFSPNDTGKGLSREVIRVARMLNRLTATRLTAAATYAAIFQAWEPGRSMAPVLNIVAKDRIAT VENLREERINRWRTAAAEAAYSVAEVPGDHFGMMSTSSEAIATEIHDWISGLVRGPHR

20

25

30

>Rv0435c - ATPase of AAA-family TB.seq 522348:524531 MW:75315 SEQ ID NO:167
VTHPDPARQLTLTARLNTSAVDSRRGVVRLHPNAIAALGIREWDAVSLTGSRTTAAVAGLAAADTAV
GTVLLDDVTLSNAGLREGTEVIVSPVTVYGARSVTLSGSTLATQSVPPVTLRQALLGKVMTVGDAVSL
LPRDLGPGTSTSAASRALAAAVGISWTSELLTVTGVDPDGPVSVQPNSLVTWGAGVPAAMGTSTAG
QVSISSPEIQIEELKGAQPQAAKLTEWLKLALDEPHLLQTLGAGTNLGVLVSGPAGVGKATLVRAVCD
GRRLVTLDGPEIGALAAGDRVKAVASAVQAVRHEGGVLLITDADALLPAAAEPVASLILSELRTAVATA
GVVLIATSARPDQLDARLRSPELCDRELGLPLPDAATRKSLLEALLNPVPTGDLNLDEIASRTPGFVVA
DLAALVREAALRAASRASADGRPPMLHQDDLLGALTVIRPLSRSASDEVTVGDVTLDDVGDMAAAK
QALTEAVLWPLQHPDTFARLGVEPPRGVLLYGPPGCGKTFVVRALASTGQLSVHAVKGSELMDKWV
GSSEKAVRELFRRARDSAPSLVFLDELDALAPRRGQSFDSGVSDRVVAALLTELDGIDPLRDVVMLG
ATNRPDLIDPALLRPGRLERLVFVEPPDAAARREILRTAGKSIPLSSDVDLDEVAAGLDGYSAADCVAL
LREAALTAMRRSIDAANVTAADLATARETVRASLDPLQVASLRKFGTKGDLRS

>Rv0436c pssA CDP-diacylglycerol-serine o-phosphatidyltransferase TB.seq 524531:525388

35 MW:31219 SEQ ID NO:168

MIGKPRGRRGVNLQILPSAMTVLSICAGLTAIKFALEHQPKAAMALIAAAAILDGLDGRVARILDAQSR

MGAEIDSLADAVNFGVTPALVLYVSMLSKWPVGWVVVLLYAVCVVLRLARYNALQDDGTQPAYAHE

FFVGMPAPAGAVSMIGLLALKMQFGEGWWTSGWFLSFWVTGTSILLVSGIPMKKMHAVSVPPNYAA ALLAVLAICAAAAVLAPYLLIWVIIIAYMCHIPFAVRSQRWLAQHPEVWDDKPKQRRAVRRASRRAHP YRPSMARLGLRKPGRRL

- >Rv0440 groEl 260 kD chaperonin 2 TB.seq 528606:530225 MW:56728 SEQ ID NO:169
   MAKTIAYDEEARRGLERGLNALADAVKVTLGPKGRNVVLEKKWGAPTITNDGVSIAKEIELEDPYEKI
   GAELVKEVAKKTDDVAGDGTTTATVLAQALVREGLRNVAAGANPLGLKRGIEKAVEKVTETLLKGAK
   EVETKEQIAATAAISAGDQSIGDLIAEAMDKVGNEGVITVEESNTFGLQLELTEGMRFDKGYISGYFVT
   DPERQEAVLEDPYILLVSSKVSTVKDLLPLLEKVIGAGKPLLIIAEDVEGEALSTLVVNKIRGTFKSVAVK
   APGFGDRRKAMLQDMAILTGGQVISEEVGLTLENADLSLLGKARKVVVTKDETTIVEGAGDTDAIAGR
   VAQIRQEIENSDSDYDREKLQERLAKLAGGVAVIKAGAATEVELKERKHRIEDAVRNAKAAVEEGIVA
   GGGVTLLQAAPTLDELKLEGDEATGANIVKVALEAPLKQIAFNSGLEPGVVAEKVRNLPAGHGLNAQT
   GVYEDLLAAGVADPVKVTRSALQNAASIAGLFLTTEAVVADKPEKEKASVPGGGDMGGMDF
- >Rv0482 murß TB.seq 570537:571643 MW:38522 SEQ ID NO:170
   MKRSGVGSLFAGAHIAEAVPLAPLTTLRVGPIARRVITCTSAEQVVAALRHLDSAAKTGADRPLVFAG
   GSNLVIAENLTDLTVVRLANSGITIDGNLVRAEAGAVFDDVVVRAIEQGLGGLECLSGIPGSAGATPVQ
   NVGAYGAEVSDTITRVRLLDRCTGEVRWVSARDLRFGYRTSVLKHADGLAVPTVVLEVEFALDPSGR
   SAPLRYGELIAALNATSGERADPQAVREAVLALRARKGMVLDPTDHDTWSVGSFFTNPVVTQDVYE
   RLAGDAATRKDGPVPHYPAPDGVKLAAGWLVERAGFGKGYPDAGAAPCRLSTKHALALTNRGGAT
   AEDVVTLARAVRDGVHDVFGITLKPEPVLIGCML
- >Rv0483 TB.seq 571708:573060 MW:47859 SEQ ID NO:171

  VVIRVLFRPVSLIPVNNSSTPQSQGPISRRLALTALGFGVLAPNVLVACAGKVTKLAEKRPPPAPRLTF

  RPADSAADVVPIAPISVEVGDGWFQRVALTNSAGKVVAGAYSRDRTIYTITEPLGYDTTYTWSGSAV

  GHDGKAVPVAGKFTTVAPVKTINAGFQLADGQTVGIAAPVIIQFDSPISDKAAVERALTVTTDPPVEGG

  WAWLPDEAQGARVHWRPREYYPAGTTVDVDAKLYGLPFGDGAYGAQDMSLHFQIGRRQVVKAEV

  SSHRIQVVTDAGVIMDFPCSYGEADLARNVTRNGIHVVTEKYSDFYMSNPAAGYSHIHERWAVRISN

  NGEFIHANPMSAGAQGNSNVTNGCINLSTENAEQYYRSAVYGDPVEVTGSSIQLSYADGDIWDWAV

  DWDTWVSMSALPPPAAKPAATQIPVTAPVTPSDAPTPSGTPTTTNGPGG
  - >Rv0489 gpm phosphoglycerate mutase i TB.seq 578424:579170 MW:27217 SEQ ID NO:172 MANTGSLVLLRHGESDWNALNLFTGWVDVGLTDKGQAEAVRSGELIAEHDLLPDVLYTSLLRRAITT AHLALDSADRLWIPVRRSWRLNERHYGALQGLDKAETKARYGEEQFMAWRRSYDTPPPPIERGSQ FSQDADPRYADIGGGPLTECLADVVARFLPYFTDVIVGDLRVGKTVLIVAHGNSLRALVKHLDQMSDD EIVGLNIPTGIPLRYDLDSAMRPLVRGGTYLDPEAAAAGAAAVAGQGRG

>Rv0490 senX 3sensor histidine kinase TB.seq 579347:580576 MW:44794 SEQ ID NO:173
VTVFSALLLAGVLSALALAVGGAVGMRLTSRVVEQRQRVATEWSGITVSQMLQCIVTLMPLGAAVVD
THRDVVYLNERAKELGLVRDRQLDDQAWRAARQALGGEDVEFDLSPRKRSATGRSGLSVHGHARL
LSEEDRRFAVVFVHDQSDYARMEAARRDFVANVSHELKTPVGAMALLAEALLASADDSETVRRFAE
KVLIEANRLGDMVAELIELSRLQGAERLPNMTDVDVDTIVSEAISRHKVAADNADIEVRTDAPSNLRVL
GDQTLLVTALANLVSNAIAYSPRGSLVSISRRRRGANIEIAVTDRGIGIAPEDQERVFERFFRGDKARS
RATGGSGLGLAIVKHVAANHDGTIRVWSKPGTGSTFTLALPALIEAYHDDERPEQAREPELRSNRSQ
REEELSR

- >Rv0500 proC pyrroline-5-carboxylate reductase TB.seq 590081:590965 MW:30172
  SEQ ID NO:174
  MLFGMARIAIIGGGSIGEALLSGLLRAGRQVKDLVVAERMPDRANYLAQTYSVLVTSAADAVENATFV
  VVAVKPADVEPVIADLANATAAAENDSAEQVFVTVVAGITIAYFESKLPAGTPVVRAMPNAAALVGAG
  VTALAKGRFVTPQQLEEVSALFDAVGGVLTVPESQLDAVTAVSGSGPAYFFLLVEALVDAGVGVGLS
  RQVATDLAAQTMAGSAAMLLERMEQDQGGANGELMGLRVDLTASRLRAAVTSPGGTTAAALRELE
  RGGFRMAVDAAVQAAKSRSEQLRITPE
- >Rv0528 TB.seq 618303:619889 MW:57132 SEQ ID NO:175

  MWRSLTSMGTALVLLFLLALAAIPGALLPQRGLNAAKVDDYLAAHPLIGPWLDELQAFDVFSSFWFTA

  1YVLLFVSLVGCLAPRTIEHARSLRATPVAAPRNLARLPKHAHARLAGEPAALAATITGRLRGWRSITR
  QQGDSVEVSAEKGYLREFGNLVFHFALLGLLVAVAVGKLFGYEGNVIVIADGGPGFCSASPAAFDSF
  RAGNTVDGTSLHPICVRVNNFQAHYLPSGQATSFAADIDYQADPATADLIANSWRPYRLQVNHPLRV
  GGDRVYLQGHGYAPTFTVTFPDGQTRTSTVQWRPDNPQTLLSAGVVRIDPPAGSYPNPDERRKHQI
  AIQGLLAPTEQLDGTLLSSRFPALNAPAVAIDIYRGDTGLDSGRPQSLFTLDHRLIEQGRLVKEKRVNL
  RAGQQVRIDQGPAAGTVVRFDGAVPFVNLQVSHDPGQSWVLVFAITMMAGLLVSLLVRRRRVWARI
  TPTTAGTVNVELGGLTRTDNSGWGAEFERLTGRLLAGFEARSPDMAEAAAGTGRDVD
  - >Rv0667 rpoB [beta] subunit of RNA polymerase TB.seq 759805:763320 MW:129220 SEQ ID NO:176
- LADSRQSKTAASPSPSRPQSSSNNSVPGAPNRVSFAKLREPLEVPGLLDVQTDSFEWLIGSPRWRE SAAERGDVNPVGGLEEVLYELSPIEDFSGSMSLSFSDPRFDDVKAPVDECKDKDMTYAAPLFVTAEF INNNTGEIKSQTVFMGDFPMMTEKGTFIINGTERVVVSQLVRSPGVYFDETIDKSTDKTLHSVKVIPSR GAWLEFDVDKRDTVGVRIDRKRRQPVTVLLKALGWTSEQIVERFGFSEIMRSTLEKDNTVGTDEALL DIYRKLRPGEPPTKESAQTLLENLFFKEKRYDLARVGRYKVNKKLGLHVGEPITSSTLTEEDVVATIEY LVRLHEGQTTMTVPGGVEVPVETDDIDHFGNRRLRTVGELIQNQIRVGMSRMERVVRERMTTQDVE AITPQTLINIRPVVAAIKEFFGTSQLSQFMDQNNPLSGLTHKRRLSALGPGGLSRERAGLEVRDVHPS HYGRMCPIETPEGPNIGLIGSLSVYARVNPFGFIETPYRKVVDGVVSDEIVYLTADEEDRHVVAQANS

PCT/US00/31152

5

10

15

20

25

30

PIDADGRFVEPRVLVRRKAGEVEYVPSSEVDYMDVSPRQMVSVATAMIPFLEHDDANRALMGANMQ RQAVPLVRSEAPLVGTGMELRAAIDAGDVVVAEESGVIEEVSADYITVMHDNGTRRTYRMRKFARSN HGTCANQCPIVDAGDRVEAGQVIADGPCTDDGEMALGKNLLVAIMPWEGHNYEDAIILSNRLVEEDV LTSIHIEEHEIDARDTKLGAEEITRDIPNISDEVLADLDERGIVRIGAEVRDGDILVGKVTPKGETELTPE ERLLRAIFGEKAREVRDTSLKVPHGESGKVIGIRVFSREDEDELPAGVNELVRVYVAQKRKISDGDKL AGRHGNKGVIGKILPVEDMPFLADGTPVDIILNTHGVPRRMNIGQILETHLGWCAHSGWKVDAAKGV PDWAARLPDELLEAQPNAIVSTPVFDGAQEAELQGLLSCTLPNRDGDVLVDADGKAMLFDGRSGEP FPYPVTVGYMYIMKLHHLVDDKIHARSTGPYSMITQQPLGGKAQFGGQRFGEMECWAMQAYGAAY TLQELLTIKSDDTVGRVKVYEAÏVKGENIPEPGIPESFKVLLKELQSLCLNVEVLSSDGAAIELREGEDE DLERAAANLGINLSRNESASVEDLA

>Rv0668 rpoC [beta]' subunit of RNA polymerase TB.seq 763368:767315 MW:146740 SEQ ID NO:177

VLDVNFFDELRIGLATAEDIRQWSYGEVKKPETINYRTLKPEKDGLFCEKIFGPTRDWECYCGKYKRV RFKGIICERCGVEVTRAKVRRERMGHIELAAPVTHIWYFKGVPSRLGYLLDLAPKDLEKIIYFAAYVITS VDEEMRHNELSTLEAEMAVERKAVEDQRDGELEARAQKLEADLAELEAEGAKADARRKVRDGGER EMRQIRDRAQRELDRLEDIWSTFTKLAPKQLIVDENLYRELVDRYGEYFTGAMGAESIQKLIENFDIDA EAESLRDVIRNGKGQKKLRALKRLKVVAAFQQSGNSPMGMVLDAVPVIPPELRPMVQLDGGRFATS DLNDLYRRVINRNNRLKRLIDLGAPEIIVNNEKRMLQESVDALFDNGRRGRPVTGPGNRPLKSLSDLL KGKQGRFRQNLLGKRVDYSGRSVIVVGPQLKLHQCGLPKLMALELFKPFVMKRLVDLNHAQNIKSAK RMVERQRPQVWDVLEEVIAEHPVLLNRAPTLHRLGIQAFEPMLVEGKAIQLHPLVCEAFNADFDGDQ MAVHLPLSAEAQAEARILMLSSNNILSPASGRPLAMPRLDMVTGLYYLTTEVPGDTGEYQPASGDHP ETGVYSSPAEAIMAADRGVLSVRAKIKVRLTQLRPPVEIEAELFGHSGWQPGDAWMAETTLGRVMF NELLPLGYPFVNKQMHKKVQAAIINDLAERYPMIVVAQTVDKLKDAGFYWATRSGVTVSMADVLVPP RKKEILDHYEERADKVEKQFQRGALNHDERNEALVEIWKEATDEVGQALREHYPDDNPIITIVDSGAT GNFTQTRTLAGMKGLVTNPKGEFIPRPVKSSFREGLTVLEYFINTHGARKGLADTALRTADSGYLTRR LVDVSQDVIVREHDCQTERGIVVELAERAPDGTLIRDPYIETSAYARTLGTDAVDEAGNVIVERGQDL GDPEIDALLAAGITQVKVRSVLTCATSTGVCATCYGRSMATGKLVDIGEAVGIVAAQSIGEPGTQLTM RTFHQGGVGEDITGGLPRVQELFEARVPRGKAPIADVTGRVRLEDGERFYKITIVPDDGGEEVVYDKI SKRQRLRVFKHEDGSERVLSDGDHVEVGQQLMEGSADPHEVLRVQGPREVQIHLVREVQEVYRAQ GVSIHDKHIEVIVRQMLRRVTIIDSGSTEFLPGSLIDRAEFEAENRRVVAEGGEPAAGRPVLMGITKAS LATDSWLSAASFQETTRVLTDAAINCRSDKLNGLKENVIIGKLIPAGTGINRYRNIAVQPTEEARAAAYT **IPSYEDQYYSPDFGAATGAAVPLDDYGYSDYR** 

35 >Rv0711 atsA TB.seq 806333:808693 MW:86216 SEQ ID NO:178 MAPEATEAFNGTIELDIRDSEPDWGPYAAPVAPEHSPNILYLVWDDVGIATWDCFGGLVEMPAMTRV AERGVRLSQFHTTALCSPTRASLLTGRNATTVGMATIEEFTDGFPNCNGRIPADTALLPEVLAEHGYN

TYCVGKWHLTPLEESNMASTKRHWPTSRGFERFYGFLGGETDQWYPDLVYDNHPVSPPGTPEGG
YHLSKDIADKTIEFIRDAKVIAPDKPWFSYVCPGAGHAPHHVFKEWADRYAGRFDMGYERYREIVLE
RQKALGIVPPDTELSPINPYLDVPGPNGETWPLQDTVRPWDSLSDEEKKLFCRMAEVFAGFLSYTDA
QIGRILDYLEESGQLDNTIIVVISDNGASGEGGPNGSVNEGKFFNGYIDTVAESMKLFDHLGGPQTYN
HYPIGWAMAFNTPYKLFKRYASHEGGIADPAIISWPNGIAAHGEIRDNYVNVSDITPTVYDLLGMTPP
GTVKGIPQKPMDGVSFIAALADPAADTGKTTQFYTMLGTRGIWHEGWFANTIHAATPAGWSNFNAD
RWELFHIAADRSQCHDLAAEHPDKLEELKALWFSEAAKYNGLPLADLNLLETMTRSRPYLVSERASY
VYYPDCADVGIGAAVEIRGRSFAVLADVTIDTTGAEGVLFKHGGAHGGHVLFVRDGRLHYVYNFLGE
RQQLVSSSGPVPSGRHLLGVRYLRTGTVPNSHTPVGDLELFFDENLVGALTNVLTHPGTFGLAGAAI
SVGRNGGSAVSSHYEAPFAFTGGTITQVTVDVSGRPFEDVESDLALAFSRD

>Rv0764c - lanosterol 14-demethylase cytochrome P450 TB.seq 856683:858035 MW:50879 SEQ ID NO:179

MSAVALPRVSGGHDEHGHLEEFRTDPIGLMQRVRDECGDVGTFQLAGKQVVLLSGSHANEFFRA GDDDLDQAKAYPFMTPIFGEGVVFDASPERRKEMLHNAALRGEQMKGHAATIEDQVRRMIADWGE AGEIDLLDFFAELTIYTSSACLIGKKFRDQLDGRFAKLYHELERGTDPLAYVDPYLPIESFRRRDEARN GLVALVADIMNGRIANPPTDKSDRDMLDVLIAVKAETGTPRFSADEITGMFISMMFAGHHTSSGTASW TLIELMRHRDAYAAVIDELDELYGDGRSVSFHALRQIPQLENVLKETLRLHPPLIILMRVAKGEFEVQG HRIHEGDLVAASPAISNRIPEDFPDPHDFVPARYEQPRQEDLLNRWTWIPFGAGRHRCVGAAFAIMQI KAIFSVLLREYEFEMAQPPESYRNDHSKMVVQLAQPACVRYRRRTGV

>Rv0861c - DNA helicase TB.seq 958524:960149 MW:59773 SEQ ID NO:180

VQSDKTVLLEVDHELAGAARAAIAPFAELERAPEHVHTYRITPLALWNARAAGHDAEQVVDALVSYS
RYAVPQPLLVDIVDTMARYGRLQLVKNPAHGLTLVSLDRAVLEEVLRNKKIAPMLGARIDDDTVVVHP
SERGRVKQLLLKIGWPAEDLAGYVDGEAHPISLHQEGWQLRDYQRLAADSFWAGGSGVVVLPCGA
GKTLVGAAAMAKAGATTLILVTNIVAARQWKRELVARTSLTENEIGEFSGERKEIRPVTISTYQMITRR
TKGEYRHLELFDSRDWGLIIYDEVHLLPAPVFRMTADLQSKRRLGLTATLIREDGREGDVFSLIGPKR
YDAPWKDIEAQGWIAPAECVEVRVTMTDSERMMYATAEPEERYRICSTVHTKIAVVKSILAKHPDEQ
TLVIGAYLDQLDELGAELGAPVIQGSTRTSEREALFDAFRRGEVATLVVSKVANFSIDLPEAAVAVQVS
GTFGSRQEEAQRLGRILRPKADGGGAIFYSVVARDSLDAEYAAHRQRFLAEQGYGYIIRDADDLLGP

>Rv0904c accD3 TB.seq 1006694:1008178 MW:51741 SEQ ID NO:181
VSRITTDQLRHAVLDRGSFVSWDSEPLAVPVADSYARELAAARAATGADESVQTGEGRVFGRRVAV
VACEFDFLGGSIGVAAAERITAAVERATAERLPLLASPSSGGTRMQEGTVAFLQMVKIAAAIQLHNQA
RLPYLVYLRHPTTGGVFASWGSLGHLTVAEPGALIGFLGPRVYELLYGDPFPSGVQTAENLRRHGIID
GVVALDRLRPMLDRALTVLIDAPEPLPAPQTPAPVPDVPTWDSVVASRRPDRPGVRQLLRHGATDR

5

10

15

20

25

30

VLLSGTDQGEAATTLLALARFGGQPTVVLGQQRAVGGGGSTVGPAALREARRGMALAAELCLPLVL VIDAAGPALSAAAEQGGLAGQIAHCLAELVTLDTPTVSILLGQGSGGPALAMLPADRVLAALHGWLAP LPPEGASAIVFRDTAHAAELAAAQGIRSADLLKSGIVDTIVPEYPDAADEPIEFALRLSNAIAAEVHALR KIPAPERLATRLQRYRRIGLPRD

5

10

- >RV0983 TB.seq 1099064:1100455 MW:46454 SEQ ID NO:182

  MAKLARVVGLVQEEQPSDMTNHPRYSPPPQQPGTPGYAQGQQQTYSQQFDWRYPPSPPPQPTQY
  RQPYEALGGTRPGLIPGVIPTMTPPPGMVRQRPRAGMLAIGAVTIAVVSAGIGGAAASLVGFNRAPA
  GPSGGPVAASAAPSIPAANMPPGSVEQVAAKVVPSVVMLETDLGRQSEEGSGIILSAEGLILTNNHVI
  AAAAKPPLGSPPPKTTVTFSDGRTAPFTVVGADPTSDIAVVRVQGVSGLTPISLGSSSDLRVGQPVLA
  IGSPLGLEGTVTTGIVSALNRPVSTTGEAGNQNTVLDAIQTDAAINPGNSGGALVNMNAQLVGVNSAI
  ATLGADSADAQSGSIGLGFAIPVDQAKRIADELISTGKASHASLGVQVTNDKDTLGAKIVEVVAGGAA
  ANAGVPKGVVVTKVDDRPINSADALVAAVRSKAPGATVALTFQDPSGGSRTVQVTLGKAEQ
- 15 >Rv1008 Similar to E.coli protein YcfH TB.seq 1127087:1127878 MW:29066 SEQ ID NO:183
  LVDAHTHLDACGARDADTVRSLVERAAAAGVTAVVTVADDLESARWVTRAAEWDRRVYAAVALHPT
  RADALTDAARAELERLVAHPRVVAVGETGIDMYWPGRLDGCAEPHVQREAFAWHIDLAKRTGKPLM
  IHNRQADRDVLDVLRAEGAPDTVILHCFSSDAAMARTCVDAGWLLSLSGTVSFRTARELREAVPLMP
  VEQLLVETDAPYLTPHPHRGLANEPYCLPYTVRALAELVNRRPEEVALITTSNARRAYGLGWMRQ

20

>Rv1009 - lipoprotein, similar to various other MTB proteins TB.seq 1128089:1129174 MW:38079
SEQ ID NO:184
MLRLVVGALLLVLAFAGGYAVAACKTVTLTVDGTAMRVTTMKSRVIDIVEENGFSVDDRDDLYPAAG
VQVHDADTIVLRRSRPLQISLDGHDAKQVWTTASTVDEALAQLAMTDTAPAAASRASRVPLSGMALP
VVSAKTVQLNDGGLVRTVHLPAPNVAGLLSAAGVPLLQSDHVVPAATAPIVEGMQIQVTRNRIKKVTE
RLPLPPNARRVEDPEMNMSREVVEDPGVPGTQDVTFAVAEVNGVETGRLPVANVVVTPAHEAVVR
VGTKPGTEVPPVIDGSIWDAIAGCEAGGNWAINTGNGYYGGVQFDQGTWEANGGLRYAPRADLAT
REEQIAVAEVTRLRQGWGAWPVCAARAGAR

30 >Rv1010 ksgA 16S rRNA dimethyltransferase TB.seq 1129150:1130100 MW:34647 SEQ ID NO:185

SEQ ID NO:185

MCCTSGCALTIRLLGRTEIRRLAKELDFRPRKSLGQNFVHDANTVRRVVAASGVSRSDLVLEVGPGL
GSLTLALLDRGATVTAVEIDPLLASRLQQTVAEHSHSEVHRLTVVNRDVLALRREDLAAAPTAVVANL
PYNVAVPALLHLLVEFPSIRVVTVMVQAEVAERLAAEPGSKEYGVPSVKLRFFGRVRRCGMVSPTVF
WPIPRVYSGLVRIDRYETSPWPTDDAFRRRVFELVDIAFAQRRKTSRNAFVQWAGSGSESANRLLAA
SIDPARRGETLSIDDFVRLLRRSGGSDEATSTGRDARAPDISGHASAS

35 .

>Rv1011 - Similar to E.coli protein YcbH TB.seq 1130189:1131106 MW:31350 SEQ ID NO:186

VPTGSVTVRVPGKVNLYLAVGDRREDGYHELTTVFHAVSLVDEVTVRNADVLSLELVGEGADQLPTD ERNLAWQAAELMAEHVGRAPDVSIMIDKSIPVAGGMAGGSADAAAVLVAMNSLWELNVPRRDLRML AARLGSDVPFALHGGTALGTGRGEELATVLSRNTFHWVLAFADSGLLTSAVYNELDRLREVGDPPRL GEPGPVLAALAAGDPDQLAPLLGNEMQAAAVSLDPALARALRAGVEAGALAGIVSGSGPTCAFLCTS ASSAIDVGAQLSGAGVCRTVRVATGPVPGARVVSAPTEV

>Rv1106c - cholesterol dehydrogenase TB.seq 1232845:1233954 MW:40743 SEQ ID NO:187

MLRRMGDASLTTELGRVLVTGGAGFVGANLVTTLLDRGHWVRSFDRAPSLLPAHPQLEVLQGDITD

ADVCAAAVDGIDTIFHTAAIIELMGGASVTDEYRQRSFAVNVGGTENLLHAGQRAGVQRFVYTSSNS

VVMGGQNIAGGDETLPYTDRFNDLYTETKVVAERFVLAQNGVDGMLTCAIRPSGIWGNGDQTMFRK

LFESVLKGHVKVLVGRKSARLDNSYVHNLIHGFILAAAHLVPDGTAPGQAYFINDAEPINMFEFARPVL

EACGQRWPKMRISGPAVRWVMTGWQRLHFRFGFPAPLLEPLAVERLYLDNYFSIAKARRDLGYEPL

15 FTTQQALTECLPYYVSLFEQMKNEARAEKTAATVKP

>Rv1110 lytB2 TB.seq 1236183:1237187 MW:36298 SEQ ID NO:188
MVPTVDMGIPGASVSSRSVADRPNRKRVLLAEPRGYCAGVDRAVETVERALQKHGPPVYVRHEIVH
NRHVVDTLAKAGAVFVEETEQVPEGAIVVFSAHGVAPTVHVSASERNLQVIDATCPLVTKVHNEARR
FARDDYDILLIGHEGHEEVVGTAGEAPDHVQLVDGVDAVDQVTVRDEDKVVWLSQTTLSVDETMEIV
GRLRRFPKLQDPPSDDICYATQNRQVAVKAMAPECELVIVVGSRNSSNSVRLVEVALGAGARAAH
LVDWADDIDSAWLDGVTTVGVTSGASVPEVLVRGVLERLAECGYDIVQPVTTANETLVFALPRELRS
PR

25 >Rv1216c - TB.seq 1359473:1360144 MW:24863 SEQ ID NO:189
MHIGLKIFIWGVLGLVVFGALLFGPAGTFDYWQAWVFLAAFVSTTIGPTIYLARNDPAALQRRMRSGP
LAEGRTIQKFIVIGAFLGFFAMMVLSACDHRYGWSSVPAAVCVIGDVLVMTGLGIAMLVVIQNRYAAS
TVRVEAGQILASDGLYKIVRHPMYAGNVVMMTGIPLALGSYWAMFILVPGTLVLVFRILDEEKLLTQEL
SGYREYRQLVRYRLVPYVW

>Rv1223 htta TB.seq 1365810:1367456 MW:56547 SEQ ID NO:190
VSHLSQRMAGLLRVHGEWSRSVDTRVDTDNAMPARFSAQIQNEDEVTSDQGNNGGPNGGGRLAP
RPVFRPPVDPASRQAFGRPSGVQGSFVAERVRPQKYQDQSDFTPNDQLADPVLQEAFGRPFAGAE
SLQRHPIDAGALAAEKDGAGPDEPDDPWRDPAAAAALGTPALAAPAPHGALAGSGKLGVRDVLFGG
KVSYLALGILVAIALVIGGIGGVIGRKTAEVVDAFTTSKVTLSTTGNAQEPAGRFTKVAAAVADSVVTIE
SVSDQEGMQGSGVIVDGRGYIVTNNHVISEAANNPSQFKTTVVFNDGKEVPANLVGRDPKTDLAVLK
VDNVDNLTVARLGDSSKVRVGDEVLAVGAPLGLRSTVTQGIVSALHRPVPLSGEGSDTDTVIDAIQTD

5

20

30

WO 01/35317

ASINHGNSGGPLIDMDAQVIGINTAGKSLSDSASGLGFAIPVNEMKLVANSLIKDGKIVHPTLGISTRSV SNAIASGAQVANVKAGSPAQKGGILENDVIVKVGNRAVADSDEFVVAVRQLAIGQDAPIEVVREGRH VTLTVKPDPDST

- >Rv1224 TB.seq 1367461:1367853 MW:14083 SEQ ID NO:191
  VFANIGWWEMLVLVMVGLVVLGPERLPGAIRWAASALRQARDYLSGVTSQLREDIGPEFDDLRGHL
  GELQKLRGMTPRAALTKHLLDGDDSLFTGDFDRPTPKKPDAAGSAGPDATEQIGAGPIPFDSDAT
- >Rv1229c mrp similar to MRP/NBP35 ATP-binding proteins TB.seq 1371778:1372947 MW:41064

  SEQ ID NO:192

  MPSRLHSAVMSGTRDGDLNAAIRTALGKVIDPELRRPITELGMVKSIDTGPDGSVHVEIYLTIAGCPKK
  SEITERVTRAVADVPGTSAVRVSLDVMSDEQRTELRKQLRGDTREPVIPFAQPDSLTRVYAVASGKG
  GVGKSTVTVNLAAAMAVRGLSIGVLDADIHGHSIPRMMGTTDRPTQVESMILPPIAHQVKVISIAQFTQ
  GNTPVVWRGPMLHRALQQFLADVYWGDLDVLLLDLPPGTGDVAISVAQLIPNAELLVVTTPQLAAAE

  VAERAGSIALQTRQRIVGVVENMSGLTLPDGTTMQVFGEGGGRLVAERLSRAVGADVPLLGQIPLDP
  ALVAAGDSGVPLVLSSPDSAIGKELHSIADGLSTRRRGLAGMSLGLDPTRR
  - >Rv1239c corA magnesium and cobalt transport protein TB.seq 1381943:1383040 MW:41470 SEQ ID NO:193
- VFPGFDALPEVLRPVARPQPPNAHPVAQPPAQALVDCGVYVCGQRLPGKYTYAAALREVREIELTG QEAFVWIGLHEPDENQMQDVADVFGLHPLAVEDAVHAHQRPKLERYDETLFLVLKTVNYVPHESVV LAREIVKTGEIMIFVGKDFVVTVRHGEHGGLSEVRKRMDADPEHLRLGPYAVMHAIADYVVDHYLEVT NLMETDIDSIEEVAFAPGRKLDIEPIYLLKREVVELRRCVNPLSTAFQRMQTESKDLISKEVRRYLRDV ADHQTEAADQIASYDDMLNSLVQAALARVGMQQNMDMRKISAWAGIIAVPTMIAGIYGMNFHFMPEL
- 35 >Rv1294 thrA homoserine dehydrogenase TB.seq 1449373:1450695 MW:45522 SEQ ID NO:195 VPGDEKPVGVAVLGLGNVGSEVVRIIENSAEDLAARVGAPLVLRGIGVRRVTTDRGVPIELLTDDIEEL VAREDVDIVVEVMGPVEPSRKAILGALERGKSVVTANKALLATSTGELAQAAESAHVDLYFEAAVAGA

PCT/US00/31152

IPVIRPLTQSLAGDTVLRVAGIVNGTTNYILSAMDSTGADYASALADASALGYAEADPTADVEGYDAA AKAAILASIAFHTRVTADDVYREGITKVTPADFGSAHALGCTIKLLSICERITTDEGSQRVSARVYPALV PLSHPLAAVNGAFNAVVVEAEAAGRLMFYGQGAGGAPTASAVTGDLVMAARNRVLGSRGPRESKY AQLPVAPMGFIETRYYVSMNVADKPGVLSAVAAEFAKREVSIAEVRQEGVVDEGGRRVGARIVVVTH LATDAALSETVDALDDLDVVQGVSSVIRLEGTGL

>Rv1323 fadA4 acetyl-CoA C-acetyltransferase (aka thiL) TB.seq 1485860:1487026 MW:40049 SEQ ID NO:196

VIVAGARTPIGKLMGSLKDFSASELGAIAIKGALEKANVPASLVEYVIMGQVLTAGAGQMPARQAAVA

AGIGWDVPALTINKMCLSGIDAIALADQLIRAREFDVVVAGGQESMTKAPHLLMNSRSGYKYGDVTVL

DHMAYDGLHDVFTDQPMGALTEQRNDVDMFTRSEQDEYAAASHQKAAAAWKDGVFADEVIPVNIP

QRTGDPLQFTEDEGIRANTTAAALAGLKPAFRGDGTITAGSASQISDGAAAVVVMNQEKAQELGLTW

LAEIGAHGVVAGPDSTLQSQPANAINKALDREGISVDQLDVVEINEAFAAVALASIRELGLNPQIVNVN

GGAIAVGHPLGMSGTRITLHAALQLARRGSGVGVAALCGAGGQGDALILRAG

15

20

25

5

>Rv1389 gmk putative guanylate kinase TB.seq 1564399:1565022 MW:22064 SEQ ID NO:197 VSVGEGPDTKPTARGQPAAVGRVVVLSGPSAVGKSTVVRCLRERIPNLHFSVSATTRAPRPGEVDG VDYHFIDPTRFQQLIDQGELLEWAEIHGGLHRSGTLAQPVRAAAATGVPVLIEVDLAGARAIKKTMPE AVTVFLAPPSWQDLQARLIGRGTETADVIQRRLDTARIELAAQGDFDKVVVNRRLESACAELVSLLVG TAPGSP

>Rv1407 fmu similar to Fmu protein TB.seq 1583099:1584469 MW:48494 SEQ ID NO:198 MTPRSRGPRRPLDPARRAAFETLRAVSARDAYANLVLPALLAQRGIGGRDAAFATELTYGTCRAR GLLDAVIGAAAERSPQAIDPVLLDLLRLGTYQLLRTRVDAHAAVSTTVEQAGIEFDSARAGFVNGVLR TIAGRDERSWVGELAPDAQNDPIGHAAFVHAHPRWIAQAFADALGAAVGELEAVLASDDERPAVHLA ARPGVLTAGELARAVRGTVGRYSPFAVYLPRGDPGRLAPVRDGQALVQDEGSQLVARALTLAPVDG DTGRWLDLCAGPGGKTALLAGLGLQCAARVTAVEPSPHRADLVAQNTRGLPVELLRVDGRHTDLDP GFDRVLVDAPCTGLGALRRRPEARWRRQPADVAALAKLQRELLSAAIALTRPGGVVLYATCSPHLAE TVGAVADALRRHPVHALDTRPLFEPVIAGLGEGPHVQLWPHRHGTDAMFAAALRRLT

30

35

>Rv1409 ribG riboflavin biosynthesis TB.seq 1585192:1586208 MW:35367 SEQ ID NO:199 MNVEQVKSIDEAMGLAIEHSYQVKGTTYPKPPVGAVIVDPNGRIVGAGGTEPAGGDHAEVVALRRAG GLAAGAIVVVTMEPCNHYGKTPPCVNALIEARVGTVVYAVADPNGIAGGGAGRLSAAGLQVRSGVLA EQVAAGPLREWLHKQRTGLPHVTWKYATSIDGRSAAADGSSQWISSEAARLDLHRRRAIADAILVGT GTVLADDPALTARLADGSLAPQQPLRVVVGKRDIPPEARVLNDEARTMMIRTHEPMEVLRALSDRTD VLLEGGPTLAGAFLRAGAINRILAYVAPILLGGPVTAVDDVGVSNITNALRWQFDSVEKVGPDLLLSLV AR

>Rv1440 secG TB.seq 1617715:1618065 MW:12140 SEQ ID NO:200 VAGVTAAVSARLKADEARRPGFYAAGSGPLPQVRGSTLPVMELALQITLIVTSVLVVLLVLLHRAKGG GLSTLFGGGVQSSLSGSTVVEKNLDRLTLFVTGIWLVSIIGVALLIKYR

>Rv1484 inha TB.seq 1674200:1675006 MW:28529 SEQ ID NO:201
MTGLLDGKRILVSGIITDSSIAFHIARVAQEQGAQLVLTGFDRLRLIQRITDRLPAKAPLLELDVQNEEH
LASLAGRVTEAIGAGNKLDGVVHSIGFMPQTGMGINPFFDAPYADVSKGIHISAYSYASMAKALLPIM
NPGGSIVGMDFDPSRAMPAYNWMTVAKSALESVNRFVAREAGKYGVRSNLVAAGPIRTLAMSAIVG
GALGEEAGAQIQLLEEGWDQRAPIGWNMKDATPVAKTVCALLSDWLPATTGDIIYADGGAHTQLL

10

15

>RV1617 pykA pyruvate kinase TB.seq 1816187:1817602 MW:50668 SEQ ID NO:202
VTRRGKIVCTLGPATQRDDLVRALVEAGMDVARMNFSHGDYDDHKVAYERVRVASDATGRAVGVL
ADLQGPKIRLGRFASGATHWAEGETVRITVGACEGSHDRVSTTYKRLAQDAVAGDRVLVDDGKVAL
VVDAVEGDDVVCTVVEGGPVSDNKGISLPGMNVTAPALSEKDIEDLTFALNLGVDMVALSFVRSPAD
VELVHEVMDRIGRRVPVIAKLEKPEAIDNLEAIVLAFDAVMVARGDLGVELPLEEVPLVQKRAIQMARE
NAKPVIVATQMLDSMIENSRPTRAEASDVANAVLDGADALMLSGETSVGKYPLAAVRTMSRIICAVEE
NSTAAPPLTHIPRTKRGVISYAARDIGERLDAKALVAFTQSGDTVRRLARLHTPLPLLAFTAWPEVRS
QLAMTWGTETFIVPKMQSTDGMIRQVDKSLLELARYKRGDLVVIVAGAPPGTVGSTNLIHVHRIGEDD
V

20

>Rv1630 rpsA 30S ribosomal protein S1 TB.seq 1833540:1834982 MW:53203 SEQ ID NO:203 MPSPTVTSPQVAVNDIGSSEDFLAAIDKTIKYFNDGDIVEGTIVKVDRDEVLLDIGYKTEGVIPARELSIK HDVDPNEVVSVGDEVEALVLTKEDKEGRLILSKKRAQYERAWGTIEALKEKDEAVKGTVIEVVKGGLI LDIGLRGFLPASLVEMRRVRDLQPYIGKEIEAKIIELDKNRNNVVLSRRAWLEQTQSEVRSEFLNNLQK GTIRKGVVSSIVNFGAFVDLGGVDGLVHVSELSWKHIDHPSEVVQVGDEVTVEVLDVDMDRERVSLS LKATQEDPWRHFARTHAIGQIVPGKVTKLVPFGAFVRVEEGIEGLVHISELAERHVEVPDQVVAVGDD AMVKVIDIDLERRRISLSLKQANEDYTEEFDPAKYGMADSYDEQGNYIFPEGFDAETNEWLEGFEKQ RAEWEARYAEAERRHKMHTAQMEKFAAAEAAGRGADDQSSASSAPSEKTAGGSLASDAQLAALRE KLAGSA

30

35

25

>Rv1631 - TB.seq 1835011:1836231 MW:44669 SEQ ID NO:204
MLRIGLTGGIGAGKSLLSTTFSQCGGIVVDGDVLAREVVQPGTEGLASLVDAFGRDILLADGALDRQA
LAAKAFRDDESRGVLNGIVHPLVARRRSEIIAAVSGDAVVVEDIPLLVESGMAPLFPLVVVVHADVELR
VRRLVEQRGMAEADARARIAAQASDQQRRAVADVWLDNSGSPEDLVRRARDVWNTRVQPFAHNL
AQRQIARAPARLVPADPSWPDQARRIVNRLKIACGHKALRVDHIGSTAVSGFPDFLAKDVIDIQVTVE
SLDVADELAEPLLAAGYPRLEHITQDTEKTDARSTVGRYDHTDSAALWHKRVHASADPGRPTNVHLR

VHGWPNQQFALLFVDWLAANPGAREDYLTVKCDADRRADGELARYVTAKEPWFLDAYQRAWEWA DAVHWRP

>Rv1706c - TB.seq 1932695:1933876 MW:39779 SEQ ID NO:205

5 MTLDVPVNQGHVPPGSVACCLVGVTAVADGIAGHSLSNFGALPPEINSGRMYSGPGSGPLMAAAAA WDGLAAELSSAATGYGAAISELTNMRWWSGPASDSMVAAVLPFVGWLSTTATLAEQAAMQARAAA AAFEAAFAMTVPPPAIAANRTLLMTLVDTNWFGQNTPAIATTESQYAEMWAQDAAAMYGYASAAAP ATVLTPFAPPPQTTNATGLVGHATAVAALRGQHSWAAAIPWSDIQKYWMMFLGALATAEGFIYDSG GLTLNALQFVGGMLWSTALAEAGAAEAAAGAGGAAGWSAWSQLGAGPVAASATLAAKIGPMSVPP GWSAPPATPQAQTVARSIPGIRSAAEAAETSVLLRGAPTPGRSRAAHMGRRYGRRLTVMADRPNVG

>Rv1745c - similar to Q46822 ORF\_O182 TB.seq 1971381:1971989 MW:22490 SEQ ID NO:206 MTRSYRPAPPIERVVLLNDRGDATGVADKATVHTGDTPLHLAFSSYVFDLHDQLLITRRAATKRTWP AVWTNSCCGHPLPGESLPGAIRRRLAAELGLTPDRVDLILPGFRYRAAMADGTVENEICPVYRVQVD QQPRPNSDEVDAIRWLSWEQFVRDVTAGVIAPVSPWCRSQLGYLTKLGPCPAQWPVADDCRLPKA AHGN

>Rv1800 - TB.seq 2039451:2041415 MW:67068 SEQ ID NO:207
MLPNFAVLPPEVNSARVFAGAGSAPMLAAAAAWDDLASELHCAAMSFGSVTSGLVVGWWQGSASA
20 AMVDAAASYIGWLSTSAAHAEGAAGLARAAVSVFEEALAATVHPAMVAANRAQVASLVASNLFGQN
APAIAALESLYECMWAQDAAAMAGYYVGASAVATQLASWLQRLQSIPGAASLDARLPSSAEAPMGV
VRAVNSAIAANAAAAQTVGLVMGGSGTPIPSARYVELANALYMSGSVPGVIAQALFTPQGLYPVVVIK
NLTFDSSVAQGAVILESAIRQQIAAGNNVTVFGYSQSATISSLVMANLAASADPPSPDELSFTLIGNPN
NPNGGVATRFPGISFPSLGVTATGATPHNLYPTKIYTIEYDGVADFPRYPLNFVSTLNAIAGTYYVHSN
25 YFILTPEQIDAAVPLTNTVGPTMTQYYIIRTENLPLLEPLRSVPIVGNPLANLVQPNLKVIVNLGYGDPA
YGYSTSPPNVATPFGLFPEVSPVVIADALVAGTQQGIGDFAYDVSHLELPLPADGSTMPSTAPGSGT
PVPPLSIDSLIDDLQVANRNLANTISKVAATSYATVLPTADIANAALTIVPSYNIHLFLEGIQQALKGDPM
GLVNAVGYPLAADVALFTAAGGLQLLIIISAGRTIANDISAIVP

>Rv1844c gnd 6-phosphogluconate dehydrogenase (Gram -) TB.seq 2093732:2095186
 MW:51548 SEQ ID NO:208
 MSSSESPAGIAQIGVTGLAVMGSNIARNFARHGYTVAVHNRSVAKTDALLKEHSSDGKFVRSETIPEF
 LAALEKPRRVLIMVKAGEATDADAVINELADAMEPGDIIIDGGNALYTDTMRREKAMRERGLHFVGAG
 ISGGEEGALNGPSIMPGGPAESYQSLGPLLEEISAHVDGVPCCTHIGPDGSGHFVKMVHNGIEYSDM
 QLIGEAYQLMRDGLGLTAPAIADVFTEWNNGDLDSYLVEITAEVLRQTDAKTGKPLVDVIVDRAEQKG
 TGRWTVKSALDLGVPVTGIAEAVFARALSGSVGQRSAASGLASGKLGEQPADPATFTEDVRQALYA
 SKIVAYAQGFNQIQAGSAEFGWDITPGDLATIWRGGCIIRAKFLNHIKEAFDASPNLASLIVAPYFRGA

VESAIDSWRRVVSTAAQLGIPTPGFSSALSYYDALRTARLPAALTQAQRDFFGAHTYGRIDEPGKFHT LWSSDRTEVPV

>Rv1900c lipJ TB.seq 2146246:2147631 MW:49685 SEQ ID NO:209

VAQAPHIHRTRYAKCGDMDIAYQVLGDGPTDLLVLPGPFVPIDSIDDEPSLYRFHRRLASFSRVIRLDH RGVGLSSRLAAITTLGPKFWAQDAIAVMDAVGCEQATIFAPSFHAMNGLVLAADYPERVRSLIVVNGS ARPLWAPDYPVGAQVRRADPFLTVALEPDAVERGFDVLSIVAPTVAGDDVFRAWWDLAGNRAGPP SIARAVSKVIAEADVRDVLGHIEAPTLILHRVGSTYIPVGHGRYLAEHIAGSRLVELPGTDTLYWVGDT GPMLDEIEEFITGVRGGADAERMLATIMFTDIVGSTQHAAALGDDRWRDLLDNHDTIVCHEIQRFGGR EVNTAGDGFVATFTSPSAAIACADDIVDAVAALGIEVRIGIHAGEVEVRDASHGTDVAGVAVHIGARVC ALAGPSEVLVSSTVRDIVAGSRHRFAERGEQELKGVPGRWRLCVLMRDDATRTR

>Rv1967 - TB.seq 2210599:2211624 MW:36516 SEQ ID NO:210
MRENLGGVVVRLGVFLAVCLLTAFLLIAVFGEVRFGDGKTYYAEFANVSNLRTGKLVRIAGVEVGKVT
RISINPDATVRVQFTADNSVTLTRGTRAVIRYDNLFGDRYLALEEGAGGLAVLRPGHTIPLARTQPALD
LDALIGGFKPLFRALNPEQVNALSEQLLHAFAGQGPTIGSLLAQSAAVTNTLADRDRLIGQVITNLNVV
LGSLGAHTDRLDQAVTSLSALIHRLAQRKTDISNAVAYTNAAAGSVADLLSQARAPLAKVVRETDRVA
GIAAADHDYLDNLLNTLPDKYQALVRQGMYGDFFAFYLCDVVLKVNGKGGQPVYIKLAGQDSGRCA
PK

20

25

30

15

>Rv1975 - TB.seq 2218050:2218712 MW:23650 SEQ ID NO:211
MSRRASATCALSATTAVAIMAAPAARADDKRLNDGVVANVYTVQRQAGCTNDVTINPQLQLAAQWH
TLDLLNNRHLNDDTGSDGSTPQDRAHAAGFRGKVAETVAINPAVAISGIELINQWYYNPAFFAIMSDC
ANTQIGVWSENSPDRTVVVAVYGQPDRPSAMPPRGAVTGPPSPVAAQENVPIDPSPDYDASDEIEY
GINWLPWILRGVYPPPAMPPQ

>Rv1981c nrdF ribonucleotide reductase small subunit TB.seq 2224221:2225186 MW:36591 SEQ ID NO:212

MTGKLVERVHAINWNRLLDAKDLQVWERLTGNFWLPEKIPLSNDLASWQTLSSTEQQTTIRVFTGLT LLDTAQATVGAVAMIDDAVTPHEEAVLTNMAFMESVHAKSYSSIFSTLCSTKQIDDAFDWSEQNPYL QRKAQIIVDYYRGDDALKRKASSVMLESFLFYSGFYLPMYWSSRGKLTNTADLIRLIIRDEAVHGYYIG YKCQRGLADLTDAERADHREYTCELLHTLYANEIDYAHDLYDELGWTDDVLPYMRYNANKALANLG YQPAFDRDTCQVNPAVRAALDPGAGENHDFFSGSGSSYVMGTHQPTTDTDWDF

35 >Rv2092c helY helicase, Ski2 subfamily TB.seq 2349335:2352052 MW:99576 SEQ ID NO:213 VTELAELDRFTAELPFSLDDFQQRACSALERGHGVLVCAPTGAGKTVVGEFAVHLALAAGSKCFYTT PLKALSNQKHTDLTARYGRDQIGLLTGDLSVNGNAPVVVMTTEVLRNMLYADSPALQGLSYVVMDE

VHFLADRMRGPVWEEVILQLPDDVRVVSLSATVSNAEEFGGWIQTVRGDTTVVVDEHRPVPLWQHV
LVGKRMFDLFDYRIGEAEGQPQVNRELLRHIAHRREADRMADWQPRRRGSGRPGFYRPPGRPEVI
AKLDAEGLLPAITFVFSRAGCDAAVTQCLRSPLRLTSEEERARIAEVIDHRCGDLADSDLAVLGYYEW
REGLLRGLAAHHAGMLPAFRHTVEELFTAGLVKAVFATETLALGINMPARTVVLERLVKFNGEQHMP
LTPGEYTQLTGRAGRRGIDVEGHAVVIWHPEIEPSEVAGLASTRTFPLRSSFAPSYNMTINLVHRMGP
QQAHRLLEQSFAQYQADRSVVGLVRGIERGNRILGEIAAELGGSDAPILEYARLRARVSELERAQARA
SRLQRRQAATDALAALRRGDIITITHGRRGGLAVVLESARDRDDPRPLVLTEHRWAGRISSADYSGTT
PVGSMTLPKRVEHRQPRVRRDLASALRSAAAGLVIPAARRVSEAGGFHDPELESSREQLRRHPVHT
SPGLEDQIRQAERYLRIERDNAQLERKVAAATNSLARTFDRFVGLLTEREFIDGPATDPVVTDDGRLL
ARIYSESDLLVAECLRTGAWEGLKPAELAGVVSAVVYETRGGDGQGAPFGADVPTPRLRQALTQTS
RLSTTLRADEQAHRITPSREPDDGFVRVIYRWSRTGDLAAALAAADVNGSGSPLLAGDFVRWCRQV
LDLLDQVRNAAPNPELRATAKRAIGDIRRGVVAVDAG

>Rv2101 helZ helicase, Snf2/Rad54 family TB.seq 2360238:2363276 MW:111632

15 SEQ ID NO:214

**SEGAVGE** 

5

10

20

25

30

MLVLHGFWSNSGGMRLWAEDSDLLVKSPSQALRSARPHPFAAPADLIAGIHPGKPATAVLLLPSLRS
APLDSPELIRLAPRPAARTDPMLLAWTVPVVDLDPTAALAAFDQPAPDVRYGASVDYLAELAVFAREL
VERGRVLPQLRRDTHGAAACWRPVLQGRDVVAMTSLVSAMPPVCRAEVGGHDPHELATSALDAMV
DAAVRAALSPMDLLPPRRGRSKRHRAVEAWLTALTCPDGRFDAEPDELDALAEALRPWDDVGIGTV
GPARATFRLSEVETENEETPAGSLWRLEFLLQSTQDPSLLVPAEQAWNDDGSLRRWLDRPQELLLT
ELGRASRIFPELVPALRTACPSGLELDADGAYRFLSGTAAVLDEAGFGVLLPSWWDRRRKLGLVLSA
YTPVDGVVGKASKFGREQLVEFRWELAVGDDPLSEEEIAALTETKSPLIRLRGQWVALDTEQMRRGL
EFLERKPTGRKTTAEILALAASHPDDVDTPLEVTAVRADGWLGDLLAGAAAASLQPLDPPDGFTATLR
PYQQRGLAWLAFLSSLGLGSCLADDMGLGKTVQLLALETLESVQRHQDRGVGPTLLLCPMSLVGN
WPQEAARFAPNLRVYAHHGGARLHGEALRDHLERTDLVVSTYTTATRDIDELAEYEWNRVVLDEAQ
AVKNSLSRAAKAVRRLRAAHRVALTGTPMENRLAELWSIMDFLNPGLLGSSERFRTRYAIPIERHGHT
EPAERLRASTRPYILRRLKTDPAIIDDLPEKIEIKQYCQLTTEQASLYQAVVADMMEKIENTEGIERRGN
VLAAMAKLKQVCNHPAQLLHDRSPVGRRSGKVIRLEEILEEILAEGDRVLCFTQFTEFAELLVPHLAAR
FGRAARDIAYLHGGTPRKRRDEMVARFQSGDGPPIFLLSLKAGGTGLNLTAANHVVHLDRWWNPAV
ENQATDRAFRIGQRRTVQVRKFICTGTLEEKIDEMIEEKKALADLVVTDGEGWLTELSTRDLREVFAL

>Rv2110c prcB proteasome [beta]-type subunit 2 TB.seq 2369727:2370599 MW:30274 SEQ ID NO:215

35 VTWPLPDRLSINSLSGTPAVDLSSFTDFLRRQAPELLPASISGGAPLAGGDAQLPHGTTIVALKYPGG
VVMAGDRRSTQGNMISGRDVRKVYITDDYTATGIAGTAAVAVEFARLYAVELEHYEKLEGVPLTFAG
KINRLAIMVRGNLAAAMQGLLALPLLAGYDIHASDPQSAGRIVSFDAAGGWNIEEEGYQAVGSGSLFA

KSSMKKLYSQVTDGDSGLRVAVEALYDAADDDSATGGPDLVRGIFPTAVIIDADGAVDVPESRIAELA RAIIESRSGADTFGSDGGEK

>Rv2118c - = B2126\_C1\_165 (83.6%) TB.seq 2377471:2378310 MW:30091 SEQ ID NO:216
VSATGPFSIGERVQLTDAKGRRYTMSLTPGAEFHTHRGSIAHDAVIGLEQGSVVKSSNGALFLVLRPL
LVDYVMSMPRGPQVIYPKDAAQIVHEGDIFPGARVLEAGAGSGALTLSLLRAVGPAGQVISYEQRAD
HAEHARRNVSGCYGQPPDNWRLVVSDLADSELPDGSVDRAVLDMLAPWEVLDAVSRLLVAGGVLM
VYVATVTQLSRIVEALRAKQCWTEPRAWETLQRGWNVVGLAVRPQHSMRGHTAFLVATRRLAPGA
VAPAPLGRKREGRDG

10

5

>Rv2144c - TB.seq 2404166:2404519 MW:12028 SEQ ID NO:217
MLIIALVLALIGLLALVFAVVTSNQLVAWVCIGASVLGVALLIVDALRERQQGGADEADGAGETGVAEE
ADVDYPEEAPEESQAVDAGVIGSEEPSEEASEATEESAVSADRSDDSAK

- >Rv2146c TB.seq 2405667:2405954 MW:10805 SEQ ID NO:218
  LVVFFQILGFALFIFWLLLIARVVVEFIRSFSRDWRPTGVTVVILEIIMSITDPPVKVLRRLIPQLTIGAVRF
  DLSIMVLLLVAFIGMQLAFGAAA
- >Rv2147c TB.seq 2406119:2406841 MW:27630 SEQ ID NO:219

  VNSHCSHTFITDNRSPRARRGHAMSTLHKVKAYFGMAPMEDYDDEYYDDRAPSRGYARPRFDDDY

  GRYDGRDYDDARSDSRGDLRGEPADYPPPGYRGGYADEPRFRPREFDRAEMTRPRFGSWLRNST

  RGALAMDPRRMAMMFEDGHPLSKITTLRPKDYSEARTIGERFRDGSPVIMDLVSMDNADAKRLVDF

  AAGLAFALRGSFDKVATKVFLLSPADVDVSPEERRRIAETGFYAYQ
- 25 >Rv2148c TB.seq 2406841:2407614 MW:27694 SEQ ID NO:220
  MAADLSAYPDRESELTHALAAMRSRLAAAAEAAGRNVGEIELLPITKFFPATDVAILFRLGCRSVGES
  REQEASAKMAELNRLLAAAELGHSGGVHWHMVGRIQRNKAGSLARWAHTAHSVDSSRLVTALDRA
  VVAALAEHRRGERLRVYVQVSLDGDGSRGGVDSTTPGAVDRICAQVQESEGLELVGLMGIPPLDWD
  PDEAFDRLQSEHNRVRAMFPHAIGLSAGMSNDLEVAVKHGSTCVRVGTALLGPRRLRSP

30

35

>Rv2150c ftsZ TB.seq 2408386:2409522 MW:38757 SEQ ID NO:221
MTPPHNYLAVIKVVGIGGGGVNAVNRMIEQGLKGVEFIAINTDAQALLMSDADVKLDVGRDSTRGLG
AGADPEVGRKAAEDAKDEIEELLRGADMVFVTAGEGGGTGTGGAPVVASIARKLGALTVGVVTRPF
SFEGKRRSNQAENGIAALRESCDTLIVIPNDRLLQMGDAAVSLMDAFRSADEVLLNGVQGITDLITTP
GLINVDFADVKGIMSGAGTALMGIGSARGEGRSLKAAEIAINSPLLEASMEGAQGVLMSIAGGSDLGL
FEINEAASLVQDAAHPDANIIFGTVIDDSLGDEVRVTVIAAGFDVSGPGRKPVMGETGGAHRIESAKA
GKLTSTLFEPVDAVSVPLHTNGATLSIGGDDDDVDVPPFMRR

PCT/US00/31152

>Rv2152c murC TB.seq 2410639:2412120 MW:51146 SEQ ID NO:222

VSTEQLPPDLRRVHMVGIGGAGMSGIARILLDRGGLVSGSDAKESRGVHALRARGALIRIGHDASSL

DLLPGGATAVVTTHAAIPKTNPELVEARRRGIPVVLRPAVLAKLMAGRTTLMVTGTHGKTTTTSMLIVA

LQHCGLDPSFAVGGELGEAGTNAHHGSGDCFVAEADESDGSLLQYTPHVAVITNIESDHLDFYGSVE

AYVAVFDSFVERIVPGGALVVCTDDPGGAALAQRATELGIRVLRYGSVPGETMAATLVSWQQQGVG

AVAHIRLASELATAQGPRVMRLSVPGRHMALNALGALLAAVQIGAPADEVLDGLAGFEGVRRFELV

GTCGVGKASVRVFDDYAHHPTEISATLAAARMVLEQGDGGRCMVVFQPHLYSRTKAFAAEFGRALN

AADEVFVLDVYGAREQPLAGVSGASVAEHVTVPMRYVPDFSAVAQQVAAAASPGDVIVTMGAGDVT

LLGPEILTALRVRANRSAPGRPGVLG

>Rv2153c murg TB.seq 2412120:2413349 MW:41829 SEQ ID NO:223
VKDTVSQPAGGRGATAPRPADAASPSCGSSPSADSVSVVLAGGGTAGHVEPAMAVADALVALDPR
VRITALGTLRGLETRLVPQRGYHLELITAVPMPRKPGGDLARLPSRVWRAVREARDVLDDVDADVVV
GFGGYVALPAYLAARGLPLPPRRRRRIPVVIHEANARAGLANRVGAHTADRVLSAVPDSGLRRAEVV
GVPVRASIAALDRAVLRAEARAHFGFPDDARVLLVFGGSQGAVSLNRAVSGAAADLAAAGVCVLHA
HGPQNVLELRRRAQGDPPYVAVPYLDRMELAYAAADLVICRAGAMTVAEVSAVGLPAIYVPLPIGNG
EQRLNALPVVNAGGGMVVADAALTPELVARQVAGLLTDPARLAAMTAAAARVGHRDAAGQVARAAL
AVATGAGARTTT

20

15

>Rv2154c ftsW TB.seq 2413349:2414920 MW:56306 SEQ ID NO:224

VLTRLLRRGTSDTDGSQTRGAEPVEGQRTGPEEASNPGSARPRTRFGAWLGRPMTSFHLIIAVAALL

TTLGLIMVLSASAVRSYDDDGSAWVIFGKQVLWTLVGLIGGYVCLRMSVRFMRRIAFSGFAITIVMLVL

VLVPGIGKEANGSRGWFVVAGFSMQPSELAKMAFAIWGAHLLAARRMERASLREMLIPLVPAAVVAL

ALIVAQPDLGQTVSMGIILLGLLWYAGLPLRVFLSSLAAVVVSAAILAVSAGYRSDRVRSWLNPENDP

QDSGYQARQAKFALAQGGIFGDGLGQGVAKWNYLPNAHNDFIFAIIGEELGLVGALGLLGLFGLFAY

TGMRIASRSADPFLRLLTATTTLWVLGQAFINIGYVIGLLPVTGLQLPLISAGGTSTAATLSLIGIIANAAR

HEPEAVAALRAGRDDKVNRLLRLPLPEPYLPPRLEAFRDRKRANPQPAQTQPARKTPRTAPGQPAR

QMGLPPRPGSPRTADPPVRRSVHHGAGQRYAGQRRTRRVRALEGQRYG

30

35

25

>Rv2155c murd TB.seq 2414935:2416392 MW:49314 SEQ ID NO:225

VLDPLGPGAPVLVAGGRVTGQAVAAVLTRFGATPTVCDDDPVMLRPHAERGLPTVSSSDAVQQITG

YALVVASPGFSPATPLLAAAAAAGVPIWGDVELAWRLDAAGCYGPPRSWLVVTGTNGKTTTTSMLH

AMLIAGGRRAVLCGNIGSAVLDVLDEPAELLAVELSSFQLHWAPSLRPEAGAVLNIAEDHLDWHATM

AEYTAAKARVLTGGVAVAGLDDSRAAALLDGSPAQVRVGFRLGEPAARELGVRDAHLVDRAFSDDL

TLLPVASIPVPGPVGVLDALAAAALARSVGVPAGAIADAVTSFRVGRHRAEVVAVADGITYVDDSKAT

NPHAARASVLAYPRVVWIAGGLLKGASLHAEVAAMASRLVGAVLIGRDRAAVAEALSRHAPDVPVVQ

VVAGEDTGMPATVEVPVACVLDVAKDDKAGETVGAAVMTAAVAAARRMAQPGDTVLLAPAGASFD QFTGYADRGEAFATAVRAVIR

>Rv2156c murX TB.seq 2416397:2417473 MW:37714 SEQ ID NO:226

5 MRQILIAVAVAVTVSILLTPVLIRLFTKQGFGHQIREDGPPSHHTKRGTPSMGGVAILAGIWAGYLGAH LAGLAFDGEGIGASGLLVLGLATALGGVGFIDDLIKIRRSRNLGLNKTAKTVGQITSAVLFGVLVLQFRN AAGLTPGSADLSYVREIATVTLAPVLFVLFCVVIVSAWSNAVNFTDGLDGLAAGTMAMVTAAYVLITF WQYRNACVTAPGLGCYNVRDPLDLALIAAATAGACIGFLWWNAAPAKIFMGDTGSLALGGVIAGLSV TSRTEILAVVLGALFVAEITSVVLQILTFRTTGRRMFRMAPFHHHFELVGWAETTVIIRFWLLTAITCGL GVALFYGEWLAAVGA

>Rv2157c murf TB.seq 2417473:2419002 MW:51634 SEQ ID NO:227
MIELTVAQIAEIVGGAVADISPQDAAHRRVTGTVEFDSRAIGPGGLFLALPGARADGHDHAASAVAAG
AAVVLAARPVGVPAIVVPPVAAPNVLAGVLEHDNDGSGAAVLAALAKLATAVAAQLVAGGLTIIGITGS
SGKTSTKDLMAAVLAPLGEVVAPPGSFNNELGHPWTVLRATRRTDYLILEMAARHHGNIAALAEIAPP
SIGVVLNVGTAHLGEFGSREVIAQTKAELPQAVPHSGAVVLNADDPAVAAMAKLTAARVVRVSRDNT
GDVWAGPVSLDELARPRFTLHAHDAQAEVRLGVCGDHQVTNALCAAAVALECGASVEQVAAALTAA
PPVSRHRMQVTTRGDGVTVIDDAYNANPDSMRAGLQALAWIAHQPEATRRSWAVLGEMAELGEDAI
AEHDRIGRLAVRLDVSRLVVVGTGRSISAMHHGAVLEGAWGSGEATADHGADRTAVNVADGDAALA
LLRAELRPGDVVLVKASNAAGLGAVADALVADDTCGSVRP

>Rv2158c murE TB.seq 2419002:2420606 MW:55310 SEQ ID NO:228

VSSLARGISRRRTEVATQVEAAPTGLRPNAVVGVRLAALADQVGAALAEGPAQRAVTEDRTVTGVTL
RAQDVSPGDLFAALTGSTTHGARHVGDAIARGAVAVLTDPAGVAEIAGRAAVPVLVHPAPRGVLGGL

25 AATVYGHPSERLTVIGITGTSGKTTTTYLVEAGLRAAGRVAGLIGTIGIRVGGADLPSALTTPEAPTLQA
MLAAMVERGVDTVVMEVSSHALALGRVDGTRFAVGAFTNLSRDHLDFHPSMADYFEAKASLFDPDS
ALRARTAVVCIDDDAGRAMAARAADAITVSAADRPAHWRATDVAPTDAGGQQFTAIDPAGVGHHIGI
RLPGRYNVANCLVALAILDTVGVSPEQAVPGLREIRVPGRLEQIDRGQGFLALVDYAHKPEALRSVLT
TLAHPDRRLAVVFGAGGDRDPGKRAPMGRIAAQLADLVVVTDDNPRDEDPTAIRREILAGAAEVGGD
AQVVEIADRRDAIRHAVAWARPGDVVLIAGKGHETGQRGGGRVRPFDDRVELAAALEALERRA

>Rv2159c - TB.seq 2420632:2421663 MW:36377 SEQ ID NO:229
MKFVNHIEPVAPRRAGGAVAEVYAEARREFGRLPEPLAMLSPDEGLLTAGWATLRETLLVGQVPRG
RKEAVAAAVAASLRCPWCVDAHTTMLYAAGQTDTAAAILAGTAPAAGDPNAPYVAWAAGTGTPAGP
PAPFGPDVAAEYLGTAVQFHFIARLVLVLLDETFLPGGPRAQQLMRRAGGLVFARKVRAEHRPGRST
RRLEPRTLPDDLAWATPSEPIATAFAALSHHLDTAPHLPPPTRQVVRRVVGSWHGEPMPMSSRWTN

EHTAELPADLHAPTRLALLTGLAPHQVTDDDVAAARSLLDTDAALVGALAWAAFTAARRIGTWIGAAA EGQVSRQNPTG

>Rv2163c pbpB TB.seq 2425049:2427085 MW:72506 SEQ ID NO:230

- VSRAAPRRASQSQSTRPARGLRRPPGAQEVGQRKRPGKTQKARQAQEATKSRPATRSDVAPAGR STRARRTRQVVDVGTRGASFVFRHRTGNAVILVLMLVAATQLFFLQVSHAAGLRAQAAGQLKVTDV QPAARGSIVDRNNDRLAFTIEARALTFQPKRIRRQLEEARKKTSAAPDPQQRLRDIAQEVAGKLNNKP DAAAVLKKLQSDETFVYLARAVDPAVASAICAKYPEVGAERQDLRQYPGGSLAANVVGGIDWDGHG LLGLEDSLDAVLAGTDGSVTYDRGSDGVVIPGSYRNRHKAVHGSTVVLTLDNDIQFYVQQQVQQAK NLSGAHNVSAVVLDAKTGEVLAMANDNTFDPSQDIGRQGDKQLGNPAVSSPFEPGSVNKIVAASAVI EHGLSSPDEVLQVPGSIQMGGVTVHDAWEHGVMPYTTTGVFGKSSNVGTLMLSQRVGPERYYDML RKFGLGQRTGVGLPGESAGLVPPIDQWSGSTFANLPIGQGLSMTLLQMTGMYQAIANDGVRVPPRII KATVAPDGSRTEEPRPDDIRVVSAQTAQTVRQMLRAVVQRDPMGYQQGTGPTAGVPGYQMAGKT GTAQQINPGCGCYFDDVYWITFAGIATADNPRYVIGIMLDNPARNSDGAPGHSAAPLFHNIAGWLMQ RENVPLSPDPGPPLVLQAT
- >Rv2165c TB.seq 2428236:2429423 MW:42498 SEQ ID NO:231

  VQTRAPWSLPEATLAYFPNARFVSSDRDLGAGAAPGIAASRSTACQTWGGITVADPGSGPTGFGHV

  PVLAQRCFELLTPALTRYYPDGSQAVLLDATIGAGGHAERFLEGLPGLRLIGLDRDPTALDVARSRLV

  20 RFADRLTLVHTRYDCLGAALAESGYAAVGSVDGILFDLGVSSMQLDRAERGFAYATDAPLDMRMDP

  TTPLTAADIVNTYDEAALADILRRYGEERFARRIAAGIVRRRAKTPFTSTAELVALLYQAIPAPARRVGG

  HPAKRTFQALRIAVNDELESLRTAVPAALDALAIGGRIAVLAYQSLEDRIVKRVFAEAVASATPAGLPV

  ELPGHEPRFRSLTHGAERASVAEIERNPRSTPVRLRALQRVEHRAQSQQWATEKGDS
- 25 >Rv2166c TB.seq 2429428:2429856 MW:15912 SEQ ID NO:232 MFLGTYTPKLDDKGRLTLPAKFRDALAGGLMVTKSQDHSLAVYPRAAFEQLARRASKAPRSNPEAR AFLRNLAAGTDEQHPDSQGRITLSADHRRYASLSKDCVVIGAVDYLEIWDAQAWQNYQQIHEENFSA ASDEALGDIF
  - >Rv2197c TB.seq 2461505:2462146 MW:22481 SEQ ID NO:233
- MVSRYSAYRRGPDVISPDVIDRILVGACAAVWLVFTGVSVAAAVALMDLGRGFHEMAGNPHTTWVL YAVIVVSALVIVGAIPVLLRARRMAEAEPATRPTGASVRGGRSIGSGHPAKRAVAESAPVQHADAFEV AAEWSSEAVDRIWLRGTVVLTSAIGIALIAVAAATYLMAVGHDGPSWISYGLAGVVTAGMPVIEWLYA RQLRRVVAPQSS
  - >Rv2198c TB.seq 2462149:2463045 MW:30955 SEQ ID NO:234
- 35 MSGPNPPGREPDEPESEPVSDTGDERASGNHLPPVAGGGDKLPSDQTGETDAYSRAYSAPESEHV TGGPYVPADLRLYDYDDYEESSDLDDELAAPRWPWVVGVAAIIAAVALVVSVSLLVTRPHTSKLATG DTTSSAPPVQDEITTTKPAPPPPPPAPPPTTEIPTATETQTVTVTPPPPPPPPATTTAPPPATTTTAAAP

PPTTTTPTGPRQVTYSVTGTKAPGDIISVTYVDAAGRRRTQHNVYIPWSMTVTPISQSDVGSVEASSL FRVSKLNCSITTSDGTVLSSNSNDGPQTSC

>Rv2199c - TB.seq 2463234:2463650 MW:14866 SEQ ID NO:235

5 MHIEARLFEFVAAFFVVTAVLYGVLTSMFATGGVEWAGTTALALTGGMALIVATFFRFVARRLDSRPE DYEGAEISDGAGELGFFSPHSWWPIMVALSGSVAAVGIALWLPWLIAAGVAFILASAAGLVFEYYVGP EKH

>Rv2200c ctaC TB.seq 2463661:2464749 MW:40449 SEQ ID NO:236

10 VTPRGPGRLQRLSQCRPQRGSGGPARGLRQLALAAMLGALAVTVSGCSWSEALGIGWPEGITPEA HLNRELWIGAVIASLAVGVIVWGLIFWSAVFHRKKNTDTELPRQFGYNMPLELVLTVIPFLIISVLFYFT VVVQEKMLQIAKDPEVVIDITSFQWNWKFGYQRVNFKDGTLTYDGADPERKRAMVSKPEGKDKYGE ELVGPVRGLNTEDRTYLNFDKVETLGTSTEIPVLVLPSGKRIEFQMASADVIHAFWVPEFLFKRDVMP NPVANNSVNVFQIEEITKTGAFVGHCAEMCGTYHSMMNFEVRVVTPNDFKAYLQQRIDGKTNAEALR AINQPPLAVTTHPFDTRRGELAPQPVG

>Rv2427c proA g-glutamyl phosphate reductase TB.seq 2724231:2725475 MW:43746 SEQ ID NO:237

MTVPAPSQLDLRQEVHDAARRARVAARRLASLPTTVKDRALHAAADELLAHRDQILAANAEDLNAAR EADTPAAMLDRLSLNPQRVDGIAAGLRQVAGLRDPVGEVLRGYTLPNGLQLRQQRVPLGVVGMIYE GRPNVTVDAFGLTLKSGNAALLRGSSSAAKSNEALVAVLRTALVGLELPADAVQLLSAADRATVTHLI QARGLVDVVIPRGGAGLIEAVVRDAQVPTIETGVGNCHVYVHQAADLDVAERILLNSKTRRPSVCNA AETLLVDAAIAETALPRLLAALQHAGVTVHLDPDEADLRREYLSLDIAVAVVDGVDAAIAHINEYGTGH TEAIVTTNLDAAQRFTEQIDAAAVMVNASTAFTDGEQFGFGAEIGISTQKLHARGPMGLPELTSTKWI AWGAGHTRPA

>Rv2438c - similar to YHN4\_YEAST P38795 TB.seq 2734793:2737006 MW:80492 SEQ ID NO:238

MGLLGGQSGPRVGSGPVGSIPTPVNAAICQQRGGFHGVERGYSAGDSGVLTSLGDNERTMNFYSA YQHGFVRVAACTHHTTIGDPAANAASVLDMARACHDDGAALAVFPELTLSGYSIEDVLLQDSLLDAV EDALLDLVTESADLLPVLVVGAPLRHRHRIYNTAVVIHRGAVLGVVPKSYLPTYREFYERRQMAPGD GERGTIRIGGADVAFGTDLLFAASDLPGFVLHVEICEDMFVPMPPSAEAALAGATVLANLSGSPITIGR AEDRRLLARSASARCLAAYVYAAAGEGESTTDLAWDGQTMIWENGALLAESERFPKGVRRSVADVD TELLRSERLRMGTFDDNRRHHRELTESFRRIDFALDPPAGDIGLLREVERFPFVPADPQRLQQDCYE AYNIQVSGLEQRLRALDYPKVVIGVSGGLDSTHALIVATHAMDREGRPRSDILAFALPGFATGEHTKN NAIKLARALGVTFSEIDIGDTARLMLHTIGHPYSVGEKVYDVTFENVQAGLRTDYLFRIANQRGGIVLG TGDLSELALGWSTYGVGDQMSHYNVNAGVPKTLIQHLIRWVISAGEFGEKVGEVLQSVLDTEITPELI

20

25

30

PTGEEELQSSEAKVGPFALQDFSLFQVLRYGFRPSKIAFLAWHAWNDAERGNWPPGFPKSERPSYS LAEIRHWLQIFVQRFYSFSQFKRSALPNGPKVSHGGALSPRGDWRAPSDMSARIWLDQIDREVPKG

>Rv2439c proB glutamate 5-kinase TB.seq 2737118:2738245 MW:38789 SEQ ID NO:239

MRSPHRDAIRTARGLVVKVGTTALTTPSGMFDAGRLAGLAEAVERRMKAGSDVVIVSSGAIAAGIEPL
GLSRRPKDLATKQAAASVGQVALVNSWSAAFARYGRTVGQVLLTAHDISMRVQHTNAQRTLDRLRA
LHAVAIVNENDTVATNEIRFGDNDRLSALVAHLVGADALVLLSDIDGLYDCDPRKTADATFIPEVSGPA
DLDGVVAGRSSHLGTGGMASKVAAALLAADAGVPVLLAPAADAATALADASVGTVFAARPARLSAR
RFWVRYAAEATGALTLDAGAVRAVVRQRRSLLAAGITAVSGRFCGGDVVELRAPDAAMVARGVVAY
DASELATMVGRSTSELPGELRRPVVHADDLVAVSAKQAKQV

>Rv2440c obg Obg GTP-binding protein TB.seq 2738248:2739684 MW:50430 SEQ ID NO:240

VPRFVDRVVIHTRAGSGGNGCASVHREKFKPLGGPDGGNGGRGGSIVFVVDPQVHTLLDFHFRPHL

TAASGKHGMGNNRDGAAGADLEVKVPEGTVVLDENGRLLADLVGAGTRFEAAAGGRGGLGNAALA
SRVRKAPGFALLGEKGQSRDLTLELKTVADVGLVGFPSAGKSSLVSAISAAKPKIADYPFTTLVPNLG
VVSAGEHAFTVADVPGLIPGASRGRGLGLDFLRHIERCAVLVHVVDCATAEPGRDPISDIDALETELA
CYTPTLQGDAALGDLAARPRAVVLNKIDVPEARELAEFVRDDIAQRGWPVFCVSTATRENLQPLIFGL
SQMISDYNAARPVAVPRRPVIRPIPVDDSGFTVEPDGHGGFVVSGARPERWIDQTNFDNDEAVGYL
ADRLARLGVEEELLRLGARSGCAVTIGEMTFDWEPQTPAGEPVAMSGRGTDPRLDSNKRVGAAER
KAARSRRREHGDG

>Rv2441c rpmA 50S ribosomal protein L27 TB.seq 2739773:2740030 MW:8969 SEQ ID NO:241

25 MAHKKGASSSRNGRDSAAQRLGVKRYGGQVVKAGEILVRQRGTKFHPGVNVGRGGDDTLFAKTAG AVEFGIKRGRKTVSIVGSTTA

>Rv2442c rpIU 50S ribosomal protein L21 TB.seq 2740048:2740359 MW:11152 SEQ ID NO:242

30 MMATYAIVKTGGKQYKVAVGDVVKVEKLESEQGEKVSLPVALVVDGATVTTDAKALAKVAVTGEVLG HTKGPKIRIHKFKNKTGYHKRQGHRQQLTVLKVTGIA

>Rv2448c vaiS valyI-tRNA synthase TB.seq 2747596:2750223 MW:97822 SEQ ID NO:243 MLPKSWDPAAMESAIYQKWLDAGYFTADPTSTKPAYSIVLPPPNVTGSLHMGHALEHTMMDALTRR KRMQGYEVLWQPGTDHAGIATQSVVEQQLAVDGKTKEDLGRELFVDKVWDWKRESGGAIGGQMR RLGDGVDWSRDRFTMDEGLSRAVRTIFKRLYDAGLIYRAERLVNWSPVLQTAISDLEVNYRDVEGEL VSFRYGSLDDSQPHIVVATTRVETMLGDTAIAVHPDDERYRHLVGTSLAHPFVDRELAIVADEHVDPE

5

10

25

30

35

FGTGAVKVTPAHDPNDFEIGVRHQLPMPSILDTKGRIVDTGTRFDGMDRFEARVAVRQALAAQGRV VEEKRPYLHSVGHSERSGEPIEPRLSLQWWVRVESLAKAAGDAVRNGDTVIHPASMEPRWFSWVD DMHDWCISRQLWWGHRIPIWYGPDGEQVCVGPDETPPQGWEQDPDVLDTWFSSALWPFSTLGW PDKTAELEKFYPTSVLVTGYDILFFWVARMMMFGTFVGDDAAITLDGRRGPQVPFTDVFLHGLIRDE SGRKMSKSKGNVIDPLDWVEMFGADALRFTLARGASPGGDLAVSEDAVRASRNFGTKLFNATRYAL LNGAAPAPLPSPNELTDADRWILGRLEEVRAEVDSAFDGYEFSRACESLYHFAWDEFCDWYLELAK TQLAQGLTHTTAVLAAGLDTLLRILHPVIPFLTEALWLALTGRESLVSADWPEPSGISVDLVAAQRIND MQKLVTEVRRFRSDQGLADRQKVPARMHGVRDSDLSNQVAAVTSLAWLTEPGPDFEPSVSLEVRL GPEMNRTVVVELDTSGTIDVAAERRRLEKELAGAQKELASTAAKLANADFLAKAPDAVIAKIRDRQRV AQQETERITTRLAALQ

>RV2482c plsB2 TB.seq 2786915:2789281 MW:88284 SEQ ID NO:244

VTKPAADASAVLTAEDTLVLASTATPVEMELIMGWLGQQRARHPDSKFDILKLPPRNAPPAALTALVE
QLEPGFASSPQSGEDRSIVPVRVIWLPPADRSRAGKVAALLPGRDPYHPSQRQQRRILRTDPRRAR

VVAGESAKVSELRQQWRDTTVAEHKRDFAQFVSRRALLALARAEYRILGPQYKSPRLVKPEMLASA
RFRAGLDRIPGATVEDAGKMLDELSTGWSQVSVDLVSVLGRLASRGFDPEFDYDEYQVAAMRAALE
AHPAVLLFSHRSYIDGVVVPVAMQDNRLPPVHMFGGINLSFGLMGPLMRRSGMIFIRRNIGNDPLYK
YVLKEYVGYVVEKRFNLSWSIEGTRSRTGKMLPPKLGLMSYVADAYLDGRSDDILLQGVSICFDQLH
EITEYAAYARGAEKTPEGLRWLYNFIKAQGERNFGKIYVRFPEAVSMRQYLGAPHGELTQDPAAKRL
ALQKMSFEVAWRILQATPVTATGLVSALLLTTRGTALTLDQLHHTLQDSLDYLERKQSPVSTSALRLR
SREGVRAAADALSNGHPVTRVDSGREPVWYIAPDDEHAAAFYRNSVIHAFLETSIVELALAHAKHAE
GDRVAAFWAQAMRLRDLLKFDFYFADSTAFRANIAQEMAWHQDWEDHLGVGGNEIDAMLYAKRPL
MSDAMLRVFFEAYEIVADVLRDAPPDIGPEELTELALGLGRQFVAQGRVRSSEPVSTLLFATARQVAV
DQELIAPAADLAERRVAFRRELRNILRDFDYVEQIARNQFVACEFKARQGRDRI

>Rv2509 - putative oxidoreductase TB.seq 2824676:2825479 MW:28014 SEQ ID NO:245 MPIPAPSPDARAVVTGASQNIGAALATELAARGHHLIVTARREDVLTELAARLADKYRVTVDVRPADL ADPQERSKLADELAARPISILCANAGTATFGPIASLDLAGEKTQVQLNAVAVHDLTLAVLPGMIERKAG GILISGSAAGNSPIPYNATYAATKAFVNTFSESLRGELRGSGVHVTVLAPGPVRTELPDASEASLVEKL VPDFLWISTEHTARVSLNALERNKMRVVPGLTSKAMSVASQYAPRAIVAPIVGAFYKRLGGS

>Rv2524c fas fatty acid synthase TB.seq 2840124:2849330 MW:326226 SEQ ID NO:246
VTIHEHDRVSADRGGDSPHTTHALVDRLMAGEPYAVAFGGQGSAWLETLEELVSATGIETELATLVG
EAELLLDPVTDELIVVRPIGFEPLQWVRALAAEDPVPSDKHLTSAAVSVPGVLLTQIAATRALARQGM
DLVATPPVAMAGHSQGVLAVEALKAGGARDVELFALAQLIGAAGTLVARRRGISVLGDRPPMVSVTN
ADPERIGRLLDEFAQDVRTVLPPVLSIRNGRRAVVITGTPEQLSRFELYCRQISEKEEADRKNKVRGG
DVFSPVFEPVQVEVGFHTPRLSDGIDIVAGWAEKAGLDVALARELADAILIRKVDWVDEITRVHAAGA

WO 01/35317

RWILDLGPGDILTRLTAPVIRGLGIGIVPAATRGGQRNLFTVGATPEVARAWSSYAPTVVRLPDGRVK LSTKFTRLTGRSPILLAGMTPTTVDAKIVAAAANAGHWAELAGGGQVTEEIFGNRIEQMAGLLEPGRT YQFNALFLDPYLWKLQVGGKRLVQKARQSGAAIDGVVISAGIPDLDEAVELIDELGDIGISHVVFKPGT IEQIRSVIRIATEVPTKPVIMHVEGGRAGGHHSWEDLDDLLLATYSELRSRANITVCVGGGIGTPRRAA EYLSGRWAQAYGFPLMPIDGILVGTAAMATKESTTSPSVKRMLVDTQGTDQWISAGKAQGGMASSR SQLGADIHEIDNSASRCGRLLDEVAGDAEAVAERRDEIIAAMAKTAKPYFGDVADMTYLQWLRRYVE LAIGEGNSTADTASVGSPWLADTWRDRFEQMLQRAEARLHPQDFGPIQTLFTDAGLLDNPQQAIAAL LARYPDAETVQLHPADVPFFVTLCKTLGKPVNFVPVIDQDVRRWWRSDSLWQAHDARYDADAVCIIP GTASVAGITRMDEPVGELLDRFEQAAIDEVLGAGVEPKDVASRRLGRADVAGPLAVVLDAPDVRWA GRTVTNPVHRIADPAEWQVHDGPENPRATHSSTGARLQTHGDDVALSVPVSGTWVDIRFTLPANTV DGGTPVIATEDATSAMRTVLAIAAGVDSPEFLPAVANGTATLTVDWHPERVADHTGVTATFGEPLAP SLTNVPDALVGPCWPAVFAAIGSAVTDTGEPVVEGLLSLVHLDHAARVVGQLPTVPAQLTVTATAAN ATDTDMGRVVPVSVVVTGADGAVIATLEERFAILGRTGSAELADPARAGGAVSANATDTPRRRRRDV TITAPVDMRPFAVVSGDHNPIHTDRAAALLAGLESPIVHGMWLSAAAQHAVTATDGQARPPARLVG WTARFLGMVRPGDEVDFRVERVGIDQGAEIVDVAARVGSDLVMSASARLAAPKTVYAFPGQGIQHK GMGMEVRARSKAARKVWDTADKFTRDTLGFSVLHVVRDNPTSIIASGVHYHHPDGVLYLTQFTQVA MATVAAAQVAEMREQGAFVEGAIACGHSVGEYTALACVTGIYQLEALLEMVFHRGSKMHDIVPRDEL GRSNYRLAAIRPSQIDLDDADVPAFVAGIAESTGEFLEIVNFNLRGSQYAIAGTVRGLEALEAEVERRR ELTGGRRSFILVPGIDVPFHSRVLRVGVAEFRRSLDRVMPRDADPDLIIGRYIPNLVPRLFTLDRDFIQ EIRDLVPAEPLDEILADYDTWLRERPREMARTVFIELLAWQFASPVRWIETQDLLFIEEAAGGLGVERF VEIGVKSSPTVAGLATNTLKLPEYAHSTVEVLNAERDAAVLFATDTDPEPEPEEDEPVAESPAPDVVS EAAPVAPAASSAGPRPDDLVFDAADATLALIALSAKMRIDQIEELDSIESITDGASSRRNQLLVDLGSE LNLGAIDGAAESDLAGLRSQVTKLARTYKPYGPVLSDAINDQLRTVLGPSGKRPGAIAERVKKTWELG EGWAKHVTVEVALGTREGSSVRGGAMGHLHEGALADAASVDKVIDAAVASVAARQGVSVALPSAG SGGGATIDAAALSEFTDQITGREGVLASAARLVLGQLGLDDPVNALPAAPDSELIDLVTAELGADWPR LVAPVFDPKKAVVFDDRWASAREDLVKLWLTDEGDIDADWPRLAERFEGAGHVVATQATWWQGKS LAAGRQIHASLYGRIAAGAENPEPGRYGGEVAVVTGASKGSIAASVVARLLDGGATVIATTSKLDEER LAFYRTLYRDHARYGAALWLVAANMASYSDVDALVEWIGTEQTESLGPQSIHIKDAQTPTLLFPFAAP RVVGDLSEAGSRAEMEMKVLLWAVQRLIGGLSTIGAERDIASRLHVVLPGSPNRGMFGGDGAYGEA KSALDAVVSRWHAESSWAARVSLAHALIGWTRGTGLMGHNDAIVAAVEEAGVTTYSTDEMAALLLD LCDAESKVAAARSPIKADLTGGLAEANLDMAELAAKAREQMSAAAAVDEDAEAPGAIAALPSPPRGF TPAPPPQWDDLDVDPADLVVIVGGAEIGPYGSSRTRFEMEVENELSAAGVLELAWTTGLIRWEDDP QPGWYDTESGEMVDESELVQRYHDAVVQRVGIREFVDDGAIDPDHASPLLVSVFLEKDFAFVVSSE ADARAFVEFDPEHTVIRPVPDSTDWQVIRKAGTEIRVPRKTKLSRVVGGQIPTGFDPTVWGISADMA GSIDRLAVWNMVATVDAFLSSGFSPAEVMRYVHPSLVANTQGTGMGGGTSMQTMYHGNLLGRNKP NDIFQEVLPNIIAAHVVQSYVGSYGAMIHPVAACATAAVSVEEGVDKIRLGKAQLVVAGGLDDLTLEGII GFGDMAATADTSMMCGRGIHDSKFSRPNDRRRLGFVEAQGGGTILLARGDLALRMGLPVLAVVAFA

5

10

15

20

25

30

PCT/US00/31152 WO 01/35317

QSFGDGVHTSIPAPGLGALGAGRGGKDSPLARALAKLGVAADDVAVISKHDTSTLANDPNETELHER LADALGRSEGAPLFVVSQKSLTGHAKGGAAVFQMMGLCQILRDGVIPPNRSLDCVDDELAGSAHFV WVRDTLRLGGKFPLKAGMLTSLGFGHVSGLVALVHPQAFIASLDPAQRADYQRRADARLLAGQRRL ASAIAGGAPMYQRPGDRRFDHHAPERPQEASMLLNPAARLGDGEAYIG

5

10

15

20

>Rv2555c alaS alanyl-tRNA synthase TB.seq 2873772:2876483 MW:97326 SEQ ID NO:247
VQTHEIRKRFLDHFVKAGHTEVPSASVILDDPNLLFVNAGMVQFVPFFLGQRTPPYPTATSIQKCIRTP
DIDEVGITTRHNTFFQMAGNFSFGDYFKRGAIELAWALLTNSLAAGGYGLDPERIWTTVYFDDDEAV
RLWQEVAGLPAERIQRRGMADNYWSMGIPGPCGPSSEIYYDRGPEFGPAGGPIVSEDRYLEVWNL
VFMQNERGEGTTKEDYQILGPLPRKNIDTGMGVERIALVLQDVHNVYETDLLRPVIDTVARVAARAYD
VGNHEDDVRYRIIADHSRTAAILIGDGVSPGNDGRGYVLRRLLRRVIRSAKLLGIDAAIVGDLMATVRN
AMGPSYPELVADFERISRIAVAEETAFNRTLASGSRLFEEVASSTKKSGATVLSGSDAFTLHDTYGFPI
ELTLEMAAETGLQVDEIGFRELMAEQRRRAKADAAARKHAHADLSAYRELVDAGATEFTGFDELRS
QARILGIFVDGKRVPVVAHGVAGGAGEGQRVELVLDRTPLYAESGGQIADEGTISGTGSSEAARAAV
TDVQKIAKTLWVHRVNVESGEFVEGDTVIAAVDPGWRRGATQGHSGTHMVHAALRQVLGPNAVQA
GSLNRPGYLRFDFNWQGPLTDDQRTQVEEVTNEAVQADFEVRTFTEQLDKAKAMGAIALFGESYPD
EVRVVEMGGPFSLELCGGTHVSNTAQIGPVTILGESSIGSGVRRVEAYVGLDSFRHLAKERALMAGL
ASSLKVPSEEVPARVANLVERLRAAEKELERVRMASARAAATNAAAGAQRIGNVRLVAQRMSGGMT
AADLRSLIGDIRGKLGSEPAVVALIAEGESQTVPYAVAANPAAQDLGIRANDLVKQLAVAVEGRGGGK
ADLAQGSGKNPTGIDAALDAVRSEIAVIARVG

>Rv2580c hisS histidyl-tRNA synthase TB.seq 2904822:2906090 MW:45118 SEQ ID NO:248
VTEFSSFSAPKGVPDYVPPDSAQFVAVRDGLLAAARQAGYSHIELPIFEDTALFARGVGESTDVVSKE
MYTFADRGDRSVTLRPEGTAGVVRAVIEHGLDRGALPVKLCYAGPFFRYERPQAGRYRQLQQVGV
EAIGVDDPALDAEVIAIADAGFRSLGLDGFRLEITSLGDESCRPQYRELLQEFLFGLDLDEDTRRRAGI
NPLRVLDDKRPELRAMTASAPVLLDHLSDVAKQHFDTVLAHLDALGVPYVINPRMVRGLDYYTKTAF
EFVHDGLGAQSGIGGGGRYDGLMHQLGGQDLSGIGFGLGVDRTVLALRAEGKTAGDSARCDVFGV
PLGEAAKLRLAVLAGRLRAAGVRVDLAYGDRGLKGAMRAAARSGARVALVAGDRDIEAGTVAVKDL

TTGEQVSVSMDSVVAEVISRLAG

30

35

>Rv2614c thrS threonyl-tRNA synthase TB.seq 2941190:2943265 MW:77123 SEQ ID NO:249 MSAPAQPAPGVDGGDPSQARIRVPAGTTAATAVGEAGLPRRGTPDAIVVVRDADGNLRDLSWVPD VDTDITPVAANTDDGRSVIRHSTAHVLAQAVQELFPQAKLGIGPPITDGFYYDFDVPEPFTPEDLAALE KRMRQIVKEGQLFDRRVYESTEQARAELANEPYKLELVDDKSGDAEIMEVGGDELTAYDNLNPRTR ERVWGDLCRGPHIPTTKHIPAFKLTRSSAAYWRGDQKNASLQRIYGTAWESQEALDRHLEFIEEAQR RDHRKLGVELDLFSFPDEIGSGLAVFHPKGGIVRRELEDYSRRKHTEAGYQFVNSPHITKAQLFHTSG HLDWYADGMFPPMHIDAEYNADGSLRKPGQDYYLKPMNCPMHCLIFRARGRSYRELPLRLFEFGTV

YRYEKSGVVHGLTRVRGLTMDDAHIFCTRDQMRDELRSLLRFVLDLLADYGLTDFYLELSTKDPEKF VGAEEVWEEATTVLAEVGAESGLELVPDPGGAAFYGPKISVQVKDALGRTWQMSTIQLDFNFPERF GLEYTAADGTRHRPVMIHRALFGSIERFFGILTEHYAGAFPAWLAPVQVVGIPVADEHVAYLEEVATQ LKSHGVRAEVDASDDRMAKKIVHHTNHKVPFMVLAGDRDVAAGAVSFRFGDRTQINGVARDDAVAA IVAWIADRENAVPTAELVKVAGRE

>Rv2697c dut deoxyuridine triphosphatase TB.seq 3013683:3014144 MW:15772 SEQ ID NO:250 VSTTLAIVRLDPGLPLPSRAHDGDAGVDLYSAEDVELAPGRRALVRTGVAVAVPFGMVGLVHPRSGL ATRVGLSIVNSPGTIDAGYRGEIKVALINLDPAAPIVVHRGDRIAQLLVQRVELVELVEVSSFDEAGLAS TSRGDGGHGSSGGHASL

>Rv2782c pepR protease/peptidase, M16 family (insulinase) TB.seq 3089045:3090358 MW:47074 SEQ ID NO:251

MPRRSPADPAAALAPRRTTLPGGLRVVTEFLPAVHSASVGVWVGVGSRDEGATVAGAAHFLEHLLF KSTPTRSAVDIAQAMDAVGGELNAFTAKEHTCYYAHVLGSDLPLAVDLVADVVLNGRCAADDVEVER DVVLEEIAMRDDDPEDALADMFLAALFGDHPVGRPVIGSAQSVSVMTRAQLQSFHLRRYTPERMVV AAAGNVDHDGLVALVREHFGSRLVRGRRPVAPRKGTGRVNGSPRLTLVSRDAEQTHVSLGIRTPGR GWEHRWALSVLHTALGGGLSSRLFQEVRETRGLAYSVYSALDLFADSGALSVYAACLPERFADVMR VTADVLESVARDGITEAECGIAKGSLRGGLVLGLEDSSSRMSRLGRSELNYGKHRSIEHTLRQIEQVT VEEVNAVARHLLSRRYGAAVLGPHGSKRSLPQQLRAMVG

>Rv2783c gpsl pppGpp synthase and polyribonucleotide phosphorylase TB.seq
3090339:3092594 MW:79736 SEQ ID NO:252
MSAAEIDEGVFETTATIONGSFGTRTIRFETGRLALQAAGAVVAYLDDDNMLLSATTASKNPKEHFDF

FPLTVDVEERMYAAGRIPGSFFRREGRPSTDAILTCRLIDRPLRPSFVDGLRNEIQIVVTILSLDPGDLY DVLAINAASASTQLGGLPFSGPIGGVRVALIDGTWVGFPTVDQIERAVFDMVVAGRIVEGDVAIMMVE AEATENVVELVEGGAQAPTESVVAAGLEAAKPFIAALCTAQQELADAAGKSGKPTVDFPVFPDYGED VYYSVSSVATDELAAALTIGGKAERDQRIDEIKTQVVQRLADTYEGREKEVGAALRALTKKLVRQRILT DHFRIDGRGITDIRALSAEVAVVPRAHGSALFERGETQILGVTTLDMIKMAQQIDSLGPETSKRYMHH YNFPPFSTGETGRVGSPKRREIGHGALAERALVPVLPSVEEFPYAIRQVSEALGSNGSTSMGSVCAS

TLALLNAGVPLKAPVAGIAMGLVSDDIQVEGAVDGVVERRFVTLTDILGAEDAFGDMDFKVAGTKDFV
TALQLDTKLDGIPSQVLAGALEQAKDARLTILEVMAEAIDRPDEMSPYAPRVTTIKVPVDKIGEVIGPK
GKVINAITEETGAQISIEDDGTVFVGATDGPSAQAAIDKINAIANPQLPTVGERFLGTVVKTTDFGAFVS
LLPGRDGLVHISKLGKGKRIAKVEDVVNVGDKLRVEIADIDKRGKISLILVADEDSTAAATDAATVTS
>Rv2793c truB tRNA pseudouridine 55 synthase TB.seq 3102364:3103257 MW:31821

SEQ ID NO:253

MSATGPGIVVIDKPAGMTSHDVVGRCRRIFATRRVGHAGTLDPMATGVLVIGIERATKILGLLTAAPKS

YAATIRLGQTTSTEDAEGQVLQSVPAKHLTIEAIDAAMERLRGEIRQVPSSVSAIKVGGRRAYRLARQ

5

10

15

20

25

30

PCT/US00/31152

GRSVQLEARPIRIDRFELLAARRRDQLIDIDVEIDCSSGTYIRALARDLGDALGVGGHVTALRRTRVGR FELDQARSLDDLAERPALSLSLDEACLLMFARRDLTAAEASAAANGRSLPAVGIDGVYAACDADGRVI ALLRDEGSRTRSVAVLRPATMHPG

>Rv2797c - TB.seq 3105619:3107304 MW:58761 SEQ ID NO:254
VPLTVADIDRWNAQAVREVFHAASARAEVTFEASRQLAALSIFANSGGKTAEAAAHHNAGIRRDLDA
HGNEALAVARAADRAADGIVKVQSELAALRHAAAAAELTIDALINRVVPIPGLRSTEAQWARTLAKQT
ELQAELDAIMAEANAVDEELASAVNMADGDAPIPADSGPPVGPEGLTPTQLASDANEERLREERARL
QAHLERLQAEYDQLSVRAARDYHNGILDGDAVGRLAALTDELSAARGRLGELDAVDEALSRAPETYL
TQLQIPEDPNQQVLAAVAVGNPDTAANVSVTVPGVGSTTRGALPGMVTEARDLRSEVIRQLNAAGK
PASVATIAWMGYHPPPNPLDTGSAGDLWQTMTDGQAHAGAADLSRYLQQVRANNPSGHLTVLGHS
YGSLTASLALQDLDAQSAHPVNDVVFYGSPGLELYSPAQLGLDHGHAYVMQAPHDLITNLVAPLAPL
HGWGLDPYLTPGFTELSSQAGFDPGGIWRDGVYAHGDYPRSFLDAAGQPQLRMSGYNLAAIAAGL
PDNTVGPPLLPPILGGGMPAAPGPALRGGR

15

30

>Rv2864c ponA2 TB.seq 3175454:3177262 MW:63015 SEQ ID NO:255

MVTKTTLASATSGLLLLAVVAMSGCTPRPQGPGPAAEKFFAALAIGDTASAAQLSDNPNEAREALNA
AWAGLQAAHLDAQVLSAKYAEDTGTVAYRFSWHLPKDRIWTYDGQLKMARDEGRWHVRWTTSGL
HPKLGEHQTFALRADPPRRASVNEVGGTDVLVPGYLYHYSLDAGQAGRELFGTAHAVVGALHPFDD

TLNDPQLLAEQASSSTQPLDLVTLHADDSNRVAAAIGQLPGVVITPQAELLPTDKHFAPAVLNDVKKA
VVDELDGKAGWRVVSVNQNGVDVSVLHEVAPSPASSVSITLDRVVQNAAQHAVNTRGGKAMIVVIK
PSTGEILAIAQNAGADADGPVATTGLYPPGSTFKMITAGAAVERDLATPETLLGCPGEIDIGHRTIPNY
GGFDLGVVPMSRAFASSCNTTFAELSSRLPPRGLTQAARRYGIGLDYQVDGITTVTGSVPPTVDLAE
RTEDGFGQGKVLASPFGMALVAATVAAGKTPVPQLIAGRPTAVEGDATPISQKMIDALRPMMRLVVT
NGTAKEIAGCGEVFGKTGEAEFPGGSHSWFAGYRGDLAFASLIVGGGSSEYAVRMTKVMFESLPPG

YLA

>Rv2868c gcpE TB.seq 3179368:3180528 MW:40451 SEQ ID NO:256

VTVGLGMPQPPAPTLAPRRATRQLMVGNVGVGSDHPVSVQSMCTTKTHDVNSTLQQIAELTAAGC

DIVRVACPRQEDADALAEIARHSQIPVVADIHFQPRYIFAAIDAGCAAVRVNPGNIKEFDGRVGEVAKA

AGAAGIPIRIGVNAGSLDKRFMEKYGKATPEALVESALWEASLFEEHGFGDIKISVKHNDPVVMVAAY

ELLAARCDYPLHLGVTEAGPAFQGTIKSAVAFGALLSRGIGDTIRVSLSAPPVEEVKVGNQVLESLNL

RPRSLEIVSCPSCGRAQVDVYTLANEVTAGLDGLDVPLRVAVMGCVVNGPGEAREADLGVASGNGK

GQIFVRGEVIKTVPEAQIVETLIEEAMRLAAEMGEQDPGATPSGSPIVTVS

>Rv2869c - TB.seq 3180548:3181759 MW:42835 SEQ ID NO:257

35 MMFVTGIVLFALAILISVALHECGHMWVARRTGMKVRRYFVGFGPTLWSTRRGETEYGVKAVPLGG FCDIAGMTPVEELDPDERDRAMYKQATWKRVAVLFAGPGMNLAICLVLIYAIALVWGLPNLHPPTRAV IGETGCVAQEVSQGKLEQCTGPGPAALAGIRSGDVVVKVGDTPVSSFDEMAAAVRKSHGSVPIVVE RDGTAIVTYVDIESTQRWIPNGQGGELQPATVGAIGVGAARVGPVRYGVFSAMPATFAVTGDLTVEV GKALAALPTKVGALVRAIGGGQRDPQTPISVVGASIIGGDTVDHGLWVAFWFFLAQLNLILAAINLLPL LPFDGGHIAVAVFERIRNMVRSARGKVAAAPVNYLKLLPATYVVLVLVVGYMLLTVTADLVNPIRLFQ >Rv2870c - TB.s q 3181770:3183077 MW:45324 SEQ ID NO:258

- VATGGRVVIRRRGDNEVVAHNDEVTNSTDGRADGRLRVVVLGSTGSIGTQALQVIADNPDRFEVVG LAAGGAHLDTLLRQRAQTGVTNIAVADEHAAQRVGDIPYHGSDAATRLVEQTEADVVLNALVGALGL RPTLAALKTGARLALANKESLVAGGSLVLRAARPGQIVPVDSEHSALAQCLRGGTPDEVAKLVLTAS GGPFRGWSAADLEHVTPEQAGAHPTWSMGPMNTLNSASLVNKGLEVIETHLLFGIPYDRIDVVVHP QSIIHSMVTFIDGSTIAQASPPDMKLPISLALGWPRRVSGAAAACDFHTASSWEFEPLDTDVFPAVEL
- ARQAGVAGGCMTAVYNAANEEAAAAFLAGRIGFPAIVGIIADVLHAADQWAVEPATVDDVLDAQRWA
  RERAQRAVSGMASVAIASTAKPGAAGRHASTLERS
  - >Rv2922c smc member of Smc1/Cut3/Cut14 family TB.seq 3234189:3238055 MW:139610 SEQ ID NO:259
- VGAGSRFPLVDPLPSVGARPDRLRGQPRRRTRAGGRPGSARCVPEAAAAAAGRHDTGPRRQSRR
  RLVAVDGADHRVQRAVIWPLVYLKSLTLKGFKSFAAPTTLRFEPGITAVVGPNGSGKSNVVDALAWV
  MGEQGAKTLRGGKMEDVIFAGTSSRAPLGRAEVTVSIDNSDNALPIEYTEVSITRRMFRDGASEYEIN
  GSSCRLMDVQELLSDSGIGREMHVIVGQGKLEEILQSRPEDRRAFIEEAAGVLKHRKRKEKALRKLDT
  MAANLARLTDLTTELRRQLKPLGRQAEAAQRAAAIQADLRDARLRLAADDLVSRRAEREAVFQAEAA
  MRREHDEAAARLAVASEELAAHESAVAELSTRAESIQHTWFGLSALAERVDATVRIASERAHHLDIEP
  VAVSDTDPRKPEELEAEAQQVAVAEQQLLAELDAARARLDAARAELADRERRAAEADRAHLAAVRE
- EADRREGLARLAGQVETMRARVESIDESVARLSERIEDAAMRAQQTRAEFETVQGRIGELDQGEVG
  LDEHHERTVAALRLADERVAELQSAERAAERQVASLRARIDALAVGLQRKDGAAWLAHNRSGAGLF
  GSIAQLVKVRSGYEAALAAALGPAADALAVDGLTAAGSAVSALKQADGGRAVLVLSDWPAPQAPQS
  ASGEMLPSGAQWALDLVESPPQLVGAMIAMLSGVAVVNDLTEAMGLVEIRPELRAVTVDGDLVGAG
- 25 WVSGGSDRKLSTLEVTSEIDKARSELAAAEALAAQLNAALAGALTEQSARQDAAEQALAALNESDTAI SAMYEQLGRLGQEARAAEEEWNRLLQQRTEQEAVRTQTLDDVIQLETQLRKAQETQRVQVAQPIDR QAISAAADRARGVEVEARLAVRTAEERANAVRGRADSLRRAAAAEREARVRAQQARAARLHAAAVA AAVADCGRLLAGRLHRAVDGASQLRDASAAQRQQRLAAMAAVRDEVNTLSARVGELTDSLHRDEL ANAQAALRIEQLEQMVLEQFGMAPADLITEYGPHVALPPTELEMAEFEQARERGEQVIAPAPMPFDR
- VTQERRAKRAERALAELGRVNPLALEEFAALEERYNFLSTQLEDVKAARKDLLGVVADVDARILQVFN
  DAFVDVEREFRGVFTALFPGGEGRLRLTEPDDMLTTGIEVEARPPGKKITRLSLLSGGEKALTAVAML
  VAIFRARPSPFYIMDEVEAALDDVNLRRLLSLFEQLREQSQIIIITHQKPTMEVADALYGVTMQNDGITA
  VISQRMRGQQVDQLVTNSS
  - >Rv2925c mc RNAse III TB.seq 3239829:3240548 MW:25400 SEQ ID NO:260
    MIRSRQPLLDALGVDLPDELLSLALTHRSYAYENGGLPTNERLEFLGDAVLGLTITDALFHRHPDRSE
    GDLAKLRASVVNTQALADVARRLCAEGLGVHVLLGRGEANTGGADKSSILADGMESLLGAIYLQHGM

PCT/US00/31152 WO 01/35317

EKAREVILRLFGPLLDAAPTLGAGLDWKTSLQELTAARGLGAPSYLVTSTGPDHDKEFTAVVVVMDS EYGSGVGRSKKEAEQKAAAAAWKALEVLDNAMPGKTSA

>Rv2934 ppsD TB.seq 3262245:3267725 MW:193317 SEQ ID NO:261

MTSLAERAAQLSPNARAALARELVRAGTTFPTDICEPVAVVGIGCRFPGNVTGPESFWQLLADGVDT 5 IEQVPPDRWDADAFYDPDPSASGRMTTKWGGFVSDVDAFDADFFGITPREAVAMDPQHRMLLEVA WEALEHAGIPPDSLSGTRTGVMMGLSSWDYTIVNIERRADIDAYLSTGTPHCAAVGRIAYLLGLRGPA VAVDTACSSSLVAIHLACQSLRLRETDVALAGGVQLTLSPFTAIALSKWSALSPTGRCNSFDANADGF VRGEGCGVVVLKRLADAVRDQDRVLAVVRGSATNSDGRSNGMTAPNALAQRDVITSALKLADVTPD SVNYVETHGTGTVLGDPIEFESLAATYGLGKGQGESPCALGSVKTNIGHLEAAAGVAGFIKAVLAVQR 10 GHIPRNLHFTRWNPAIDASATRLFVPTESAPWPAAAGPRRAAVSSFGLSGTNAHVVVEQAPDTAVAA AGGMPYVSALNVSGKTAARVASAAAVLADWMSGPGAAAPLADVAHTLNRHRARHAKFATVIARDRA EAIAGLRALAAGQPRVGVVDCDQHAGGPGRVFVYSGQGSQWASMGQQLLANEPAFAKAVAELDPI FVDQVGFSLQQTLIDGDEVVGIDRIQPVLVGMQLALTELWRSYGVIPDAVIGHSMGEVSAAVVAGALT PEQGLRVITTRSRLMARLSGQGAMALLELDADAAEALIAGYPQVTLAVHASPRQTVIAGPPEQVDTVI 15 AAVATQNRLARRVEVDVASHHPIIDPILPELRSALADLTPQPPSIPIISTTYESAQPVADADYWSANLRN PVRFHQAVTAAGVDHNTFIEISPHPVLTHALTDTLDPDGSHTVMSTMNRELDQTLYFHAQLAAVGVA ASEHTTGRLVDLPPTPWHHQRFWVTDRSAMSELAATHPLLGAHIEMPRNGDHVWQTDVGTEVCPW LADHKVFGQPIMPAAGFAEIALAAASEALGTAADAVAPNIVINQFEVEQMLPLDGHTPLTTQLIRGGDS QIRVEIYSRTRGGEFCRHATAKVEQSPRECAHAHPEAQGPATGTTVSPADFYALLRQTGQHHGPAF 20 AALSRIVRLADGSAETEISIPDEAPRHPGYRLHPVVLDAALQSVGAAIPDGEIAGSAEASYLPVSFETIR VYRDIGRHVRCRAHLTNLDGGTGKMGRIVLINDAGHIAAEVDGIYLRRVERRAVPLPLEQKIFDAEWT ESPIAAVPAPEPAAETTRGSWLVLADATVDAPGKAQAKSMADDFVQQWRSPMRRVHTADIHDESAV LAAFAETAGDPEHPPVGVVVFVGGASSRLDDELAAARDTVWSITTVVRAVVGTWHGRSPRLWLVTG GGLSVADDEPGTPAAASLKGLVRVLAFEHPDMRTTLVDLDITQDPLTALSAELRNAGSGSRHDDVIA 25 WRGERRFVERLSRATIDVSKGHPVVRQGASYVVTGGLGGLGLVVARWLVDRGAGRVVLGGRSDPT DEQCNVLAELQTRAEIVVVRGDVASPGVAEKLIETARQSGGQLRGVVHAAAVIEDSLVFSMSRDNLE RVWAPKATGALRMHEATADCELDWWLGFSSAASLLGSPGQAAYACASAWLDALVGWRRASGLPA AVINWGPWSEVGVAQALVGSVLDTISVAEGIEALDSLLAADRIRTGVARLRADRALVAFPEIRSISYFT QVVEELDSAGDLGDWGGPDALADLDPGEARRAVTERMCARIAAVMGYTDQSTVEPAVPLDKPLTEL 30 GLDSLMAVRIRNGARADFGVEPPVALILQGASLHDLTADLMRQLGLNDPDPALNNADTIRDRARQRA **AARHGAAMRRRPKPEVQGG** 

>Rv2946c pks1 TB.seq 3291503:3296350 MW:166642 SEQ ID NO:262
VISARSAEALTAQAGRLMAHVQANPGLDPIDVGCSLASRSVFEHRAVVVGASREQLIAGLAGLAAGE
PGAGVAVGQPGSVGKTVVVFPGQGAQRIGMGRELYGELPVFAQAFDAVADELDRHLRLPLRDVIW
GADADLLDSTEFAQPALFAVEVASFAVLRDWGVLPDFVMGHSVGELAAAHAAGVLTLADAAMLVVA

RGRLMQALPAGGAMVAVAASEDEVEPLLGEGVGIAAINAPESVVISGAQAAANAIADRFAAQGRRVH QLAVSHAFHSPLMEPMLEEFARVAARVQAREPQLGLVSNVTGELAGPDFGSAQYWVDHVRRPVRF ADSARHLQTLGATHFIEAGPGSGLTGSIEQSLAPAEAMVVSMLGKDRPELASALGAAGQVFTTGVPV QWSAVFAGSGGRRVQLPTYAFQRRRFWETPGADGPADAAGLGLGATEHALLGAVVERPDSDEVVL TGRLSLADQPWLADHVVNGVVLFPGAGFVELVIRAGDEVGCALIEELVLAAPLVMHPGVGVQVQVVV 5 GAADESGHRAVSVYSRGDQSQGWLLNAEGMLGVAAAETPMDLSVWPPEGAESVDISDGYAQLAE RGYAYGPAFQGLVAIWRRGSELFAEVVAPGEAGVAVDRMGMHPAVLDAVLHALGLAVEKTQASTET RLPFCWRGVSLHAGGAGRVRARFASAGADAISVDVCDATGLPVLTVRSLVTRPITAEQLRAAVTAAG GASDQGPLEVVWSPISVVSGGANGSAPPAPVSWADFCAGSDGDASVVVWELESAGGQASSVVGS VYAATHTALEVLQSWLGADRAATLVVLTHGGVGLAGEDISDLAAAAVWGMARSAQAENPGRIVLIDT 10 DAAVDASVLAGVGEPQLLVRGGTVHAPRLSPAPALLALPAAESAWRLAAGGGGTLEDLVIQPCPEV QAPLQAGQVRVAVAAVGVNFRDVVAALGMYPGQAPPLGAEGAGVVLETGPEVTDLAVGDAVMGFL GGAGPLAVVDQQLVTRVPQGWSFAQAAAVPVVFLTAWYGLADLAEIKAGESVLIHAGTGGVGMAAV QLARQWGVEVFVTASRGKWDTLRAMGFDDDHIGDSRTCEFEEKFLAVTEGRGVDVVLDSLAGEFV DASLRLLVRGGRFLEMGKTDIRDAQEIAANYPGVQYRAFDLSEAGPARMQEMLAEVRELFDTRELH 15 RLPVTTWDVRCAPAAFRFMSQARHIGKVVLTMPSALADRLADGTVVITGATGAVGGVLARHLVGAY GVRHLVLASRRGDRAEGAAELAADLTEAGAKVQVVACDVADRAAVAGLFAQLSREYPPVRGVIHAA GVLDDAVITSLTPDRIDTVLRAKVDAAWNLHQATSDLDLSMFALCSSIAATVGSPGQGNYSAANAFLD GLAAHRQAAGLAGISLAWGLWEQPGGMTAHLSSRDLARMSRSGLAPMSPAEAVELFDAALAIDHPL AVATLLDRAALDARAQAGALPALFSGLARRPRRRQIDDTGDATSSKSALAQRLHGLAADEQLELLVG 20 LVCLQAAAVLGRPSAEDVDPDTEFGDLGFDSLTAVELRNRLKTATGLTLPPTVIFDHPTPTAVAEYVA QQMSGSRPTESGDPTSQVVEPAAAEVSVHA >Rv3014c ligA DNA ligase TB.seq 3372545:3374617 MW:75258 SEQ ID NO:263 VSSPDADQTAPEVLRQWQALAEEVREHQFRYYVRDAPIISDAEFDELLRRLEALEEQHPELRTPDSP TQLVGGAGFATDFEPVDHLERMLSLDNAFTADELAAWAGRIHAEVGDAAHYLCELKIDGVALSLVYR 25 EGRLTRASTRGDGRTGEDVTLNARTIADVPERLTPGDDYPVPEVLEVRGEVFFRLDDFQALNASLVE EGKAPFANPRNSAAGSLRQKDPAVTARRRLRMICHGLGHVEGFRPATLHQAYLALRAWGLPVSEHT TLATDLAGVRERIDYWGEHRHEVDHEIDGVVVKVDEVALQRRLGSTSRAPRWAIAYKYPPEEAQTKL LDIRVNVGRTGRITPFAFMTPVKVAGSTVGQATLHNASEIKRKGVLIGDTVVIRKAGDVIPEVLGPVVE LRDGSEREFIMPTTCPECGSPLAPEKEGDADIRCPNARGCPGQLRERVFHVASRNGLDIEVLGYEAG 30

LDEDGFRRLLADGPASRT

35 >Rv3025c - NifS-like protein TB.seq 3383885:3385063 MW:40948 SEQ ID NO:264

MAYLDHAATTPMHPAAIEAMAAVQRTIGNASSLHTSGRSARRRIEEARELIADKLGARPSEVIFTAGG

TESDNLAVKGIYWARRDAEPHRRRIVTTEVEHHAVLDSVNWLVEHEGAHVTWLPTAADGSVSATAL

VALLQAKVIADEGELFALTERDLLRTDLFRTKAGELSANGKRLLVNLDKAKAAPLWRVLVALSIRHVGP TAARALATEFGSLDAIAAASTDQLAAVEGVGPTIAAAVTEWFAVDWHREIVDKWRAAGVRMVDERD ESVPRTLAGLTIVVTGSLTGFSRDDAKEAIVARGGKAAGSVSKKTNYVVAGDSPGSKYDKAVELGVPI

REALQSHDDVALVSVMWANNEVGTILPIAEMSVVAMEFGVPMHSDAIQAVGQLPLDFGASGLSAMS VAGHKFGGPPGVGALLLRRDVTCVPLMHGGGQERDIRSGTPDVASAVGMATAAQIAVDGLEENSAR LRLLRDRLVEGVLAEIDDVCLNGADDPMRLAGNAHFTFRGCEGDALLMLLDANGIECSTGSACTAGV AQPSHVLIAMGVDAASARGSLRLSLGHTSVEADVDAALEVLPGAVARARRAALAAAGASR

5

10

>Rv3080c pknK serine-threonine protein kinase TB.seq 3442656:3445985 MW:119420 SEQ ID NO:265

MTDVDPHATRRDLVPNIPAELLEAGFDNVEEIGRGGFGVVYRCVQPSLDRAVAVKVLSTDLDRDNLE RFLREQRAMGRLSGHPHIVTVLQVGVLAGGRPFIVMPYHAKNSLETLIRRHGPLDWRETLSIGVKLA GALEAAHRVGTLHRDVKPGNILLTDYGEPQLTDFGIARIAGGFETATGVIAGSPAFTAPEVLEGASPTP ASDVYSLGATLFCALTGHAAYERRSGERVIAQFLRITSQPIPDLRKQGLPADVAAAIERAMARHPADR PATAADVGEELRDVQRRNGVSVDEMPLPVELGVERRRSPEAHAAHRHTGGGTPTVPTPPTPATKY RPSVPTGSLVTRSRLTDILRAGGRRRLILIHAPSGFGKSTLAAQWREELSRDGAAVAWLTIDNDDNNE VWFLSHLLESIRRVRPTLAESLGHVLEEHGDDAGRYVLTSLIDEIHENDDRIAVVIDDWHRVSDSRTQ AALGELLDNGCHHI QI IVTSWSRAGLPVGRLRIGDELAEIDSAALRFDTDEAAALLNDAGGLRLPRAD

15 AALGFLLDNGCHHLQLIVTSWSRAGLPVGRLRIGDELAEIDSAALRFDTDEAAALLNDAGGLRLPRAD VQALTTSTDGWAAALRLAALSLRGGGDATQLLRGLSGASDVIHEFLSENVLDTLEPELREFLLVASVT ERTCGGLASALAGITNGRAMLEEAEHRGLFLQRTEDDPNWFRFHQMFADFLHRRLERGGSHRVAEL HRRASAWFAENGYLHEAVDHALAAGDPARAVDLVEQDETNLPEQSKMTTLLAIVQKLPTSMVVSRA RLQLAIAWANILLQRPAPATGALNRFETALGRAELPEATQADLRAEADVLRAVAEVFADRVERVDDLL AEAMSRPDTLPPRVPGTAGNTAALAAICRFEFAEVYPLLDWAAPYQEMMGPFGTVYAQCLRGMAAR

AEAMSRPDTLPPRVPGTAGNTAALAAICRFEFAEVYPLLDWAAPYQEMMGPFGTVYAQCLRGMAAR NRLDIVAALQNFRTAFEVGTAVGAHSHAARLAGSLLAELLYETGDLAGAGRLMDESYLLGSEGGAVD YLAARYVIGARVKAAQGDHEGAADRLSTGGDTAVQLGLPRLAARINNERIRLGIALPAAVAADLLAPR TIPRDNGIATMTAELDEDSAVRLLSAGDSADRDQACQRAGALAAAIDGTRRPLAALQAQILHIETLAAT GRESDARNELAPVATKCAELGLSRLLVDAGLA

25 >Rv3106 fprA adrenodoxin and NADPH ferredoxin reductase TB.seq 3474004:3475371 MW:49342 SEQ ID NO:266

MRPYYIAIVGSGPSAFFAAASLLKAADTTEDLDMAVDMLEMLPTPWGLVRSGVAPDHPKIKSISKQFE KTAEDPRFRFFGNVVVGEHVQPGELSERYDAVIYAVGAQSDRMLNIPGEDLPGSIAAVDFVGWYNA HPHFEQVSPDLSGARAVVIGNGNVALDVARILLTDPDVLARTDIADHALESLRPRGIQEVVIVGRRGPL QAAFTTLELRELADLDGVDVVIDPAELDGITDEDAAAVGKVCKQNIKVLRGYADREPRPGHRRMVFR FLTSPIEIKGKRKVERIVLGRNELVSDGSGRVAAKDTGEREELPAQLVVRSVGYRGVPTPGLPFDDQ SGTIPNVGGRINGSPNEYVVGWIKRGPTGVIGTNKKDAQDTVDTLIKNLGNAKEGAECKSFPEDHAD

QVADWLAARQPKLVTSAHWQVIDAFERAAGEPHGRPRVKLASLAELLRIGLG >Rv3235 - TB.seq 3611296:3611934 MW:22659 SEQ ID NO:267

35 MMASNQTAAQHSSATLQQAPRSIDDAGGCPLTISPIANSPGDTFAVTPVVEYEPPPRNIPPCGQSSH AARRPHTPQLARRQPIRPSGRAPAAVTSTAKSPRLRQAGTFADAALRRVLEVIDRRRPVGQLRPLLA

PGLVDSVLAVSRTAAGHQQGAAMLRRIRLTPAGPDTADTAAEVFGTYSRGDRIHAIACRVEQRPAGN **ETRWLMVALHIG** 

>Rv3255c manA mannose-6-phosphat isomerase TB.seq 3635040:3636263 MW:43340 **SEQ ID NO:268** 

- VELLRGALRTYAWGSRTAIAEFTGRPVPAAHPEAELWFGAHPGDPAWLQTPHGQTSLLEALVADPE 5 GQLGSASRARFGDVLPFLVKVLAADEPLSLQAHPSAEQAVEGYLREERMGIPVSSPVRNYRDTSHK PELLVALQPFEALAGFREAARTTELLRALAVSDLDPFIDLLSEGSDADGLRALFTTWITAPQPDIDVLV PAVLDGAIQYVSSGATEFGAEAKTVLELGERYPGDAGVLAALLLNRISLAPGEAIFLPAGNLHAYVRG FGVEVMANSDNVLRGGLTPKHVDVPELLRVLDFAPTPKARLRPPIRREGLGLVFETPTDEFAATLLVL
- DGDHLGHEVDASSGHDGPQILLCTEGSATVHGKCGSLTLQRGTAAWVAADDGPIRLTAGQPAKLFR 10 **ATVGL**

>Rv3264c rmlA2 glucose-1-phosphate thymidyltransferase TB.seq 3644897:3645973 MW:37840 **SEQ ID NO:269** 

LATHQVDAVVLVGGKGTRLRPLTLSAPKPMLPTAGLPFLTHLLSRIAAAGIEHVILGTSYKPAVFEAEF GDGSALGLQIEYVTEEHPLGTGGGIANVAGKLRNDTAMVFNGDVLSGADLAQLLDFHRSNRADVTL 15 QLVRVGDPRAFGCVPTDEEDRVVAFLEKTEDPPTDQINAGCYVFERNVIDRIPQGREVSVEREVFPA LLADGDCKIYGYVDASYWRDMGTPEDFVRGSADLVRGIAPSPALRGHRGEQLVHDGAAVSPGALLI GGTVVGRGAEIGPGTRLDGAVIFDGVRVEAGCVIERSIIGFGARIGPRALIRDGVIGDGADIGARCELL SGARVWPGVFLPDGGIRYSSDV

20

25

30

35

>Rv3368c - TB.seq 3780334:3780975 MW:23734 SEQ ID NO:270 MTLNLSVDEVLTTTRSVRKRLDFDKPVPRDVLMECLELALQAPTGSNSQGWQWVFVEDAAKKKAIA DVYLANARGYLSGPAPEYPDGDTRGERMGRVRDSATYLAEHMHRAPVLLIPCLKGREDESAVGGVS FWASLFPAVWSFCLALRSRGLGSCWTTLHLLDNGEHKVADVLGIPYDEYSQGGLLPIAYTQGIDFRP **AKRLPAESVTHWNGW** 

>Rv3382c lytB1 TB.seq 3796447:3797433 MW:34667 SEQ ID NO:271 MAEVFVGPVAQGYASGEVTVLLASPRSFCAGVERAIETVKRVLDVAEGPVYVRKQIVHNTVVVAELR DRGAVFVEDLDEIPDPPPGAVVVFSAHGVSPAVRAGADERGLQVVDATCPLVAKVHAEAARFAAR GDTVVFIGHAGHEETEGTLGVAPRSTLLVQTPADVAALNLPEGTQLSYLTQTTLALDETADVIDALRA RFPTLGQPPSEDICYATTNRQRALQSMVGECDVVLVIGSCNSSNSRRLVELAQRSGTPAYLIDGPDDI EPEWLSSVSTIGVTAGASAPPRLVGQVIDALRGYASITVVERSIATETVRFGLPKQVRAQ

>Rv3418c groES 10 kD chaperone TB.seq 3836985:3837284 MW:10773 SEQ ID NO:272 VAKVNIKPLEDKILVQANEAETTTASGLVIPDTAKEKPQEGTVVAVGPGRWDEDGEKRIPLDVAEGDT VIYSKYGGTEIKYNGEEYLILSARDVLAVVSK

>Rv3423c air TB.seq 3840193:3841416 MW:43357 SEQ ID NO:273

VKRFWENVGKPNDTTDGRGTTSLAMTPISQTPGLLAEAMVDLGAIEHNVRVLREHAGHAQLMAVVK

ADGYGHGATRVAQTALGAGAAELGVATVDEALALRADGITAPVLAWLHPPGIDFGPALLADVQVAVS

SLRQLDELLHAVRRTGRTATVTVKVDTGLNRNGVGPAQFPAMLTALRQAMAEDAVRLRGLMSHMV

YADKPDDSINDVQAQRFTAFLAQAREQGVRFEVAHLSNSSATMARPDLTFDLVRPGIAVYGLSPVPA

LGDMGLVPAMTVKCAVALVKSIRAGEGVSYGHTWIAPRDTNLALLPIGYADGVFRSLGGRLEVLINGR

RCPGVGRICMDQFMVDLGPGPLDVAEGDEAILFGPGIRGEPTAQDWADLVGTIHYEVVTSPRGRITR

TYREAENR

>Rv3490 otsA [alpha],-trehalose-phosphate synthase TB.seq 3908232:3909731 MW:55864
 SEQ ID NO:274
 MAPSGGQEAQICDSETFGDSDFVVVANRLPVDLERLPDGSTTWKRSPGGLVTALEPVLRRRRGAW
 VGWPGVNDDGAEPDLHVLDGPIIQDELELHPVRLSTTDIAQYYEGFSNATLWPLYHDVIVKPLYHRE
 WWDRYVDVNQRFAEAASRAAAHGATVWVQDYQLQLVPKMLRMLRPDLTIGFFLHIPFPPVELFMQ
 MPWRTEIIQGLLGADLVGFHLPGGAQNFLILSRRLVGTDTSRGTVGVRSRFGAAVLGSRTIRVGAFPI
 SVDSGALDHAARDRNIRRRAREIRTELGNPRKILLGVDRLDYTKGIDVRLKAFSELLAEGRVKRDDTV
 VVQLATPSRERVESYQTLRNDIERQVGHINGEYGEVGHPVVHYLHRPAPRDELIAFFVASDVMLVTP
 LRDGMNLVAKEYVACRSDLGGALVLSEFTGAAAELRHAYLVNPHDLEGVKDGIEEALNQTEEAGRR
 RMRSLRRQVLAHDVDRWAQSFLDALAGAHPRGQG

>Rv3598c iysS Iysyi-tRNA synthase TB.seq 4041423:4042937 MW:55678 SEQ ID NO:275
VSAADTAEDLPEQFRIRRDKRARLLAQGRDPYPVAVPRTHTLAEVRAAHPDLPIDTATEDIVGVAGRV
IFARNSGKLCFATLQDGDGTQLQVMISLDKVGQAALDAWKADVDLGDIVYVHGAVISSRRGELSVLA
DCWRIAAKSLRPLPVAHKEMSEESRVRQRYVDLIVRPEARAVARLRIAVVRAIRTALQRRGFLEVETP
VLQTLAGGAAARPFATHSNALDIDLYLRIAPELFLKRCIVGGFDKVFELNRVFRNEGADSTHSPEFSM
LETYQTYGTYDDSAVVTRELIQEVADEAIGTRQLPLPDGSVYDIDGEWATIQMYPSLSVALGEEITPQT
TVDRLRGIADSLGLEKDPAIHDNRGFGHGKLIEELWERTVGKSLSAPTFVKDFPVQTTPLTRQHRSIP
GVTEKWDLYLRGIELATGYSELSDPVVQRERFADQARAAAAGDDEAMVLDEDFLAALEYGMPPCTG
TGMGIDRLLMSLTGLSIRETVLFPIVRPHSN

>Rv3600c - similar to Bacillus subtilis protein YacB TB.seq 4043041:4043856 MW:29274
SEQ ID NO:276
VLLAIDVRNTHTVVGLLSGMKEHAKVVQQWRIRTESEVTADELALTIDGLIGEDSERLTGTAALSTVPS
VLHEVRIMLDQYWPSVPHVLIEPGVRTGIPLLVDNPKEVGADRIVNCLAAYDRFRKAAIVVDFGSSICV
DVVSAKGEFLGGAIAPGVQVSSDAAAARSAALRRVELARPRSVVGKNTVECMQAGAVFGFAGLVDG
LVGRIREDVSGFSVDHDVAIVATGHTAPLLLPELHTVDHYDQHLTLQGLRLVFERNLEVQRGRLKTAR

20

25

30

>Rv3606c folk 7,8-dihydro-6-hydroxymethylpterin pyrophosphokinase TB.seq
4048181:4048744 MW:20732 SEQ ID NO:277
MTRVVLSVGSNLGDRLARLRSVADGLGDALIAASPIYEADPWGGVEQGQFLNAVLIADDPTCEPREW
LRRAQEFERAAGRVRGQRWGPRNLDVDLIACYQTSATEALVEVTARENHLTLPHPLAHLRAFVLIPW
IAVDPTAQLTVAGCPRPVTRLLAELEPADRDSVRLFRPSFDLNSRHPVSRAPES
>Rv3607c folx may be involved in folate biosynthesis TB.seq 4048744:4049142 MW:14553
MADRIELRGLTVHGRHGVYDHERVAGQRFVIDVTVWIDLAEAANSDDLADTYDYVRLASRAAEIVAG
PPRKLIETVGAEIADHVMDDQRVHAVEVAVHKPQAPIPQTFDDVAVVIRRSRRGGRGWVVPAGGAV

NVSADTPHVPVRYGNVVAEVRADLLASVADAVAAGVDPARLVLDPGLGFAKTAQHNWAILHALP ELVATGIPVLVGASRKRFLGALLAGPDGVMRPTDGRDTATAVISALAALHGAWGVRVHDVRASVDAI KVVEAWMGAERIERDG

>Rv3609c fole GTP cyclohydrolase I TB.seq 4049977:4050582 MW:22395 SEQ ID NO:279 MSQLDSRSASARIRVFDQQRAEAAVRELLYAIGEDPDRDGLVATPSRVARSYREMFAGLYTDPDSVL NTMFDEDHDELVLVKEIPMYSTCEHHLVAFHGVAHVGYIPGDDGRVTGLSKIARLVDLYAKRPQVQE RLTSQIADALMKKLDPRGVIVVIEAEHLCMAMRGVRKPGSVTTTSAVRGLFKTNAASRAEALDLILRK

>Rv3610c ftsH inner membrane protein, chaperone TB.seq 4050601:4052880 MW:81987
 MNRKNVTRTITAIAVVVLLGWSFFYFSDDTRGYKPVDTSVAITQINGDNVKSAQIDDREQQLRLILKKG
 NNETDGSEKVITKYPTGYAVDLFNALSAKNAKVSTVVNQGSILGELLVYVLPLLLLVGLFVMFSRMQG
 GARMGFGFGKSRAKQLSKDMPKTTFADVAGVDEAVEELYEIKDFLQNPSRYQALGAKIPKGVLLYGP
 PGTGKTLLARAVAGEAGVPFFTISGSDFVEMFVGVGASRVRDLFEQAKQNSPCIIFVDEIDAVGRQR
 GAGLGGGHDEREQTLNQLLVEMDGFGDRAGVILIAATNRPDILDPALLRPGRFDRQIPVSNPDLAGR
 RAVLRVHSKGKPMAADADLDGLAKRTVGMTGADLANVINEAALLTARENGTVITGPALEEAVDRVIG

GPRRKGRIISEQEKKITAYHEGGHTLAAWAMPDIEPIYKVTILARGRTGGHAVAVPEEDKGLRTRSEMI AQLVFAMGGRAAEELVFREPTTGAVSDIEQATKIARSMVTEFGMSSKLGAVKYGSEHGDPFLGRTM GTQPDYSHEVAREIDEEVRKLIEAAHTEAWEILTEYRDVLDTLAGELLEKETLHRPELESIFADVEKRP RLTMFDDFGGRIPSDKPPIKTPGELAIERGEPWPQPVPEPAFKAAIAQATQAAEAARSDAGQTGHGA

30 RLTMFDDFGGRIPSDKPPIKTPGELAIERGEPWPQPVPEPAFKAAIAQATQAAEAARSDAGQTGHGA NGSPAGTHRSGDRQYGSTQPDYGAPAGWHAPGWPPRSSHRPSYSGEPAPTYPGQPYPTGQADP GSDESSAEQDDEVSRTKPAHG

>Rv3671c - TB.seq 4112322:4113512 MW:40722 SEQ ID NO:280

MTPSQWLDIAVLAVAFIAAISGWRAGALGSMLSFGGVLLGATAGVLLAPHIVSQISAPRAKLFAALFLIL ALVVVGEVAGVVLGRAVRGAIRNRPIRLIDSVIGVGVQLVVVLTAAWLLAMPLTQSKEQPELAAAVKG SRVLARVNEAAPTWLKTVPKRLSALLNTSGLPAVLEPFSRTPVIPVASPDPALVNNPVVAATEPSVVKI RSLAPRCQKVLEGTGFVISPDRVMTNAHVVAGSNNVTVYAGDKPFEATVVSYDPSVDVAILAVPHLP

35

PPPLVFAAEPAKTGADVVVLGYPGGGNFTATPARIREAIRLSGPDIYGDPEPVTRDVYTIRADVEQGD SGGPLIDLNGQVLGVVFGAAIDDAETGFVLTAGEVAGQLAKIGATQPVGTGACVS

>Rv3682 ponA2 TB.seq 4121913:4124342 MW:84637 SEQ ID NO:281

MPERLPAAITVLKLAGCCLLASVVATALTFPFAGGLGLMSNRASEVVANGSAQLLEGQVPAVSTMVD AKGNTIAWLYSQRRFEVPSDKIANTMKLAIVSIEDKRFADHSGVDWKGTLTGLAGYASGDLDTRGGS 5 TLEQQYVKNYQLLVTAQTDAEKRAAVETTPARKLREIRMALTLDKTFTKSEILTRYLNLVSFGNNSFG VQDAAQTYFGINASDLNWQQAALLAGMVQSTSTLNPYTNPDGALARRNVVLDTMIENLPGEAEALR AAKAEPLGVLPQPNELPRGCIAAGDRAFFCDYVQEYLSRAGISKEQVATGGYLIRTTLDPEVQAPVKA AIDKYASPNLAGISSVMSVIKPGKDAHKVLAMASNRKYGLDLEAGETMRPQPFSLVGDGAGSIFKIFT

TAAALDMGMGINAQLDVPPRFQAKGLGSGGAKGCPKETWCVVNAGNYRGSMNVTDALATSPNTAF 10 AKLISQVGVGRAVDMAIKLGLRSYANPGTARDYNPDSNESLADFVKRQNLGSFTLGPIELNALELSNV AATLASGGVWCPPNPIDQLIDRNGNEVAVTTETCDQVVPAGLANTLANAMSKDAVGSGTAAGSAGA AGWDLPMSGKTGTTEAHRSAGFVGFTNRYAAANYIYDDSSSPTDLCSGPLRHCGSGDLYGGNEPS RTWFAAMKPIANNFGEVQLPPTDPRYVDGAPGSRVPSVAGLDVDAARQRLKDAGFQVADQTNSVN 15

SSAKYGEVVGTSPSGQTIPGSIVTIQISNGIPPAPPPPPLPEDGGPPPPVGSQVVEIPGLPPITIPLLAP **PPPAPPP** 

>Rv3721c dnaZX DNA polymerase III,[gamma] (dnaZ) and t (dnaX) TB.seq 4164995:4166728 MW:61892 SEQ ID NO:282

VALYRKYRPASFAEVVGQEHVTAPLSVALDAGRINHAYLFSGPRGCGKTSSARILARSLNCAQGPTA NPCGVCESCVSLAPNAPGSIDVVELDAASHGGVDDTRELRDRAFYAPVQSRYRVFIVDEAHMVTTA 20 GFNALLKIVEEPPEHLIFIFATTEPEKVLPTIRSRTHHYPFRLLPPRTMRALLARICEQEGVVVDDAVYP LVIRAGGGSPRDTLSVLDQLLAGAADTHVTYTRALGLLGVTDVALIDDAVDALAACDAAALFGAIESVI DGGHDPRRFATDLLERFRDLIVLQSVPDAASRGVVDAPEDALDRMREQAARIGRATLTRYAEVVQA GLGEMRGATAPRLLLEVVCARLLLPSASDAESALLQRVERIETRLDMSIPAPQAVPRPSAAAAEPKHQ PAREPRPVLAPTPASSEPTVAAVRSMWPTVRDKVRLRSRTTEVMLAGATVRALEDNTLVLTHESAPL 25 ARRLSEQRNADVLAEALKDALGVNWRVRCETGEPAAAASPVGGGANVATAKAVNPAPTANSTQRD

EEEHMLAEAGRGDPSPRRDPEEVALELLQNELGARRIDNA >Rv3783 - TB.seq 4229255:4230094 MW:32337 SEQ ID NO:283

MTFMDAQASFQTQSRTLARVRGDLVDGFRRHELWLHLGWQDIKQRYRRSVLGPFWITIATGTTAVA MGGLYSKLFRLELSEHLPYVTLGLIVWNLINAAILDGAEVFVANEGLIKQLPAPLSVHVYRLVWRQMIF FAHNIVIYFVIAIIFPKPWSWADLSFLPALALIFLNCVWVSLCFGILATRYRDIGPLLFSVVQLLFFMTPII WNDETLRRQGAGRWSSIVELNPLLHYLDIVRAPLLGAHQELRHWLVVLVLTVVGWMLAAFAMRQYR **ARVPYWV** 

>Rv3789 - TB.seq 4235371:4235733 MW:13378 SEQ ID NO:284

MRFVVTGGLAGIVDFGLYVVLYKVAGLQVDLSKAISFIVGTITAYLINRRWTFQAEPSTARFVAVMLLY 35 GITFAVQVGLNHLCLALLHYRAWAIPVAFVIAQGTATVINFIVQRAVIFRIR >Rv3790 - TB.seq 4235776:4237158 MW:50164 SEQ ID NO:285

MLSVGATTTATRLTGWGRTAPSVANVLRTPDAEMIVKAVARVAESGGGRGAIARGLGRSYGDNAQN
GGGLVIDMTPLNTIHSIDADTKLVDIDAGVNLDQLMKAALPFGLWVPVLPGTRQVTVGGAIACDIHGK
NHHSAGSFGNHVRSMDLLTADGEIRHLTPTGEDAELFWATVGGNGLTGIIMRATIEMTPTSTAYFIAD
GDVTASLDETIALHSDGSEARYTYSSAWFDAISAPPKLGRAAVSRGRLATVEQLPAKLRSEPLKFDAP
QLLTLPDVFPNGLANKYTFGPIGELWYRKSGTYRGKVQNLTQFYHPLDMFGEWNRAYGPAGFLQYQ
FVIPTEAVDEFKKIIGVIQASGHYSFLNVFKLFGPRNQAPLSFPIPGWNICVDFPIKDGLGKFVSELDRR
VLEFGGRLYTAKDSRTTAETFHAMYPRVDEWISVRRKVDPLRVFASDMARRLELL
>Rv3791 - TB.seq 4237162:4237923 MW:27470 SEQ ID NO:286
MVLDAVGNPQTVLLLGGTSEIGLAICERYLHNSAARIVLACLPDDPRREDAAAAMKQAGARSVELIDF
DALDTDSHPKMIEAAFSGGDVDVAIVAFGLLGDAEELWQNQRKAVQIAEINYTAAVSVGVLLAEKMR

DALDTDSHPKMIEAAFSGGDVDVAIVAFGLLGDAEELWQNQRKAVQIAEINYTAAVSVGVLLAEKMR
AQGFGQIIAMSSAAGERVRRANFVYGSTKAGLDGFYLGLSEALREYGVRVLVIRPGQVRTRMSAHLK
EAPLTVDKEYVANLAVTASAKGKELVWAPAAFRYVMMVLRHIPRSIFRKLPI
>Rv3794 emba TB.seq 4243230:4246511 MW:115694 SEQ ID NO:287
VPHDGNERSHRIARLAAVVSGIAGLLLCGIVPLLPVNQTTATIFWPQGSTADGNITQITAPLVSGAPRA

15 LDISIPCSAIATLPANGGLVLSTLPAGGVDTGKAGLFVRANQDTVVVAFRDSVAAVAARSTIAAGGCS
ALHIWADTGGAGADFMGIPGGAGTLPPEKKPQVGGIFTDLKVGAQPGLSARVDIDTRFITTPGALKKA
VMLLGVLAVLVAMVGLAALDRLSRGRTLRDWLTRYRPRVRVGFASRLADAAVIATLLLWHVIGATSS
DDGYLLTVARVAPKAGYVANYYRYFGTTEAPFDWYTSVLAQLAAVSTAGVWMRLPATLAGIACWLIV
SRFVLRRLGPGPGGLASNRVAVFTAGAVFLSAWLPFNNGLRPEPLIALGVLVTWVLVERSIALGRLAP
AAVAIIVATLTATLAPQGLIALAPLLTGARAIAQRIRRRRATDGLLAPLAVLAAALSLITVVVFRDQTLATV
AESARIKYKVGPTIAWYQDFLRYYFLTVESNVEGSMSRRFAVLVLLFCLFGVLFVLLRRGRVAGLASG

PAWRLIGTTAVGLLLLTFTPTKWAVQFGAFAGLAGVLGAVTAFTFARIGLHSRRNLTLYVTALLFVLA
WATSGINGWFYVGNYGVPWYDIQPVIASHPVTSMFLTLSILTGLLAAWYHFRMDYAGHTEVKDNRR
NRILASTPLLVVAVIMVAGEVGSMAKAAVFRYPLYTTAKANLTALSTGLSSCAMADDVLAEPDPNAGM
LQPVPGQAFGPDGPLGGISPVGFKPEGVGEDLKSDPVVSKPGLVNSDASPNKPNAAITDSAGTAGG
KGPVGINGSHAALPFGLDPARTPVMGSYGENNLAATATSAWYQLPPRSPDRPLVVVSAAGAIWSYK
EDGDFIYGQSLKLQWGVTGPDGRIQPLGQVFPIDIGPQPAWRNLRFPLAWAPPEADVARIVAYDPNL
SPEQWFAFTPPRVPVLESLQRLIGSATPVLMDIATAANFPCQRPFSEHLGIAELPQYRILPDHKQTAA
SSNLWQSSSTGGPFLFTQALLRTSTIATYLRGDWYRDWGSVEQYHRLVPADQAPDAVVEEGVITVP
GWGRPGPIRALP

>Rv3795 embB TB.seq 4246511:4249804 MW:118023 SEQ ID NO:288
MTQCASRRKSTPNRAILGAFASARGTRWVATIAGLIGFVLSVATPLLPVVQTTAMLDWPQRGQLGSV
TAPLISLTPVDFTATVPCDVVRAMPPAGGVVLGTAPKQGKDANLQALFVVVSAQRVDVTDRNVVILS
VPREQVTSPQCQRIEVTSTHAGTFANFVGLKDPSGAPLRSGFPDPNLRPQIVGVFTDLTGPAPPGLA
VSATIDTRFSTRPTTLKLLAIIGAIVATVVALIALWRLDQLDGRGSIAQLLLRPFRPASSPGGMRRLIPAS
WRTFTLTDAVVIFGFLLWHVIGANSSDDGYILGMARVADHAGYMSNYFRWFGSPEDPFGWYYNLLA
LMTHVSDASLWMRLPDLAAGLVCWLLLSREVLPRLGPAVEASKPAYWAAAMVLLTAWMPFNNGLR

35

5

10

15

20

25

30

PEGIIALGSLVTYVLIERSMRYSRLTPAALAVVTAAFTLGVQPTGLIAVAALVAGGRPMLRILVRRHRLV
GTLPLVSPMLAAGTVILTVVFADQTLSTVLEATRVRAKIGPSQAWYTENLRYYYLILPTVDGSLSRRFG
FLITALCLFTAVFIMLRRKRIPSVARGPAWRLMGVIFGTMFFLMFTPTKWVHHFGLFAAVGAAMAALT
TVLVSPSVLRWSRNRMAFLAALFFLLALCWATTNGWWYVSSYGVPFNSAMPKIDGITVSTIFFALFAI
AAGYAAWLHFAPRGAGEGRLIRALTTAPVPIVAGFMAAVFVASMVAGIVRQYPTYSNGWSNVRAFV
GGCGLADDVLVEPDTNAGFMKPLDGDSGSWGPLGPLGGVNPVGFTPNGVPEHTVAEAIVMKPNQP
GTDYDWDAPTKLTSPGINGSTVPLPYGLDPARVPLAGTYTTGAQQQSTLVSAWYLLPKPDDGHPLV
VVTAAGKIAGNSVLHGYTPGQTVVLEYAMPGPGALVPAGRMVPDDLYGEQPKAWRNLRFARAKMP
ADAVAVRVVAEDLSLTPEDWIAVTPPRVPDLRSLQEYVGSTQPVLLDWAVGLAFPCQQPMLHANGIA
EIPKFRITPDYSAKKLDTDTWEDGTNGGLLGITDLLLRAHVMATYLSRDWARDWGSLRKFDTLVDAP
PAQLELGTATRSGLWSPGKIRIGP

>RV3834c serS seryltrna synthase TB.seq 4307655:4308911 MW:45293 SEQ ID NO:289
VIDLKLLRENPDAVRRSQLSRGEDPALVDALLTADAARRAVISTADSLRAEQKAASKSVGGASPEERP
PLLRRAKELAEQVKAAEADEVEAEAAFTAAHLAISNVIVDGVPAGGEDDYAVLDVVGEPSYLENPKD
HLELGESLGLIDMQRGAKVSGSRFYFLTGRGALLQLGLLQLALKLAVDNGFVPTIPPVLVRPEVMVGT
GFLGAHAEEVYRVEGDGLYLVGTSEVPLAGYHSGEILDLSRGPLRYAGWSSCFRREAGSHGKDTRG
IIRVHQFDKVEGFVYCTPADAEHEHERLLGWQRQMLARIEVPYRVIDVAAGDLGSSAARKFDCEAWI
PTQGAYRELTSTSNCTTFQARRLATRYRDASGKPQIAATLNGTLATTRWLVAILENHQRPDGSVRVP
DALVPFVGVEVLEPVA

>Rv3907c pcnA polynucleotide polymerase TB.seq 4391631:4393070 MW:53057 SEQ ID NO:290 VPEAVQEADLLTAAAVALNRHAALLRELGSVFAAAGHELYLVGGSVRDALLGRLSPDLDFTTDARPE RVQEIVRPWADAVWDTGIEFGTVGVGKSDHRMEITTFRADSYDRVSRHPEVRFGDCLEGDLVRRDF TTNAMAVRVTATGPGEFLDPLGGLAALRAKVLDTPAAPSGSFGDDPLRMLRAARFVSQLGFAVAPR VRAAIEEMAPQLARISAERVAAELDKLLVGEDPAAGIDLMVQSGMGAVVLPEIGGMRMAIDEHHQHK DVYQHSLTVLRQAIALEDDGPDLVLRWAALLHDIGKPATRRHEPDGGVSFHHHEVVGAKMVRKRMR ALKYSKQMIDDISQLVYLHLRFHGYGDGKWTDSAVRRYVTDAGALLPRLHKLVRADCTTRNKRRAAR LQASYDRLEERIAELAAQEDLDRVRPDLDGNQIMAVLDIPAGPQVGEAWRYLKELRLERGPLSTEEA TTELLSWWKSRGNR

A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims.

## WHAT IS CLAIMED IS:

5

10

15

20

25

1. A method for identifying a nucleic acid or a polypeptide sequence that may be a target for a drug comprising the following steps:

- (a) providing a first nucleic acid or a polypeptide sequence that is known to be a drug target;
- (b) providing at least one algorithm selected from the group consisting of a "domain fusion" method, a "phylogenetic profile" method and a "physiologic linkage" method, wherein the algorithm is capable analyzing a functional relationship between nucleic acid or polypeptide sequences; and
- (c) comparing the first nucleic acid or the polypeptide drug target sequence to a plurality of sequences using at least one of the algorithms as set forth in step (b) to identify a second sequence that has a functional relationship to the first sequence, thereby identifying a nucleic acid or a polypeptide sequence that may be a target for a drug.
- 2. A method for identifying a nucleic acid or a polypeptide sequence that may be essential for the growth or viability of an organism comprising the following steps:
- (a) providing a first nucleic acid or a polypeptide sequence that is known to be essential for the growth or viability of an organism;
- (b) providing at least one algorithm capable analyzing a functional relationship between nucleic acid or polypeptide sequences selected from the group consisting of a "domain fusion" method, a "phylogenetic profile" method and a "physiologic linkage" method; and
- (c) comparing the first nucleic acid or the polypeptide sequence to a plurality of sequences using at least one of the algorithms as set forth in step (b) to identify a second sequence that has a functional relationship to the first sequence, thereby identifying a nucleic acid or a polypeptide sequence that may be essential for the growth or viability of an organism.
- The method of claim 1 or claim 2, wherein the drug is an antimicrobial drug.

4. The method of claim 1 or claim 2, wherein the first nucleic acid or a polypeptide sequence is derived from a pathogen.

- 5. The method of claim 4, wherein the pathogen is a microorganism.
- 6. The method of claim 1 or claim 2, wherein the microorganism is Mycobacterium tuberculosis (MTB).
- 7. The method of claim 1 or claim 2, wherein the plurality of sequences used to identify a second sequence comprises a database of the gene sequences of an entire genome of an organism.
  - 8. The method of claim 1 or claim 2, wherein the plurality of sequences used to identify a second sequence comprises a database of the gene sequences derived from a pathogen.
    - 9. The method of claim 1 or claim 2, wherein the "phylogenetic profile" method algorithm comprises
      - (a) obtaining data, comprising a list of proteins from at least two genomes;
    - (b) comparing the list of proteins to form a protein phylogenetic profile for each protein, wherein the protein phylogenetic profile indicates the presence or absence of a protein belonging to a particular protein family in each of the at least two genomes based on homology of the proteins; and
    - (c) grouping the list of proteins based on similar profiles, wherein proteins with similar profiles are indicated to have a functional relationship.
    - 10. The method of claim 9, wherein the phylogenetic profile is in the form of a vector, matrix or phylogenetic tree.
  - The method of claim 9, comprising determining the significance of homology between the proteins by computing a probability (p) value threshold.

5

15

20

12. The method of claim 11, wherein the probability is set with respect to the value 1/NM, based on the total number of sequence comparisons that are to be performed, wherein N is the number of proteins in the first organism's genome and M in all other genomes.

- 13. The method of claim 9, wherein the presence or absence is by calculating an evolutionary distance.
- 14. The method of claim 13, wherein the evolutionary distance is calculated by:
  - (a) aligning two sequences from the list of proteins;
- (b) determining an evolution probability process by constructing a conditional probability matrix: p(aa→aa'), where aa and aa' are any amino acids, said conditional probability matrix being constructed by converting an amino acid substitution matrix from a log odds matrix to said conditional probability matrix;
- (c) accounting for an observed alignment of the constructed conditional probability matrix by taking the product of the conditional probabilities for each aligned pair during the alignment of the two sequences, represented by  $P(p) = \prod_{n} p(aa_n \rightarrow aa'_n)$ ; and
- (d) determining an evolutionary distance  $\alpha$  from powers equation  $p'=p^{\alpha}(aa\rightarrow aa')$ , maximizing for P.
- 15. The method of claim 14, wherein the conditional probability matrix is defined by a Markov process with substitution rates, over a fixed time interval.
- 16. The method of claim 14, where the conversion from an amino acid substitution matrix to a conditional probability matrix is represented by:

$$P_B(i \to j) = p(j)2^{\hat{}} \frac{\text{BLOSUM62}_{ij}}{2},$$

5

10

15

20

where BLOSUM62 is an amino acid substitution matrix, and  $P(i\rightarrow j)$  is the probability that amino acid i is replaced by amino acid j through point mutations according to BLOSUM62 scores.

17. The method of claim 16, where Pj's are the abundances of amino acid j and are computed by solving a plurality of linear equations given by the normalization condition that:

$$\sum_{i} P_{B}(i \to j) = 1.$$

- 18. The method of claim 1 or claim 2, wherein the "physiologic linkage" method algorithm identifies proteins and nucleic acids that participate in a common functional pathway.
  - 19. The method of claim 1 or claim 2, wherein the "physiologic linkage" method algorithm comprises identifies proteins and nucleic acids that participate in the synthesis of a common structural complex.
  - 20. The method of claim 1 or claim 2, wherein the "physiologic linkage" method algorithm comprises identifies proteins and nucleic acids that participate in a common metabolic pathway.

20

15

- 21. The method of claim 1 or claim 2, wherein the "domain fusion" method algorithm comprises
- (a) aligning a first primary amino acid sequence of multiple distinct non-homologous polypeptides to second primary amino acid sequence of a plurality of proteins; and
- (b) for any alignment found between the first primary amino acid sequences of all of such multiple distinct non-homologous polypeptides and at least one protein of the second primary amino acid sequences, outputting an indication identifying the aligned second primary amino acid sequence as an indication of a functional link between the aligned first and second polypeptide sequences.

30

22. The method of claim 21, wherein the aligning is performed by an algorithm selected from the group consisting of a Smith-Waterman algorithm, Needleman-Wunsch algorithm, a BLAST algorithm, a FASTA algorithm, and a PSI-BLAST algorithm.

- 23. The method of claim 21, wherein the multiple distinct non-homologous polypeptides are obtained by translating a nucleic acid sequence from a genome database.
- 24. The method of claim 21, wherein the plurality of proteins have a known function.
  - 25. The method of claim 21, wherein at least one of the multiple distinct non-homologous polypeptides has a known function.
  - 26. The method of claim 21, wherein at least one of the multiple distinct non-homologous polypeptides has an unknown function.
  - The method of claim 21, wherein the alignment is based on the degree of homology of the multiple distinct non-homologous polypeptides to the plurality of proteins.
  - 28. The method of claim 21, further comprising determining the significance of the aligned and identified second primary amino acid sequence by computing a probability (p) value threshold.
  - The method of claim 28, wherein the probability threshold is set with respect to the value 1/NM, based on the total number of sequence comparisons that are to be performed, wherein N is the number of proteins in a first organism's genome and M in all other genomes.
  - 30. The method of claim 21, further comprising filtering excessive functional links between one first primary amino acid sequence of multiple distinct non-

5

15

20

25

homologous polypeptides and an excessive number of other distinct non-homologous polypeptides for any alignment found between the first primary amino acid sequences of the distinct non-homologous polypeptides and at least one of the second primary amino acid sequences of the plurality of proteins.

5

31. A computer program product, stored on a computer-readable medium, for identifying a nucleic acid or a polypeptide sequence that may be a target for a drug, the computer program product comprising instructions for causing a computer system to be capable of:

10

- (a) inputting a first nucleic acid or a polypeptide sequence that is known to be a drug target;
- (b) accessing at least one algorithm capable analyzing a functional relationship between nucleic acid or polypeptide sequences selected from the group consisting of a "domain fusion" method, a "phylogenetic profile" method and a "physiologic linkage" method; and
- (c) comparing the first nucleic acid or the polypeptide drug target sequence to a plurality of sequences using at least one of the algorithms set forth in step (b) to identify a second sequence that has a functional relationship to the first sequence and generating an output identifying a nucleic acid or a polypeptide sequence that may be a target for a drug.

20

15

32. A computer program product, stored on a computer-readable medium, for identifying a nucleic acid or a polypeptide sequence that may be essential for the growth or viability of an organism, the computer program product comprising instructions for causing a computer system to be capable of:

25

- (a) providing a first nucleic acid or a polypeptide sequence that is known to be essential for the growth or viability of an organism;
- (b) accessing at least one algorithm capable analyzing a functional relationship between nucleic acid or polypeptide sequences selected from the group consisting of a "domain fusion" method, a "phylogenetic profile" method and a "physiologic linkage" method; and


(c) comparing the first nucleic acid or the polypeptide sequence to a plurality of sequences using at least one of the algorithms set forth in step (b) to identify a second sequence that has a functional relationship to the first sequence and generating an output identifying a nucleic acid or a polypeptide sequence that may be essential for the growth or viability of an organism.

## 33. A computer system, comprising:

- (a) a processor; and
- (b) a computer program product as set forth in claim 31 or claim 32.

10

Figure 1






Figure 2

Links established by phylogenetic profile
 Genes clustered by gene proximity
 Proteins of known function





Figure 3



PCT/US00/31152

Figure 4

WO 01/35317





Figure 5



## INTERNATIONAL SEARCH REPORT

International application N .
PCT/US00/31152

A. CLASSIFICATION OF SUBJECT MATTER				
IPC(7) :G06F 19/00 US CL :702/19				
According t	International Patent Classification (IPC) or t both	national classification and IPC		
	DS SEARCHED			
Minimum documentation searched (classification system followed by classification symbols)				
		•		
U.S. : '	702/19	·		
Documentati	ion searched other than minimum documentation to the e	extent that such documents are included i	n the fields searched	
Dictinguistation sent and sent				
		_		
Electronic d	lata base consulted during the international search (nan	ne of data base and, where practicable,	search terms used)	
STN ON				
SINON	LINE			
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where app	propriate, of the relevant passages	Relevant to claim No.	
v	MARCOTTE et al " A COMBI	NED ALGORITHM FOR	1-33	
X	GENOMEWIDE PREDICTION OF			
	NATURE GB, 04 November 1999, vol.	402 no. 6757, pages 83-86		
	HATORE OB, 04 November 1999, von	( <b>02</b> , <b>1.0</b> ( 0.0), pages 10		
$\mathbf{x}$	PELLEGRINI M et al. "Assigning prot	ein functions by comparative	1-33	
Λ	genome analysis: protein phylogenetic p	rofiles". April 1999, vol. 96,		
	pages 4285-4288; the whole document			
	pages 4205-4200, ale whole decument			
x	ENRIGHT A J et al. Protein interaction	maps for complete genomes	1-33	
A	based on gene fusion elements. Nature	. 04 November 1999, Vol.		
	402, pages 86-90, the whole document			
	102, pages 66 75, and			
$\mathbf{x}$	TATUSOV R L et al. A Genomic per	spective on protein families.	1-33	
	Science, 24 October 1997, vol. 278, pages 631-637, the whole			
	document.			
X Purther documents are listed in the continuation of Box C. See patent family annex.				
Special categories of cited documents:     Ister document published after the international filing date or pricrity date and not in conflict with the application but cited to understand.				
*A* document defining the general state of the art which is not considered the principle or theory underlying the invention				
to be of particular relevance  "X"  document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive state.			e claimed invention cannot be ered to involve an inventive step	
*L* document which may throw doubts on priority claim(s) or which is when the document is taken alone				
l ci	ited to establish the publication date of another citation or other pecial reason (as specified)	"Y" document of particular relevance; the considered to involve an inventive	step when the document is	
.O. q	ocument referring to an oral disclosure, use, exhibition or other	combined with one or more other such being obvious to a person skilled in	h documents, such combination	
·P· de	ocument published prior to the international filing date but later than ne priority date claimed	"&" document member of the same pater		
Date of the actual completion of the international search  Date of mailing of the international search report				
28 FEBRUARY 2001 11 APR 2001				
Name and mailing address of the ISA/US  Authorized officer				
Commissioner of Patents and Trademarks				
	Box PCT Washington, D.C. 20231  MICHAEL BORIN			
1	No. (703) 305-3230	Telephone No. V(703) 308-0196	//	

## INTERNATIONAL SEARCH REPORT

International application N .
PCT/US00/31152

	tion). DOCUMENTS CONSIDERED TO BE RELEVANT	Relevant to claim No.
Category*	Citation f document, with indication, where appropriate, of the relevant passages	
ĸ	MARCOTTE E et al. Detecting protein function and protein- protein interactions from genome sequences. Science, 30 July 1999, vol. 285, pages 751-753, the whole document	1-33
4	EISEN M et al. Cluster analysis amd display of genome-wide expression patterns. Proceedings of Natl. Acad. Sci., USA, December 1998, vol. 95, pages 14683-14868.	1-33
K,P	WO 00/45322 (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA), 03 August 2000, claims 1-77.	1-33
		,

Form PCT/ISA/210 (continuation of second sheet) (July 1998) \*